<SEC-DOCUMENT>0001048477-22-000018.txt : 20220429
<SEC-HEADER>0001048477-22-000018.hdr.sgml : 20220429
<ACCEPTANCE-DATETIME>20220429130254
ACCESSION NUMBER:		0001048477-22-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220429
DATE AS OF CHANGE:		20220429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		22872860

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bmrn-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639,d:cd2b94b05172492a9fffc0163ccafcc1--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:bmrn="http://www.bmrn.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bmrn-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV8yLTEtMS0xLTQ1NDQx_4525c2fa-2830-4bd5-a9a5-c131707d1925">false</ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV8zLTEtMS0xLTQ1NDQx_a5339ace-1181-41d1-b636-4c74b5c289bc">2022</ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV80LTEtMS0xLTQ1NDQx_764558ad-a65c-4eb9-b026-fdebc1177d95">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV81LTEtMS0xLTQ1NDQx_79f2cdf9-1f8d-43b6-b13a-fbf434761ea7">0001048477</ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV82LTEtMS0xLTQ1NDQx_df993a8f-9130-4e85-afc4-49e4b1dd913d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie54c42f5d5ad4f02b10f1329b8e06482_D20220101-20220331" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id952376c72fe492898bd2bb8f3c2ba18_D20210101-20211231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bmrn-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa05a7fa135456a8fe312c91de5e0ee_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5017a08d58224e19b728357a77f28248_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i63654500f0694941a974905d3087a5ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9964555943664f0cb773a445f771d126_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87ec807037b48a1827df1aaa0055934_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if973bfa7c942477d8a27516ba36f112e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c36f51afd949d2922a9403458ff14e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e39e6909554b2fb8708ff366791343_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3672150712a44391a3ca9ba235561a68_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib209ba21e10b4555b66a335b31afd83c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b01dbbc2904243b9407a39a5cd814d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabde523660c4e0bb4175d419336ec3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36be7b3ebd4244dd822037d737ee85c5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id953c96ff17c4c53bb75b4fa1aed178e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83218bf734f4322a2d42769d9866f47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b7832f66eca4ae3aadf7917fe918857_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f86851fcae34ae2a4d65e7a6c993a18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be8e4176b874e8ebabfd30bfa5f25d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8922e4d2b913460fbd96bbc32f58fb8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce4e8fcc10349509bc910ed5fc7d1f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e50effa4c044d1a1f56b02b147b183_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65140d9974ff4879ad2575de4f85ba00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c04fe803925410fb3dc8389bd8d71b8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae5076ed26c4e069af93432359b1543_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7db0e866934747a0ef27975afd832f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3649606ceb74fcf8df8cc4b91928646_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc492906fa645578549b49d3cf4ce75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i837ed5d736814a3bbeb99f71701e965d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11e992c2c33410da4c7f9aa950bb1c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48ead339f954703bef2ad6408f75e1d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7810dda9d65495381e007327ae9c35c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003577bf2fb84683baafc0afbded1f79_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bebefd2f4b14a17ad7eff862468738f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8037f34da784a8da052f3d100568fdc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475042e9abf7443a90e179783dd443f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4fc146174c44dfac7293154917c0cd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f4e3af7d5541438a52d3a255447f9a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b20b1e79404e219e16bb43665c85f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19740758cf5742bd95d6aa74d07388eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06655e4513d7439fb94059adafe0bba4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9adf0006647246c1a686f4e093f0039b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376acb983838406dafef8389effeae4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib088395ca9b54cd5ab2856cb12431e57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadebcf821247497ba93eafb227624346_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54c42f5d5ad4f02b10f1329b8e06482_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id952376c72fe492898bd2bb8f3c2ba18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd980138ba04ea4aa0bf850eba714f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca8e30ed951424daed017118d432eef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9569970b087c446aaf59bf7e94224bd2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">bmrn:ValoctocogeneRoxaparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11cc1a5725ab4723b0462ef1a3028473_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67c5cd0a2b524859bbb3035e15216170_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4c0ea303bc4617bff30b97f3119d8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac071ae2357499a807f15a7c6d7c22d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea9395534ba42e3a0190935fdfbb79d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id06e40f8e2ee4cf4a3d50677fc6227a2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67fb8408fad4a14a69938859aaf1ffe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bd403d599a4cae83b4124e73e69e92_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5305ac356c4dae82b317efba8e3eed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af36fbb7aca467c8d91640910e44cbf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeee18ee6d494c7790cf41fe0038c831_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id262761c1fad424b90e86b74ae146097_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98efc0e12da4354a0d424854f64af5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a1cedc9eed4bfab32ee8743471c711_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia462eb49aaaf40e997e1a56cd4ffe090_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i478e66d57d4645caa9b700a5fd1ef8eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4cd46ba90ab490ab24b52d5a3097a86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7475279edad54e10a67e1ba4a06c239c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9059f91d0ea641c8a3ca5f6af90239be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e1bbedcd77d4d4e9132645838dec1f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b2a564c9924e1593e108f04e0e05fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27016ee9414a53ac394d4ec7659333_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018f94a349524435963ac9c426ebd9da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8e222c468d40d181487297a7c0cbd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6783e8d375468bb371c65e2e9858b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40b5097a4704fd29443d8189ff20cfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3c8c6419414c7397306df2567d9a10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3e175895dd4eddaf85bea4d5710175_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8702f41faa34d58a58f591cc29c5186_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a67b5f17b74d8d875e70d77ac24e0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb2fa6470f64208b9cca9caed841242_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10323adbf43747cc8e67c4d6d61a7601_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d9103e14e34a25a637947fb0294c86_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied746eb100554a6386b2c27894ffc0e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693b3a7b97e1437ebca5874be75ea456_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82a5008ad32467abe48f8d161ab8af8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73022b6d871f47e28feede850e27c229_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e5ec0991924f7c96ecf3ccf3bb217f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0d508ddf7e40db989b324877ca4949_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28b615c8a794db39d946b9acae01f69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27917553b8fd4dfbac5fe095c7b4bde6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06dfaccfdbe46caac6458766a03b73f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7f9f8463ea496caae776a4ddbd016b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021baed86234498eaefce274645b825b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9174aac2384a699993569e2b6eb445_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f2f900f6b144a0975d6dc3d49144ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5618c6fb44d74a64909673a57923b8ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3985bd1ab09f4ea0bbe878344b3713b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1adb2627443a447f8c92c839abeda3a7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482d5788d5874458a97a7e25c5406e22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125b9e8420b44a9498f4af3776f779da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d039887887e460290fb9430275f52d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5119ab19f704add84d831075c4fe20f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b30d6f7853643148004a14e6c5d0fdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c517e48e00e4becb6f7ce5b1310c741_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3fbdd624724d3d85d457df11a2b0ec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa52acc498d4cdab18b97d9c59c01b9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59ded9cd6c34aa1968e85dc2a793158_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id0331cf243884e099d67f815a061dcd2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a61fb3318b44b2ba23a29e3998e0700_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8cf35d33be44d27a7f0d3b047d0f271_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3059cd10734ed783cd2d2634b0d82b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b1717d96134283ae50ccf10e9f13ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c3fc76077b46a996c89411439fc65e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d46d1b4201e4019aa70b698c03d7415_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f51f53032a84b1b89b05ca56aa74445_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840b2f2e120540f98c612afa3ec823f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4c4bfebe294de7b1a98930ea9835b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01504b7547d48c29809551d9fa94665_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>bmrn:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ic74a170ac59147cca285f25489fe3660_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc468e5fd8a42e2b1558768f37e6571_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ef15ea138648cca1e80f4d3e259dc9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica5c489de8f841848c2154b45041d920_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491df707a2b5489fb420d6bc1f228e19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89eb3a13235f4740a02e03ada4aacecf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie708c87270e9415c898a4aeae0af25bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895d2189edd943fdadd1d2c44e8fa735_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d78c3903b24697b01c59cc20ff5358_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20640d60dab64a039c473a7175a0a267_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i594041ae57af40ccab0c62019799787e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b892fdeb6e14ef287c0f6a538ac8c13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1103deb96054b26b048779411774904_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9f090883124d2198ad6215aa997c28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ff03d00b5648269908ec5e62655bb4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id742c4f384be442b8fca74da0bbbaa4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4557550c4f422393773b243642092c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f201c2b5d348ee8cef94eeee757986_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9306ad4c27064a6b9826f59953cafc24_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a14de3abadb40778471e66184af280a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ff7532c1ae49528158820bb4da4aea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecad8ebdb8c244bd98a2afd89bba0a2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cdbd316d31b4d1cab319df9d84f7f77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23782facb41e4a0394006d0c61111460_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c33100f90b40bca71ded15376adfcb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e5f24d472d4e82b55a8346cd4fc93b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdf37db79194886b085e0309823a025_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf584b76688449d949ae03ea7a23992_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6c8323762a4a68a579e56d15514782_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8a05482b8a475f87dfd720c5c6b2f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f73aa86157436b89f7042549ab2cdf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoThreeAndFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e84ec89b6c4d8ea066d35c5ace7603_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoThreeAndFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4519e269765428dbc66faaaa2646940_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6f40e5c0bf4422a0a81cb722132751_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5407662ac25040bf8b124d95a9d5af58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da3b672cc79498eb14a326a63d8c950_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d5c38e0f09439dbdf86382f3b59459_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae90bf0fe46c464d9eb1ead18b979c57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19465b1578ec4dd28c910af817bceab3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03cdf675716d437c964339c1910bdbdc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0fd632f5fd41e287a0b11cae9cbeca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008d8298bf11412ba45a7ea365cc12cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0087b7e6ba4593890bb5c30ab38817_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4910a2e24b7045899f96c49194daa7f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33737b08299431889d37d12a1d70178_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85312ddaf862450190f331615f114ab7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530302b04890455682f0ab0adc4d162e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib721cab6f4a2424680bcabdd246154df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99beaf0bac24ae7a8e8559e31363de0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275d3e6c3fa2449e9f081a92e87e1c21_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bad4330064641499986ec8dd304acef_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62 id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe" order="1"></ix:relationship></ix:resources></ix:header></div><div id="icd2b94b05172492a9fffc0163ccafcc1_1"></div><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMjU_49568a7d-995a-468d-9beb-700fb7202f3a">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6OWVjNzk1MGNmMGZiNGM1MGI0NjliOTk5ZDJjYWVhZTAvdGFibGVyYW5nZTo5ZWM3OTUwY2YwZmI0YzUwYjQ2OWI5OTlkMmNhZWFlMF8wLTAtMS0xLTQ1NDQx_6e35cafc-1c64-4293-8323-cbe006549a00"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6OWVjNzk1MGNmMGZiNGM1MGI0NjliOTk5ZDJjYWVhZTAvdGFibGVyYW5nZTo5ZWM3OTUwY2YwZmI0YzUwYjQ2OWI5OTlkMmNhZWFlMF8wLTAtMS0xLTQ1NDQx_f9cb8620-bdfe-4232-8acb-549a82123cc3">&#9746;</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yMTE_deaca2d5-a9ef-4f74-bd3b-2ed3c208f1ef">March&#160;31, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YzQzNTM2NDQyMjNkNDEyZjhkODJjOTM2NWI5ZmMxNmIvdGFibGVyYW5nZTpjNDM1MzY0NDIyM2Q0MTJmOGQ4MmM5MzY1YjlmYzE2Yl8wLTAtMS0xLTQ1NDQx_2112a309-fa83-4b92-b473-6c2086c19a2a"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YzQzNTM2NDQyMjNkNDEyZjhkODJjOTM2NWI5ZmMxNmIvdGFibGVyYW5nZTpjNDM1MzY0NDIyM2Q0MTJmOGQ4MmM5MzY1YjlmYzE2Yl8wLTAtMS0xLTQ1NDQx_d1437d1f-15b0-4573-bd1a-48d9f97bee08">&#9744;</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> .</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8zMjE_ee62d3dc-f1d3-474e-8aeb-4e291485a84b">000-26727</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8zNjU_81d80d55-a67c-4f15-9797-b2804ea5185b">BioMarin Pharmaceutical Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTAtMS0xLTQ1NDQx_5e00c763-875f-44e6-8fe6-0597b04ed1a7"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTAtMS0xLTQ1NDQx_71a6dc3f-d688-4597-8249-65241935e5e6">Delaware</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTMtMS0xLTQ1NDQx_1eec61c3-9da2-4d0b-bc9f-5ffc48fe958b"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTMtMS0xLTQ1NDQx_5adaf7dd-348c-4b31-890c-17b64a0eef51">68-0397820</ix:nonNumeric></ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTAtMS0xLTQ1NDQx_53bbf259-ccaf-4381-ba9a-56ab07502274"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTAtMS0xLTQ1NDQx_ca27083b-5acd-4d34-b7a5-34a95cba12df">770 Lindaro Street</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTEtMS0xLTQ1NDQx_29b0c8cd-6f86-4d22-a28b-93d9ca51c7a7"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTEtMS0xLTQ1NDQx_c651cf8c-409c-42da-a2f6-6c5fd5f7bfb2">San Rafael</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTItMS0xLTQ1NDQx_31ffc0f2-0918-49c3-b83b-3c3060d04bfb"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTItMS0xLTQ1NDQx_aa58eae4-ef9a-4c42-9835-3f7bb7d17b05">California</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTMtMS0xLTQ1NDQx_89546f9e-3aec-4a29-acb5-a8c967c7e901"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTMtMS0xLTQ1NDQx_ccb6d38a-13d4-4838-b005-0ad453234c56">94901</ix:nonNumeric></ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV80Njk_d8095216-72f6-48ea-8b02-42515f76432b">415</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV80NzM_ee8dcf15-66ec-428a-b1cb-2c3cdcbbaf5d">506-6700</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:31.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTAtMS0xLTQ1NDQx_b7b684ad-dd19-4da6-a51c-903ac47b037a"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTAtMS0xLTQ1NDQx_bfb011f9-e22a-4e62-8e14-623fa1a7d68e">Common Stock, par value $0.001</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTItMS0xLTQ1NDQx_44dff287-0a28-4db4-801c-bf6d4af6387e"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTItMS0xLTQ1NDQx_eab252d4-a669-4a06-a055-2e2def4e946f">BMRN</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTQtMS0xLTQ1NDQx_2e438fe7-6ba1-4da5-8cb7-724f2e801e81"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTQtMS0xLTQ1NDQx_b7c7d84e-c4aa-4fdc-ac4a-7e74bb4c463e">The Nasdaq Global Select Market</ix:nonNumeric></ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMDE5_1d9160cd-5700-442d-8d6b-c3e11c2c6395">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMzQ3_9b30b03c-5c37-4097-88e5-400b9c0659f4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:26.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8wLTAtMS0xLTQ1NDQx_1e8800a8-7157-45d7-896a-1b74e6e14304">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;Reporting&#160;Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8yLTYtMS0xLTQ1NDQx_b0589e76-82a4-4edb-a65c-92c0c90a38c1">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8zLTItMS0xLTQ1NDQx_beeb09ac-a324-489f-903e-408217ee8239">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yMDg3_dfbb5022-6e24-4865-8040-1d2840afd2ff">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Applicable only to corporate issuers:</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="ibaa05a7fa135456a8fe312c91de5e0ee_I20220425" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yNzQ4Nzc5MDcxODg5_3fe5ddf6-481a-4bcb-82cb-c4098cc95826">184,995,348</ix:nonFraction> shares of common stock, par value $0.001, outstanding as of April&#160;25, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_4"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to &#8220;BioMarin,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to BioMarin Pharmaceutical Inc. and, where appropriate, its wholly owned subsidiaries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Brineura</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Kuvan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Naglazyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Palynziq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vimizim</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Voxzogo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are our registered trademarks. Aldurazyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this report are the property of their respective owners.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; as defined under securities laws. Many of these statements can be identified by the use of terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; would,&#8221; &#8220;projects,&#8221; &#8220;continues,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; &#8220;opportunity&#8221; or the negative versions of these terms and other similar expressions. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in &#8220;Risk Factors,&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q as well as information provided elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2021, which was filed with the Securities and Exchange Commission (the SEC) on February&#160;25, 2022. You should carefully consider that information before you make an investment decision.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of the Company&#8217;s management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, the Company does not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The discussion of the Company&#8217;s financial condition and results of operations should be read in conjunction with the Company&#8217;s Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash flows or stock price. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business and Operational Risks</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">The COVID-19 pandemic could continue to materially adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenues could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">The sale of generic versions of Kuvan by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in Kuvan revenues faster than expected.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Risks</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenues from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the Food and Drug Administration, the European Medicines Agency and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenues from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Valoctocogene Roxaparvovec</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional development and treatment risks in relation to our other, more traditional drug development programs.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">As compared to our other, more traditional products, our gene therapy product candidate valoctocogene roxaparvovec, if approved, may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial and Financing Risks</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we continue to incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Risks</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to International Operations</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">We conduct a significant amount of our sales and operations outside of the United States (U.S.), which subjects us to additional business risks that could adversely affect our revenues and results of operations.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenues in these countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Risks</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_13">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets as of March&#160;31, 2022 (Unaudited) and December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three months ended March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Stockholders&#8217; Equity (Unaudited) for the three months ended March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_118">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_79">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_103">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_106">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_106">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_109">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_109">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_112">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_112">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_115">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_115">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_118">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_118">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_121">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_121">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_124">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_124">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_127">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_127">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_130">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibits</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_130">62</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd2b94b05172492a9fffc0163ccafcc1_133">64</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_16"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March&#160;31, 2022 and December&#160;31, 2021 </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0xLTEtMS00NTQ0MQ_c6756d2a-10f9-4bdb-a8d9-73def0774916">605,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0xLTEtMS00NTQ0MQ_8da3b357-18ee-4f4c-92cd-47b26706a7b6">450,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0xLTEtMS00NTQ0MQ_60885410-639c-42da-a5fc-6a169ced1f35">430,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e">373,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0xLTEtMS00NTQ0MQ_08f0705e-0096-4da0-a210-f9eb90df692d">786,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1">776,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0xLTEtMS00NTQ0MQ_e94d98be-711a-4a4d-9773-2befda3c8015">121,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018">110,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0xLTEtMS00NTQ0MQ_b88c7bbf-b47c-4d68-b295-6c65f7c502ad">2,394,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87">2,274,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMS0xLTEtNDU0NDE_0ce2b0f0-d422-43df-9f9e-19dc4e66041b">462,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMS0xLTEtNDU0NDE_c7435ce6-b859-4204-a473-89df7ecee70f">1,039,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21">1,035,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMS0xLTEtNDU0NDE_d5592dc1-26cf-4c7b-887d-3cfbf2c0617c">374,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603">388,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMS0xLTEtNDU0NDE_634ceccb-754b-4475-b916-84931ff8311f">196,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6">196,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMS0xLTEtNDU0NDE_f584c110-2d57-48eb-a4da-e2abec956d67">1,446,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65">1,449,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMS0xLTEtNDU0NDE_9d9945fa-e013-4349-a657-1228b36dd4f4">149,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f">151,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMS0xLTEtNDU0NDE_0e94a408-aa06-4bfc-8e9a-ed85c9ffcaca">6,062,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a">6,003,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMS0xLTEtNDU0NDE_eba05f30-6ec4-44fd-b8b4-429c420b3292">426,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6">491,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMS0xLTEtNDU0NDE_dee859ff-58a1-4d59-bc74-362cc070b755">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMS0xLTEtNDU0NDE_e408e6e2-02d4-4885-ba73-5a9793dcb7f1">490,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8">539,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term convertible debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMS0xLTEtNDU0NDE_0031927e-6fb3-4179-8797-1b5edf20fd0e">1,080,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5">1,079,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMS0xLTEtNDU0NDE_c92ec190-7f53-4f98-b22a-1e92534752bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMS0xLTEtNDU0NDE_e1e79e06-8b00-4f26-aaf5-f57509511d20">100,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101">98,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMS0xLTEtNDU0NDE_3632270c-e871-424b-81a8-30c6acdf1a58">1,671,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a">1,732,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8xOA_a33fd101-fbf4-476f-852f-11d99544ac33"><ix:nonFraction unitRef="usdPerShare" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8xOA_ce8fa225-5885-4ac4-b1a3-8a53fe8771c4">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8zMg_34c74f2d-ac46-4411-9a99-f3d0a62f7e50"><ix:nonFraction unitRef="shares" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8zMg_d2a99c68-746f-412c-a5fd-a96e260e9cc8">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl81NA_765c49f3-23ca-44c0-a4f8-c6f158e7c25c"><ix:nonFraction unitRef="shares" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl81NA_a4a6b11b-5fb1-49bf-8783-1d90a981f29f">184,901,764</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl82MQ_667081be-534e-491e-9538-8675f6619513"><ix:nonFraction unitRef="shares" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl82MQ_e6c6ea5e-f4df-4de8-9c73-148739385561">183,912,514</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMS0xLTEtNDU0NDE_c6db3604-0528-4880-a1e7-12ef2c81d9e4">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMS0xLTEtNDU0NDE_a71aa71a-5873-4ed3-bf5a-d5e48a85c0ac">5,206,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7">5,191,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:CommonStockIssuedEmployeeStockTrust" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMS0xLTEtNDU0NDE_2dd5b88b-74a3-4fcd-91e3-1a2c8df83bc6">9,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:CommonStockIssuedEmployeeStockTrust" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5">9,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMS0xLTEtNDU0NDE_eaaf5c7f-bfff-4fe9-8473-e48bc10268fd">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMS0xLTEtNDU0NDE_229b1f9a-372b-4128-87c6-c7d12e690e53">804,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe">925,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMS0xLTEtNDU0NDE_78018010-b69b-4080-8e69-513d64305457">4,391,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11">4,270,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMS0xLTEtNDU0NDE_1714fb0f-af1e-4414-9183-d729161c212a">6,062,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756">6,003,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></ix:footnote></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2022 and 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">REVENUES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMy01LTEtMS00NTQ0MQ_54b39845-1aed-4dd0-bd76-d63baddf7f8f">505,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMy03LTEtMS00NTQ0MQ_9f382898-ee37-4c3a-b8f2-231fed618a3a">467,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87ec807037b48a1827df1aaa0055934_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNC01LTEtMS00NTQ0MQ_31641286-64b0-46df-8e1e-dd5aa815d48f">13,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNC03LTEtMS00NTQ0MQ_6b1769e4-98fb-42a5-bc1b-28311f686f53">18,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNS01LTEtMS00NTQ0MQ_4266404b-defe-46aa-a3da-659e90055e63">519,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNS03LTEtMS00NTQ0MQ_b655aecb-0b26-4ba6-816d-5c228e1285e3">486,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNy01LTEtMS00NTQ0MQ_bd19bc6c-e3f4-44b1-a5de-f20e118a9c4f">116,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNy03LTEtMS00NTQ0MQ_cb88a9f1-d1d0-472b-ba5d-8b8106430566">120,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOC01LTEtMS00NTQ0MQ_a6e835a5-2792-41a8-89aa-be84eae6460e">160,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOC03LTEtMS00NTQ0MQ_efd1dbfb-8a32-4d2d-b594-72fc5428bd78">148,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOS01LTEtMS00NTQ0MQ_8b889101-e803-4139-b425-1244800e26a8">194,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOS03LTEtMS00NTQ0MQ_fc3242f2-9e34-4e45-b330-ffec136d9011">174,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset amortization and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="bmrn:IntangibleAssetAmortizationAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTAtNS0xLTEtNDU0NDE_f53f7d2b-09f0-477a-8d20-466ae8d4ff24">17,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="bmrn:IntangibleAssetAmortizationAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTAtNy0xLTEtNDU0NDE_e3bf69c5-69f4-4404-9a8a-18fd2ee71e3c">17,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTEtNS0xLTEtNDU0NDE_90cdd34b-7f8e-43e2-aa50-03ad343ab47b">108,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTEtNy0xLTEtNDU0NDE_8fd8ec5a-7e73-44ce-9a15-d656ff750258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTItNS0xLTEtNDU0NDE_ebfe8f82-9f26-4168-b790-5d4b3f12a626">382,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTItNy0xLTEtNDU0NDE_192eed73-94cc-4188-ae31-cb2198a8f5dc">460,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTMtNS0xLTEtNDU0NDE_33c3e09b-b9c4-433d-95ba-f6ef588f81b7">137,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTMtNy0xLTEtNDU0NDE_64e9f2fb-7e1c-436c-8559-33cb8673e7e5">25,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTYtNS0xLTEtNDU0NDE_b07e8d3f-f8b9-481b-a479-4b928e05aa94">1,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTYtNy0xLTEtNDU0NDE_7e39da3f-176a-4d87-b114-5fae4e9b113b">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTctNS0xLTEtNDU0NDE_1bff763e-ec6c-4011-b4a0-fc18380c44e8">3,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTctNy0xLTEtNDU0NDE_b060b941-9646-47fe-ab74-ff7a91ab098a">3,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTgtNS0xLTEtNDU0NDE_ec7ceb16-98ed-41d8-9b0d-df1edddfefa4">1,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTgtNy0xLTEtNDU0NDE_ab673383-5484-4541-a0be-b56e86fc6c1f">493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INCOME BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTktNS0xLTEtNDU0NDE_4bcea9c7-4a72-42d7-841f-d7395d80f886">134,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTktNy0xLTEtNDU0NDE_a9f06b16-62f0-4389-bd9d-a9d690bed7d6">23,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjAtNS0xLTEtNDU0NDE_e0a653b5-aae4-46bd-bfce-37be3c86c3d8">13,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjAtNy0xLTEtNDU0NDE_bc2831c4-735d-4f53-a121-304e5fbda370">5,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjEtNS0xLTEtNDU0NDE_08e62fc9-1967-44cc-a49c-6d50f35b5b1a">120,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjEtNy0xLTEtNDU0NDE_82be69fa-c26d-4db2-bad4-96231e388b98">17,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME PER SHARE, BASIC</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjItNS0xLTEtNDU0NDE_155f3ccb-8a01-4adb-b555-892bb39ac45a">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjItNy0xLTEtNDU0NDE_26879a00-78c7-4fb5-ad87-bb459747a302">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCOME PER SHARE, DILUTED</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjMtNS0xLTEtNDU0NDE_43f70aec-a3b5-41ae-8ad7-2a6d210dedf2">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjMtNy0xLTEtNDU0NDE_7dd5b9d1-7dbe-4af4-9a9c-fc1c84bb7bb8">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjQtNS0xLTEtNDU0NDE_3570fd3d-f94d-4b09-b1d4-08b27cff00f3">183,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjQtNy0xLTEtNDU0NDE_78ad95bc-24ab-44f6-86ca-19a2cfe0545d">181,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjUtNS0xLTEtNDU0NDE_738ca209-9530-4c6e-bea0-9e3d35028d44">194,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjUtNy0xLTEtNDU0NDE_2e566349-2d5f-4da3-ac55-8c57040fefd9">184,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COMPREHENSIVE INCOME</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjctNS0xLTEtNDU0NDE_499c1dc1-f808-4278-8a9b-bcf64e0b87d4">105,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjctNy0xLTEtNDU0NDE_c92d6738-07e6-4b90-8c06-e88eb7f7dd7f">38,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Three Months Ended March&#160;31, 2022 and 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"></td><td style="width:68.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock, beginning balances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if973bfa7c942477d8a27516ba36f112e_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711">183,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1c36f51afd949d2922a9403458ff14e_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3">181,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88e39e6909554b2fb8708ff366791343_D20220101-20220331" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNC01LTEtMS00NTQ0MQ_35a7c3c4-6ed3-4df8-b367-fc147c239a6f">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNC03LTEtMS00NTQ0MQ_9f0a6d3b-38b5-4314-9123-c89d3e4b370d">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock, ending balances</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNi01LTEtMS00NTQ0MQ_435f6ce3-e4ce-4267-b432-30930a1b35be">184,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3672150712a44391a3ca9ba235561a68_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNi03LTEtMS00NTQ0MQ_a858f21c-88ae-4624-b8f3-9f2cf25ffebc">182,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity, beginning balances</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66">4,270,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib209ba21e10b4555b66a335b31afd83c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c">4,106,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balances</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if973bfa7c942477d8a27516ba36f112e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c36f51afd949d2922a9403458ff14e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e39e6909554b2fb8708ff366791343_D20220101-20220331" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTEtNS0xLTEtNDU0NDE_2f744a65-8198-41d2-a940-a2c579b87d11">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331" decimals="-3" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTEtNy0xLTEtNDU0NDE_cf44c91e-8458-4611-bf06-d44a94b47652">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTItNS0xLTEtNDU0NDE_70d32c0c-94ad-4da2-abd6-5271bcdf8bd0">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672150712a44391a3ca9ba235561a68_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTItNy0xLTEtNDU0NDE_b96905e4-1d8d-463d-b30a-b38995b1b0f6">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b01dbbc2904243b9407a39a5cd814d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682">5,191,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabde523660c4e0bb4175d419336ec3b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe">4,993,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331" decimals="-3" sign="-" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTUtNS0xLTEtNDU0NDE_873791d3-f2c7-4117-a279-b47afda7d186">33,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331" decimals="-3" sign="-" name="bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTUtNy0xLTEtNDU0NDE_6ddcc1da-496c-4b1d-8a69-e390e93d5c3c">29,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTYtNS0xLTEtNDU0NDE_3027673f-dd26-4bf2-81f8-3cc9e922ea67">48,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTYtNy0xLTEtNDU0NDE_e83e0f6c-af68-4380-ab9d-c88fbc3c6510">47,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331" decimals="-3" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTgtNS0xLTEtNDU0NDE_41674897-1e07-4e38-a020-127e0cee2956">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331" decimals="-3" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTgtNy0xLTEtNDU0NDE_3a724ab5-f03c-476c-bf4f-180467e07045">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be7b3ebd4244dd822037d737ee85c5_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTktNS0xLTEtNDU0NDE_4b226f13-2a5e-436b-ac72-49febcc95957">5,206,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id953c96ff17c4c53bb75b4fa1aed178e_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTktNy0xLTEtNDU0NDE_4a4190ca-ef87-419f-984f-84520f254011">5,010,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company common stock held by the NQDC:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic83218bf734f4322a2d42769d9866f47_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62">9,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b7832f66eca4ae3aadf7917fe918857_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50">9,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f86851fcae34ae2a4d65e7a6c993a18_D20220101-20220331" decimals="-3" sign="-" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjctNS0xLTEtNDU0NDE_ba1a4dee-8c8c-4014-95e5-791b62fcbaff">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be8e4176b874e8ebabfd30bfa5f25d3_D20210101-20210331" decimals="-3" sign="-" name="bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjctNy0xLTEtNDU0NDE_6f27233e-1f22-4351-8f3b-44103b351a7a">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8922e4d2b913460fbd96bbc32f58fb8a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjgtNS0xLTEtNDU0NDE_9c2c6b74-0169-44c9-8484-ea32dd36c166">9,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ce4e8fcc10349509bc910ed5fc7d1f0_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjgtNy0xLTEtNDU0NDE_2815d10a-3528-466e-bade-fe7abb32ade8">9,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e50effa4c044d1a1f56b02b147b183_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65140d9974ff4879ad2575de4f85ba00_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623">16,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c04fe803925410fb3dc8389bd8d71b8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzItNS0xLTEtNDU0NDE_344dff68-86d4-442e-ac6e-dbcfe200cd12">15,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae5076ed26c4e069af93432359b1543_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzItNy0xLTEtNDU0NDE_e91443af-ee64-4c3e-be7b-52a5c2515dd8">21,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7db0e866934747a0ef27975afd832f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzMtNS0xLTEtNDU0NDE_0f1ee247-db08-4e0c-a377-c98178e6fbcf">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3649606ceb74fcf8df8cc4b91928646_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzMtNy0xLTEtNDU0NDE_cdf24450-3470-427b-aedf-f52125b68bb1">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Deficit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dc492906fa645578549b49d3cf4ce75_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b">925,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i837ed5d736814a3bbeb99f71701e965d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac">861,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11e992c2c33410da4c7f9aa950bb1c2_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzctNS0xLTEtNDU0NDE_c2e88b57-d4aa-4cca-9aff-a7456408df17">120,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48ead339f954703bef2ad6408f75e1d_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzctNy0xLTEtNDU0NDE_07d5cbae-801b-42e9-a7a5-a63765e60fba">17,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7810dda9d65495381e007327ae9c35c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzgtNS0xLTEtNDU0NDE_4d480ab9-ddd9-4d15-8671-80f37d6312d6">804,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003577bf2fb84683baafc0afbded1f79_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzgtNy0xLTEtNDU0NDE_f70cea95-2a8c-441f-a6d4-22ea5cc0b8c3">844,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity, ending balances</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzktNS0xLTEtNDU0NDE_06e15b13-004b-492c-8555-6b91c01a9281">4,391,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzktNy0xLTEtNDU0NDE_a6c9cbea-9378-4dfd-92f9-8e92d2d4f964">4,162,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe" footnoteRole="http://www.xbrl.org/2003/role/footnote">The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</ix:footnote></span></div><div style="margin-top:10pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31, 2022 and 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.977%"><tr><td style="width:1.0%"></td><td style="width:74.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMy0xLTEtMS00NTQ0MQ_18167e18-d36d-4ca6-aed1-da0b3b83dab4">120,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMy0zLTEtMS00NTQ0MQ_b963076f-b3de-4ffb-873e-c113a06cc60a">17,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNS0xLTEtMS00NTQ0MQ_18fab828-f851-43c6-96d1-70ffae3bafdd">27,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNS0zLTEtMS00NTQ0MQ_06950263-9a9a-4a3e-8852-2bfdae24cd0a">27,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNi0xLTEtMS00NTQ0MQ_2d39bde4-c2e1-47a5-a3b9-553f3a358eed">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNi0zLTEtMS00NTQ0MQ_64b832cc-0cfc-491e-8fd9-674bcf91c976">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premium on investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNy0xLTEtMS00NTQ0MQ_26b0e016-49cf-4a8d-ae66-bb1633c160c4">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNy0zLTEtMS00NTQ0MQ_ac785c81-8ef0-4723-8686-6b08d7b721f7">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOC0xLTEtMS00NTQ0MQ_ee93df28-4599-43f0-bdd8-68884fc1ae8c">47,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOC0zLTEtMS00NTQ0MQ_820f75ac-7393-4be4-b37c-455277089490">49,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOS0xLTEtMS00NTQ0MQ_b033bbe7-c4b1-4686-b2dc-13eac48ea131">108,000</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOS0zLTEtMS00NTQ0MQ_ed45f6df-57a8-4fe0-8597-8b53d530ddb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTEtMS0xLTEtNDU0NDE_c45e26d8-6518-4c88-add3-85dc911c91cd">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTEtMy0xLTEtNDU0NDE_f181fc1d-cdaa-4670-85be-7f8545d9ce53">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized foreign exchange (gain) loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTItMS0xLTEtNDU0NDE_2ab6881f-4b7a-416e-841e-bd735919596b">6,887</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTItMy0xLTEtNDU0NDE_aca6eba2-97e2-41a6-9312-34ae977925c2">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTMtMS0xLTEtNDU0NDE_e28bfffe-98e0-46a5-8570-fd830ee926db">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTMtMy0xLTEtNDU0NDE_d2b6e664-a87a-4681-99da-b96d0904240d">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTQtMS0xLTEtNDU0NDE_f9b6abc9-d334-4e80-9c28-fbe5136b72bf">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTQtMy0xLTEtNDU0NDE_3c0f6d62-4661-4fda-8bf7-39fbb0669d75">871</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTYtMS0xLTEtNDU0NDE_9437f756-9c42-4756-8526-9527dab8213b">54,813</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTYtMy0xLTEtNDU0NDE_c86a82c9-5bcb-45b7-bcdb-97721bb75f93">40,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTctMS0xLTEtNDU0NDE_351f422c-b77c-492e-97ca-be922d01b563">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTctMy0xLTEtNDU0NDE_d0729c57-a1b5-4e96-9d61-14eca9a4610a">6,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTgtMS0xLTEtNDU0NDE_58ef50f2-2d26-4da7-beb9-53baef863851">8,011</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTgtMy0xLTEtNDU0NDE_13c0dbee-8a7c-471f-93c0-669fc573b73f">42,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTktMS0xLTEtNDU0NDE_d1a6dc75-4821-4178-b13c-b57e711f0063">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTktMy0xLTEtNDU0NDE_5edea341-080d-47b8-9b73-aeb208cf4dbb">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjAtMS0xLTEtNDU0NDE_1bcf071a-12b4-4d26-b676-5fa7390ac358">78,143</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjAtMy0xLTEtNDU0NDE_48172d51-6e29-444b-9fca-55b400a89d2f">72,304</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjEtMS0xLTEtNDU0NDE_90c038fd-6db1-4da0-8940-5a7b087ec645">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjEtMy0xLTEtNDU0NDE_0ca035e1-3368-49a0-a907-2da51cfc86fe">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjItMS0xLTEtNDU0NDE_9e3ecc96-e759-48da-8ff6-79c82c2491c8">45,431</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjItMy0xLTEtNDU0NDE_3256de5d-bb39-4c2c-bb18-42b2a4321ba7">113,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjQtMS0xLTEtNDU0NDE_be371b14-bf09-4b8e-a317-f9860fbff7a0">28,817</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjQtMy0xLTEtNDU0NDE_18b1845c-4851-4604-9f0d-a98973019841">25,507</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjUtMS0xLTEtNDU0NDE_98c4a1d2-351c-4d05-8bda-b100d99f9e86">155,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjUtMy0xLTEtNDU0NDE_d4f26021-d01a-4efb-a2e6-4b18cbb285d3">194,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of available-for-sale securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjYtMS0xLTEtNDU0NDE_299a983f-751c-4993-8674-128156c07083">147,361</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjYtMy0xLTEtNDU0NDE_f2484cfb-1eb1-4939-9edd-40c2904b8d32">237,171</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of nonfinancial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="bmrn:ProceedsFromSaleOfNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjctMS0xLTEtNDU0NDE_38b9ac9d-ff37-49ab-91b6-55df800c0b20">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="bmrn:ProceedsFromSaleOfNonfinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjctMy0xLTEtNDU0NDE_c75be8b5-a0a9-4387-8112-9a756f120582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjgtMS0xLTEtNDU0NDE_10ae6fad-1788-41c9-8598-242413134bef">1,858</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjgtMy0xLTEtNDU0NDE_f846e825-12dc-4e8b-b16d-e44914ad4dc7">2,747</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzEtMS0xLTEtNDU0NDE_7f4d54f0-42b2-41db-a608-04d93bbbacf5">87,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzEtMy0xLTEtNDU0NDE_bd2e6009-deb8-48d2-8fb3-199f41a130bf">70,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of awards under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzMtMS0xLTEtNDU0NDE_44f9c2cd-452c-490f-8c02-d03c5c191f1b">8,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzMtMy0xLTEtNDU0NDE_ffcf03f6-f6af-4d0f-8a42-fe929bd9bd9a">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzQtMS0xLTEtNDU0NDE_e11193c9-a679-489f-9d96-9ecf7a7e383f">32,949</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzQtMy0xLTEtNDU0NDE_cdbc5f3d-3a6c-44b8-a8fa-20c59c9743e7">29,097</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal repayments of financing leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzktMS0xLTEtNDU0NDE_8aac57f5-44d3-48f1-89a7-7f43bb560050">566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzktMy0xLTEtNDU0NDE_5b5475ad-f515-4469-a1ad-a9e6757f129b">1,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDEtMS0xLTEtNDU0NDE_49c59555-654a-4bad-a7ab-4c920d3c8c20">25,280</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDEtMy0xLTEtNDU0NDE_fac0deaf-8216-4160-8e39-3d0e2ce18a63">24,364</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDItMS0xLTEtNDU0NDE_57389b3d-7c3d-4307-b9dc-6c7835499705">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDItMy0xLTEtNDU0NDE_3d99300c-1c97-4547-af90-24d6a304b7cc">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET INCREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDMtMS0xLTEtNDU0NDE_c931db81-5c21-4c04-b27c-bf45a309ce07">18,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDMtMy0xLTEtNDU0NDE_83d9a503-ab4e-498c-94c6-4a7f8d058292">18,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDUtMS0xLTEtNDU0NDE_0ad326eb-45b5-48c9-948f-1c5bbbb21a37">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib209ba21e10b4555b66a335b31afd83c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDUtMy0xLTEtNDU0NDE_bf29f7c5-8a5a-484d-8d58-70209db9f365">649,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDYtMS0xLTEtNDU0NDE_40efa4bd-2381-4006-9c08-39ff4b5a20ab">605,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDYtMy0xLTEtNDU0NDE_97b58d00-2bad-46ee-ab4a-fcc82696f903">667,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SUPPLEMENTAL CASH FLOW DISCLOSURES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDgtMS0xLTEtNDU0NDE_bc6ae781-01b9-41c9-b63e-e62043127df8">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDgtMy0xLTEtNDU0NDE_ec9233d7-9cb7-40b5-9faf-e64a827a7373">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDktMS0xLTEtNDU0NDE_a5791472-b1f9-4e79-842e-108379f580fe">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDktMy0xLTEtNDU0NDE_007c2d4b-cea8-431f-a7bb-931dd145cf06">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities related to fixed assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTEtMS0xLTEtNDU0NDE_c048b232-b40b-47e2-817d-cd94fa4f094b">2,481</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTEtMy0xLTEtNDU0NDE_90018bbf-9995-4f43-a6ef-23a586f39166">12,795</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTItMS0xLTEtNDU0NDE_c2baaac7-052e-4cfe-accc-ece1b924061f">637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTItMy0xLTEtNDU0NDE_4f19246b-0b12-4d33-9687-68bf2816d66e">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:103%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:103%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:103%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzYzOA_441abd6e-de47-4d34-8cc8-3bbd64e4fc78" continuedAt="i701e23ee2d984fc28fbdef488ff974d6" escape="true">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i701e23ee2d984fc28fbdef488ff974d6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#8217;s portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzYzOQ_f3bb459a-436e-466c-a2d8-65aa8c2905b2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2022 or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzY0MA_7073eaca-e618-48f0-81f1-c5f8c0164b9b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022, as compared to the significant accounting policies disclosed in Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzY0MQ_721a41c7-fb03-407b-b92d-2e4d4ae523e0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three months ended March&#160;31, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of significance or potential significance to the Company.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTM5MQ_f0505037-0be6-416d-80bf-a7b8fb107286" continuedAt="ib43545d00ae14432857b0e3ce2e0163b" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ib43545d00ae14432857b0e3ce2e0163b" continuedAt="ie9229898934d432bb495f985449db266"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities were classified as available-for-sale at March&#160;31, 2022 and December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTM5Mg_6a99c76b-5420-4315-a104-82f2e35502e8" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xLTEtMS00NTQ0MQ_4f72d025-5cd5-4867-b562-3c1b5361ff97">441,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0zLTEtMS00NTQ0MQ_6b21946a-5519-403a-a913-2fea8c7c5575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy01LTEtMS00NTQ0MQ_11aa3617-8f7e-4949-85e2-ce951cd95bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy03LTEtMS00NTQ0MQ_87505b2a-dc49-439a-867b-3153c13bcce7">441,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy05LTEtMS00NTQ0MQ_ec18d321-ef05-4d52-9404-80ee9a6c895a">441,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xMS0xLTEtNDU0NDE_25d29991-161a-434b-afef-f9212b0a71d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xMy0xLTEtNDU0NDE_2904e8f1-8d28-4270-9cd5-8b4fe906f870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xLTEtMS00NTQ0MQ_60fa5cb0-1cf3-4634-8af0-92c0c7f4d282">160,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0zLTEtMS00NTQ0MQ_7157b71f-9567-4a95-97c6-875f91bbf564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi01LTEtMS00NTQ0MQ_91fcbc59-1486-404b-b707-fec2c167788b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi03LTEtMS00NTQ0MQ_ae937c9d-a9f8-4d31-9244-0bdb13c13c18">160,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi05LTEtMS00NTQ0MQ_da34cea0-2da6-49f1-b5f2-e2cb54172914">160,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xMS0xLTEtNDU0NDE_85cc7d1e-0dda-4f48-a43a-9ae983b3a3e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xMy0xLTEtNDU0NDE_d782d0e0-e11e-4340-82d1-d1ba6d919082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xLTEtMS00NTQ0MQ_2163c0ab-3e05-435d-bddf-fc138c0cf0e1">585,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0zLTEtMS00NTQ0MQ_d2ca7275-bb6d-4df2-af0b-df15a1956348">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy01LTEtMS00NTQ0MQ_ac833e70-7eee-4221-8621-28c87f2caede">9,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy03LTEtMS00NTQ0MQ_0115afbf-2658-48ba-98fd-f77f7069f0c7">575,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy05LTEtMS00NTQ0MQ_94a8da40-f5e0-4bc2-a770-8199aa850746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xMS0xLTEtNDU0NDE_63f622b9-4c5d-4b0f-b6d1-739640be28c1">240,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xMy0xLTEtNDU0NDE_39d4b0ce-812c-4b0c-94e0-39091548db77">334,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xLTEtMS00NTQ0MQ_7c0d1d05-0b71-46d4-aa7c-c587b335c0d5">237,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0zLTEtMS00NTQ0MQ_26fb4326-2ac3-46fb-ab3e-e02495e82d3a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC01LTEtMS00NTQ0MQ_bc2c5fe0-fb25-48d3-9571-5bf0bb07b468">2,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC03LTEtMS00NTQ0MQ_829d453f-bee4-49dc-9d5e-e671b3fa017e">235,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC05LTEtMS00NTQ0MQ_a3c3fab0-e428-4a52-8941-7610292eb007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xMS0xLTEtNDU0NDE_35404d8f-fe97-479c-b2a5-0e9b29fb3879">155,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8037f34da784a8da052f3d100568fdc_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xMy0xLTEtNDU0NDE_1b0d1d0b-b735-4289-aafd-6ac6f5cbbbb1">80,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xLTEtMS00NTQ0MQ_02492387-3179-4807-9efb-a5b6730e29f2">50,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0zLTEtMS00NTQ0MQ_1eebaba7-8ec1-4458-9b08-9e4a453dee3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS01LTEtMS00NTQ0MQ_e094056c-eb5c-4c97-b59c-97570aba2ab8">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS03LTEtMS00NTQ0MQ_56da068c-46a6-4cbb-a8ee-101c16ea4d59">50,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS05LTEtMS00NTQ0MQ_dde1b1a2-181e-4cab-8356-65d63da85682">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xMS0xLTEtNDU0NDE_a6820c59-571e-4f41-9eab-2f0b69ca2ae6">47,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475042e9abf7443a90e179783dd443f4_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xMy0xLTEtNDU0NDE_7265ee85-93e7-4a5d-a68f-f1a620b98c59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMS0xLTEtNDU0NDE_c94c32f6-b800-4540-980c-1c59b80251a9">51,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMy0xLTEtNDU0NDE_fab0d376-06f5-4961-ac29-4d8e697b01dc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtNS0xLTEtNDU0NDE_a95a9ed4-d810-4377-8494-1409406b2951">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtNy0xLTEtNDU0NDE_f2710f33-0113-48c0-9014-6397e3c83de2">51,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtOS0xLTEtNDU0NDE_a156cfce-36be-4787-879b-d700806e0a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMTEtMS0xLTQ1NDQx_38053745-4282-4e02-9712-1e41e2baeb45">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMTMtMS0xLTQ1NDQx_caabfd5b-d857-4d30-a4da-8b2553cc8846">47,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMS0xLTEtNDU0NDE_91e005f7-028c-4645-bb79-8c9f965a8f0f">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMy0xLTEtNDU0NDE_67d1b9a7-9e52-43f6-a1d1-928e758771d2">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtNS0xLTEtNDU0NDE_9eccb108-400f-492f-b9c4-99168a8d238a">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtNy0xLTEtNDU0NDE_66e28ce6-fc74-4737-a5fd-5889374b764d">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtOS0xLTEtNDU0NDE_41b7404d-d8e9-456b-8cbb-fc3b55ce495d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMTEtMS0xLTQ1NDQx_a55fe8fd-c1f3-414d-ab32-c6bf1856d281">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMTMtMS0xLTQ1NDQx_2b6569e7-7dda-4467-9e6c-3ad94e08a485">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMS0xLTEtNDU0NDE_f60339a6-6843-4a28-941b-fe7fd7618987">1,089,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMy0xLTEtNDU0NDE_a5a94339-477d-40b0-846f-a5d78d846280">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItNS0xLTEtNDU0NDE_f7cdd0c8-2df7-4b00-ac53-b9d31b146d88">12,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItNy0xLTEtNDU0NDE_caab1b6e-ee38-4ad7-8cec-2fd3d600021f">1,077,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItOS0xLTEtNDU0NDE_f97712a3-4dbf-4997-8323-aca3cc4ce02f">163,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMTEtMS0xLTQ1NDQx_c7a84e7f-e296-4ea7-87bf-caf896f756c3">450,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMTMtMS0xLTQ1NDQx_a93fa255-5470-4a80-bd1c-654c65bc1d96">462,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMS0xLTEtNDU0NDE_32e8f063-40ae-4ac3-ab0c-afabbfa3d571">1,531,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMy0xLTEtNDU0NDE_cf001c6a-29c9-4720-9f3d-e223fcaca4d3">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtNS0xLTEtNDU0NDE_2457b1a2-d70a-4018-bf25-f85b0186f841">12,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtNy0xLTEtNDU0NDE_faaae260-8af5-430d-862a-d3cfc57e19a8">1,519,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtOS0xLTEtNDU0NDE_110f1cfd-3ab8-4be6-9b98-d1b13d8921fc">605,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMTEtMS0xLTQ1NDQx_d9f58451-ebcb-4c9c-a6c4-38490b30e96d">450,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMTMtMS0xLTQ1NDQx_06345c87-9a18-414d-853e-b3096e7070b6">462,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xLTEtMS00NTQ0MQ_d99b40a5-2b5d-4b64-8da5-cb1d99c481ad">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0zLTEtMS00NTQ0MQ_dcdfef2d-8722-4e67-b971-7c9a4db18203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy01LTEtMS00NTQ0MQ_580ba105-5251-4fee-8545-b200a8c902a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy03LTEtMS00NTQ0MQ_96aec560-5ba9-4abb-9057-3224ed9adf19">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy05LTEtMS00NTQ0MQ_5e2060cc-1909-4cb5-9353-005bdc485046">301,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xMS0xLTEtNDU0NDE_fb31557f-6f50-4b10-9504-77a95f704824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xMy0xLTEtNDU0NDE_245b95bb-4515-4cb0-ab29-19b198bb34f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xLTEtMS00NTQ0MQ_3c5f528d-1bd8-414e-87ac-b53b3be1d4ec">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0zLTEtMS00NTQ0MQ_3e2c0407-a9c2-4ba4-86a7-1432f734b016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi01LTEtMS00NTQ0MQ_f041b863-ee5a-4f06-be42-851f96030e20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi03LTEtMS00NTQ0MQ_09099f55-da25-4e21-9847-d9add84609d3">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi05LTEtMS00NTQ0MQ_0c49a157-6881-4829-8067-a986f162c66b">285,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xMS0xLTEtNDU0NDE_dbbc1291-6134-42db-a1bb-a474583102ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xMy0xLTEtNDU0NDE_179d83fd-457b-462c-b391-cace7bee1279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xLTEtMS00NTQ0MQ_66e1656f-2c01-4796-85ba-83507dabfd6a">584,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0zLTEtMS00NTQ0MQ_1f8819ec-ef07-4e8d-b3e6-cdc2b896f790">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy01LTEtMS00NTQ0MQ_54795d56-b616-4c34-858b-be03a94ee373">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy03LTEtMS00NTQ0MQ_5dc3af72-e963-40fe-a12a-49d085305f70">582,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy05LTEtMS00NTQ0MQ_3696ab75-9b77-4520-9c96-a353bb6a7190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xMS0xLTEtNDU0NDE_0f161aab-e9bb-4802-88c1-88cdc55439a2">200,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xMy0xLTEtNDU0NDE_b81d9248-ea38-40a5-ab24-bd0f1ef50ab0">381,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xLTEtMS00NTQ0MQ_0fb0c7b7-b9f0-456a-a25d-08b4038592f0">224,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0zLTEtMS00NTQ0MQ_600ddaea-a02e-40c7-b76b-d1cfd78ab3dc">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS01LTEtMS00NTQ0MQ_dba688cd-0d4a-4376-94e8-ee897fa33cb9">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS03LTEtMS00NTQ0MQ_4310f972-9bae-4120-8498-d17d39341344">224,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS05LTEtMS00NTQ0MQ_c9918e99-bed7-4c70-8be0-021d414c028d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xMS0xLTEtNDU0NDE_832149a3-7450-4b3b-bb0b-5d7e2c8d69b0">146,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xMy0xLTEtNDU0NDE_57bdd425-122d-46f4-84e9-3b783c0cf534">78,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMS0xLTEtNDg3NTk_6e16cb29-561b-4d6b-8835-2ef429ccedba">68,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMy0xLTEtNDg3NTk_f47bf1ce-b925-4ac5-a50f-b56fa814c315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNS0xLTEtNDg3NTk_ae0d0e1d-f73c-42b2-9bf2-f547daf9f212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNy0xLTEtNDg3NTk_713e1be4-bc42-4345-8d66-72522382225a">68,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtOS0xLTEtNDg3NTk_88ac4964-0df0-40b8-a8bf-3db4d2385a4c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTEtMS0xLTQ4NzU5_516021c4-9463-467f-9a7a-f57a01f63943">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTMtMS0xLTQ4NzU5_973a69f4-2b7c-411f-8f08-6d332790ac02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMS0xLTEtNDU0NDE_5e189d75-a5fa-43b6-872b-808e6bf659f4">56,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMy0xLTEtNDU0NDE_82d438a1-ee06-4621-ad81-24018ebbded9">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNS0xLTEtNDU0NDE_fd5104f0-6b0b-449c-9880-d15534b68e0a">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNy0xLTEtNDU0NDE_88af5a02-e98a-49f4-98e7-8c5ea91d0aa0">56,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtOS0xLTEtNDU0NDE_d0e74895-af44-4259-99f9-0bd870cc5df2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTEtMS0xLTQ1NDQx_76548112-5770-4d96-869f-0a41e0ebbf44">9,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTMtMS0xLTQ1NDQx_b608a99a-2a75-4960-bb05-3e1a53ad9652">47,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMS0xLTEtNDU0NDE_35ffde7d-2477-4af6-8f86-bfbe7a2178db">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMy0xLTEtNDU0NDE_77a5e59e-dde7-4695-bb52-09d94ecb22d7">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtNS0xLTEtNDU0NDE_4b42cfbf-c96d-4fe1-a3b8-d4d01a42e140">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtNy0xLTEtNDU0NDE_c0874878-dd49-447e-a820-56d47439a832">3,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtOS0xLTEtNDU0NDE_3f061074-c983-4581-9f9e-0cb67d7d2c17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMTEtMS0xLTQ1NDQx_9cb3ed4f-46eb-4e2f-8842-acdd8f691ece">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376acb983838406dafef8389effeae4c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMTMtMS0xLTQ1NDQx_321f2e36-d7ea-4a5d-9cdc-e46f974d7bb3">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMS0xLTEtNDU0NDE_2f52c625-a93c-443e-ac2d-7629a93df8a2">1,222,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMy0xLTEtNDU0NDE_d9765520-7f7a-43f6-aec7-4bccb8945a29">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItNS0xLTEtNDU0NDE_7b2f2f2b-9cc2-4843-aacd-176c805af2ac">2,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItNy0xLTEtNDU0NDE_7755e1e1-d11b-4410-bfab-326f1ff7b60b">1,220,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItOS0xLTEtNDU0NDE_a7067699-578a-42a2-a852-2347f9b21b59">286,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMTEtMS0xLTQ1NDQx_73419e10-5021-4e3b-838a-fee534964cd5">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMTMtMS0xLTQ1NDQx_90ae6e35-aaa1-4166-ab62-4d9c86e6b9e5">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMS0xLTEtNDU0NDE_5d2c8693-5699-4cc3-b7de-d0ea8af10458">1,523,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMy0xLTEtNDU0NDE_b588bec7-4c3a-4613-8752-bb420393ebf8">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtNS0xLTEtNDU0NDE_4e206acb-29c8-49e3-81e8-859f36035c34">2,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtNy0xLTEtNDU0NDE_230e22d1-b776-4079-97a4-c07eac05c89c">1,521,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtOS0xLTEtNDU0NDE_152c1bf5-d7f4-4403-baae-88198deac09e">587,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMTEtMS0xLTQ1NDQx_82d1dd47-d753-411e-b9ad-5637de6173c4">426,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMTMtMS0xLTQ1NDQx_050ee5c1-f895-43d9-bf53-5b167716be27">507,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231" name="bmrn:ShortTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMzMz_278bea95-cda7-4718-a23c-50fbcd1ef547"><ix:nonNumeric contextRef="iadebcf821247497ba93eafb227624346_D20220101-20220331" name="bmrn:ShortTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMzMz_a4d09fd9-ed90-4ac2-903f-b6497850ec32">one year</ix:nonNumeric></ix:nonNumeric> or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1">one</span></span> and <ix:nonNumeric contextRef="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDE3_3b03ee9a-cf1f-4779-94e3-4a8875f5d5da"><ix:nonNumeric contextRef="iadebcf821247497ba93eafb227624346_D20220101-20220331" name="bmrn:LongTermMarketableSecuritiesMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDE3_4c8c71e9-89ba-4231-838f-c3a9cb25beac">five years</ix:nonNumeric></ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#8217;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ie9229898934d432bb495f985449db266">The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#8217;s strategic investments was $<ix:nonFraction unitRef="usd" contextRef="i8fd980138ba04ea4aa0bf850eba714f7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTI2Mg_4c440d78-ab59-4681-ae15-d427b951821b"><ix:nonFraction unitRef="usd" contextRef="i6ca8e30ed951424daed017118d432eef_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTI2Mg_f749d2cf-710c-45cd-b548-893a2013e826">16.5</ix:nonFraction></ix:nonFraction> million. These investments were recorded in Other Assets in the Company&#8217;s Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzNA_221e7947-25f6-4bbb-b061-32caf28eeed3" continuedAt="ie4f6dd0d0e5f4c9f876ea5124074be2e" escape="true">SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</ix:nonNumeric></span></div><ix:continuation id="ie4f6dd0d0e5f4c9f876ea5124074be2e" continuedAt="i4b35a0604c904892bd958818c179c179"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Balance Sheet Information </span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzMg_0be37cea-e89d-4ec7-9914-d063402676a9" escape="true"><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMS0xLTEtMS00NTQ0MQ_bb783ed1-535a-46c4-8614-603c6273e10b">92,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMS0zLTEtMS00NTQ0MQ_044d39c9-9b9f-41da-8b91-22b20aacb6cc">80,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMi0xLTEtMS00NTQ0MQ_fdaf6b40-365c-4dcc-876c-dd02dd24a52e">402,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMi0zLTEtMS00NTQ0MQ_f2be163f-10a7-46af-80ee-1a24b4227ab9">415,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMy0xLTEtMS00NTQ0MQ_3b4fcdf4-d638-44d2-b25e-a5c14a610d05">291,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMy0zLTEtMS00NTQ0MQ_11f9e2a5-642c-4afa-bd77-1630384d78e8">281,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfNC0xLTEtMS00NTQ0MQ_331275e7-d2c7-401e-bfdc-d93518e1b1b3">786,356</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfNC0zLTEtMS00NTQ0MQ_07e9d002-bcfb-468e-a78d-72890cfb2d24">776,669</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory as of March&#160;31, 2022, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $<ix:nonFraction unitRef="usd" contextRef="i9569970b087c446aaf59bf7e94224bd2_I20220331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY0OTI2NzQ0Nzc1OQ_93b70dc4-cd68-4402-8f28-92e27944b775">11.3</ix:nonFraction> million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the first quarter of 2022, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec by the European Medicines Agency had been significantly reduced and the Company expects to realize economic benefit in the future. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings and correspondence with the relevant regulatory authorities following the submission of the additional two-year follow-up safety and efficacy data requested by the regulatory agencies in the third quarter of 2020, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, and commercialization and marketplace trends.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#8217;s policies on inventory produced prior to regulatory approval.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzOQ_2a8e4479-7bb0-4d84-b4ad-29e3963e564b" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMS0xLTEtMS00NTQ0MQ_151cf821-557a-4830-b084-1116e7273569">1,780,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMS0zLTEtMS00NTQ0MQ_20c71c41-6456-46e6-979c-1e32b784b9bb">1,756,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMi0xLTEtMS00NTQ0MQ_cf5031bc-0e7c-403c-b5bd-db46ac0f7187">741,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMi0zLTEtMS00NTQ0MQ_8f064e3b-f888-4f1c-af55-b6207ce18234">720,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMy0xLTEtMS00NTQ0MQ_3f9ce954-575d-4c7e-ace3-101e56c2eba5">1,039,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMy0zLTEtMS00NTQ0MQ_72691516-e99d-4d05-82cb-965bc9674335">1,035,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense, net of amounts capitalized into inventory, for the three months ended March&#160;31, 2022 and March&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY1NQ_e3a7f5a6-74ea-48c8-988e-7865e0a50d67">11.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY0OTI2NzQ0NDgwNA_5d246303-d9ce-4c86-a403-96a2e33e3d58">12.5</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzMw_1b3ce909-e8fb-46df-b7f4-c7caaaa87fd5" continuedAt="id1f3725e6072467db6ca041e6b307c40" escape="true">Intangible Assets, Net consisted of the following:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="id1f3725e6072467db6ca041e6b307c40"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMS0xLTEtMS00NTQ0MQ_e477e628-4350-4d76-9e71-cb4e305227f7">678,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMS0zLTEtMS00NTQ0MQ_4a3d2d71-b09f-4abc-b358-72bcb7672f54">677,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMi0xLTEtMS00NTQ0MQ_bb9035a4-2897-406c-8bbe-50b738cb9009">304,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMi0zLTEtMS00NTQ0MQ_535fe139-5d50-4bb5-b9cd-7e4ab84fdb21">288,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMy0xLTEtMS00NTQ0MQ_d1ed0f25-eeb1-4fe6-aef1-3576e90409d3">374,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMy0zLTEtMS00NTQ0MQ_289916d2-c747-4656-92f7-9d11b3a65e0f">388,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i4b35a0604c904892bd958818c179c179"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzNg_0e5676dc-8fc1-4ad1-becd-96868f5b6301" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMS0xLTEtMS00NTQ0MQ_3bf365ee-5035-4073-9814-0b58514c0677">187,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMS0zLTEtMS00NTQ0MQ_c44847cb-f52a-4853-8723-d77ce25a428a">193,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMi0xLTEtMS00NTQ0MQ_2dca9c56-75b0-44ee-916c-a8636b27a87f">127,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMi0zLTEtMS00NTQ0MQ_3bffec36-1d97-485b-b2d0-343a47433eb4">204,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="bmrn:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMy0xLTEtMS00NTQ0MQ_2cb5b367-b9f7-4885-b4ea-8fda873255af">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="bmrn:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMy0zLTEtMS00NTQ0MQ_f60d264a-7b06-44aa-8702-14d088838f0f">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNC0xLTEtMS00NTQ0MQ_69418ad5-271c-45a3-8c81-2f145d06be7c">16,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNC0zLTEtMS00NTQ0MQ_a311af88-c624-46e4-8648-0f2f931b0e54">15,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNi0xLTEtMS00NTQ0MQ_4ffe5aa9-ed66-4a65-a9e2-e72c99e325f0">12,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNi0zLTEtMS00NTQ0MQ_43c59116-da1f-475c-a685-c2dbcb0de581">6,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNS0xLTEtMS00NTQ0MQ_c3276693-ed5d-4de5-936e-4b8242c0a510">10,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="bmrn:OperatingAndFinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNS0zLTEtMS00NTQ0MQ_4a2e3196-62a7-4d31-8587-5d46f4941189">10,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNy0xLTEtMS00NTQ0MQ_a0283a45-5539-4980-82f3-cfa1f5a08d4d">5,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNy0zLTEtMS00NTQ0MQ_db279cb4-b80b-42fa-8e11-51f5f4432487">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOC0xLTEtMS00NTQ0MQ_c54bf2b9-c1c4-44bd-b087-07e8e874bcd0">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOC0zLTEtMS00NTQ0MQ_87c6183e-dd5e-463d-ac30-c1cc48c551b0">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0xLTEtMS01MTg4OA_1dc994c5-af54-46ce-9632-f5628dbf8fe6">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0zLTEtMS01MTg4OA_989879ae-f66d-4099-8860-7e483f090e09">6,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0xLTEtMS00NTQ0MQ_6c50e91d-d9ea-44b4-b704-5da63906e493">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0zLTEtMS00NTQ0MQ_2ec3f720-6bdd-45df-9d66-efef6952d509">4,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMTAtMS0xLTEtNDU0NDE_e2a72322-2397-49aa-8b69-6356085e07c2">426,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMTAtMy0xLTEtNDU0NDE_c6002b3c-16f2-4b66-9091-755242ddc0c2">491,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Statement of Comprehensive Income Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on Sale of Nonfinancial Assets, Net in the first quarter of 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the FDA in connection with the U.S. approval of Voxzogo. As a result of the PRV sale, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMjE5OTAyMzI2MDA3Ng_da77f89a-0748-4cb0-b803-f502c01b0bd3">108.0</ix:nonFraction>&#160;million net gain on sale of nonfinancial assets in the Company's Consolidated Statement of Comprehensive Income.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE5Mg_07860636-b8a6-4194-926c-864e031076bc" continuedAt="ic5cbbc856fce41b281493628cb2e8419" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic5cbbc856fce41b281493628cb2e8419" continuedAt="iba1a2afde1264189a37503538ea474c9"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Business Overview and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE4Nw_bbbc3f81-5350-4e01-aa0c-b98833a5d6cc" continuedAt="ibf7d026b3f3d4446b1d0e950361842b0" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021.&#160;Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note 6 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="usd" contextRef="i11cc1a5725ab4723b0462ef1a3028473_I20211231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_1073be44-8ae5-4f52-8f1a-14f64d7067ac"><ix:nonFraction unitRef="usd" contextRef="i67c5cd0a2b524859bbb3035e15216170_I20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_697efc28-cd4e-417a-b329-778744ce8cd7"><ix:nonFraction unitRef="usd" contextRef="i11cc1a5725ab4723b0462ef1a3028473_I20211231" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_95fb2baa-a1b2-4324-b0fd-0955a0525980"><ix:nonFraction unitRef="usd" contextRef="i67c5cd0a2b524859bbb3035e15216170_I20220331" decimals="INF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_96644de1-d0e7-466a-bb14-0c7eb5df7310">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of March&#160;31, 2022 or December&#160;31, 2021.</span></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="iba1a2afde1264189a37503538ea474c9" continuedAt="i550e91978a2842269d05be80adf8bf9f"><ix:continuation id="ibf7d026b3f3d4446b1d0e950361842b0"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4c0ea303bc4617bff30b97f3119d8a_I20220331" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC0yLTEtMS00NTQ0MQ_32abf80d-8f7a-4c1a-b1e0-0d8b1dd09f87">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac071ae2357499a807f15a7c6d7c22d_I20220331" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC00LTEtMS00NTQ0MQ_a3d98e62-a524-43b1-be11-a89db3e47743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC02LTEtMS00NTQ0MQ_03e085ce-ec9e-442f-b3b5-5890eba5d6aa">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4c0ea303bc4617bff30b97f3119d8a_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy0yLTEtMS00NTQ0MQ_23787584-2182-47cb-ae65-f89399ccbd83">22,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac071ae2357499a807f15a7c6d7c22d_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy00LTEtMS00NTQ0MQ_b8922acd-609f-4589-95f1-62b4c657352b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy02LTEtMS00NTQ0MQ_0c0648ca-69ba-4743-b305-58320c6461da">22,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea9395534ba42e3a0190935fdfbb79d_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC0yLTEtMS00NTQ0MQ_84a31a84-d92c-465c-b2d4-f792ea5c8c85">2,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06e40f8e2ee4cf4a3d50677fc6227a2_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC00LTEtMS00NTQ0MQ_693a4f1b-1dd3-4684-be31-23b2f59019f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67fb8408fad4a14a69938859aaf1ffe_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC02LTEtMS00NTQ0MQ_21b1e65e-b4d4-427a-a44c-5f94f1dc4da1">2,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS0yLTEtMS00NTQ0MQ_70dba730-7512-4015-8dd1-d43cfba24518">24,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS00LTEtMS00NTQ0MQ_65bcbd63-2f7f-46d4-92a8-3979ebabb56e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS02LTEtMS00NTQ0MQ_0078ef9f-1069-4a65-a96d-049a93634547">24,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtMi0xLTEtNDU0NDE_eb5ecd11-4916-4b21-90aa-a76c5f11d57f">27,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtNC0xLTEtNDU0NDE_cb83f729-ba08-4dd6-82ab-67b2dcd4689d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtNi0xLTEtNDU0NDE_2a74acc1-d6e9-476d-9b23-4315308cc6ef">27,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeee18ee6d494c7790cf41fe0038c831_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtMi0xLTEtNDU0NDE_e7f3c1d2-7710-4dc1-97c1-45bb1749db7e">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id262761c1fad424b90e86b74ae146097_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtNC0xLTEtNDU0NDE_c587b482-c101-4d50-b36c-f8d545f4096a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98efc0e12da4354a0d424854f64af5c_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtNi0xLTEtNDU0NDE_f0f93bf8-4b99-4e45-a653-2be282021513">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a1cedc9eed4bfab32ee8743471c711_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtMi0xLTEtNDU0NDE_78863775-5fcf-411c-9aa6-89d6da3e1f9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia462eb49aaaf40e997e1a56cd4ffe090_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtNC0xLTEtNDU0NDE_cb7029f8-997c-4cbd-9047-0b29c8b5d4db">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478e66d57d4645caa9b700a5fd1ef8eb_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtNi0xLTEtNDU0NDE_32eb5358-5c0f-40d6-a110-693c3f9700d4">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtMi0xLTEtNDU0NDE_28e216d0-98aa-4029-809f-8afa68676859">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtNC0xLTEtNDU0NDE_45f28e7f-45d0-442d-9467-56df137ab08f">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtNi0xLTEtNDU0NDE_3ec27114-481e-4e67-b6db-10efe8aaf7f5">66,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeee18ee6d494c7790cf41fe0038c831_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctMi0xLTEtNDU0NDE_487db7a2-98e0-4dba-bdbf-551a6af7f54e">22,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id262761c1fad424b90e86b74ae146097_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctNC0xLTEtNDU0NDE_b2812c41-0251-40d5-ae05-a2ba191e5cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98efc0e12da4354a0d424854f64af5c_I20220331" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctNi0xLTEtNDU0NDE_a4e88312-fdd8-450d-95a0-f610fc7931d5">22,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtMi0xLTEtNDU0NDE_aa703837-3ff6-45ca-b3f8-6d41a34f88ff">25,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtNC0xLTEtNDU0NDE_b561e5ba-821a-4a92-aebf-952fccb0e951">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtNi0xLTEtNDU0NDE_a3a20478-ce82-43e7-8b2f-041d5b6b965c">89,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.917%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cd46ba90ab490ab24b52d5a3097a86_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC0zLTEtMS00NTQ0MQ_750547e6-9aee-4afa-99d9-4af90824886a">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7475279edad54e10a67e1ba4a06c239c_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC01LTEtMS00NTQ0MQ_3fa20f3d-f8c7-4044-8711-85dcb94c67d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9059f91d0ea641c8a3ca5f6af90239be_I20211231" decimals="-3" name="bmrn:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC03LTEtMS00NTQ0MQ_1b7b082f-5b83-4ae1-8a09-93b8bc7014b6">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cd46ba90ab490ab24b52d5a3097a86_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC0zLTEtMS00NTQ0MQ_c2dda3c3-b944-4680-92a6-5f0985f620a6">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7475279edad54e10a67e1ba4a06c239c_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC01LTEtMS00NTQ0MQ_1cdba1a2-2610-4e53-9c3c-eac8d978bc1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9059f91d0ea641c8a3ca5f6af90239be_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC03LTEtMS00NTQ0MQ_bc47b224-37db-4ef7-9fd2-9c525c55905d">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1bbedcd77d4d4e9132645838dec1f9_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS0zLTEtMS00NTQ0MQ_69fe7320-3f86-4ea2-9af3-d4240cb39ee0">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b2a564c9924e1593e108f04e0e05fe_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS01LTEtMS00NTQ0MQ_7cbd79d6-e586-481f-a149-51578e6f8b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27016ee9414a53ac394d4ec7659333_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS03LTEtMS00NTQ0MQ_24be4c54-1117-451e-a3e3-bbe636401b23">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtMy0xLTEtNDU0NDE_f7ea6ed8-3cde-44a6-a610-8300b65a263c">26,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtNS0xLTEtNDU0NDE_19ea1253-7368-4bac-8362-504f343cc031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231" decimals="-3" name="bmrn:OtherAssetsNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtNy0xLTEtNDU0NDE_bdffa70d-2126-401a-9284-a55b1e861b25">26,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItMy0xLTEtNDU0NDE_268e2e9b-51ce-47ab-9126-166fba93cd88">28,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItNS0xLTEtNDU0NDE_842ba45e-77a5-40ef-a967-9f687f37d7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItNy0xLTEtNDU0NDE_fb6d248c-bbe1-47c3-a182-e737380dcedc">28,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtMy0xLTEtNDU0NDE_1da15873-7d6e-4aa3-b717-68613b0d1ccd">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f94a349524435963ac9c426ebd9da_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtNS0xLTEtNDU0NDE_a55bbad8-b660-4cf3-af34-40127164b3d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8e222c468d40d181487297a7c0cbd4_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtNy0xLTEtNDU0NDE_1cf14f2d-72a0-40f9-8b98-4a688701ecb4">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6783e8d375468bb371c65e2e9858b9_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtMy0xLTEtNDU0NDE_cdd784ef-aaaf-45ff-97b3-3884c2bff97d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b5097a4704fd29443d8189ff20cfc_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtNS0xLTEtNDU0NDE_94a59982-659a-44ca-ac88-e8fc0deebfc5">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c8c6419414c7397306df2567d9a10_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtNy0xLTEtNDU0NDE_440465bb-1588-4c84-9469-22d9b5cd0898">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctMy0xLTEtNDU0NDE_c27a4b2c-f276-4ad8-8a83-8e4be39f23c4">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctNS0xLTEtNDU0NDE_89d4f0d4-e8ba-4e76-9eef-52299af3a5af">48,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctNy0xLTEtNDU0NDE_123990cd-6886-49c5-972d-258ef901c913">50,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktMy0xLTEtNDU0NDE_7907db74-1d91-4beb-98e2-39e5aaeec6fe">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f94a349524435963ac9c426ebd9da_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktNS0xLTEtNDU0NDE_7a2a2dff-99c4-4dd6-9ea0-9b0984202dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8e222c468d40d181487297a7c0cbd4_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktNy0xLTEtNDU0NDE_3b210bd8-8f77-4152-a42b-a497983d7100">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6783e8d375468bb371c65e2e9858b9_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtMy0xLTEtNDU0NDE_cbde504c-cbd7-4c2b-9e5c-800bae7dcdd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b5097a4704fd29443d8189ff20cfc_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtNS0xLTEtNDU0NDE_a95253ad-a306-4373-9e35-a12561859cf6">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c8c6419414c7397306df2567d9a10_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtNy0xLTEtNDU0NDE_9585abcf-48a9-429a-af6f-9b85b9720c8e">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtMy0xLTEtNDU0NDE_8dd67e03-0a5b-45d0-902f-022d85adb69b">23,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtNS0xLTEtNDU0NDE_52dfbdcb-185a-4aed-8868-f721d36d5fbc">15,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231" decimals="-3" name="bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtNy0xLTEtNDU0NDE_da914f3d-dec3-4c5d-a202-df69c970ac35">39,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItMy0xLTEtNDU0NDE_19ba8020-91b2-4303-b1a6-47343422ef89">25,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItNS0xLTEtNDU0NDE_d91e2ea8-03e4-46c4-a702-df04705a3d21">63,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItNy0xLTEtNDU0NDE_31ca2359-7f91-4ae4-8ff0-0d655d32b3d2">89,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The restricted investments at March&#160;31, 2022 and December&#160;31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the three months ended March&#160;31, 2022.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i550e91978a2842269d05be80adf8bf9f"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE4OA_000c38a4-a2b7-4625-b612-67b84e6f6583" continuedAt="i62e7b0af389646f581e00b4fc976157e" escape="true">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:continuation id="i62e7b0af389646f581e00b4fc976157e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3e175895dd4eddaf85bea4d5710175_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMC0xLTEtMS00NTQ0MQ_157ae862-d9be-4dc2-9297-17fe0a5393cf">63,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMS0xLTEtMS00NTQ0MQ_63936dd9-303a-467e-a6eb-cf0cdb8284a6">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331" decimals="-3" sign="-" name="bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMi0xLTEtMS00NTQ0MQ_b99b8f5c-91fa-4552-886d-abc66a54736c">1,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8702f41faa34d58a58f591cc29c5186_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMy0xLTEtMS00NTQ0MQ_50133a87-ff36-42c3-b2ba-185c7b21c4f3">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxNQ_8a298d7f-6959-4f16-bda2-26b9fb82139b" continuedAt="i75fd62b378bd4502adae8936f38f7d9a" escape="true">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</ix:nonNumeric></span></div><ix:continuation id="i75fd62b378bd4502adae8936f38f7d9a" continuedAt="iad5498475c28463f8800ee6269acb2bd"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange forward contracts (forward contracts) to protect against the reduction in value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to <ix:nonNumeric contextRef="i24a67b5f17b74d8d875e70d77ac24e0a_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfNDcz_11118d39-154e-4a5d-97d8-4bd4478aacb5">one year, nine months</ix:nonNumeric>. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to <ix:nonNumeric contextRef="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfNzcw_1f9c0384-56da-46ac-bd4c-8ecab369d33d">three months</ix:nonNumeric>. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxMQ_9f60ddd4-58cc-4d4d-8c25-a367de985497" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb2fa6470f64208b9cca9caed841242_I20220331" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMi0xLTEtMS00NTQ0MQ_02460b57-8463-49d5-88cc-0876fe00cac1">650,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10323adbf43747cc8e67c4d6d61a7601_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMi0zLTEtMS00NTQ0MQ_bf458bf8-35cd-4108-aeb4-ee5b0583afd8">740,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d9103e14e34a25a637947fb0294c86_I20220331" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMy0xLTEtMS00NTQ0MQ_565a3122-6a14-4498-afbc-3a2fac1e7be2">147,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied746eb100554a6386b2c27894ffc0e4_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMy0zLTEtMS00NTQ0MQ_20775108-b09b-490c-aaf8-fdb42ce35bdb">183,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693b3a7b97e1437ebca5874be75ea456_I20220331" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNi0xLTEtMS00NTQ0MQ_b0281739-d83e-4611-bce0-e8601829e0dc">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82a5008ad32467abe48f8d161ab8af8_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNi0zLTEtMS00NTQ0MQ_6841c87c-44a8-41c2-8163-06cda086ad0b">113,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73022b6d871f47e28feede850e27c229_I20220331" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNy0xLTEtMS00NTQ0MQ_826b596f-3ab2-4b7d-9b19-2619205fe0de">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e5ec0991924f7c96ecf3ccf3bb217f_I20211231" decimals="-3" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNy0zLTEtMS00NTQ0MQ_e48bc032-c00c-4964-b4e3-d0f38a367694">31,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="iad5498475c28463f8800ee6269acb2bd"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxMw_803743d2-8f6f-45ef-bbb1-d9a655da3b00" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0d508ddf7e40db989b324877ca4949_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMy0xLTEtMS00NTQ0MQ_9eacc1b4-ad8c-46a1-bb28-2b547dc5f0f5">20,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28b615c8a794db39d946b9acae01f69_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMy0zLTEtMS00NTQ0MQ_e074d842-72f6-4d27-8c32-dfeaa03f7ae0">17,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27917553b8fd4dfbac5fe095c7b4bde6_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNC0xLTEtMS00NTQ0MQ_594b13ae-d4a0-4c9c-917a-e95574657e1e">3,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06dfaccfdbe46caac6458766a03b73f_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNC0zLTEtMS00NTQ0MQ_a8ee0037-3ae2-4a2c-95a7-06b4f647715e">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7f9f8463ea496caae776a4ddbd016b_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNS0xLTEtMS00NTQ0MQ_fbde6bfd-da57-47d8-82c3-809e0201f4ac">24,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021baed86234498eaefce274645b825b_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNS0zLTEtMS00NTQ0MQ_a6fad16f-b99b-45d2-98e0-03c193df746d">22,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9174aac2384a699993569e2b6eb445_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOC0xLTEtMS00NTQ0MQ_23451751-f785-41a8-9aec-01975610c18f">12,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f2f900f6b144a0975d6dc3d49144ac_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOC0zLTEtMS00NTQ0MQ_a2af7fa0-7da7-40ab-af95-7d9b6bccdac9">5,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5618c6fb44d74a64909673a57923b8ff_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOS0xLTEtMS00NTQ0MQ_41a6448d-6271-4468-b8ac-c5f10f599cd6">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3985bd1ab09f4ea0bbe878344b3713b2_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOS0zLTEtMS00NTQ0MQ_509fa542-1cbf-467d-9b83-5ccb49d89313">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7f9f8463ea496caae776a4ddbd016b_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTAtMS0xLTEtNDU0NDE_0a31cf50-adc6-4ae9-83ff-3283c4c2002a">15,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021baed86234498eaefce274645b825b_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTAtMy0xLTEtNDU0NDE_a3651e1b-8c22-4d44-9185-e023a34a1ecb">6,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1adb2627443a447f8c92c839abeda3a7_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTQtMS0xLTEtNDU0NDE_d7d6c313-7ac3-41f0-8f81-0394bc07e2ab">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482d5788d5874458a97a7e25c5406e22_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTQtMy0xLTEtNDU0NDE_d17a777e-79c9-40cb-a3ee-3025f676b8a3">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125b9e8420b44a9498f4af3776f779da_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTgtMS0xLTEtNDU0NDE_9157f81c-af45-4692-9a13-aba9814dd198">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d039887887e460290fb9430275f52d1_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTgtMy0xLTEtNDU0NDE_7c509c61-6c1a-4f9c-a034-a5e3aa5a2e1a">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjItMS0xLTEtNDU0NDE_7af95e13-e9bf-4759-9c88-76a52f7b09dc">24,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjItMy0xLTEtNDU0NDE_e1710900-ef13-4ff1-acce-1b304608d8a6">22,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjMtMS0xLTEtNDU0NDE_432825df-b73a-4703-b50e-3c98e3403625">15,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjMtMy0xLTEtNDU0NDE_7e277982-af2f-41e1-a052-0cdec15c3298">7,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIwOQ_4735723f-5316-4d6e-95e9-947483fd3882" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC0xLTEtMS00NTQ0MQ_9875c97f-2f7d-4833-ac47-8eb4a23508cb">505,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5119ab19f704add84d831075c4fe20f_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC0zLTEtMS00NTQ0MQ_99e0d7b7-d2c2-4430-b8f3-d8f3f7f43692">5,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC01LTEtMS00NTQ0MQ_23240146-33bf-41a6-b58c-c72f99dfe38d">467,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30d6f7853643148004a14e6c5d0fdb_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC03LTEtMS00NTQ0MQ_efe5218e-7b57-41d5-91ad-937c438fbe63">2,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS0xLTEtMS00NTQ0MQ_954d5577-3686-4a08-8b24-b8d40796e2a7">382,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c517e48e00e4becb6f7ce5b1310c741_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS0zLTEtMS00NTQ0MQ_b038c1c1-6f15-4e33-b802-ce15aba4c099">1,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS01LTEtMS00NTQ0MQ_1c1b2622-c5c4-4f73-88fc-8d0936383647">460,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3fbdd624724d3d85d457df11a2b0ec_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS03LTEtMS00NTQ0MQ_9d8d3219-c017-41fa-b2d3-f2c6e1f9a40b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfOC0zLTEtMS00NTQ0MQ_edaeb304-1158-4e1d-9c84-21afd35f9dd0">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa52acc498d4cdab18b97d9c59c01b9_D20210101-20210331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfOC03LTEtMS00NTQ0MQ_eaa2d614-23c6-4aaa-83ee-e1c8e9ebceb3">4,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company expects to reclassify unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-5" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMTk1MA_a3dc2951-5f4f-4c9b-92e2-9370183b3eee">7.6</ix:nonFraction> million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:15pt;text-indent:45pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc1OA_79cbacd7-0000-4fc1-8f81-bb15f048c0c3" continuedAt="i12a25e7a23714bbbb83d740b2f7fd4eb" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="i12a25e7a23714bbbb83d740b2f7fd4eb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTYx_16fd4442-c357-4c0a-8926-62b02025521e">1.1</ix:nonFraction> billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc2MA_59d3859f-7b56-4515-b239-e6a485aebc79" continuedAt="i76080f546dcf42aa89234e209ec3669d" escape="true">The following table summarizes information regarding the Company&#8217;s convertible debt:</ix:nonNumeric></span></div><ix:continuation id="i76080f546dcf42aa89234e209ec3669d"><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjNkMzczYTk3ZDdkMzRmZjM4MjlkOGU4ODMxZWNlMDA4XzQ_372e102e-8f10-4374-b9e8-0ac6ae9f728d"><ix:nonFraction unitRef="number" contextRef="id0331cf243884e099d67f815a061dcd2_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjNkMzczYTk3ZDdkMzRmZjM4MjlkOGU4ODMxZWNlMDA4XzQ_66e6c854-339a-4c46-bd7d-bb4aeb26ced2">1.25</ix:nonFraction></ix:nonFraction>% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0331cf243884e099d67f815a061dcd2_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0xLTEtMS00NTQ0MQ_d63c35b1-20a5-4d05-b90c-cc391d804873">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0zLTEtMS00NTQ0MQ_afe235d9-8c0a-4e65-b79c-32d9beb83ee7">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0331cf243884e099d67f815a061dcd2_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMi0xLTEtMS00NTQ0MQ_21515feb-70f7-4373-bf10-2393e3271750">10,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMi0zLTEtMS00NTQ0MQ_e71d8182-3dc4-4f11-8c94-6b29a8a2c44f">10,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0331cf243884e099d67f815a061dcd2_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMy0xLTEtMS00NTQ0MQ_3980b374-e7ca-4935-a2f6-c546f6ef61ee">589,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMy0zLTEtMS00NTQ0MQ_68db228f-8de1-46ed-ba9b-ae7cf073e89b">589,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjIwNTM3MDk5MTZmYTRlZDRhN2MzODRjYTgyOWQxOTE0XzQ_5488deaa-888a-46dc-bfb0-4436478145ed"><ix:nonFraction unitRef="number" contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjIwNTM3MDk5MTZmYTRlZDRhN2MzODRjYTgyOWQxOTE0XzQ_c79344cb-8d08-4409-a40c-b21dd4826b21">0.599</ix:nonFraction></ix:nonFraction>% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0xLTEtMS00NTQ0MQ_31b2ebaf-9bc1-474a-96f9-1f73b80be05f">495,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0zLTEtMS00NTQ0MQ_a535eab7-9107-46c4-b7ce-038239264bda">495,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNi0xLTEtMS00NTQ0MQ_4c2d90b7-218a-435e-8403-3899abe5ce49">4,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNi0zLTEtMS00NTQ0MQ_0f18b940-cebe-436b-b821-5553a3ea79ae">4,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNy0xLTEtMS00NTQ0MQ_2b9e4723-aff4-4363-85dc-2b2bf7f8f1b6">490,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNy0zLTEtMS00NTQ0MQ_21763353-00aa-4722-b4dc-79324e82ddbe">490,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfOS0xLTEtMS00NTQ0MQ_e512a572-2f45-4193-8820-16696f91a1bf">1,080,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfOS0zLTEtMS00NTQ0MQ_a93d0698-a3c2-4663-bf57-12ec2bdc4d18">1,079,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0331cf243884e099d67f815a061dcd2_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTItMS0xLTEtNDU0NDE_dfb6f355-7b75-4f0f-9f7a-20928d349106">604,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTItMy0xLTEtNDU0NDE_4778d231-6410-4422-aad4-4b976bf63e1e">625,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTMtMS0xLTEtNDU0NDE_c4d34bda-5c02-427a-abe6-52880a61ab48">497,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTMtMy0xLTEtNDU0NDE_8ba9b96e-e627-4468-923d-4be20ac1c825">521,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTQtMS0xLTEtNDU0NDE_3c3f70b1-a592-49f5-8238-c970a950dca2">1,101,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63654500f0694941a974905d3087a5ea_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTQtMy0xLTEtNDU0NDE_008fd81c-69b7-4ded-bfe0-f2c89068cf57">1,146,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The fair value of the Company&#8217;s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc2Mw_1de6a6dc-7d9f-41ad-887e-93dba88220c9" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s convertible debt consisted of the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.716%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMi01LTEtMS00NTQ0MQ_3fc9358a-b12e-4689-b4f6-318b686b0a07">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMi03LTEtMS00NTQ0MQ_43a6f7ea-5cdf-4c4b-ae79-c63ef889e4a8">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMy01LTEtMS00NTQ0MQ_79d52430-62e1-4a51-aa45-e26d1b658554">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMy03LTEtMS00NTQ0MQ_dc0663d5-6245-46de-b770-67cd309c0882">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNC01LTEtMS00NTQ0MQ_d635a963-74ba-4206-bb5a-d515e668534c">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNC03LTEtMS00NTQ0MQ_c1f45995-85e8-402a-8480-0e3e22bd0bb4">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNS01LTEtMS00NTQ0MQ_0a479330-2bd3-4343-bc39-9b20f978e339">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNS03LTEtMS00NTQ0MQ_5e0e2391-f49c-4fb3-8b48-c71f1d0fae64">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 10 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#8217;s convertible debt.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="i9a61fb3318b44b2ba23a29e3998e0700_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTA4OA_d54569c9-80f6-40cc-aa01-ef125a647cfa">200.0</ix:nonFraction>&#160;million which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of March&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="id8cf35d33be44d27a7f0d3b047d0f271_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTU5OA_1bd26540-154e-4458-b431-d0a5811d0cf1">no</ix:nonFraction> amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RleHRyZWdpb246YjkyYjg3ZWJiNmRmNGM2OGFhZGFiZThkMmU3ODllZjFfNDQ2_977aac50-0a67-43e4-afe4-726d905f18ec" continuedAt="i5a971440c66f491dbec483947b83bbbe" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</ix:nonNumeric></span></div><ix:continuation id="i5a971440c66f491dbec483947b83bbbe"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RleHRyZWdpb246YjkyYjg3ZWJiNmRmNGM2OGFhZGFiZThkMmU3ODllZjFfNDUw_4337e36c-67df-4668-bd0d-1e447754c2af" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3059cd10734ed783cd2d2634b0d82b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi0xLTEtMS00NTQ0MQ_a1b967dc-ace2-4684-9bc2-3a9f8b4a129e">15,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99b1717d96134283ae50ccf10e9f13ca_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi0zLTEtMS00NTQ0MQ_4ffa53d3-7d7e-4281-af7f-1d0c9819d205">1,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e50effa4c044d1a1f56b02b147b183_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi03LTEtMS00NTQ0MQ_9d73fb43-fadd-48e1-8204-cfe829b31301">14,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy0xLTEtMS00NTQ0MQ_92d41021-d552-4370-9489-f548bdda470c">3,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy0zLTEtMS00NTQ0MQ_595451bb-1195-4a26-95d0-459b4efeb31b">10,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy03LTEtMS00NTQ0MQ_7ef21d19-f3a0-436a-8e17-e87df91d73d9">13,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC0xLTEtMS00NTQ0MQ_803b89d9-83bd-4c7a-b5d1-cf953da162fa">4,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC0zLTEtMS00NTQ0MQ_1e1aa4fb-e311-4e7d-bf4f-52b7342dee41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC03LTEtMS00NTQ0MQ_1c2b49da-1c72-4f9f-b7ac-94ddb33a7988">4,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS0xLTEtMS00NTQ0MQ_259f36a1-3a27-4b73-a1f9-671cb294d55c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS0zLTEtMS00NTQ0MQ_06198eb7-175b-4b5e-b935-022e0b0c2df6">2,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS03LTEtMS00NTQ0MQ_5739eb2d-1811-4be2-a253-1bb3a51e7804">2,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi0xLTEtMS00NTQ0MQ_5c58e35f-72ac-4c51-8025-e63d49d8d17a">7,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi0zLTEtMS00NTQ0MQ_d74cd268-7ef8-4ec3-81c9-f2e8b5018b13">7,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi03LTEtMS00NTQ0MQ_e17d13f7-9142-4bdc-ab5d-6584e6ec45d0">15,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c3fc76077b46a996c89411439fc65e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy0xLTEtMS00NTQ0MQ_bf489644-7ba2-48c5-85e0-f8ade36363e0">8,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d46d1b4201e4019aa70b698c03d7415_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy0zLTEtMS00NTQ0MQ_5aba5235-60fa-463e-b6ea-f9925af93072">9,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7db0e866934747a0ef27975afd832f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy03LTEtMS00NTQ0MQ_0fff3cef-8da0-4b08-ba53-30371a345dbb">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f51f53032a84b1b89b05ca56aa74445_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi0xLTEtMS00NTQ0MQ_a647c71b-66d2-41e5-ae09-e86e0b1a788e">20,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840b2f2e120540f98c612afa3ec823f1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi0zLTEtMS00NTQ0MQ_23013fb7-e777-4e9d-ab54-d530bda20ece">3,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65140d9974ff4879ad2575de4f85ba00_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi03LTEtMS00NTQ0MQ_9dd5edbb-3b52-427a-b358-11d6bd4cad77">16,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy0xLTEtMS00NTQ0MQ_c8dab8f0-a5a3-4572-a97a-f98014167c09">19,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy0zLTEtMS00NTQ0MQ_b34692f4-95f6-413d-a4b7-2af3200c4691">1,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy03LTEtMS00NTQ0MQ_90c19534-e489-4e41-93e0-5f41a8e825b5">17,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC0xLTEtMS00NTQ0MQ_c6cd8107-8252-4152-9660-a1a93f6424b2">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC0zLTEtMS00NTQ0MQ_c4ce5212-1081-4de9-8b08-bb21cb279183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC03LTEtMS00NTQ0MQ_7c924852-a4c7-4abe-bf4b-5a9d3738fc9c">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS0xLTEtMS00NTQ0MQ_6e475122-073e-4aa3-b402-80afc338e8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS0zLTEtMS00NTQ0MQ_8feceaae-5f75-4f92-a354-6007a527fc43">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS03LTEtMS00NTQ0MQ_b48c19bc-1934-4f71-8466-54ff211f5846">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi0xLTEtMS00NTQ0MQ_1ce9bb32-4ca0-409e-a546-97f7fd8d4dfa">22,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi0zLTEtMS00NTQ0MQ_ad6f1070-11a0-4ee2-94d7-5a8aebc6679c">1,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi03LTEtMS00NTQ0MQ_29d96e8a-d559-4616-a0cb-55490d67842e">21,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4c4bfebe294de7b1a98930ea9835b9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy0xLTEtMS00NTQ0MQ_3367f6ba-fb5f-4234-8583-f8b7ba51acd2">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01504b7547d48c29809551d9fa94665_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy0zLTEtMS00NTQ0MQ_0f5144b6-ef00-4e89-8fff-47280fa422e2">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3649606ceb74fcf8df8cc4b91928646_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy03LTEtMS00NTQ0MQ_0ee49a34-d08c-4566-be2f-bf82e2ae9d9c">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For additional discussion of reclassifications from AOCI see Note 5 &#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Derivative Instruments and Hedging Strategies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQzNw_c6125b46-416a-4aca-a41f-1012b48ec4cc" continuedAt="i96c4bdc895c64c4b9ac021789eb55d0e" escape="true">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i96c4bdc895c64c4b9ac021789eb55d0e" continuedAt="ie1c74f0eda2b474793ad2aa5ed22e74a"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY0OTI2NzQ0ODUwNg_69eac079-c990-4937-b7b0-57399ef712c9">one</ix:nonFraction> business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQ0Mg_3ab6bb3d-1fb9-458c-897f-fed3e4c23bc4" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates total Net Product Revenues by product.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.739%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74a170ac59147cca285f25489fe3660_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMy01LTEtMS00NTQ0MQ_8906ef14-bac7-470b-99b3-9e3f80c3761a">183,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc468e5fd8a42e2b1558768f37e6571_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMy03LTEtMS00NTQ0MQ_282d2a5c-12c5-4094-a4a5-6ca166b220f7">158,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ef15ea138648cca1e80f4d3e259dc9_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNC01LTEtMS00NTQ0MQ_9ceff8cb-eb6c-4141-afd6-68f0a5160213">128,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5c489de8f841848c2154b45041d920_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNC03LTEtMS00NTQ0MQ_31e0d814-9e74-427b-abd8-6556cdedbb87">107,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491df707a2b5489fb420d6bc1f228e19_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNS01LTEtMS00NTQ0MQ_be500fc9-dbef-4afe-88c1-5f18726ee32d">59,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89eb3a13235f4740a02e03ada4aacecf_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNS03LTEtMS00NTQ0MQ_3ceeb12c-a27b-4197-a478-658ed5d8a498">70,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie708c87270e9415c898a4aeae0af25bd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNi01LTEtMS00NTQ0MQ_e965b79b-20b0-4947-8ae1-dc0da345c69e">54,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895d2189edd943fdadd1d2c44e8fa735_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNi03LTEtMS00NTQ0MQ_dea9c83c-fa87-4ba2-abc4-d54e501de434">54,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d78c3903b24697b01c59cc20ff5358_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNy01LTEtMS00NTQ0MQ_666cba5d-24d2-4e44-a66c-8a1e1db33978">36,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20640d60dab64a039c473a7175a0a267_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNy03LTEtMS00NTQ0MQ_35018147-330d-4f14-a0f2-ab4b418e540c">27,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594041ae57af40ccab0c62019799787e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfOC01LTEtMS00NTQ0MQ_879b479b-7ea2-478a-bb4d-fd5619a928bc">19,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b892fdeb6e14ef287c0f6a538ac8c13_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfOC03LTEtMS00NTQ0MQ_6863c844-19a5-4d6a-bacf-b9dfeaf04327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1103deb96054b26b048779411774904_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTAtNS0xLTEtNDU0NDE_6c6478fe-1d9a-4e11-9224-ee7581841e1e">481,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTAtNy0xLTEtNDU0NDE_6c7683c4-f87a-42f5-a507-ccc0bd0839ab">417,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTEtNS0xLTEtNDU0NDE_769c5627-307e-4b7b-8844-dce05df594b1">24,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTEtNy0xLTEtNDU0NDE_a8ec6110-89f0-49b7-9468-13cf048784a9">50,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNS0xLTEtNDU0NDE_7b91a65a-579a-4a64-88be-bbf68ad5799e">505,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNy0xLTEtNDU0NDE_c40ff62c-c8e2-472a-aaa7-dc3a012fad5f">467,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87ec807037b48a1827df1aaa0055934_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNS0xLTEtNTEwMTM_7ec9cb8a-0e1f-4aa4-9b78-3cda581d90f3">13,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNy0xLTEtNTEwMTM_eb0981b4-eb3d-4b2f-87f7-f06d3677efa7">18,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTMtNS0xLTEtNTEwMTM_0bc393ee-ba35-4878-a835-646ca94e4431">519,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTMtNy0xLTEtNTEwMTM_2aa1bf94-2d99-40cd-9c59-885034a017c5">486,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#8217;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#8217;s revenues and results of operations if sales in the respective regions experience difficulties. <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQ0NA_e93e9cf6-4ee1-44c8-954f-827b9b8fb8d8" continuedAt="i896254f98e90474cbb035a55624a1aec" escape="true">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i896254f98e90474cbb035a55624a1aec"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.026%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9f090883124d2198ad6215aa997c28_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi01LTEtMS01NDMwOQ_36d6ecf6-411a-4e08-aa4f-fe017447f371">156,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff03d00b5648269908ec5e62655bb4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi03LTEtMS01NDMwOQ_0c9e350d-4515-4c86-bdeb-b3640fd60149">148,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id742c4f384be442b8fca74da0bbbaa4e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi01LTEtMS00NTQ0MQ_315f08c5-6770-4bc8-8d6c-af821ae70167">150,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4557550c4f422393773b243642092c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi03LTEtMS00NTQ0MQ_63ddefbd-ecf5-4b87-96e5-cfea69cb39eb">155,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middle East</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f201c2b5d348ee8cef94eeee757986_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC01LTEtMS01NDI3Ng_b0978954-6f1a-4363-861c-781b3ccebac0">65,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9306ad4c27064a6b9826f59953cafc24_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC03LTEtMS01NDI3Ng_389f808f-3058-4109-82f9-fc389b8e7b64">15,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a14de3abadb40778471e66184af280a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC01LTEtMS00NTQ0MQ_71bb2988-6464-4afc-837c-271e9b5d1c76">62,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ff7532c1ae49528158820bb4da4aea_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC03LTEtMS00NTQ0MQ_41788225-2aba-4f3a-a724-6c579c2d59fb">59,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecad8ebdb8c244bd98a2afd89bba0a2e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNS01LTEtMS00NTQ0MQ_0d4cfa7b-8718-4386-a608-2a694889cd4c">45,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cdbd316d31b4d1cab319df9d84f7f77_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNS03LTEtMS00NTQ0MQ_82ebf015-072b-4899-8e3c-8efd27957028">38,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1103deb96054b26b048779411774904_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNi01LTEtMS00NTQ0MQ_4658ef6c-b64d-486f-b319-33f6b52079c4">481,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNi03LTEtMS00NTQ0MQ_c67473a2-5e45-460b-b180-4e6c9b0b386d">417,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNy01LTEtMS00NTQ0MQ_1c2a51dd-6d70-43c2-ba85-d3043b95de4f">24,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNy03LTEtMS00NTQ0MQ_62a17b41-0e7f-4a2e-8bcd-1dca518b8a86">50,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfOC01LTEtMS00NTQ0MQ_b723fc9f-ed62-488f-ab09-f86921cb9c17">505,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfOC03LTEtMS00NTQ0MQ_57345b1f-a749-485d-b623-512c2ed774f9">467,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="ie1c74f0eda2b474793ad2aa5ed22e74a"><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQzOA_fc4586ff-997c-42f5-8cba-d2d8728f872b" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.739%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23782facb41e4a0394006d0c61111460_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMi01LTEtMS00NTQ0MQ_3af21d70-6565-41e7-93d4-a2bee404c072">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21c33100f90b40bca71ded15376adfcb_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMi03LTEtMS00NTQ0MQ_d9e8cffa-3adf-4a79-8524-e726fe86a401">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5e5f24d472d4e82b55a8346cd4fc93b_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMy01LTEtMS00NTQ0MQ_0545e860-cd0f-483c-a5fe-b65cc47f8c94">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fdf37db79194886b085e0309823a025_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMy03LTEtMS00NTQ0MQ_c1f71391-4c40-4222-8fb8-a17949b0885e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bf584b76688449d949ae03ea7a23992_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNC01LTEtMS00NTQ0MQ_aaa2415c-381e-438a-ac99-2d681d9dc6a2">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f6c8323762a4a68a579e56d15514782_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNC03LTEtMS00NTQ0MQ_8c930eb3-6799-43f1-89e3-31dc2465ecff">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief8a05482b8a475f87dfd720c5c6b2f3_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS01LTEtMS00OTAyNQ_8099f1bf-11ec-472a-bac0-b6fdc61fcdbd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21f73aa86157436b89f7042549ab2cdf_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS03LTEtMS00OTAyNQ_eed8a20b-67a2-48b5-889c-17032e33eaca">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS01LTEtMS00NTQ0MQ_57fb6fb1-876f-4462-9b1d-f8ba0eca5059">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e84ec89b6c4d8ea066d35c5ace7603_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS03LTEtMS00NTQ0MQ_3d451dc4-9b76-4ecd-94fa-8977f058695a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for <ix:nonFraction unitRef="number" contextRef="ie4519e269765428dbc66faaaa2646940_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY1Nw_d60516a7-d7a8-4bd5-9eda-b714e5030f15">21</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ieb6f40e5c0bf4422a0a81cb722132751_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY2NA_c611dd6d-97e7-4ce2-a3be-d8b6a9a9845c">14</ix:nonFraction>% of the Company&#8217;s March&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021, when two customers accounted for <ix:nonFraction unitRef="number" contextRef="i5407662ac25040bf8b124d95a9d5af58_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTc3OA_406507a1-4f7a-450f-8030-f1702274fa25">28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5da3b672cc79498eb14a326a63d8c950_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTc4NQ_572abef9-9736-4e48-afe4-f341a11ab648">16</ix:nonFraction>% of the accounts receivable balance, respectively. As of March&#160;31, 2022, and December&#160;31, 2021, the accounts receivable balance for Sanofi included $<ix:nonFraction unitRef="usd" contextRef="ic4d5c38e0f09439dbdf86382f3b59459_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTkwOQ_2c08ef9a-2f8f-4016-a8fa-f793e888ec79">61.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae90bf0fe46c464d9eb1ead18b979c57_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTkxNg_715c5b0a-82d1-4e1e-9628-ddd1e51161e3">67.9</ix:nonFraction> million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#8217; financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the three months ended March&#160;31, 2022 and 2021, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and the Company anticipates a continued impact due to COVID-19 on its financial results in 2022. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment could affect the Company&#8217;s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company&#8217;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfNDg4_dc060c71-73ef-4073-9559-43168dc0884e" continuedAt="id1b444af6b82428bba3163e3a6382301" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="id1b444af6b82428bba3163e3a6382301"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfNDkw_0a590d6a-144e-4345-b2d3-178a9df512ff" continuedAt="iffa2de00b91642d58b0ea9bd5c0bed2d" escape="true">Compensation expense included in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:&#160;</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:9pt"><ix:continuation id="iffa2de00b91642d58b0ea9bd5c0bed2d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.739%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19465b1578ec4dd28c910af817bceab3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMi01LTEtMS00NTQ0MQ_05e5306b-b3a2-49a3-85df-ae6442248681">4,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03cdf675716d437c964339c1910bdbdc_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMi03LTEtMS00NTQ0MQ_bce01f85-115f-45a6-b964-ad576a4382df">6,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0fd632f5fd41e287a0b11cae9cbeca_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMy01LTEtMS00NTQ0MQ_e45ac6bb-e52d-4e47-b3cf-d28f0cbc4707">17,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008d8298bf11412ba45a7ea365cc12cf_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMy03LTEtMS00NTQ0MQ_4b709d77-0bb2-4328-9685-f6146d34e5c3">17,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0087b7e6ba4593890bb5c30ab38817_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNC01LTEtMS00NTQ0MQ_7ea4e08b-2e00-44a7-8862-2b53fa4e1b92">26,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4910a2e24b7045899f96c49194daa7f4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNC03LTEtMS00NTQ0MQ_60b13511-9778-4b2e-bf8f-d3d550b15331">25,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNS01LTEtMS00NTQ0MQ_179e6f85-688d-40c4-aa4b-193e2aa57cf8">47,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNS03LTEtMS00NTQ0MQ_4d47471e-74e1-43c8-9d34-7987df78111a">49,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfMTY0OTI2NzQ0MjYyMQ_8b2ff151-9756-43c8-af73-f4dd3842de18">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfMTY0OTI2NzQ0MjYyOQ_6850328f-bf73-4e87-b9bb-efa7963a7dce">4.4</ix:nonFraction> million was capitalized into inventory for the three months ended March&#160;31, 2022 and 2021, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyNA_31fbba7e-2693-4d29-a390-1c5ea85c0a9a" continuedAt="iaa27e747c98f42c9a28a0ef4984908d7" escape="true">NET INCOME PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="iaa27e747c98f42c9a28a0ef4984908d7"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#8217;s Employee Share Purchase Plan (ESPP), unvested RSUs, the Company&#8217;s common stock held by the NQDC and contingent issuances of common stock related to the Company&#8217;s convertible debt.</span></div><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyMA_691adc95-f02d-42d0-bf53-daade779fc67" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):</span></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.739%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMy01LTEtMS00NTQ0MQ_4cda4003-dffa-4c1a-8d4f-2694f5936717">120,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMy03LTEtMS00NTQ0MQ_087cb9d2-c673-4cc9-962e-6de875bd885a">17,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on convertible notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNC01LTEtMS00NTQ0MQ_f1f3c4a3-0092-4d37-982b-c2731da92d04">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNC03LTEtMS00NTQ0MQ_c43cf07b-2194-4358-bb9f-e2c872793603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNS01LTEtMS00NTQ0MQ_8cd7f5b8-7e67-4026-bb92-26b85a3f8a10">123,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNS03LTEtMS00NTQ0MQ_22e106ac-e5db-4631-b03b-7c2e93fa5d24">17,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNy01LTEtMS00NTQ0MQ_9686dc07-bf24-4752-bb37-3c777db52e11">183,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNy03LTEtMS00NTQ0MQ_ddcab8ee-33fd-4dbf-89c8-96413faa2e45">181,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfOS01LTEtMS00NTQ0MQ_d57bf0db-f2b8-4a05-a790-68d328f34fe6">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie33737b08299431889d37d12a1d70178_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfOS03LTEtMS00NTQ0MQ_384eb2de-86b1-4369-9441-7c3431d1827e">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85312ddaf862450190f331615f114ab7_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTAtNS0xLTEtNDU0NDE_c8d0ad95-1894-4060-8d1a-cf0659cd9b14">4,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTAtNy0xLTEtNDU0NDE_cbcd323f-0534-4738-bca4-aa79637b8454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTEtNS0xLTEtNDU0NDE_0e422fbe-4ac6-4b12-b75b-d1f626259cad">3,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i530302b04890455682f0ab0adc4d162e_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTEtNy0xLTEtNDU0NDE_d046868c-dd6d-4092-8734-3b39832324f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTMtNS0xLTEtNDU0NDE_45bf6ea8-b9a7-4056-a56b-68102b1a7e2a">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTMtNy0xLTEtNDU0NDE_5f4069f9-2856-4c2b-a80b-1a4d7193d4d7">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTQtNS0xLTEtNDU0NDE_b7f9952d-bdd3-4d5d-a532-949fd2a1d7ea">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTQtNy0xLTEtNDU0NDE_a2ec6f41-65a8-4b45-b808-bdc1f0f2f302">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company&#8217;s common stock held by the NQDC</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib721cab6f4a2424680bcabdd246154df_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTUtNS0xLTEtNDU0NDE_7d893b1f-baef-4519-8c1b-34ede5f2885c">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99beaf0bac24ae7a8e8559e31363de0_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTUtNy0xLTEtNDU0NDE_c339c5a0-725c-494d-b9d1-67efa4f5ca22">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTYtNS0xLTEtNDU0NDE_f73a6eb0-f237-40e2-8925-6204540585ea">194,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTYtNy0xLTEtNDU0NDE_5c773e15-f714-4f35-a056-d361dc9ea0a4">184,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTctNS0xLTEtNDU0NDE_ab6114f0-0270-4da8-acd7-01a0a3b02f8a">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTctNy0xLTEtNDU0NDE_9d11de9c-cf04-4893-9efe-30f029b8b4b4">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTgtNS0xLTEtNDU0NDE_504a33ee-1e6f-4a33-b3c3-c5f9eaa09781">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTgtNy0xLTEtNDU0NDE_eeacf975-8785-4d7c-937c-2d7f13a979e2">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyMg_89d4850c-a5b6-4bf2-a7ca-3349bedf1775" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands):</span></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfMi01LTEtMS00NTQ0MQ_2e5e6f59-e3cf-4609-b99f-a317eaf3cbf9">6,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie33737b08299431889d37d12a1d70178_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfMi03LTEtMS00NTQ0MQ_59db6042-ed37-47c4-a73c-2885c1fed6fe">6,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85312ddaf862450190f331615f114ab7_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC01LTEtMS00Nzk2NA_99e8e50b-0ac6-4c66-8a46-7d94585f0d40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC03LTEtMS00Nzk2NA_7cb6f960-90a4-4617-b19a-b681d80edb88">4,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC01LTEtMS00NTQ0MQ_8e4817aa-6ba6-428d-8578-b723259123f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i530302b04890455682f0ab0adc4d162e_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC03LTEtMS00NTQ0MQ_86c16ef6-d2e7-4cf8-a651-aadebd74d301">3,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNi01LTEtMS00NTQ0MQ_9c32d3ed-d810-4b3e-9bc2-267dd344f08e">4,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNi03LTEtMS00NTQ0MQ_b49f310a-89a4-4ecb-88e9-0b843ae7a409">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNy01LTEtMS00NTQ0MQ_ca9a51f0-15a4-40f2-81c4-c4f3fcce700c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNy03LTEtMS00NTQ0MQ_0448d083-46d3-4d02-b2b2-5633ba5215f1">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfOS01LTEtMS00NTQ0MQ_83f323cf-26de-417e-b064-a3df3feb95a3">10,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfOS03LTEtMS00NTQ0MQ_010a23e9-db87-49a8-ba0b-ac690e2180e4">18,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMjMwNQ_aa319ef1-aefe-441b-8b50-69ad8b78f7d9" continuedAt="i6e3709a923744ffe9b08b724b84f35cf" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i6e3709a923744ffe9b08b724b84f35cf" continuedAt="i73cc9468aecf46db89c67b292ec0b948"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#8217;s general </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)</span></div></div><ix:continuation id="i73cc9468aecf46db89c67b292ec0b948"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company was subject to contingent payments considered reasonably possible of $<ix:nonFraction unitRef="usd" contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfNzEx_cb20c67f-3a4b-4489-819b-0846ec27340d">788.5</ix:nonFraction> million, including $<ix:nonFraction unitRef="usd" contextRef="i275d3e6c3fa2449e9f081a92e87e1c21_D20211001-20211231" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMTY0OTI2NzQ0NTIyNg_21a16422-79b4-4dab-9854-dbeb1aa8bc54">389.0</ix:nonFraction> million related to an early stage development program licensed from a third party in the fourth quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="i2bad4330064641499986ec8dd304acef_D20200401-20200630" decimals="-5" name="bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMTY0OTI2NzQ0NTIyMg_79acc10b-441a-4e53-8b53-211a69270861">225.0</ix:nonFraction> million related to an early stage development program licensed from a third party in the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;D activities. These amounts are included as R&amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services, production services and facility construction services. As of March&#160;31, 2022, such commitments were estimated at approximately $<ix:nonFraction unitRef="usd" contextRef="i5017a08d58224e19b728357a77f28248_I20220331" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMjE2MQ_5858ab24-365a-4a10-a74a-93786fd604b2">117.5</ix:nonFraction> million, all of which were short-term. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risk factor related to the impact of the coronavirus pandemic, &#8220;The COVID-19 pandemic could continue to materially adversely affect our business, results of operations and financial condition.&#8221; described in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A in this Quarterly Report on Form 10-Q, amongst the other risk factors. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled &#8220;Forward-Looking Statements&#8221; that appears at the beginning of this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Condensed Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and are presented in U.S. Dollars (USD).</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions, except as otherwise disclosed)</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are a global biotechnology company that develops and commercializes innovative therapies for people with serious</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">significant benefit over existing products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our portfolio consists of seven commercial therapies and multiple clinical and preclinical product candidates. A summary of our commercial products, as of March&#160;31, 2022, is provided below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:82.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.195%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products marketed by BioMarin:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim (elosulfase alpha)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS&#160;IVA&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme (galsulfase)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS&#160;VI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan (sapropterin dihydrochloride)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq (pegvaliase-pqpz)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura (cerliponase alfa)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLN2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo (vosoritide)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achondroplasia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Products not marketed by BioMarin:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme (laronidase)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS&#160;I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(6)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of Mucopolysaccharidosis IV Type A</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of Mucopolysaccharidosis VI</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of phenylketonuria</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For adult patients with PKU</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of late infantile neuronal ceroid lipofuscinosis type 2</span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">For the treatment of Mucopolysaccharidosis I</span></div><div style="margin-top:3pt;padding-left:4.5pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of our on-going clinical development programs, as of March&#160;31, 2022, is provided below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:59.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.782%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Clinical Development Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Indication</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valoctocogene roxaparvovec</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe Hemophilia A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 307 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primary hyperoxaluria</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hereditary Angioedema</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Phase 1/2</span></td></tr></table></div><div style="margin-top:3pt;padding-left:40.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The FDA placed a clinical hold in September 2021 and requested data for additional non-clinical studies in February 2022. We will communicate next steps for the program when available.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions, except as otherwise disclosed)</span></div></div><div style="margin-top:18pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Highlights</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Key components of our results of operations include the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:75.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development (R&amp;D) expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative (SG&amp;A) expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108.0)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">See &#8220;Results of Operations&#8221; below for discussion of our results for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Uncertainty Relating to the COVID-19 Pandemic</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to affect economies and business around the world. Our global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and our overall business operations were impacted by COVID-19 during the three months ended March&#160;31, 2022 and 2021, and we anticipate a continued impact on our financial results in 2022. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor related to the impact of the coronavirus pandemic, &#8220;The COVID-19 pandemic could continue to materially adversely affect our business, results of operations and financial condition.&#8221; described in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report, for additional details on the impact of the COVID-19 pandemic. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Developments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continued to grow our commercial business and advance our product candidate pipeline during 2022. We believe that the combination of our internal research programs, acquisitions and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Below is a summary of key business developments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Continued Emphasis on Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Late-stage Regulatory Portfolio</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.81pt">Voxzogo: The global launch of Voxzogo is actively underway, with market access and reimbursement progressing as anticipated. Since December 2021, we have seen worldwide increases in the number of children being treated with commercial Voxzogo and in the number of active markets contributing to Voxzogo sales.</span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketing authorization reviews of Voxzogo are in process in Japan and Australia, with potential approvals in those countries in 2022.</span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the quarter, we provided a top-line update on the Phase 2 randomized, double-blind, placebo-controlled Voxzogo study in infants and young children up to five years of age with achondroplasia. 52-week results trended in favor of Voxzogo compared to placebo on height Z-score and annualized growth velocity, and with no worsening in proportionality in the overall study population. We intend to initiate discussions with regulatory health authorities to discuss next steps regarding efforts to expand access to Voxzogo treatment for this younger age group. We expect to share results from this study at a scientific meeting mid-year 2022. </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.46pt">Valoctocogene roxaparvovec: The European Medicines Agency (EMA) continues to review our Marketing Authorization Application (MAA) for valoctocogene roxaparvovec and we expect a Committee for Medicinal Products for Human Use opinion mid-year 2022. We have provided the EMA with two-year follow-up safety and efficacy data from the GENEr8-1 study. </span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on favorable results from the two-year follow-up safety and efficacy data from the GENEr8-1 study, we are targeting BLA resubmission for valoctocogene roxaparvovec in June 2022 followed by an expected six-month </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions, except as otherwise disclosed)</span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">review procedure by the FDA. A pre-submission interaction with the FDA is scheduled later in the second quarter of 2022 to discuss our BLA resubmission efforts.</span></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the first quarter of 2022, we announced that a subject treated with valoctocogene roxaparvovec in the Phase 2 study over five years ago reported a salivary gland mass in late 2021. The event was reported as unrelated to valoctocogene roxaparvovec by the investigator. The subject was successfully treated and we conducted a genomic analysis from a tissue sample containing the mass. On April 27, 2022, we announced the findings from the completed analysis showed a comparable pattern of integration between healthy and tumor containing tissues, with no evidence emerging that vector integration contributed to the salivary gland mass. These data will be supplied to the EMA, as part of the ongoing review of our MAA, as well as included in the BLA resubmission.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Select Earlier-stage Development Portfolio</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.81pt">BMN 255 for primary hyperoxaluria type 1, a subset of chronic renal disease: We have completed the single ascending dose arm of the First-in-Human study and are analyzing the results. We believe the availability of a potent, orally bioavailable, small molecule like BMN 255 may be able to significantly reduce disease and treatment burden in certain people with chronic renal disease.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.81pt">BMN 331 gene therapy product candidate for Hereditary Angioedema (HAE): During the first quarter of 2022, we announced that we began dosing patients in the Phase 1/2 HAERMONY study to evaluate BMN 331, an investigational AAV5-mediated gene therapy for people living with HAE. The FDA granted Orphan Disease Designation status to BMN 331 in 2021.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In preparing our Condensed Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The full extent to which the ongoing COVID-19 pandemic could continue to directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs will depend on future developments that continue to remain highly uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates during the three months ended March&#160;31, 2022, compared to those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the Securities and Exchange Commission on February&#160;25, 2022.</span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 1 to our accompanying Condensed Consolidated Financial Statements for a description of recent accounting pronouncements, if any, and our expectation of their impact on our results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net Product Revenues consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.402%"><tr><td style="width:1.0%"></td><td style="width:67.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by BioMarin</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net Product Revenues include revenues generated from our approved products. In the U.S., our commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program, and Aldurazyme is marketed worldwide by Sanofi. Outside the U.S., our commercial products are sold to authorized distributors or directly to government purchasers or hospitals, which act as the end-users. In certain countries, governments place large periodic orders for our products. The timing of these large government orders can be inconsistent and can create significant quarter to quarter variation in our revenues.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in Net Product Revenues for the three months ended March&#160;31, 2022 as compared to 2021 was primarily attributed to the following:</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Vimizim and Naglazyme: higher product sales primarily attributed to new patients initiating therapy and timing of orders in the Middle East and Europe;</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Voxzogo: commercial sales due to new patients initiating therapy in Europe and the U.S. following EMA and FDA regulatory approvals in the third and fourth quarters of 2021, respectively;</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Brineura: higher sales primarily due to new patients initiating therapy in Europe; partially offset by</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Aldurazyme: lower product revenues due to timing of bulk lot product fulfillment to Sanofi; and</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Kuvan: lower sales primarily attributed to generic competition as a result of the loss of exclusivity in the U.S. that occurred in October 2020. We anticipated and prepared for this loss of exclusivity and the reduction in our market share, as well as the adverse effect on our revenues and results of operations. We expect to continue to experience adverse effects on our market share and revenues in the future due to the loss of exclusivity in the U.S. and the contracting sapropterin dihydrochloride market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In certain countries, governments place large periodic orders for our products. We expect that the timing of these large government orders will continue to be inconsistent, which may create significant period to period variation in our revenues. We anticipate the COVID-19 pandemic will have a continued impact on the remainder of 2022 Net Product Revenues as many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Although we continue to work with our patient community and health care providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from the doses of our products that are missed by patients and the lost revenue from delayed treatment starts for new patients will never be recouped.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See the risk factors &#8220;The sale of generic versions of Kuvan by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in Kuvan revenues faster than expected&#8221; and &#8220;The COVID-19 pandemic could continue to materially adversely affect our business, results of operations and financial condition&#8221; in &#8220;Risk Factors&#8221; included in Part II, Item 1A of this Quarterly Report for additional information on risks we face.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We face exposure to movements in foreign currency exchange rates, primarily the Euro. We use foreign currency exchange forward contracts to hedge a percentage of our foreign currency exposure. The following table shows our Net Product Revenues denominated in USD and foreign currencies:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales denominated in USD</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales denominated in foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unfavorable impact of foreign currency exchange rates on product sales denominated in currencies other than USD</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The unfavorable impact for the three months ended March&#160;31, 2022 as compared to 2021 was primarily driven by weakness relative to the USD associated with the Euro and Turkish Lira along with currencies from certain Latin American markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Royalty and Other Revenues</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Royalty and Other Revenues include royalties earned on net sales of products sold by third parties, up-front licensing fees, milestones achieved by licensees or sublicensees and rental income associated with the tenants in our facilities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in Royalty and Other Revenues for the three months ended March&#160;31, 2022 as compared to 2021 was primarily due the absence of the license payment received from a third party due to their achievement of a regulatory milestone in the first quarter of 2021; partially offset by an increase in royalties earned from net sales of third parties. </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to continue to earn royalties from third parties in the future.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and internal and external final formulation and packaging costs. Cost of Sales also includes royalties payable to third parties based on sales of our products and charges for inventory valuation reserves.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our Cost of Sales and gross margin:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#fefefe;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#fefefe;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#fefefe;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cost of Sales decreased for the three months ended March&#160;31, 2022 as compared to 2021 primarily due to lower sales volume of Aldurazyme and lower Palynziq manufacturing costs per unit; partially offset by higher sales volumes of Vimizim and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Naglazyme. Gross margin increased primarily due to portfolio mix with higher sales volume of products with higher margins, lower inventory reserves and the improved per unit Palynziq manufacturing costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect gross margin to range between approximately 75% and 77% over the next twelve months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our approved products. R&amp;D expense primarily includes preclinical and clinical studies, personnel and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&amp;D activities, facilities and regulatory costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We manage our R&amp;D expense by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continuously evaluate the recoverability of costs associated with pre-launch or pre-qualification manufacturing activities, and capitalize the costs incurred related to those activities if it is determined that recoverability is highly likely and therefore future revenues are expected. When regulatory approval and the likelihood of future revenues for a product candidate are less certain, the related manufacturing costs are expensed as R&amp;D expenses. We had $11.3 million of manufacturing-related costs for valoctocogene roxaparvovec capitalized as pre-launch inventory as of March&#160;31, 2022. See Note 3 to our accompanying Consolidated Financial Statements for additional information regarding our inventory. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expense consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:67.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and early development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valoctocogene roxaparvovec</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other approved products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 307</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for the three months ended March&#160;31, 2022 as compared to 2021 primarily comprised the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">higher spend in research and early development programs due to increased pre-clinical activities and IND-enabling studies for planned IND filings; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">an increase in clinical trial activities related to continued development of valoctocogene roxaparvovec; partially offset by </span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">a decrease in Voxzogo related expenses due to increased capitalization of manufacturing costs following the EU and U.S. regulatory approvals in the second half of 2021. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect R&amp;D expense to increase in future periods, primarily due to increased activities for our research and early development programs while we continue to develop our later stage programs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing (S&amp;M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">administrative (G&amp;A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SG&amp;A expenses consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;M expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G&amp;A expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total SG&amp;A expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.6&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S&amp;M expenses by product were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:68.496%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PKU Products (Kuvan and Palynziq)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MPS Products (Aldurazyme, Naglazyme and Vimizim)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valoctocogene roxaparvovec</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total S&amp;M expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in S&amp;M expense for the three months ended March&#160;31, 2022 as compared to 2021 was primarily a result of increased activities in support of Voxzogo commercial launch following EU and U.S. regulatory approvals in the latter half of 2021, and an increase in valoctocogene roxaparvovec commercial launch preparation activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in G&amp;A expense was primarily due to increased idle plant time related to maintaining our gene therapy manufacturing facility as well as higher employee-related expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect SG&amp;A expense to increase in future periods as a result of preparing to launch new products and support of our global business as it grows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets, Net</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes during the periods presented for Intangible Asset Amortization and Contingent Consideration and Gain on Sale of Nonfinancial Assets, Net were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#fefefe;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible asset amortization and contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair value of contingent consideration &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the increase in the fair value of contingent consideration for the three months ended March&#160;31, 2022 as compared to 2021 was attributable to changes in the estimated probability of achieving sales milestones related to our PKU products.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8211; the expense for the three months ended March&#160;31, 2022 as compared to 2021 was relatively flat.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of Nonfinancial Assets, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8211; the increase in the three months ended March&#160;31, 2022 as compared to 2021 is due to the sale in the first quarter of 2022 of the Priority Review Voucher (PRV) that we received in connection with the FDA approval of Voxzogo in 2021. In exchange for the PRV, we received lump sum payment of $110.0 million, which was recognized as a gain on the sale of intangible assets, net of broker fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in Interest Income for the three months ended March&#160;31, 2022 compared to 2021 was primarily due to lower interest rates. We expect Interest Income to be higher over the next 12 months due to anticipated higher interest rates and yields on our cash equivalents and investments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We incur interest expense primarily on our convertible debt. Interest Expense for the periods presented was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:68.320%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Expense for the three months ended March&#160;31, 2022 was flat as compared to 2021. We do not expect Interest Expense to fluctuate significantly over the next 12 months. See Note 6 to our accompanying Condensed Consolidated Financial Statements for additional information regarding our debt. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other Expense, Net for the periods presented was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.583%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in Other Expense, Net for the three months ended March&#160;31, 2022 compared to 2021 was primarily due to the loss on the fair value of the assets held in our deferred compensation plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in income tax expense for the three months ended March&#160;31, 2022 as compared to 2021 was primarily due to taxes on increased income recognized in the first quarter of 2022 from the sale of the PRV.</span></div><div><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our cash, cash equivalents, and investments as of March&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,519.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe our cash generated from sales of our commercial products, in addition to our cash, cash equivalents and investments will be sufficient to satisfy our liquidity requirements for at least the next 12 months. We believe we will meet longer-term expected future cash requirements and obligations through a combination of cash flows from operating activities, available cash and investments balances and available revolving loan balances. We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. For example, we may require additional financing to fund the repayment of our convertible debt, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. The timing and mix of our funding alternatives could change depending on many factors, including how much we elect to spend on our development programs, potential licenses and acquisitions of complementary technologies, products and companies or if we settle our convertible debt in cash. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the ongoing COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to be unable to pay for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">products. We will continue to monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in net cash provided by operating activities in the three months ended March&#160;31, 2022 compared to March&#160;31, 2021 was primarily attributed to the timing of cash receipts from our customers, the absence of a tax refund from a Federal carryback claim received in Q1 2021, and higher employee compensation-related payments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in net cash provided by investing activities in the three months ended March&#160;31, 2022 compared to March&#160;31, 2021 was primarily attributable to the proceeds from the sale of the PRV in the first quarter of 2022 and lower net purchases of available-for-sale debt securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the three months ended March&#160;31, 2022 compared to March&#160;31, 2021 was relatively flat.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing and Credit Facilities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our $1.1 billion (undiscounted) of total convertible debt as of March&#160;31, 2022 will impact our liquidity due to the semi-annual cash interest payments as well as the repayment of the principal amount, if not converted. As of March&#160;31, 2022, our indebtedness consisted of our 0.599% senior subordinated convertible notes due in 2024 and our 1.25% senior subordinated convertible notes due in 2027, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. For additional information related to our convertible debt see, Note 6 to our accompanying Condensed Consolidated Financial Statements and Note 10 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, we entered into an unsecured revolving credit facility of up to $200.0&#160;million credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, we amended the credit facility agreement, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes. The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of March&#160;31, 2022, there were no amounts outstanding under the credit facility and we and certain of our subsidiaries that serve as guarantors were in compliance with all covenants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Material Sources of Cash</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2022, we received a lump sum payment of $110.0&#160;million for the sale of the PRV received in connection with the U.S. approval of Voxzogo. See Note 3 to our accompanying Condensed Consolidated Financial Statements for additional discussion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except as otherwise disclosed)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Funding Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our investment in our research and early development of product candidates and continued development of our existing commercial products has a major impact on our operating performance. R&amp;D expenses for our commercial products and certain product candidates for the period since inception as of March&#160;31, 2022 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Since Program Inception</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valoctocogene roxaparvovec</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 307</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 331</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BMN 255</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other approved products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,401.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot estimate with certainty the cost to complete any of our product development programs. We may need or elect to increase our spending above our current long-term plans to be able to achieve our long-term goals. This may increase our capital requirements, including: costs associated with the commercialization of our products&#894; additional clinical trials; investments in the manufacturing of our commercial products&#894; preclinical studies and clinical trials for our product candidates&#894; potential licenses and other acquisitions of complementary technologies, products and companies&#894; and general corporate purposes. Additionally, we cannot precisely estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see &#8220;Risk Factors&#8221; included in Part II, Item 1A of this Quarterly Report on Form 10-Q, for a discussion of the reasons we are unable to estimate such information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Obligations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had obligations of approximately $117.5&#160;million, all of which was short term and primarily related to firm purchase commitments entered into in the normal course of business to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services, production services and facility construction services. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $64.0&#160;million of acquisition-related contingent consideration on our Condensed Consolidated Balance Sheet, all of which is Euro denominated and was short term. Of this amount, we expect to pay &#8364;30 million in cash in Q2 2022 to a Merck Serono related to our achievement of a Palynziq sales milestone in Q1 2022. For additional information related to our obligation to Merck Serono related to a 2016 arrangement, see Note 17 to our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Other Obligations</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our lease, contingent obligations and unrecognized tax benefits as of March&#160;31, 2022 have not materially changed from those discussed in &#8220;Financial Condition, Liquidity and Capital Resources&#8221; in Part II Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our market risks during the three months ended March&#160;31, 2022 have not materially changed from those discussed in Part II, Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_106"></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(a) Controls and Procedures</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this report.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management must apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure controls system are met.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(b) Change in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We continue to utilize the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_112"></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 25, 2020, a purported shareholder class action lawsuit was filed against us, our Chief Executive Officer, our President of Worldwide Research and Development and our Chief Financial Officer in the United States District Court in the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act). The complaint alleges that we made materially false or misleading statements regarding the clinical trials and Biologics License Application (BLA) for valoctocogene roxaparvovec by purportedly failing to disclose that differences between the Company&#8217;s Phase 1/2 and Phase 3 clinical studies limited the ability of the Phase 1/2 study to support valoctocogene roxaparvovec&#8217;s durability of effect and, as a result, that it was foreseeable that the Food and Drug Administration (FDA) would not approve the BLA without additional data. The complaint seeks an unspecified amount of damages, prejudgment and post-judgment interest, attorneys&#8217; fees, expert fees, and other costs. The lead plaintiff filed an amended complaint in February 2021, dropping our Chief Financial Officer as a defendant, and asserting that the Company misled investors about the progress of the FDA's review of our BLA for valoctocogene roxaparvovec. On April 22, 2021, we moved to dismiss the amended complaint. On January 6, 2022, the court denied our motion to dismiss. We answered the amended complaint on February 15, 2022. We believe that the claims have no merit and we intend to vigorously defend this action. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 22, 2021, a purported securities class action lawsuit was filed against us, our Chief Executive Officer, our current and prior Chief Financial Officers, and our President of Worldwide Research &amp; Development in the United States District Court for the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Exchange Act. The complaint alleges that we made materially false or misleading statements regarding BMN 307 by purportedly failing to disclose information about BMN 307&#8217;s safety profile, and by purportedly overstating BMN 307&#8217;s clinical and commercial prospects. The complaint seeks an unspecified amount of damages, pre-judgment and post-judgment interest, attorneys&#8217; fees, expert fees, and other costs. The Court appointed lead plaintiffs and lead counsel on January 10, 2022. Lead plaintiffs filed an amended complaint on March 25, 2022. We believe that the claims have no merit and we intend to vigorously defend this action.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_115"></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-90pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1A. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">An investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have marked with an asterisk (*) those risk factors below that include a substantive change from or update to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 25, 2022.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*The COVID-19 pandemic could continue to materially adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has resulted in travel restrictions, quarantines, &#8220;work-from-home&#8221; and &#8220;shelter-in-place&#8221; orders and extended shutdown of certain businesses around the world, including in many countries in which we operate. Our global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and our overall business operations have been impacted by the COVID-19 pandemic, and we expect that the pandemic will continue to adversely impact our financial results and our business generally in 2022. Ongoing and future effects of the COVID-19 pandemic (or any future pandemic) on all aspects of our business and operations, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, and the duration of such effects, are highly uncertain and difficult to predict.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely affected and will likely continue to adversely impact our product development programs, including preclinical study and clinical trial operations. We have been, and will likely continue to be, unable to initiate or continue conducting clinical trials as originally planned in certain countries and regions due to the prioritization of hospital resources toward the pandemic, difficulty in recruiting and retaining healthcare providers and staff due to their diversion toward treating COVID-19 patients or their heightened exposure to COVID-19, potential unwillingness of patients to enroll or continue in trials for fear of exposure to COVID-19 at sites, or the inability of patients to comply with clinical trial protocols as quarantines or travel restrictions impede patient movement or otherwise interrupt healthcare services. For example, we experienced delays in certain clinical trials due to COVID-19 related complications and have had to reevaluate expected timelines for those trials. In addition, we rely on independent clinical investigators, contract research organizations (CROs) and other third-party service providers to assist </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the pandemic has impacted, may continue to affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. Additionally, the COVID-19 pandemic has delayed, and may continue to postpone, necessary regulatory inspections and other interactions with regulators regarding our product candidates, which could delay review or approval of our regulatory submissions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 has adversely affected and will likely continue to affect our ability to source materials and supplies and could adversely impact our ability to manufacture and distribute our product candidates and products. The pandemic has resulted and may continue to result in reduced operations of third-party suppliers of raw materials and supplies upon whom we rely or otherwise limit our ability to obtain sufficient materials and supplies necessary for production of our therapies. Our manufacturing facilities and those of our contract manufacturers are located in areas impacted by the COVID-19 pandemic, which may result in delays or disruptions in our ability to produce product candidates and products. If we or any third party in our supply or distribution chain are adversely impacted by the COVID-19 pandemic, including as a result of required closures, staffing shortages, production slowdowns and disruptions in delivery systems, our operations may be disrupted, limiting our ability to manufacture and distribute our product candidates for clinical trials and research and development operations and our products for commercial sales. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our commercial operations have also been, and will likely continue to be, adversely impacted by the COVID-19 pandemic. Many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Treating COVID-19 patients has become the priority for many healthcare facilities and workers, so it has become, and may continue to be, difficult for some of our patients to receive our therapies that are administered by infusion. Although we are working with our patient community and healthcare providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from doses of our products that are missed by patients and the lost revenues from delayed treatment starts for new patients will never be recouped. Moreover, some patients may choose to skip infusions because they do not want to risk exposure to COVID-19 by having a healthcare provider administer the therapy at a healthcare facility or at home. The pandemic has also hindered our ability to find new patients and start treating these patients, and it has limited our sales force&#8217;s ability to promote our products to distributors, hospitals, clinics, doctors and pharmacies, which could adversely affect our revenues and results of operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic could adversely affect our workforce and the employees of companies with which we do business, thereby disrupting our business operations. Recently, we have implemented a policy of hybrid onsite and remote work for most of our employees who were previously fully remote during the first two years of the COVID-19 pandemic and whose jobs did not require them to be onsite. Continued reliance by us and the companies with which we do business on personnel working fully or partially remotely may negatively impact productivity, increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations. For our employees whose jobs require them to be onsite, we have taken precautions to avoid the spread of COVID-19 among our employees, but we cannot guarantee our workforce will not face an outbreak that could adversely impact our operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the long-term economic impact and the duration of the COVID-19 pandemic may be difficult to predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and convertible notes. In addition, a recession, further market correction or depression resulting from the COVID-19 pandemic could materially adversely affect our business and the value of our common stock and convertible notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic continues to adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in this Risk Factors section, such as those relating to our conducting a significant amount of our sales and operations outside of the U.S., exposure to changes in foreign exchange rates, our substantial indebtedness, our need to generate sufficient cash flows to service our indebtedness and finance our operations, our ability to comply with the covenants contained in the agreements that govern our indebtedness and the volatility of our stock price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All of our products target diseases with small patient populations. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve and maintain profitability. For Brineura, Naglazyme and Vimizim in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The course of treatment for patients using our products is expensive. We expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenues and gross margin will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reimbursement in the European Union (EU) and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until pricing and/or reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margin may be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenues could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely) or commercialize their products before we do. With respect to valoctocogene roxaparvovec, if the product candidate is approved, we will face a highly developed and competitive market for hemophilia A treatments. As we commercialize valoctocogene roxaparvovec, if approved, we may face intense competition from large pharmaceutical companies with extensive resources and established relationships in the hemophilia A community. If we do not compete successfully, our revenues would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as Aldurazyme, Naglazyme, and Vimizim in MPS diseases, could be greatly reduced. Moreover, if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will still depend, in part, on the acceptance of physicians, patients and healthcare payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost effective and safe. Changes in treatment method can be caused by the introduction of other companies&#8217; products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future growth and development depend in part on our ability to successfully develop new products from our research and development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals, are inherently uncertain and may not result in the commercialization of any products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as Aldurazyme, Kuvan and Naglazyme. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which may target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The sale of generic versions of Kuvan by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in Kuvan revenues faster than expected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic versions of Kuvan are available in several countries around the world, including multiple generic versions in the U.S. This generic competition has adversely affected and will continue to adversely affect our revenues from Kuvan, and we cannot accurately predict the rate of decline of Kuvan revenues in these countries. We are also aware that manufacturers are challenging our patent portfolio related to Kuvan in several jurisdictions, and one generic version of Kuvan has been approved by the European Medicines Agency (EMA), although it is not yet commercially available. If these patent challenges are successful, or if a manufacturer chooses to offer a generic version of Kuvan, notwithstanding our existing patents, our revenues may decline faster than expected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have in the past and may in the future enter into licensing arrangements, and we may not realize the benefits of such licensing arrangements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have in the past and may in the future enter into licensing arrangements with third parties. It is possible that we may not achieve financial or strategic benefits that justify a specific license, or we may otherwise not realize the benefits of such licensing arrangement. Further, licensing arrangements impose various diligence, milestone and royalty payment and other obligations on us. If we fail to comply with our obligations under any current or future licenses, our licensors may have the right to terminate these license agreements, which could harm our business prospects, financial condition and results of operations. Further, counterparties to our license agreements have in the past and may in the future allege that we have breached a license agreement, which can result in litigation or other disputes that can divert management&#8217;s attention away from our business and require us to expend resources, as well as potentially having to negotiate new or reinstated licenses with less favorable terms. Any such situation could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenues from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We must obtain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain Food and Drug Administration (FDA) approval for each product candidate that we intend to commercialize, and in the EU we must obtain approval from the European Commission (EC), based on the opinion of the Committee for Medicinal Products for Human Use of the EMA. The FDA and EC approval processes are typically lengthy and expensive, and approval is never certain. To obtain regulatory approval, we must first show that our product candidates are safe and effective for target indications through preclinical studies and clinical trials. Preclinical studies and clinical development are long, expensive and uncertain processes. Completion of clinical trials may take several years, and failure may occur at any stage of development. The length of time required varies substantially according to the type, complexity, novelty and intended use of a product candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory authority will mean that other authorities will also approve the same product candidate. Similarly, regulatory authorities may approve a product candidate for fewer or more limited indications than requested. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have had fewer interactions with regulatory authorities outside the U.S. and the EU as compared to our interactions with the FDA and EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EC approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EC does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by regulatory authorities in other non-U.S. countries or by the FDA or EC. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA or EC approval. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also rely on independent third-party CROs to file some of our non-U.S. marketing applications, and while we keep a close oversight on the activities we delegate to CROs, important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although the FDA and the EMA have programs to facilitate expedited development and accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. Accordingly, even if any of our applications receives a designation to facilitate expedited development and accelerated approval processes, these designations may not result in faster review or approval for our product candidates compared to product candidates considered for approval under conventional procedures and, in any event, do not assure ultimate approval of our product candidates by regulatory authorities. In addition, the FDA, the EMA and other comparable international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy to grant approval and may require additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">data. If we fail to obtain regulatory approval for our product candidates, we will be unable to market and sell those product candidates, which would have a negative effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may experience challenges specific to gene therapy that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials, the FDA has only approved a very small number of vector-based gene therapy products thus far. Moreover, there are very few approved gene therapy products outside the U.S. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our gene therapy product candidates in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. For example, in October 2020, it was reported that the Director of the Center for Biologics Evaluation and Research, the center of the FDA responsible for reviewing marketing applications for gene therapies, stated that the FDA will assess the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Additionally, in September 2021, the FDA held a Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) to discuss toxicity risks of adeno-associated virus (AAV) vectors for gene therapy and to seek the CTGTAC&#8217;s insight into strategies to evaluate and mitigate risks in the context of AAV vector-based product design and quality, preclinical studies, and clinical trials. Valoctocogene roxaparvovec and BMN 307 are AAV vector-based product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our treatment candidate or lead to significant post-approval studies, limitations or restrictions. For example, on August 18, 2020, the FDA issued a Complete Response Letter (CRL) to our BLA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for two-year follow-up safety and efficacy data on all study participants from our ongoing Phase 3 study of valoctocogene roxaparvovec. In January 2022, we announced results from the requested two-year data analysis from our Phase 3 study. We are planning to meet with the FDA to discuss resubmission of our BLA, including this two-year data analysis. The BLA resubmission is targeted for the second quarter of 2022. If the FDA deems our resubmission to be a complete response to the CRL, we expect the resubmission will be followed by a six-month review procedure by the FDA. With respect to BMN 307, in September 2021, the FDA placed a clinical hold on our PHEarless study. The hold was based on pre-clinical study findings from a model designed to understand the durability of BMN 307 activity in mice bearing two germline mutations, one rendering the mice immunodeficient. Of 63 animals treated, six of seven animals administered BMN 307 at the highest dose group (2e14 Vg/kg) had tumors on liver necropsy 52 weeks after dosing with evidence for integration of portions of AAV vector into the genome. No lesions were observed in any mice at 24 weeks. The clinical significance of these findings is being evaluated to assure safe and appropriate use of BMN 307. To date, we have seen no evidence from our studies or scientific literature indicating these findings are translatable to humans, species other than mice or other gene therapy vectors. The durability study was one of multiple pre-clinical studies we conducted and was not designed to test safety. However, we promptly notified the FDA upon availability of the integration site analysis results. The FDA initiated a clinical hold shortly after being notified, and we announced the hold before the next business day after we were informed of the FDA&#8217;s decision. In February 2022, the FDA requested data from additional non-clinical studies to assess the theoretical oncogenic risk to human study participants, which is expected to take several quarters. We will communicate next steps for the program when available. Continued delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring our gene therapy product candidates to market could have a negative effect on our business and financial condition. Even if we do obtain regulatory approval, ethical, social and legal concerns about gene therapy arising in the future could result in additional regulations restricting or prohibiting sale of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, some of our product candidates are intended to be used in combination with a medical device, such as an injector or other delivery system or companion diagnostic. Such products may be regulated as &#8220;combination products&#8221; in the U.S. and the EU, which are generally defined as products consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). In the U.S., each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. In the EU, if a device intended to administer a medicinal product is sold together with such medicinal product in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product is regulated as a medicinal product. In addition, the relevant general safety and performance requirements established for medical devices by EU medical devices legislation apply to the device component of such combination products. Our product candidates intended for use with separately regulated devices, or expanded indications that we may seek for our products used with such devices, may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug or biologic product and device is sought under a single application, the increased complexity of the review process may delay approval. The FDA review process and criteria are not well-established areas, which could also lead to delays in the approval process. In addition, because these devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time during the development and regulatory approval process for our products and product candidates, we engage in discussions with the FDA, the EMA and other comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory agencies globally, but we do not always follow such guidance. This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. Moreover, sometimes different regulatory agencies provide different or conflicting advice. While we attempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA, the EMA and other comparable international regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenues from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim have received regulatory approval to be commercially marketed and sold in the U.S., the EU and certain other countries, Palynziq has received regulatory approval to be commercially marketed in the U.S., the EU, and Australia</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Voxzogo has received regulatory approval to be commercially marketed in the U.S., the EU, and Brazil. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An example of the ongoing regulatory requirements our products are subject to is the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., Palynziq is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">prescribers must be certified by enrolling in the REMS program and completing training;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">prescribers must prescribe auto-injectable epinephrine with Palynziq;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">pharmacies must be certified with the REMS program and must dispense Palynziq only to patients who are authorized to receive it;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">patients must have auto-injectable epinephrine available at all times while taking Palynziq.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of Palynziq. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the Palynziq REMS program, or whether the FDA will permit modifications to the Palynziq REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute Palynziq in the U.S., impair the safety profile of Palynziq, disrupt continuity of care for Palynziq patients and/or negatively affect sales of Palynziq.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. In particular, a product may not be promoted for uses that are not approved by the FDA or the EC as reflected in the product&#8217;s approved labeling. Although the FDA and other comparable international regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. The FDA and other national competent authorities or international regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. Additionally, in the EU, it is prohibited to promote prescription drugs to the general public and we are therefore limited to promote our products exclusively to healthcare professionals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, if original FDA approval for one of our product candidates is granted via the accelerated approval pathway, we will be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of the FDA&#8217;s marketing approval for a product candidate. For example, Voxzogo is approved in the U.S. under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies. To fulfill this post-marketing requirement, we intend to use our ongoing open-label extension studies compared to available natural history. In addition, the FDA and the EC often require post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restrictions on product manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restrictions on the marketing of a product;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restrictions on product distribution;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">requirements to conduct post-marketing clinical trials;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">untitled or warning letters or other adverse publicity;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">product seizure;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">injunctions; or</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory authorities withdraws its approval of a product, we will be unable to generate revenues from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the drug development process we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early stage product candidates, we may need to perform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial will be favorable. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">slow or insufficient patient enrollment;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">slow recruitment of, and completion of necessary institutional approvals at, clinical sites;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">budgetary constraints or prohibitively high clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">longer treatment time required to demonstrate efficacy;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">lack of sufficient supplies of the product candidate;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">adverse medical events or side effects in treated patients, including immune reactions;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">lack of effectiveness of the product candidate being tested;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">availability of competitive therapies to treat the same indication as our product candidates;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">regulatory requests for additional clinical trials or preclinical studies;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">deviations in standards for Good Clinical Practice (GCP); and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services reportable to the FDA or other regulatory authority. If the FDA or other regulatory authority concludes that a financial relationship between us and a principal investigator has created a conflict of interest, the FDA or other regulatory authority may question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar rules governing clinical trials to those in place in the U.S. apply in the EU. Since January 31, 2022, a new Clinical Trials Regulation (CTR) is in force in the EU. The CTR was adopted with a view to introducing a more uniform set of the rules across the EU for the authorization of clinical trials. The relevant procedures have now been streamlined with a view to facilitating a swifter and more seamless authorization and deployment of multi-center trials occurring in more than one EU Member State. However, such authorization still involves the national regulatory authorities and Ethics Committees of each of the EU Member States where the trial is to be conducted. The CTD will continue to apply in parallel to the CTR for a transitional period. This means that clinical trials in the EU can currently be conducted in accordance with the requirements of the CTD, as implemented in national law by each EU Member State, or the CTR, as applicable, as well as applicable good clinical practice standards. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has recently come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected. For example, in the EU, governments influence the price of medicinal products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. An EU Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. Other EU Member States allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#8217; reimbursement policies will not adversely affect our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. Since its enactment, there have been executive, judicial and congressional challenges to certain aspects of the PPACA. Although the PPACA has generally been upheld thus far, it is unclear how continued challenges to the law may impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Recently there has been heightened governmental scrutiny in countries worldwide over the manner in which manufacturers set prices for their marketed products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., there have been several recent congressional inquiries, proposed and enacted federal and state legislation, and executive action designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition, individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, price disclosure and reporting requirements, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Likewise, in many EU Member States, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU Member States and other non-U.S. countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. If the price of one of our products decreases substantially in a reference price country, it could impact the price for that product in other countries. Consequently, a downward trend in prices of our products in some countries could contribute to similar downward trends elsewhere, which would have a material adverse effect on our revenues and results of operations. Moreover, in order to obtain reimbursement for our products in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our products to other available therapies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. In the EU, pursuant to the Orphan Regulation, orphan drug designation is available if a sponsor can establish that: (1) the medicine is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU at the time the application is made, or, (2) that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives derived from the orphan status, it is unlikely that the marketing of the medicine in the EU would generate sufficient return to justify the necessary investment. In both cases, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicine will be of significant benefit to those affected by that condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity (extendable to twelve years for orphan drugs that have complied with an agreed Pediatric Investigation Plan (PIP) pursuant to Regulation 1901/2006), during which similar medicines for the same indication cannot be placed on the market, is granted. MAs may also be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior to the orphan medicinal product already authorized; (ii) the MA holder for the first orphan medicinal product grants its consent; or (iii) if the MA holder of the orphan medicinal product is unable to supply sufficient quantities. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act and/or the Orphan Regulation, as applicable, to maintain a competitive position. If we do not obtain orphan drug exclusivity for our products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor product&#8217;s orphan drug exclusivity period expires. Moreover, with respect to certain biologics and gene therapies, there may be some uncertainty regarding how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidates&#8217; orphan drug exclusivities. For biologics and gene therapies, the FDA&#8217;s determination of whether a drug is the same drug or a different drug will be based on the principal molecular structural features of the products. For gene therapy products, the FDA has stated in guidance that it generally intends to consider certain key features such as transgenes and vectors used in gene therapy products to be principal molecular structural features. Further, even if we obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated approval of biological products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-approved biological product. A similar abridged MA process is available to biosimilar products in the EU. In particular, applicants for MAs of biosimilars are required to demonstrate through comprehensive comparability studies with the reference biological medicine that: a) their biological medicine is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines; and b) there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., in order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of exclusivity for reference products. In the EU, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or as a result of Marketing Authorization Applications (MAAs) in the EU, as well as our product candidates that may be approved in the future, could be reference products for biosimilar marketing applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in funding for the FDA, the EMA, other comparable international regulatory authorities and other government agencies or government shutdowns could hinder the ability of such agencies to hire and retain key leadership and other personnel or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in funding levels of government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA or the EMA to timely review and approve INDs or MAAs for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government shutdowns could also impact the ability of government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory agencies, such as the FDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Valoctocogene Roxaparvovec</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional development and treatment risks in relation to our other, more traditional drug development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the risks set forth in this Risk Factors section associated with developing more traditional pharmaceutical drugs, there are additional, unique development and treatment risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. The goal of gene therapy is to be able to correct an inborn genetic defect through administration of therapeutic genetic material containing non-defective gene copies. The gene copies are designed to reside permanently in a patient, allowing the patient to produce an essential protein or ribonucleic acid (RNA) molecule that a healthy person would normally produce. There is a risk, however, that the new gene copies will produce too little or too much of the desired protein or RNA. Although administration of a gene therapy product like our product candidate valoctocogene roxaparvovec is intended to correct an inborn genetic defect for at least several years, there is a risk that the therapeutic effect will not be durable and production of the desired protein or RNA will decrease more quickly or cease entirely earlier than expected. If the therapeutic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">effect decreases significantly or ceases entirely, it is uncertain whether redosing is possible or would be effective. Furthermore, because gene therapy treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential overproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Furthermore, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As compared to our other, more traditional products, our gene therapy product candidate valoctocogene roxaparvovec, if approved, may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the risks set forth in this Risk Factors section associated with commercializing more traditional pharmaceutical drugs, there are additional, unique commercial risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we face uncertainty with respect to the pricing, coverage and reimbursement of valoctocogene roxaparvovec, if approved. In order to recover our research and development costs and commercialize this one-time treatment on a profitable basis, we expect the cost of a single administration of valoctocogene roxaparvovec to be substantial. Therefore, we expect that coverage and reimbursement by governments and other third-party payers will be essential for the vast majority of patients to be able to afford valoctocogene roxaparvovec. Accordingly, sales of valoctocogene roxaparvovec, if approved, will depend substantially, both domestically and internationally, on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of valoctocogene roxaparvovec.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. Even if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product candidate in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of valoctocogene roxaparvovec until the product candidate has been on the market for a certain amount of time. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, valoctocogene roxaparvovec.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have implemented data access plans for our main clinical trials of valoctocogene roxaparvovec, which restrict our management&#8217;s review of emerging key efficacy data from these trials. Without access to this ongoing data, management does not have the ability to adjust the trials based on such emerging data, which could adversely impact the ultimate outcome of these trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to preserve the scientific integrity of our main valoctocogene roxaparvovec clinical trials and to allow us to only report on data at intervals that we believe will be meaningful to investors, we have implemented data access plans related to these ongoing open-label trials, which is designed to significantly mirror blinded trials. Pursuant to the plans, the ongoing emerging data for key endpoints are generally not accessed by us, with the exception that certain specific data points are reviewed by a small group of medical personnel monitoring and managing the trials, and then, only to the extent necessary to allow them to perform their monitoring responsibilities. As we disclose and publicly discuss prior data from one of these trials, such discussions do not incorporate any of the currently emerging data that are being collected and reviewed by personnel monitoring the trial and, accordingly, this prior data may differ significantly from more recent data that are only available to such personnel. Further, because our management does not have access to any of the ongoing key efficacy data and does not have the ability to adjust the trials based on such emerging data, the data access plans could adversely impact the ultimate outcome of the trials.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial and Financing Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we continue to incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for each year since our inception, with the exception of 2008, 2010 and 2020. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we fail to become profitable or are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments totaling $1.52 billion and debt obligations of $1.1 billion (undiscounted), which consisted of our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes) and our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes). The 2024 Notes and the 2027 Notes (collectively, the Notes), if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2016, we terminated our License and Commercialization Agreement with Ares Trading, S.A. (Merck Serono). Pursuant to the Termination and Transition Agreement related to Kuvan and the Termination Agreement related to Palynziq, we are obligated to make certain payments to Merck Serono if sales and development milestones are achieved. The remaining milestone payments that may become payable include up to a maximum of &#8364;60 million, in cash, if future sales milestones are met with respect to Kuvan and Palynziq.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may require additional financing to fund the repayment of the Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully market and sell our products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, number, size and scope of our preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress of research programs carried out by us;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">our possible achievement of development and commercial milestones under agreements with third parties, such as the Kuvan and Palynziq milestones under the termination agreements with Merck Serono;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Sanofi&#8217;s (formerly referred to as Sanofi Genzyme) ability to continue to successfully commercialize Aldurazyme; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">whether our convertible debt is converted to common stock in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional licenses and collaborative agreements;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional contracts for product manufacturing; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional financing facilities or arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional equity and/or equity-linked securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $1.1 billion (undiscounted) principal amount of indebtedness, including $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes and $600.0 million (undiscounted) principal amount of indebtedness under the 2027 Notes. In October 2018, we also entered into an unsecured credit agreement (the 2018 Credit Agreement) with Bank of America, N.A., as the administrative agent, swingline lender and a lender, Citibank, N.A. as letter of credit issuer and each of Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, Citibank, N.A. and Wells Fargo Securities, LLC as joint lead arrangers and joint bookrunners, providing up to $200.0&#160;million in revolving loan commitments (the 2018 Credit Facility). In May 2021, we amended the 2018 Credit Facility to, among other things, extend the maturity date of the 2018 Credit Facility from October 18, 2021 to May 28, 2024. Our indebtedness may:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">require us to use a substantial portion of our cash flow from operations to make debt service payments;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit our flexibility to plan for, or react to, changes in our business and industry;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">place us at a competitive disadvantage compared to our less leveraged competitors; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">increase our vulnerability to the impact of adverse economic and industry conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the 2018 Credit Facility contains, and any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full. If we default under the 2018 Credit Facility, the outstanding borrowings thereunder could become immediately due and payable, the 2018 Credit Facility lenders could refuse to permit additional borrowings under the facility, or it could lead to defaults under agreements governing our current or future indebtedness, including the indentures governing the Notes. If we default under any series of the Notes, such series of Notes could become immediately due and payable and it could lead to defaults under the other series of Notes and/or the 2018 Credit Facility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our outstanding indebtedness consists primarily of the 2024 Notes and 2027 Notes, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon maturity of the Notes, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we also may borrow up to $200.0&#160;million in revolving loans under the 2018 Credit Facility, which would be required to be repaid in cash at maturity on May 28, 2024.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Manufacturing Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Before we can begin commercial manufacture of our products, regulatory authorities must approve marketing applications that identify manufacturing facilities operated by us or our contract manufacturers that have passed regulatory inspection and manufacturing processes that are acceptable to the regulatory authorities. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced inspection by the FDA, and other comparable EU and other international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facility in the U.S. has been approved by the FDA and the EC for the manufacture of Palynziq, and it has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Aldurazyme, Brineura, Naglazyme, Vimizim and Voxzogo.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our manufacturing facility in Shanbally, Cork, Ireland has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Vimizim and Brineura. In addition, our third-party manufacturers&#8217; facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal or international regulatory inspection.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our product candidates and products, we may not be able to manufacture sufficient quantities. Our inability to produce enough of our product candidate at acceptable costs may result in the delay or termination of development programs. With respect to our commercial portfolio, we may not be able to manufacture our products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to valoctocogene roxaparvovec, gene therapy products are relatively novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the valoctocogene roxaparvovec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all, or commercializing valoctocogene roxaparvovec on a profitable basis, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We currently rely on third parties for portions of the manufacture of each of our commercial products. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our manufacturing processes subject us to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We depend on single-source suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">labor interruptions;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in our sources for manufacturing;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing and delivery of shipments;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">conditions affecting the cost and availability of raw materials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If our Manufacturing, Marketing and Sales Agreement with Sanofi were terminated, we could be prevented from continuing to commercialize Aldurazyme or our ability to successfully commercialize Aldurazyme would be delayed or diminished.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Sanofi and us related to Aldurazyme for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching party&#8217;s interest in Aldurazyme and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to Aldurazyme and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating party&#8217;s interest in Aldurazyme and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to Aldurazyme will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to Aldurazyme is to be sold to the highest bidder, with the proceeds to be split between Sanofi and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to Aldurazyme exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offeree&#8217;s interest in Aldurazyme and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating party&#8217;s interest in Aldurazyme and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to Aldurazyme. The Amended and Restated Collaboration Agreement between us and Sanofi will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we were obligated or given the option to buy out Sanofi&#8217;s interest in Aldurazyme and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to Aldurazyme, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Sanofi&#8217;s interest, we may be held in breach of the agreement and may lose any claim to the rights to Aldurazyme and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing Aldurazyme. If this happened, not only would our product revenues decrease, but our share price would also decline.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to International Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the sales of Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim are generated from countries other than the U.S. Similarly, we expect a significant portion of the sales of Voxzogo to be generated from countries other than the U.S. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">the increased complexity and costs inherent in managing international operations;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">political and economic instability, such as the instability caused by Russia&#8217;s invasion of Ukraine;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property in some countries outside of the U.S.;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">trade protection measures and import or export licensing requirements;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulty in staffing and managing international operations;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">differing labor regulations and business practices;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">potentially negative consequences from changes in or interpretations of tax laws;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in international medical reimbursement policies and programs;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by non-U.S. governments;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; and service providers&#8217; activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russia&#8217;s invasion of Ukraine and the related impacts to Ukraine&#8217;s infrastructure and healthcare system has significantly impacted our ability to provide our therapies to patients in Ukraine. Sanctions issued by the U.S. and other countries against Russia in response to its attack on Ukraine and related counter-sanctions issued by Russia have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenues and profitability.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenues in these countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We make a significant portion of our international sales of Brineura, Naglazyme and Vimizim through early access, special access or &#8220;named patient sales&#8221; programs in markets where we are not required to obtain regulatory approval, and we expect a significant portion of our international sales of Voxzogo will also be through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained to initiate such programs, and in some cases, special approval must be obtained for each patient. The approval normally requires an application or a lawsuit accompanied by evidence of medical need.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These programs are not well defined in some countries and are subject to changes in requirements, funding levels, unmet medical need and classification of the disease treated by our product. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders, requiring additional in-country testing and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Without the special access programs, we would need to seek full product approval or official reimbursement to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek, obtain and maintain a full product approval or official reimbursement, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*U.S. export control and economic sanctions may adversely affect our business, financial condition and operating results. Moreover, compliance with such regulatory requirements may increase our costs and negatively impact our ability to sell our products and collect cash from customers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or hinder our ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. For example, sanctions issued by the U.S. against Russia in response to its invasion of Ukraine have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia. Moreover, if we fail to comply with these laws and regulations, we could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges and fines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, the general license will be renewed in the future or we will remain in compliance with the general license. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, U.S. export control and economic sanctions may make operating in certain countries more difficult and expensive. For example, we may be unable to find distributors or financial institutions willing to facilitate the sale of our products and collection of cash from such sales in a cost-effective manner, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the U.S. and other similar laws in other countries in which we do business. We operate in a number of countries that are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered non-U.S. government officials for purposes of applicable anti-corruption laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party independent charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our international operations pose currency risks, which may adversely affect our operating results and net income.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant and growing portion of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the Great British Pound, the Canadian Dollar and several other currencies, changes in those currencies relative to the U.S. Dollar (USD) will impact our revenues and expenses. If the USD were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the USD were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. In addition, because our financial statements are reported in USD, changes in currency exchange rates between the USD and other currencies have had, and will continue to have, an impact on our results of operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of Aldurazyme, Naglazyme and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in Kuvan) has also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Patents have limited duration and expire. </span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, and the implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is also unclear whether our trade secrets are adequately protected. Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, clinical trial data submitted to the EMA in MAAs that were traditionally regarded as confidential commercial information are now subject to public disclosure. Subject to our ability to review and redact a narrow sub-set of confidential commercial information, the EU policies have resulted and will continue to result in the EMA&#8217;s public disclosure of certain of our clinical study reports, clinical trial data summaries and clinical overviews for recently completed and future MAA submissions. The move toward public disclosure of development data could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, and enabling competitors to use our data to gain approvals for their own products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Competitors may interfere with our patent process in a variety of ways. Competitors may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, a competitor could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent. Moreover, generic manufacturers may use litigation and regulatory means to obtain approval for generic versions of our products notwithstanding our filed patents or patent applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenues and financial results generally.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, such as valoctocogene roxaparvovec, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. If someone else claims we infringe its intellectual property, we would face a number of issues, including the following:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Defending a lawsuit takes significant executive resources and can be very expensive.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">If a court decides that our product infringes a competitor&#8217;s intellectual property, we may have to pay substantial damages.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may need to redesign our product so it does not infringe the intellectual property rights of others. </span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">Redesigning our product so it does not infringe the intellectual property rights of competitors may not be possible or could require substantial funds and time.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Securities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our stock price has been and may in the future be volatile, and an investment in our stock could suffer a decline in value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our stock price has been and may in the future be volatile. Our valuation and stock price may have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock will fluctuate due to factors including: </span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">product sales and profitability of our products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturing, supply or distribution of our product candidates and commercial products;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">results of clinical trials, announcements of technological innovations or new products by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">generic competition to Kuvan tablets and powder relating to our settlements with the two pharmaceutical companies described above in this Risk Factors section or potential generic competition from future competitors;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">government regulatory action affecting our product candidates, our products or our competitors&#8217; product candidates and products in both the U.S. and non-U.S. countries;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments or disputes concerning patent or proprietary rights;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">economic conditions in the U.S. or abroad;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative publicity about us or the pharmaceutical industry;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">cybersecurity incidents experienced by us or others in our industry;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">broad market fluctuations in the U.S., the EU or in other parts of the world;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">actual or anticipated fluctuations in our operating results, including due to timing of large periodic orders for our products by governments in certain countries;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in company assessments or financial estimates by securities analysts;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">acquisitions of products, businesses, or other assets; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, the stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In some cases, these fluctuations have been unrelated or disproportionate to the operating performance of those companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. For example, in September 2020, after a substantial drop in our stock price that followed an announcement providing a regulatory update regarding valoctocogene roxaparvovec, we and certain of our officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. In addition, in October 2021, after a drop in our stock price that followed an announcement providing a regulatory update regarding BMN 307, we and certain of our current and former officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. We may be the target of additional litigation of this type in the future as well. Securities litigation against us could result in substantial costs and divert our management&#8217;s time and attention from other business concerns, which could harm our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Conversion of the Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholders&#8217; meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take us over.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of us would trigger options by the respective holders of the applicable Notes to require us to repurchase such Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the Notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the U.S. as the exclusive forums for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any derivative claim or cause of action brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action for breach of a fiduciary duty owed by any director, officer or other employee of BioMarin to us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action against us or any of our directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate of incorporation or our amended and restated bylaws;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction to the Court of Chancery of the State of Delaware; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.8pt">any claim or cause of action against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. In addition, our amended and restated bylaws provide that the federal district courts of the U.S. of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either of our exclusive forum provisions to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. Our amended and restated bylaws further provide that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provisions.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We depend upon our key personnel and our ability to attract and retain qualified employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of a significant portion of our workforce or any member of our senior management or the inability to hire or retain qualified personnel could adversely affect our ability to execute our business plan and harm our operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the specialized nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officers&#8217; ability to compete with us after their employment is terminated. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. This competition has been exacerbated during the COVID-19 pandemic, and we have recently experienced increased employee turnover like many other employers in the U.S. during the &#8220;great resignation.&#8221; Due to the intense competition for talent, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. If we are unsuccessful in our recruitment and retention efforts, our business may be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our success depends on our ability to manage our growth.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product candidates that we are currently developing or may license or acquire in the future may be intended for patient populations that are significantly larger than any of the patient populations we currently target. In order to continue development and marketing of these products, if approved, we will need to significantly expand our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory and corruption risks and our management may be unable to manage successfully future market opportunities or our relationships with customers and other third parties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*New tax laws or regulations that are enacted or existing tax laws and regulations that are interpreted, modified or applied adversely to us or our customers may have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (TCJA), as modified in 2020 by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, the application of certain tax credits (including a reduction of tax credits under the Orphan Drug Act), the deductibility of expenses, the utilization of net operating losses and other deferred tax assets, and the taxation of non-U.S. earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA, the CARES Act or other existing or future laws may affect us, and certain aspects of existing laws could be repealed or modified in future legislation that is proposed or implemented by the current or a future U.S. presidential administration, Congress or other governmental authorities. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the CARES Act, or any newly enacted tax legislation. The impact of changes under the TCJA, the CARES Act, or future legislation could increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, changes in the tax laws of non-U.S. jurisdictions could arise, including as a result of the base erosion and profit shifting (BEPS) project that is being led by the Organization for Economic Co-operation and Development (OECD), and other initiatives led by the OECD or the EC. For example, the OECD, which represents a coalition of member countries including the U.S. and other countries in which we have operations, is coordinating the implementation of rules intended to be adopted from 2023 with the aim of addressing the tax challenges arising from the digitalization of the economy, specifically with respect to nexus and profit allocation and global minimum taxation. The implementation of any such rules would fundamentally change the international tax system. These changes, as adopted by countries, may increase tax uncertainty and may adversely affect our provision for income taxes, results of operations and cash flows. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#8217;s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, resulting in a higher tax liability. In addition, if a country from which income is reallocated does not agree with the reallocation, both that country and the other country to which the income was allocated could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">government healthcare programs, which may adversely affect our business, reputation, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase, order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state false claims laws, including the civil False Claims Act and the Civil Monetary Penalties Law, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, recent healthcare reform legislation has strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and non-U.S. laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the U.S., California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California consumers expanded rights to access and delete their personal information, opt out of certain personal information sales, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA will be expanded substantially on January 1, 2023 when the California Privacy Rights Act of 2020 (CPRA), becomes fully operative. The CPRA will, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, expand an individual&#8217;s private right of action and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. In addition to California, other U.S. states have recently adopted consumer data protection and privacy laws, and more U.S. states may do so in the future. Aspects of the CCPA, CPRA and similar laws in other states and their interpretation and enforcement remain uncertain. The potential effects of these laws are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Complying with these or other similar laws, regulations, amendments to or re-interpretations of existing laws and regulations, and contractual or other obligations relating to privacy, data protection, data transfers, data localization, or information security may require us to make changes to our services to enable us or our customers to meet new legal requirements, incur substantial operational costs, modify our data practices and policies, and restrict our business operations. Any actual or perceived failure by us to comply with these laws, regulations, or other obligations may lead to significant fines, penalties, regulatory investigations, lawsuits, significant costs for remediation, damage to our reputation, or other liabilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EEA Member State legislations supplementing such regulation, apply to the processing of personal data of individuals located in the EEA, including health-related information, by companies located in the EEA, or in certain circumstances, by companies located outside of the EEA. These laws impose strict obligations on the ability to collect, record, store, disclose, use and transmit personal data, including health-related information. These include several requirements relating to (i) obtaining, in some situations, the informed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). Switzerland has adopted similar restrictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The GDPR and other European data protection laws generally restrict the transfer of personal information from Europe, including the EEA and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from the EEA has been the EC&#8217;s Standard Contractual Clauses (SCCs). However, the Court of Justice of the EU (CJEU) issued a decision that called into question whether the SCCs can lawfully be used for transfers of personal information from Europe to the United States or most other countries. At present, there are few, if any, viable alternatives to the SCCs, on which we have relied for personal information transfers from Europe to the United States and other &#8220;third countries.&#8221; After the mentioned CJEU judgment, new sets of SCCs were published on June 4, 2021. Entities having entered into the old SCCs before September 27, 2021 will be able to rely on them for a transition period ending December 27, 2022. Most importantly, the use of SCCs does not any longer automatically ensure compliance with the GDPR. Instead, companies remain required to conduct a data transfer impact assessment for each transfer, which adds a compliance burden.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Potential pecuniary fines for noncompliance with the GDPR may be up to the greater of &#8364;20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process and has increased our compliance costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Substantial new laws and regulations affecting compliance have also been adopted in the U.S. and certain non-U.S. countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as investment and ownership interests held by such physicians and their immediate family members during the preceding calendar year. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many non-U.S. countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted non-U.S. legislation creates reporting obligations on payments, gifts and benefits made to these professionals; however, implementing regulations enacting such laws are still pending and subject to varying interpretations by courts and government agencies. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement agencies in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to significant criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">commitment of capital resources that might otherwise be available for the development and commercialization of our product programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively and have a material adverse effect on our business, reputation, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely significantly on our information technology systems to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse (whether intentional or inadvertent) of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively. Our ability to manage and maintain our operations, inventory and internal reports, to manufacture and ship our products to customers and timely invoice them depends significantly on our enterprise resource planning, production management and other information systems. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, cyberattack and other disruptions. Potential problems and interruptions associated with the implementation of new or upgraded technology systems or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations and expose us to greater risk of security breaches. Cybersecurity incidents, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems are becoming increasingly frequent and more sophisticated. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access or unavailability of these systems, have occurred in the past and may affect our ability in the future to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties for which we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation. Data security breaches may be the result of unauthorized or unintended activity (or lack of activity) by our employees or contractors or malware, hacking, business email compromise, phishing, ransomware or other cyberattacks directed by third parties. Third parties for which we depend on to operate our business have experienced and may continue to experience cybersecurity incidents. While we have implemented measures to protect our information and data stored in our technology systems and those of the third parties that we rely on, our efforts may not be successful.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have experienced and may continue to experience cybersecurity incidents. Although to our knowledge we have not experienced any material incident or interruption to date, if such an event were to occur it could result in a material disruption of our development programs and commercial operations, including due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information. Further, these cybersecurity incidents can lead to the public disclosure of personal information (including sensitive personal information) of our employees, clinical trial patients and others and result in demands for ransom or other forms of blackmail. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#8220;hacktivists&#8221;, nation states and others. Moreover, the costs to us to investigate and mitigate cybersecurity incidents could be significant. For example, the loss of clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security breach that results in the unauthorized access, use or disclosure of personal data may require us to notify individuals, governmental authorities, credit reporting agencies, or other parties pursuant to privacy and security laws and regulations or other obligations. Such a security compromise could harm our reputation, erode confidence in our information security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, proprietary or personal information, we could be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims, litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If a natural disaster, terrorist or criminal activity or other unforeseen event caused significant damage to our facilities or those of our third-party manufacturers and suppliers or significantly disrupted our operations or those of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair the ability for us or our third-party manufacturers to manufacture our products and product candidates. Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for Aldurazyme, Naglazyme, Voxzogo and Palynziq and is one of two manufacturing facilities for Brineura and Vimizim. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support valoctocogene roxaparvovec clinical development activities and the anticipated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">commercial demand for valoctocogene roxaparvovec, if approved. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely, impaired, and our commercialization efforts and revenues could be seriously impaired. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, other unforeseen events, such as power outages, could significantly disrupt our operations or those of our third-party manufacturers and suppliers, which could result in significant delays in the manufacture of our products and adversely impact our commercial operations and revenues. Pacific Gas and Electric Company, the electric utility in the San Francisco Bay Area where many of our facilities are located, commenced widespread blackouts during the fall of 2019 to avoid and contain wildfires sparked during strong wind events by downed power lines or equipment failures. While we have not experienced damage to our facilities or material disruption to our operations as a result of these power outages, ongoing blackouts, particularly if prolonged or frequent, could impact our business going forward. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our business is affected by macroeconomic conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counter parties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenues would be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_118"></div><div style="margin-top:10pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_121"></div><div style="margin-top:10pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_124"></div><div style="margin-top:10pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="icd2b94b05172492a9fffc0163ccafcc1_127"></div><div style="margin-top:10pt;padding-left:90pt;text-indent:-90pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312516423476/d117941dex21.htm">Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312516423476/d117941dex23.htm">Termination and Transition Agreement, dated as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.3 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1048477/000156459017002483/bmrn-ex26_494.htm">First Amendment, dated as of December 12, 2016, to the Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015 and effective as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on February 27, 2017 as Exhibit 2.6 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex32.htm">Restated Certificate of Incorporation of BioMarin Pharmaceutical Inc., previously filed with the SEC on June 12, 2017 as Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1048477/000119312520321537/d52330dex31.htm">Amended and Restated Bylaws of BioMarin Pharmaceutical Inc., previously filed with the SEC on December 18, 2020 as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="brmn-31mar22xexx101.htm">Asset Purchase Agreement by and between Eli Lilly and Company, BioMarin Pharmaceutical Inc., and BioMarin International Ltd., dated February 8, 2022. Portions of this exhibit have been omitted because they are not material and the type that the registrant treats as private or confidential</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit311-31mar22x10q.htm">Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit312-31mar22x10q.htm">Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit321-31mar22x10q.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Certification accompanies this report and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL tags for the cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022, are embedded within the Inline XBRL document.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any of the Registrant&#8217;s filings under the Securities Act of 1933, as amended, irrespective of any general incorporation language contained in any such filing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i)&#160;Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021, (ii)&#160;Condensed Consolidated Statements of Comprehensive Income for the three months ended March&#160;31, 2022 and 2021, (iii)&#160;Condensed Consolidated Statement of Stockholders&#8217; Equity for the three months ended March&#160;31, 2022 and 2021, (iv)&#160;Condensed Consolidated Statements of Cash Flows for the three months ended March&#160;31, 2022 and 2021, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="icd2b94b05172492a9fffc0163ccafcc1_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icd2b94b05172492a9fffc0163ccafcc1_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: April 29, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/&#160;BRIAN R. MUELLER</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Brian R. Mueller</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Executive&#160;Vice&#160;President, Finance &amp; Chief&#160;Financial&#160;Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Principal Accounting Officer)</span></div></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brmn-31mar22xexx101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i932828622e724cf9a2aa2b7175f2d5d5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN INFORMATION, IDENTIFIED BY, AND REPLACED WITH, A MARK OF &#8220;&#91;***&#93;&#8221; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Asset Purchase Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Eli Lilly and Company,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioMarin Pharmaceutical Inc.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">And</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioMarin International Ltd.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February 8, 2022</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i932828622e724cf9a2aa2b7175f2d5d5_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Asset Purchase Agreement</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Asset Purchase Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made and entered into as of February 8, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by and among Eli Lilly and Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), BioMarin Pharmaceutical Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">BPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and BioMarin International Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Buyer, BPI, and Seller may hereinafter be referred to individually as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Seller is the sole beneficial owner of a Priority Review Voucher (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, BPI is the nominal holder of the Priority Review Voucher on behalf of Seller, its wholly-owned Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Seller, BPI, and Buyer each (i) desire that Buyer purchase from Seller, and Seller sell, transfer and assign to Buyer, the Priority Review Voucher and all rights, benefits and entitlements appurtenant thereto, all on the terms set forth herein (such transaction, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Asset Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (ii), in furtherance thereof, have adopted and approved this Agreement and, upon the terms and subject to the conditions set forth in this Agreement, have approved the Asset Purchase and the other transactions contemplated by this Agreement in accordance with all applicable Legal Requirements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Seller, BPI, and Buyer desire to make certain representations, warranties, covenants and other agreements in connection with the Asset Purchase as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and their mutual undertakings hereinafter set forth, and intending to be legally bound, the Parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>CERTAIN DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As used in this Agreement, the following terms shall have the meanings indicated below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.8pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any Person which, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with a Party to this Agreement, for so long as such control exists, whether such Person is or becomes an Affiliate on or after the Effective Date.  A Person shall be deemed to &#8220;control&#8221; another Person if it&#58; (i) with respect to such other Person that is a corporation, owns, directly or indirectly, beneficially or legally, at least fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by such Person in a particular jurisdiction) of such other Person, or, with respect to such other Person that is not a corporation, has other comparable ownership interest&#59; or (ii) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of such other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day (i)&#160;other than Saturday or Sunday and (ii)&#160;on which commercial banks are open for business in New York, New York.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) any and all confidential and proprietary information, including but not limited to, data, results, conclusions, know-how, experience, financial information, plans and forecasts, that may be delivered, made available or communicated by a Party or its Representatives related to the subject matter hereof or otherwise in connection with this Agreement and (ii) the terms, conditions and existence of this Agreement.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will not include information that (A) is available to the public other than as a result of a disclosure by a receiving Party or its Representatives in breach of this Agreement, (B) becomes available to the recipient of such information from a third party that is not legally or contractually prohibited by the disclosing Party from disclosing such Confidential Information&#59; or (C) was developed by or for the recipient of such information without the use of or reference to any of the Confidential Information of the disclosing Party or its Affiliates.  Notwithstanding anything herein to the contrary, all Confidential Information included </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">within the Purchased Assets shall constitute Confidential Information of the Buyer from and after the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any written or oral legally binding contract, agreement, instrument, commitment or undertaking (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts and purchase orders).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Encumbrance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any lien, pledge, charge, mortgage, easement, encroachment, imperfection of title, title exception, title defect, right of possession, right of negotiation or refusal, lease, security interest, encumbrance, adverse claim, interference or restriction on use or transfer.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:25.02pt">&#8220;FDA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the United States Food and Drug Administration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.18pt">&#8220;FDA Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the United States Federal Food, Drug, and Cosmetic Act, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">FDA Approval Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the letter, dated November 19, 2021, from the FDA to Seller, Reference ID 4905458, regarding the approval of the NDA 214938 for Voxzogo (vosoritide).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any (i) supranational, national, state, municipal, local or foreign government, (ii) any court, tribunal, arbitrator, administrative agency, commission or other governmental official, authority or instrumentality, in each case whether domestic or foreign, (iii) any stock exchange or similar self-regulatory organization, or (iv) any quasi-governmental or private body exercising any regulatory, taxing or other governmental or quasi-governmental authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any federal, state, foreign, local, municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity and any orders, writs, injunctions, awards, judgments and decrees applicable to a Party or to any of its assets, properties or businesses.  Legal Requirements shall include, with respect to BPI and Seller, any responsibilities, requirements, conditions, parameters and obligations relating to the Priority Review Voucher set forth in the FDA Approval Letter or in any other correspondence received by Seller, BPI or their respective Affiliates from the FDA regarding the Priority Review Voucher and Section 529 of the FDA Act (21 U.S.C. 360ff).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means all debts, liabilities and obligations, whether presently in existence or arising hereafter, accrued or fixed, absolute or contingent, matured or unmatured, determined or determinable, asserted or unasserted, known or unknown, including those arising under any law, action or governmental order and those arising under any Contract.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means new drug application.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any natural person, company, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint venture, business organization or Governmental Entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.18pt">&#8220;Priority Review&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means a priority review of and action upon a human drug application by the FDA not later than six (6) months after the filing of such application to the FDA, as defined in the FDA Act (21 U.S.C. 360ff).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.18pt">&#8220;Priority Review Voucher&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the priority review voucher issued by the FDA to BPI, as evidenced by the FDA Approval Letter and with the tracking number PRV NDA 214938, as the sponsor of a rare pediatric disease product application, that entitles the holder of such voucher to Priority Review of a single human drug application submitted under Section 505(b)(1) of the FDA Act or a single biologic application Section 351 of the United States Public Health Service Act, as further defined in the FDA Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any claim, action, arbitration, audit, hearing, investigation, litigation, proceeding or suit (whether civil, criminal, administrative, judicial or investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity or arbitrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:24.4pt">&#8220;Purchased Assets&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the Priority Review Voucher.  The Purchased Assets shall include any and all rights, benefits and entitlements afforded to the holder thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regulatory Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any (i) new Legal Requirement, amendment or supplement to any then-existing Legal Requirement, or (ii) new, amended or supplemented term or condition imposed on the Priority Review Voucher that is not set forth in the FDA Approval Letter, that in either case (i) or (ii) has been enacted, adopted, approved or imposed between the Effective Date and the Closing Date and adversely impacts the manner in which Buyer may use, receive, hold or otherwise exploit the Priority Review Voucher.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular Person, any director, officer, manager, employee, agent, consultant, advisor, accountant, financial advisor, legal counsel or other representative of that Person.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other capitalized terms defined elsewhere in this Agreement and not defined in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall have the meanings assigned to such terms in this Agreement.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE II</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%;text-decoration:underline">PURCHASE AND SALE</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Purchase and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon the terms and subject to the conditions of this Agreement, Buyer agrees to purchase (a) from Seller, and Seller agrees to sell, transfer, convey, assign and deliver to Buyer at the Closing, all of Seller&#8217;s right, title and interest in, to and under the Purchased Assets, free and clear of all Encumbrances and (b) from BPI, and BPI agrees to sell, transfer, convey, assign and deliver to Buyer at the Closing, BPI&#8217;s nominal record interest in the Purchased Assets, which constitutes BPI&#8217;s sole interest in the Purchased Assets, free and clear of all Encumbrances.  Seller and BPI shall perform all actions necessary to cause the transfer of all right, title and interest in, to and under the Purchased Assets to Buyer.  For the avoidance of doubt, the sale, transfer, conveyance and assignment of the Purchased Assets by Seller and BPI to Buyer shall not include the sale, transfer, conveyance or assignment of any Liabilities from BPI or Seller to Buyer and Buyer shall not assume or otherwise be liable for any Liabilities of Seller, BPI or their respective Affiliates, including Liabilities related to the Purchased Assets (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Excluded Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The closing of the purchase and sale of the Purchased Assets contemplated hereby (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall take place remotely via the exchange of documents and signatures on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) Business Day after all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> have been satisfied or waived (other than those conditions which, by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) or at such other time and place as Buyer and Seller agree upon in writing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The total consideration to be paid by Buyer for all of the Purchased Assets shall be US$110,000,000 (One Hundred and Ten Million U.S. DOLLARS) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  All payments to Seller shall be made in cash by wire transfer of immediately available funds to the bank account previously specified by Seller in writing to Buyer or such other bank account specified by Seller in writing to Buyer before the Closing Date. For all tax purposes, the entire Purchase Price shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be allocated to the Priority Review Voucher, and Buyer and Seller shall make any and all required tax filings consistent therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Closing Deliverables&#59; Title Passage&#59; Delivery of Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Seller Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At the Closing, Seller and BPI shall deliver, or cause to be delivered to Buyer, each of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">a Bill of Sale in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> duly executed by Seller and BPI&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">a letter addressed to Buyer, substantially in the form set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto and duly executed by BPI, acknowledging the transfer of the Priority Review Voucher from BPI to Buyer, in accordance with applicable Legal Requirements (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Seller FDA Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Buyer Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At the Closing, Buyer shall deliver, or cause to be delivered to Seller, each of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the Purchase Price&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">a letter addressed to BPI, substantially in the form set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto and duly executed by Buyer, acknowledging the transfer of the Priority Review Voucher from BPI to Buyer, in accordance with applicable Legal Requirements (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Buyer FDA Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Title Passage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon the Closing, all of the right, title and interest in and to the Purchased Assets shall pass to Buyer, free and clear of all Encumbrances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Method of Delivery of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If reasonably practicable, on the Closing Date, but in any event within three (3) Business Days after the Closing, BPI shall duly submit to the FDA the Seller FDA Letter and Buyer shall duly submit to the FDA the Buyer FDA Letter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Filings&#59; Notifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer, BPI, and Seller agree to cooperate and assist each other with respect to all filings or notifications to any Governmental Entity related to the transfer and assignment of the Purchased Assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Joint and Several Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All obligations and other Liabilities of each of Seller and BPI hereunder are joint and several and are enforceable in full against each such Party.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>REPRESENTATIONS AND WARRANTIES OF SELLER AND BPI</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Seller and BPI, on a joint and several basis, represent and warrant to Buyer, as of the date hereof and as of the Closing Date, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Organization, Standing and Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller is a corporation duly organized and validly existing under the laws of Ireland.  Seller has the requisite corporate power and authority to own, operate and lease its properties and to carry on its business as presently conducted and is duly qualified or licensed to do business and is in good standing in each jurisdiction where the character of its properties owned or leased or the nature of its activities make such qualification or licensing necessary, except where the failure to be so qualified or licensed would not, individually or in the aggregate, reasonably be expected to adversely affect any of the Purchased Assets, Seller&#8217;s or BPI&#8217;s ability to consummate the transactions contemplated by this Agreement or Buyer&#8217;s ownership and rights with respect to any of the Purchased Assets after the Closing.  Seller is not in violation of its articles of incorporation or bylaws, in each case as amended to date.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Due Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller has the requisite corporate power and authority to execute, deliver, perform its obligations under, and consummate the transactions contemplated by, this Agreement.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">execution, delivery and performance of this Agreement, and the consummation of the Asset Purchase, have been duly and validly approved and authorized by all necessary corporate action on the part of Seller, and this Agreement has been duly executed and delivered by Seller.  This Agreement, upon execution by the Parties, will constitute a valid and binding obligation of Seller enforceable against Seller in accordance with its terms, subject only to the effect, if any, of (a)&#160;applicable bankruptcy and other similar laws affecting the rights of creditors generally and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Noncontravention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The execution and delivery by Seller and BPI of this Agreement does not, and the consummation of the transactions contemplated hereby, including the transfer of title to, ownership in, and possession of the Purchased Assets, will not, (a)&#160;result in the creation of any Encumbrance on any of the Purchased Assets or (b)&#160;conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, revocation, suspension, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, (i)&#160;any provision of the articles of incorporation or bylaws of Seller or BPI, in each case as amended to date, (ii) the Priority Review Voucher, the FDA Approval Letter or any Contract that involves or affects in any way any of the Purchased Assets or (iii) except as may be required to comply with the HSR Act, any Legal Requirements applicable to Seller, BPI or any of the Purchased Assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for the submission of the Seller FDA Letter and the filing of a Premerger Notification and Report Form under the HSR Act, no filing, authorization, consent, approval, permit, order, registration or declaration, governmental or otherwise, is required in connection with, or necessary to enable or authorize Seller or BPI to, enter into, perform its obligations under and consummate the transactions contemplated by this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Title to Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for BPI&#8217;s record ownership of the Purchased Assets, Seller is the sole and exclusive owner of all right, title and interest in and to the Purchased Assets and owns good and transferable title to the Purchased Assets free and clear of any Encumbrances.  Seller has performed all actions necessary to perfect its ownership of, and its ability to transfer, the Purchased Assets.  Seller has the full right to sell, transfer, convey, assign and deliver the Purchased Assets to Buyer at the Closing, free and clear of all Encumbrances.  The right, title and interest in and to the Purchased Assets that is to be sold, transferred, conveyed, assigned and delivered by Seller and BPI to Buyer at the Closing in accordance with this Agreement collectively constitutes the entire right, title and interest in and to the Purchased Assets and immediately following the Closing, Buyer shall have all right, title and interest in and to the Purchased Assets, free and clear of all Encumbrances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for this Agreement, there is no Contract to which Seller or BPI or any Affiliate of Seller or BPI is a party or is otherwise bound by that involves or affects (or may involve or affect) the issuance of, ownership of, transfer of, licensing of, title to, or use of any of the Purchased Assets. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Compliance With Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller, BPI and their respective Affiliates are, and at all times have been, in full compliance with each Legal Requirement that is or was applicable to (a) Seller&#8217;s, BPI&#8217;s and their respective Affiliates conduct, acts, or omissions with respect to any the Purchased Assets or (b) any of the Purchased Assets.  None of Seller, BPI or their respective Affiliates have received any written notice or other communication or, to its Knowledge, any oral notice or other oral communication, from any Person regarding any actual, alleged, possible or potential violation of, or failure to comply with, any such Legal Requirement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Legal Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There is no pending, or to Seller&#8217;s or BPI&#8217;s Knowledge, threatened Proceeding nor has there been an Proceeding involving Seller, BPI or any of their respective Affiliates, and neither Seller, BPI nor any of their respective Affiliates are a party or subject to the provisions of any judgment, and to the Knowledge of Seller and BPI, there are no any facts or circumstances that could reasonably be expected to serve as a basis for a Proceeding involving Seller, BPI or any their respective Affiliates, (a) that involves or affects (or may involve or affect) the ownership of, licensing of, title to, validity of, ability to transfer or use of any of the Purchased Assets or (b) challenging the transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">contemplated by this Agreement.  None of the Purchased Assets are subject to any order of any Governmental Entity or arbitrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Governmental Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  None of Seller, BPI or any of their respective Affiliates is required to hold any license, registration, or permit issued by any Governmental Entity to own, use or transfer the Purchased Assets, other than such licenses, registrations or permits that have already been obtained.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller and BPI are not entering into this Agreement with the actual intent to hinder, delay, or defraud any creditor of Seller or BPI.  The remaining assets of Seller and BPI after the Closing will not be unreasonably small in relation to the business in which Seller and BPI, respectively, will engage after the Closing.  After the Closing, Seller and BPI will each have the ability to pay their debts as they become due.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Revocation&#59; Use of Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Priority Review Voucher has not been terminated, cancelled or revoked.  None of Seller, BPI or any of their respective Affiliates have taken or refrained from taking any action that, and to Seller&#8217;s Knowledge there are no facts or circumstances that, could reasonably be expected to (with or without notice or lapse of time, or both) give rise to a right of FDA to revoke, cancel, suspend or terminate the Priority Review Voucher.  There is nothing that would preclude or interfere with (i) the transfer of the Purchased Assets to Buyer or (ii) Buyer&#8217;s ability to use of the Purchased Assets to obtain Priority Review or any other benefit associated with the Purchased Assets following the Closing.  There is no term or condition imposed by the FDA on the Priority Review Voucher that is not set forth in the FDA Approval Letter as of the date hereof.  Seller and BPI have provided to Buyer true and complete copies of the FDA Approval Letter, the rare pediatric disease designation issued by the FDA for Voxzogo (vosoritide) and all other correspondence received by Seller, BPI or any of their respective Affiliates from the FDA regarding the Priority Review Voucher.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Intent to Use.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> None of Seller, BPI or any of their respective Affiliates has filed or submitted to the FDA a notification of intent to use the Priority Review Voucher.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">BPI Organization, Standing and Power&#59; Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  BPI is a corporation duly organized and validly existing under the laws of the State of Delaware.  BPI has the requisite corporate power and authority to own, operate and lease its properties and to carry on its business as presently conducted and is duly qualified or licensed to do business and is in good standing in each jurisdiction where the character of its properties owned or leased or the nature of its activities make such qualification or licensing necessary, except where the failure to be so qualified or licensed would not, individually or in the aggregate, reasonably be expected to adversely affect any of the Purchased Assets, Seller&#8217;s or BPI&#8217;s ability to consummate the transactions contemplated by this Agreement or Buyer&#8217;s ownership and rights with respect to any of the Purchased Assets after the Closing.  BPI is not in violation of its certificate of incorporation or bylaws, in each case as amended to date.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">BPI Due Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  BPI has the requisite corporate power and authority to execute, deliver, perform its obligations under, and consummate the transactions contemplated by, this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the Asset Purchase, have been duly and validly approved and authorized by all necessary corporate action on the part of BPI, and this Agreement has been duly executed and delivered by BPI.  This Agreement, upon execution by the Parties, will constitute a valid and binding obligation of BPI, enforceable against BPI in accordance with its terms, subject only to the effect, if any, of (a)&#160;applicable bankruptcy and other similar laws affecting the rights of creditors generally and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">BPI Title to Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  BPI is the record owner of the Purchased Assets as nominee for, and on behalf of, Seller and such record ownership constitutes BPI&#8217;s sole right, title and interest in and to the Purchased Assets and does not include any beneficial ownership right thereto.  BPI has performed all actions necessary to perfect Seller&#8217;s ownership of, and its ability to transfer, all right, title and interest in the Purchased Assets (other than BPI&#8217;s record ownership thereof as nominee for, and on behalf of, Seller).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Marketed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  BPI has initiated marketing in the United States of the rare pediatric disease product for which the Priority Review Voucher was awarded within the 365-day period beginning on the date of the FDA approval of such rare pediatric disease product and has continuously marketed such product in the United States since its approval.  </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>REPRESENTATIONS AND WARRANTIES OF BUYER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer represents and warrants to Seller as of the date hereof and as of the Closing Date as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Organization, Standing and Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer is a corporation duly formed, validly existing and in good standing under the laws of Indiana.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer has the requisite corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.  The execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Buyer.  This Agreement has been duly executed and delivered by Buyer.  This Agreement, upon execution by the Parties, will constitute a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, subject only to the effect, if any, of (a)&#160;applicable bankruptcy and other similar laws affecting the rights of creditors generally and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Noncontravention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The execution and delivery by Buyer of this Agreement does not, and the consummation of the transactions contemplated hereby will not, conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, (a)&#160;any provision of the organizational or governing documents of Buyer, in each case as amended to date, (b)&#160;any Contract (except as would not reasonably be expected to have a material adverse effect on the Buyer&#8217;s ability to consummate the Asset Purchase) or (c) except as may be required to comply with the HSR Act, any Legal Requirements (except as would not reasonably be expected to have a material adverse effect on the Buyer&#8217;s ability to consummate the Asset Purchase).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for the submission of the Buyer FDA letter and the filing of a Premerger Notification and Report Form under the HSR Act, no filing, authorization, consent, approval, permit order, registration or declaration, governmental or otherwise, is required in connection with, or necessary to enable or authorize Buyer to enter into, perform its obligations under and consummate the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>CONDITIONS TO CLOSING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Conditions Precedent of Buyer, Seller and BPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party&#8217;s obligations to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The applicable waiting period under the HSR Act relating to the transactions contemplated by this Agreement shall have expired or been terminated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">No Injunctions or Restraints</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No temporary restraining order, preliminary or permanent injunction or other legal restraint or prohibition issued or promulgated by a Governmental Entity preventing, prohibiting or restraining the consummation of the transactions contemplated by this Agreement shall be in effect, and there shall not be any applicable Legal Requirement that makes consummation of the transactions contemplated by this Agreement illegal.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">No Governmental Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There shall not be any Proceeding commenced or pending by a Governmental Entity seeking to prohibit, limit, delay, or otherwise restrain the consummation of this Agreement and&#47;or the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties shall have made the deliveries contemplated under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Buyer&#8217;s Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The obligations of Buyer to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Accuracy of Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the representations and warranties made by Seller and BPI in this Agreement shall be true and correct in all material respects as of the date hereof and at and as of the Closing Date (or, if made as of a specified period or date, as of such period or date), except to the extent that such representations and warranties are qualified by the term &#8220;material&#8221;, or words of similar import, in which case such representations and warranties (as so written, including the terms &#8220;material&#8221;, or words of similar import) shall be true and correct in all respects at and as of the Closing Date (or, if made as of a specified period or date, as of such period or date), provided that any such failure of such representations and warranties to be true and correct in all material respects, or, as applicable, true and correct in all respects, shall be disregarded if it would not, individually or in the aggregate, reasonably be expected to delay, restrict, limit, preclude or otherwise negatively impact in a material manner the transfer and&#47;or use of the Purchased Assets to or by Buyer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Performance of Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All of the covenants and obligations that Seller and&#47;or BPI is required to comply with or to perform hereunder at or prior to the Closing Date shall have been complied with and performed in all material respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Closing Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller shall have delivered to Buyer a certificate, dated the Closing Date and duly executed by Seller, certifying that the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 5.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> have been satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">No Regulatory Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There shall not have occurred and remain in effect any Regulatory Change.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Seller&#8217;s and BPI&#8217;s Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The obligations of Seller and BPI to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Accuracy of Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the representations and warranties made by Buyer in this Agreement shall be true and correct in all material respects at and as of the Closing Date (or, if made as of a specified period or date, as of such period or date), except to the extent that such representations and warranties are qualified by the term &#8220;material&#8221;, or words of similar import, in which case such representations and warranties (as so written, including the terms &#8220;material&#8221;, or words of similar import) shall be true and correct in all respects at and as of the Closing Date (or, if made as of a specified period or date, as of such period or date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Performance of Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All of the covenants and obligations that Buyer is required to comply with or to perform hereunder at or prior to the Closing Date shall have been complied with and performed in all material respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Closing Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer shall have delivered to Seller and BPI a certificate, dated the Closing Date and duly executed by Buyer, certifying that the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> have been satisfied.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Indemnification by Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller and BPI will, jointly and severally, indemnify, defend and hold Buyer and its Affiliates and their respective directors, officers, employees and agents harmless for, from and against any and all Liabilities, losses, damages, costs and expenses (including reasonable attorneys&#8217; fees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) arising out of any claims (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Claims&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) resulting from (i) any breach of Seller&#8217;s and&#47;or BPI&#8217;s representations, warranties, covenants or obligations under this Agreement, (ii) Seller&#8217;s, BPI&#8217;s or their respective Affiliates&#8217; grossly negligent, fraudulent and&#47;or wrongful acts, omissions or misrepresentations, regardless of the form of action, in connection with this Agreement and the transactions contemplated hereunder and&#47;or (iii) all Excluded Liabilities.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Indemnification by Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Buyer will indemnify, defend and hold Seller, BPI, and their Affiliates, and their respective directors, officers, employees and agents harmless for, from and against any and all Damages arising out of any Claims resulting from (i) any breach, of Buyer&#8217;s representations, warranties, covenants or obligations under this Agreement, (ii) Buyer&#8217;s grossly negligent, fraudulent and&#47;or wrongful acts, omissions or misrepresentations, regardless of the form of action, in connection with this Agreement and the transactions contemplated hereunder, and (iii) Buyer&#8217;s, its Affiliates&#8217;, or any subsequent transferee&#8217;s use of the Priority Review Voucher. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Person entitled to indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> will hereinafter be referred to as an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Indemnitee.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  A Party obligated to indemnify an Indemnitee hereunder will hereinafter be referred to as an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Indemnitor.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Indemnitee shall inform Indemnitor of any Claim as soon as reasonably practicable after the Claim arises, it being understood and agreed that the failure to give such notice will not relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the extent that such Indemnitor is actually and materially prejudiced as a result of such failure to give notice.  The Indemnitee will permit the Indemnitor to assume direction and control of the defense of any Claim instituted or asserted by any third party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Third Party Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), at the Indemnitor&#8217;s expense, provided that (i) the Indemnitor has acknowledged its responsibility for defending such Third Party Claim in writing to the Indemnitee, (ii) such Third Party Claim is not a class action, criminal matter, or a claim in which solely non-monetary, equitable or injunctive relief against the Indemnitee is sought and (iii) the Indemnitor conducts such defense in good faith and in a diligent manner.  The Indemnitee, at the Indemnitor&#8217;s expense, will cooperate as reasonably requested in the defense of such Third Party Claim.  The Indemnitee will have the right to participate in the defense, and to retain its own counsel at its own expense, of any Third Party Claim the defense of which is controlled by the Indemnitor pursuant hereto.  If the Indemnitee is defending such Third Party Claim, the Indemnitee shall keep the Indemnitor apprised of all material developments with respect to such Third Party Claim and promptly provide the Indemnitor with copies of all correspondence and documents exchanged by the Indemnitee and the opposing party(ies) to such litigation.  The Indemnitor may not settle such Claim, or otherwise consent to an adverse judgment in such Third Party Claim, without the Indemnitee&#8217;s prior written consent&#59; provided, that, the Indemnitor shall not require such consent with respect to the settlement of any Third Party Claim (a) under which settlement the sole relief provided is for monetary damages that are paid in full by the Indemnitor, (b) which settlement would not diminish or limit or otherwise adversely affect the rights, activities or financial interests of the Indemnitee, (c) which settlement includes, as an unconditional term thereof, the giving by each claimant or plaintiff to the Indemnitee of a release from all liability in respect of such Claim&#59; and (d) which does not result in any finding or admission of fault by the Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;Any amount paid under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be treated as an adjustment to the Purchase Price for all tax purposes unless otherwise required by applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>ADDITIONAL COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties shall use commercially reasonable efforts to cause the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to be satisfied and to consummate the transactions contemplated herein as promptly as reasonably practical.  The Parties shall cooperate reasonably with each other in connection with any steps required to be taken as part of their respective obligations under this Agreement, including without limitation any notifications or filings required to be made to the FDA in connection with the transfer of the Purchased Assets, and shall (a) furnish upon request to each other such further information, (b) execute and deliver to each other such other documents, and (c) do such other acts and things, all as the other Parties may reasonably request for the purpose of carrying out the intent of this Agreement and the transactions contemplated by this Agreement, including the use of the Purchased Assets to obtain Priority Review.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Compliance with Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Seller and BPI shall, and shall cause their respective Affiliates and successors-in-interest to Voxzogo (vosoritde) to, comply with all Legal Requirements relating to the Priority Review Voucher. Without limiting the generality of the foregoing, to the extent required, now or in the future, under applicable Legal Requirements or otherwise by the FDA for the use or transfer of the Priority Review Voucher, or to avoid revocation of the Priority Review Voucher, Seller and BPI shall, and shall cause their Affiliates and each of their respective successors in interest to the rare pediatric disease product for which the Priority Review Voucher was awarded, to submit a post-approval production report to the United States Secretary of Health and Human Services not later than five (5) years after the approval of such rare pediatric disease product in accordance with section 529(e)(2)&#160;of the FDA Act..  Each of Seller and BPI shall, and shall cause and their respective Affiliates and successors-in-interest to Voxzogo (vosoritde) to, forward to Buyer any communications it receives from any Governmental Entity in respect of the Priority Review Voucher.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Nondisclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">With respect to Confidential Information received, the Parties will (i) keep the Confidential Information confidential, (ii) not use any Confidential Information for any reason, and (iii) not disclose any Confidential Information to any Person, except in each case as otherwise expressly permitted by this Agreement or with the prior written consent of the disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">A Party may disclose Confidential Information only to its Representatives on a need-to-know basis.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">A Party will (i) instruct its Representatives to comply with the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and (ii) be responsible and liable for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by it or its Representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If a Party becomes compelled by a court or is requested by a Governmental Entity to make any disclosure that is prohibited or otherwise constrained by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such Party shall provide the disclosing Party with prompt notice of such compulsion or request (to the extent legally permitted) so that it may seek an appropriate protective order or other appropriate remedy or waive compliance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the absence of a protective order or other remedy, the Party subject to the requirement to disclose may disclose that portion (and only that portion) of the Confidential Information that, based upon advice of its counsel, it is legally compelled to disclose or that has been requested by such Governmental Entity, provided, however, that such Party shall use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded by any Person to whom any Confidential Information is so disclosed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Nothing herein shall prohibit or otherwise restrict the disclosure of Confidential Information by or on behalf of Buyer or its Affiliates to the FDA or other Governmental Entity as required in connection with any filing, application or request for regulatory approval in which Priority Review is sought.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, following the Closing, Seller, BPI, and Buyer (and their Affiliates) shall have the right to issue a press release containing a description of the Asset Purchase and the Purchase Price in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties agree not to (and to ensure that their respective Affiliates do not) issue any other press releases or public announcements concerning this Agreement without the prior written consent of the other Parties (which shall not be unreasonably withheld or delayed), except as required by a Governmental Entity or applicable Legal Requirement (including the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and any stock exchange or trading market on which a Party&#8217;s securities are traded)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Party intending to disclose such information shall use reasonable efforts to provide the other Parties with advance notice of such required disclosure, and an opportunity to review and comment on such proposed disclosure (which comments shall be considered in good faith by the disclosing Party).  Notwithstanding the foregoing, without prior submission to or approval of the other Parties, any Party may issue press releases or public announcements which incorporate information concerning this Agreement which information was included in a press release or public disclosure which was previously disclosed under the terms of this Agreement.  Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and the foregoing, a Party may, without the prior consent or review by the other Parties, make filings or disclosures with any applicable tax Governmental Entity that are necessary or desirable to such Party and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Without limiting the foregoing, the Parties acknowledge that BPI will be required to file this Agreement as an exhibit to its Annual Report on Form 10-K or its Quarterly Report on Form 10-Q as filed with the SEC.  BPI shall file a redacted version of the Agreement with its Annual Report on Form 10-K or its Quarterly Report on Form 10-Q with such redactions as BPI deems appropriate pursuant to SEC Regulation S-K Item 601(b)(iv), provided that the Buyer&#8217;s name shall be redacted and BPI shall provide Lilly with a reasonable opportunity to review and comment on BPI&#8217;s other proposed redactions in advance of such filing (which timely comments shall be considered in good faith by BPI).  Notwithstanding the foregoing, the Parties acknowledge that there is no assurance that the SEC will not subsequently require BPI file a less redacted version of the Agreement or the Agreement in full.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Use of Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly provided herein, no Party shall mention or otherwise use the name, logo, or trademark of the other Parties or any of their Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance.  The restrictions imposed by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not prohibit any Party from making any disclosure identifying the other Parties that, in the opinion of the disclosing Party&#8217;s counsel, is required by applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed&#59; provided, that such Party shall submit the proposed disclosure identifying another Party in writing to the such other Party as far in advance as reasonably practicable (to the extent legally permitted) so as to provide a reasonable opportunity to comment thereon.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, without prior submission to or approval of the other Parties, any Party may mention or otherwise use the name, logo, or trademark of another Party or any of its Affiliates in connection with referencing or describing the Asset Purchase if such use was previously approved under the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Other Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Until the earlier of the Closing or the termination of this Agreement, (a) Seller and BPI shall, and shall cause their respective Affiliates to, provide Buyer with prompt written notification of the occurrence of any Regulatory Change and maintain the Priority Review Voucher in full force and effect and (b) Seller and BPI shall not, and shall cause their respective Affiliates not to (i) enter into any Contract with respect to the Purchased Assets or (ii) take or permit, or omit to take any action that could reasonably be expected to (a) prevent the satisfaction of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or (b) adversely affect any of the Purchased Assets or Seller&#8217;s or BPI&#8217;s ability to consummate the transactions contemplated by this Agreement or Buyer&#8217;s ownership and rights with respect to any of the Purchased Assets after the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Antitrust Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Unless this Agreement shall have been validly terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Buyer, Seller and BPI shall, as promptly as practicable (but no later than ten (10) Business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Days) after the Effective Date, file with the Federal Trade Commission and the Department of Justice the premerger notification and report form required as a result of the contemplated purchase and sale of the Purchased Assets and the other transactions contemplated hereby, and shall include any supplemental information requested in connection therewith, pursuant to the HSR Act. Any such filing, notification and report form and supplemental information shall be in compliance with the requirements of the HSR Act.  The Parties shall work together and shall furnish to one another such necessary information and reasonable assistance as the other may request in connection with its preparation of any filing or submission which is necessary under the HSR Act.  The Parties shall (A) cooperate with one another and keep one another apprised of the status of any communications with, and any inquiries or requests for additional information from, the Federal Trade Commission, the Department of Justice or any other applicable Governmental Entity, (B) comply promptly with any such reasonable inquiry or request, (C) subject to applicable Legal Requirements, consult and cooperate with each other in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, and proposals made or submitted to any Governmental Entity regarding the transactions contemplated by this Agreement by or on behalf of any Party, (D) not participate, or permit its Affiliates to participate, in any substantive meeting or discussion with any Governmental Entity in respect of any filings, investigation or inquiry concerning this Agreement unless, to the extent reasonably practicable, it consults with the other Parties in advance and, to the extent permitted by such Governmental Entity, gives the other Parties the opportunity to attend and participate thereat, and (E) furnish the other Parties (or, in respect of competitively sensitive materials, solely to the other Parties&#8217; outside counsel) with copies of all correspondence, filings, and communications (and memoranda setting forth the substance thereof) between a Party or its Affiliates, on the one hand, and any Governmental Entity, on the other hand, with respect to the transactions contemplated hereunder or any investigation with respect to the transactions contemplated hereunder.  Buyer shall be responsible for all filing fees under the HSR Act&#59; the Parties will individually bear all other costs and expenses required for compliance under the HSR Act.  Nothing contained in this Agreement shall require any Party to disclose to the other Parties or their outside counsel (1) documents filed pursuant to Item 4(c) and 4(d) of the Notification and Report Form under the HSR Act or communications regarding the same documents, (2) information submitted in response to any request for additional information, documents which reveal such Party&#8217;s negotiating objectives or strategies regarding the transactions contemplated hereunder (3) information relating to businesses and investments of Buyer or its Affiliates, (4) any information for which disclosure is prohibited by any Governmental Entity or (5) any information for which disclosure would waive applicable legal privilege.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">From and after the date on which the filings are made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties shall use their respective reasonable efforts to obtain any clearance required under the HSR Act for the purchase and sale of the Purchased Assets and the other transactions contemplated hereby, including replying at the earliest practicable date to any requests for information received from the Federal Trade Commission or the Department of Justice pursuant to the HSR Act and making any permitted request for early expiration or termination of the applicable waiting periods under the HSR Act as soon as possible. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding the foregoing, nothing in this Agreement shall require, or be construed to require, the Parties or any of their respective Affiliates to offer or agree to (a) (i) sell, hold, hold separate, divest, license, discontinue or limit, before or after the Closing Date, any assets, businesses, equity holdings, intellectual property, or other interests or (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses, equity holdings, intellectual property or interests (including but not limited to any requirements to enter into new contracts or modify or terminate existing contracts) or (b) any material modification or waiver of the terms and conditions of this Agreement. </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Termination Prior to Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any contrary provisions of this Agreement, the respective obligations of the Parties hereto to consummate the transactions contemplated by this Agreement may be terminated and abandoned at any time before the Closing only as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Upon the mutual written consent of Buyer and Seller&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">By either Buyer or Seller, by written notice to the other Party if the Closing has not occurred on or before the expiration of six (6) months from the date hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.1(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall not be available to any Party whose material breach of any provision set forth in this Agreement has resulted in the failure of the Closing to occur on or before such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of the termination of this Agreement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, written notice thereof shall forthwith be given to the other Parties hereto specifying the provision hereof pursuant to which such termination is made, and this Agreement shall forthwith become null and void (except for the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9.2 - 9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which shall survive any such termination) and there shall be no liability on the part of Buyer or Seller except for damages resulting from any breach of this Agreement prior to termination of this Agreement by Buyer or Seller.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><br>GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Articles I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall each survive the Closing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Taxes and Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding any other provision in this Agreement to the contrary, each respective Party shall bear and pay any and all sales taxes, income taxes, value added taxes, stamp taxes, use taxes, transfer taxes, documentary charges, recording fees or similar taxes, charges, or fees (including any penalties, interest and additions thereto) that may become payable by it or its Affiliates in connection with the Asset Purchase.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than advisory services provided by &#91;***&#93;, the fees and expenses of whom shall be paid by Seller, Seller has not engaged, retained or entered into an agreement with any investment banker, broker, finder or other intermediary who has been authorized to act on behalf of Seller who may be entitled to any fee or commission in connection with the Asset Purchase contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice or other communication required or permitted to be delivered to any Party shall be in writing and shall be deemed properly delivered, given and received&#58; (a) when delivered by hand&#59; or (b) upon such Party&#8217;s receipt after sent by registered mail, by courier or express delivery service, in any case to the address set forth beneath the name of such Party below (or to such other address as such Party shall have specified in a written notice given to the other parties hereto)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:128.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.282%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) if to Buyer, to&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eli Lilly and Company<br>Lilly Corporate Center<br>Indianapolis, Indiana  46285<br>Attention&#58;  General Counsel </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) if to Seller, to&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) if to Seller, to&#58; </font></div><div style="margin-bottom:0.12pt;padding-right:2.75pt;text-indent:0.36pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin International Ltd.</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">William Fry Solicitors</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6th Floor</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2 Grand Canal Square</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dublin 2,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ireland</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">105 Digital Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novato, CA 94949</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; General Counsel</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tel&#58; (415) 506-6700</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii) if to BPI, to&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">105 Digital Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novato, CA 94949</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; General Counsel</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tel&#58; (415) 506-6700</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as otherwise indicated, all references in this Agreement to &#8220;Articles&#8221; and &#8220;Sections&#8221; are intended to refer to Articles and Sections of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument, and shall become effective when one or more counterparts have been signed by each of the Parties hereto and delivered to the other Parties hereto, it being understood that all Parties hereto need not sign the same counterpart.  The exchange of a fully executed Agreement (in counterparts or otherwise) by electronic transmission or facsimile shall be sufficient to bind the Parties hereto to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, including all exhibits and schedules attached hereto, sets forth the entire understanding of the Parties relating to the subject matter hereof and supersedes all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">prior agreements and understandings among or between any of the Parties relating to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No Party will have the right to assign this Agreement, in whole or in part, by operation of law or otherwise, without the other Parties&#8217; express prior written consent.  Any attempt to assign this Agreement, without such consent, will be null and void and of no effect.  Notwithstanding the foregoing, any Party may assign this Agreement without the consent of the other Parties&#58; (a) to a third party that succeeds to all or substantially all of its assets or related business (whether by sale, merger, operation of law or otherwise)&#59; or (b) to an Affiliate of such Party.  Subject to the foregoing, this Agreement will bind and inure to the benefit of each Party&#8217;s successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and shall be interpreted so as reasonably to effect the intent of the parties hereto.  The Parties hereto shall use commercially reasonable efforts to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Remedies Cumulative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party hereto shall be deemed cumulative with and not exclusive of any other remedy conferred hereby or by law or equity upon such Party, and the exercise by a Party hereto of any one remedy shall not preclude the exercise of any other remedy and nothing in this Agreement shall be deemed a waiver by any Party of any right to specific performance or injunctive relief.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement) shall be governed by, enforced, and construed in accordance with, the laws of the State of New York, including its statutes of limitations, regardless of the laws that might otherwise govern under applicable principles of conflicts of law.  The Parties irrevocably and unconditionally submit to the exclusive jurisdiction of the United States District Court in New York County, New York (or if such court does not have subject matter jurisdiction, a State Court of the State of New York located in </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New York County, New York</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) solely and specifically for the purposes of any action or proceeding arising out of or in connection with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES.  THIS WAIVER APPLIES TO ANY PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Amendment&#59; Extension&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the provisions of applicable law, the Parties hereto may amend this Agreement at any time pursuant to an instrument in writing signed on behalf of each of the Parties hereto.  At any time, any Party hereto may, to the extent legally allowed, (a)&#160;extend the time for the performance of any of the obligations or other acts of the other Parties hereto, (b)&#160;waive any inaccuracies in the representations and warranties made to such Party contained herein or (c)&#160;waive compliance with any of the agreements or conditions for the benefit of such Party contained herein.  Any agreement on the part of a Party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such Party.  Without limiting the generality or effect of the preceding sentence, no delay in exercising any right under this Agreement shall constitute a waiver of such right, and no waiver of any breach or default shall be deemed a waiver of any other breach or default of the same or any other provision in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Benefit to Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i932828622e724cf9a2aa2b7175f2d5d5_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of Buyer, BPI, and Seller has caused this Asset Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.</font></div><div style="margin-top:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; David A. Ricks&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  David A. Ricks&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Chair and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:234pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIOMARIN INTERNATIONAL LTD.</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Michael O&#8217;Donnell&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Michael O&#8217;Donnell</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Brinda Balakrishnan&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Brinda Balakrishnan&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Group Vice President</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i932828622e724cf9a2aa2b7175f2d5d5_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FORM OF BILL OF SALE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Bill of Sale (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered into as of February &#91;  &#93;, 2022, by and among Eli Lilly and Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), BioMarin Pharmaceutical Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">BPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and BioMarin International Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the terms and subject to the conditions of the Asset Purchase Agreement, dated as of February 8, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Asset Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and among Buyer, Seller and BPI, Seller has agreed to sell, and Buyer has agreed to purchase, all right, title and interest in, to and under the Purchased Assets, including the Priority Review Voucher, in each case free and clear of all Encumbrances.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Buyer and Seller, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Defined Terms&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise set forth herein, capitalized terms used in this Bill of Sale shall have the meanings assigned to them in the Asset Purchase Agreement.  This Bill of Sale shall be interpreted in accordance with the rules of construction set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Asset Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Transfer of Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, (a) Seller hereby sells, assigns, transfers, and conveys to Buyer and its successors and its assigns, and Buyer hereby does purchase from Seller, all of Seller&#8217;s right, title and interest in, to and under the Purchased Assets (including the Priority Review Voucher), in each case free and clear of all Encumbrances and (b) BPI hereby sells, assigns, transfers, and conveys to Buyer and its successors and its assigns, and Buyer hereby does purchase from BPI, BPI&#8217;s record ownership of the Purchased Assets, which constitutes BPI&#8217;s sole interest in the Purchased Assets, free and clear of all Encumbrances.  The right, title and interest in and to the Purchased Assets that is sold, transferred, conveyed, assigned and delivered by Seller and BPI to Buyer hereunder collectively constitutes the entire right, title and interest in and to the Purchased Assets and upon the Closing, Buyer shall have all right, title and interest in and to the Purchased Assets, free and clear of all Encumbrances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Effective Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Bill of Sale shall be effective as of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Binding Effect&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Bill of Sale shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective legal representatives, successors and permitted assigns.  Neither this Bill of Sale, nor any term or provision hereof, may be amended, modified, superseded or cancelled except by an instrument in writing signed by each party hereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Bill of Sale and any disputes arising under or related hereto shall be governed by the rules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Asset Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Bill of Sale may be executed in one or more counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the parties hereto have caused this Bill of Sale to be executed and delivered as of the date first written above.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:234pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIOMARIN INTERNATIONAL LTD.</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="margin-top:24pt;padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="padding-left:234pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i932828622e724cf9a2aa2b7175f2d5d5_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BPI&#8217;s Transfer Acknowledgment Letter</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;BPI&#8217;s Letterhead&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Address&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RE&#58; NDA 214938 for Voxzogo (vosoritide) - Transfer of Rare Pediatric Disease Priority Review Voucher PRV NDA 214938 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Voucher</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear &#91;Buyer Contact&#93;&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reference is made to the subject NDA 214938 and all related correspondence.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please be advised that as of &#91;Date&#93;, Eli Lilly and Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has legally accepted complete ownership of the Voucher from BioMarin Pharmaceutical Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">BioMarin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  BioMarin hereby authorizes transfer of ownership of the Voucher to Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin has provided Buyer with an unredacted copy of the Voxzogo (vosoritide) (NDA 214938) approval letter from the U.S. Food and Drug Administration to BioMarin (Reference ID 4905458), which includes the Voucher (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Approval Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Buyer agrees to use the Voucher in accordance with the terms of the Approval Letter. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please do not hesitate to contact me should you have any questions or comments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc. </font></div><div style="margin-top:24pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="padding-right:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer&#8217;s Transfer Acknowledgment Letter</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Eli Lilly and Company Letterhead&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">105 Digital Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novato, CA 94949</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RE&#58; NDA 214938 for Voxzogo (vosoritide) - Transfer of Rare Pediatric Disease Priority Review Voucher PRV NDA 214938 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Voucher</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear &#91;Seller Contact&#93;&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reference is made to the subject NDA 214938 and all related correspondence </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please be advised that as of &#91;Date&#93;, Eli Lilly and Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has legally accepted complete ownership of the Voucher from BioMarin Pharmaceutical Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">BioMarin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin has provided Buyer with an unredacted copy of the Voxzogo (vosoritide) (NDA 214938) approval letter from the U.S. Food and Drug Administration (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to BioMarin (Reference ID 4905458), which includes the Voucher (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Approval Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Buyer will advise the FDA of the legal transfer of the Voucher from BioMarin to Buyer by providing a copy of this letter to the FDA, and agrees to use the Voucher in accordance with the terms of the Approval Letter. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The regulatory contact information for the Voucher is as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Buyer Contact&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please do not hesitate to contact us should you have any questions or comments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="margin-top:24pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="padding-right:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i932828622e724cf9a2aa2b7175f2d5d5_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Press Release</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(attached)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:32px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Contact&#58;</font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">             Investors&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media&#58;</font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">             Traci McCarty &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debra Charlesworth</font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">             BioMarin Pharmaceutical Inc. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BioMarin Pharmaceutical Inc.</font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">             (415) 455-7558&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(415) 455-7451</font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">DRAFT NOT For Immediate Release </font></div><div style="padding-right:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioMarin Sells Priority Review Voucher for $110 Million</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SAN RAFAEL, Calif., Feb. XX, 2022&#8212;SAN RAFAEL, Calif.,&#8212;BioMarin Pharmaceutical Inc. (Nasdaq&#58;BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in November 2021 for a lump sum payment of $110,000,000. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases.&#160;BioMarin was awarded the voucher when it received approval of VOXZOGO&#8482; (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).&#160;The transaction remains subject to customary closing conditions, including anti-trust review.&#160;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;We are pleased to announce the sale of the PRV and plan to direct the proceeds from this voucher sale towards additional investment in an already robust pipeline of investigational therapies for people with genetic diseases,&#8221; said Jean-Jacques Bienaim&#233;, Chief Executive Officer of BioMarin.&#160;&#34;We are proud to be able to participate in this program and that this voucher will be accelerating the availability of a therapy for patients.&#8221;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This is the third Priority Review Voucher that BioMarin has received.  The FDA also awarded PRVs to the company when Brineura&#174; (cerliponase alfa) and Vimizim&#174; (elosulfase alfa) were approved.  Company Management expects that the net gain on the sale of the PRV, after income taxes, will be incremental to the Company&#8217;s previously communicated expectation to earn positive GAAP net income in 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About the Rare Pediatric Disease Priority Review Voucher Program</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The program is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. A PRV is issued to the sponsor of a rare pediatric disease product application and entitles the holder to priority review of a single New Drug Application or Biologics License Application.&#160;The sponsor receives the voucher upon approval of the rare pediatric disease product application.&#160; PRVs may be sold or transferred, and there is no limit on the number of times a PRV can be transferred.&#160;&#160;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Food and Drug Administration Standard Review and Priority Review Designations</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to approval, each drug marketed in the United States must go through a detailed FDA review process. &#160;In 1992, under the Prescription Drug User Act (PDUFA), FDA agreed to specific goals for improving the drug review time and created a two-tiered system of review times - Standard Review and Priority Review.&#160; A Priority Review designation is given to drugs that provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. The FDA goal for reviewing a drug with Priority Review status is six months from the time the application is filed by the FDA, compared to 10 months under standard review.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About BioMarin</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.&#160;&#160; </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about&#58; the Company&#8217;s plans to use the PRV sale proceeds towards additional investment in BioMarin&#8217;s development programs and expectations that the net gain on the sale of the PRV, after income taxes, will be incremental to the Company&#8217;s previously communicated expectation to earn positive GAAP net income in 2022. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Additional important factors to be considered in connection with forward-looking statements are detailed from time to time under the caption &#34;Risk Factors&#34; and elsewhere in BioMarin's Securities and Exchange Commission (SEC) filings, including BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and future filings and reports by BioMarin. BioMarin undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioMarin&#174;, Brineura&#174;, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIMIZIM&#174; and VOXZOGO&#8482; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">are registered trademarks of BioMarin Pharmaceutical Inc. or its affiliates.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311-31mar22x10q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i902dad98e3714c1485f1b61b46ad4215_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Jean-Jacques Bienaim&#233;, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:33pt">I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:33pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:33pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:33pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.52pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.52pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:30.02pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.52pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:33pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.52pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:29.52pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; April&#160;29, 2022 </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.929%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; JEAN-JACQUES BIENAIM&#201;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jean-Jacques Bienaim&#233;<br>Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312-31mar22x10q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i92f44343e6a847f897b082bb23ee4b84_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Brian R. Mueller, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.51pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; April&#160;29, 2022</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;BRIAN R. MUELLER</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian R. Mueller<br>Executive Vice&#160;President, Finance &#38;<br>Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321-31mar22x10q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib94b5ac70c224a9ea8c057688aa5bdc6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We, Jean-Jacques Bienaim&#233; and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; JEAN-JACQUES&#160;BIENAIM&#201;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jean-Jacques Bienaim&#233;<br>Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; April&#160;29, 2022 </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;BRIAN R. MUELLER</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian R. Mueller<br>Executive&#160;Vice&#160;President, Finance &#38; <br>Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; April&#160;29, 2022 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bmrn-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.bmrn.com/20220331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bmrn.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.bmrn.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTS">
        <link:definition>2103102 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>2304301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" roleURI="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail">
        <link:definition>2405401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION" roleURI="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION">
        <link:definition>2107103 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables" roleURI="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables">
        <link:definition>2308302 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialStatementsInformationScheduleofInventoryDetail" roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail">
        <link:definition>2409403 - Disclosure - Supplemental Financial Statements Information - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialStatementsInformationNarrativeDetails" roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails">
        <link:definition>2410404 - Disclosure - Supplemental Financial Statements Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2411405 - Disclosure - Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails" roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails">
        <link:definition>2412406 - Disclosure - Supplemental Financial Statements Information - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail">
        <link:definition>2413407 - Disclosure - Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2114104 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2315303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" roleURI="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" roleURI="http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES">
        <link:definition>2118105 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables">
        <link:definition>2319304 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail">
        <link:definition>2420410 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail" roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail">
        <link:definition>2421411 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail">
        <link:definition>2422412 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail">
        <link:definition>2423413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.bmrn.com/role/DEBT">
        <link:definition>2124106 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.bmrn.com/role/DEBTTables">
        <link:definition>2325305 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtAdditionalInformationDetail" roleURI="http://www.bmrn.com/role/DebtAdditionalInformationDetail">
        <link:definition>2426414 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofConvertibleDebtDetail" roleURI="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail">
        <link:definition>2427415 - Disclosure - Debt - Summary of Convertible Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofInterestExpenseonConvertibleDebtDetail" roleURI="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail">
        <link:definition>2428416 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS">
        <link:definition>2129107 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables">
        <link:definition>2330306 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" roleURI="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail">
        <link:definition>2431417 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION">
        <link:definition>2132108 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables">
        <link:definition>2333307 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail">
        <link:definition>2434418 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail">
        <link:definition>2435419 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail">
        <link:definition>2436420 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail">
        <link:definition>2437421 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.bmrn.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2138109 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2339308 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetail" roleURI="http://www.bmrn.com/role/StockBasedCompensationExpenseDetail">
        <link:definition>2440422 - Disclosure - Stock-Based Compensation - Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2441423 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERCOMMONSHARE" roleURI="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE">
        <link:definition>2142110 - Disclosure - NET INCOME PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERCOMMONSHARETables" roleURI="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables">
        <link:definition>2343309 - Disclosure - NET INCOME PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareScheduleofEarningsPerShareDetails" roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails">
        <link:definition>2444424 - Disclosure - Net Income Per Common Share - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail">
        <link:definition>2445425 - Disclosure - Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2146111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2447426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bmrn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" abstract="true" name="ForeignGovernmentAndOtherDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndGeographicInformationLineItems" abstract="true" name="ConcentrationRiskAndGeographicInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_RoyaltyAndOtherMember" abstract="true" name="RoyaltyAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ThirdPartyMember" abstract="true" name="ThirdPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ValoctocogeneRoxaparvovecMember" abstract="true" name="ValoctocogeneRoxaparvovecMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" abstract="false" name="ConcentrationRiskAndSegmentReportingDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_CustomerOneTwoThreeAndFourMember" abstract="true" name="CustomerOneTwoThreeAndFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherLiabilitiesCurrentFairValueDisclosure" abstract="false" name="OtherLiabilitiesCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductSevenMember" abstract="true" name="ProductSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ScheduleOfInterestExpensesLineItems" abstract="true" name="ScheduleOfInterestExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CustomersMember" abstract="true" name="CustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" abstract="false" name="SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ShortTermMarketableSecuritiesMaturityPeriod" abstract="false" name="ShortTermMarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_ProductOneMember" abstract="true" name="ProductOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ScheduleOfInterestExpensesTable" abstract="true" name="ScheduleOfInterestExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CustomerFourMember" abstract="true" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bmrn_RestrictedInvestmentsMember" abstract="true" name="RestrictedInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" abstract="true" name="NonqualifiedDeferredCompensationPlanAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProductFourMember" abstract="true" name="ProductFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" abstract="true" name="NonqualifiedDeferredCompensationPlanLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_EarlyStageDevelopmentProgramMember" abstract="true" name="EarlyStageDevelopmentProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_StrategicInvestmentMember" abstract="true" name="StrategicInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProceedsFromSaleOfNonfinancialAssets" abstract="false" name="ProceedsFromSaleOfNonfinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" abstract="true" name="ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" abstract="true" name="A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" abstract="true" name="SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" abstract="false" name="SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_OtherAssetsNoncurrentFairValueDisclosure" abstract="false" name="OtherAssetsNoncurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductSixMember" abstract="true" name="ProductSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProductTwoMember" abstract="true" name="ProductTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndGeographicInformationAbstract" abstract="true" name="ConcentrationRiskAndGeographicInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" abstract="true" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_ProductsExcludingProductOneMember" abstract="true" name="ProductsExcludingProductOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" abstract="true" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" abstract="false" name="OtherLiabilitiesNoncurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" abstract="true" name="ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" abstract="false" name="ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConcentrationRiskAndGeographicInformationTable" abstract="true" name="ConcentrationRiskAndGeographicInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" abstract="true" name="CommonStockIssuableToEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_IntangibleAssetAmortizationAndContingentConsideration" abstract="false" name="IntangibleAssetAmortizationAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ContingentPaymentMember" abstract="true" name="ContingentPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ProductEightMember" abstract="true" name="ProductEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_LongTermMarketableSecuritiesMaturityPeriod" abstract="false" name="LongTermMarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bmrn_ProductThreeMember" abstract="true" name="ProductThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" abstract="true" name="ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bmrn-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5e6bd5c-e398-4d98-835a-ee5e350f94bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_AssetsCurrent_c5e6bd5c-e398-4d98-835a-ee5e350f94bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5d7ccc35-18d5-4ae4-ab6b-5feef7fdd472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5d7ccc35-18d5-4ae4-ab6b-5feef7fdd472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ec7148f0-84f4-4a6c-a7d2-d3e1d411707e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ec7148f0-84f4-4a6c-a7d2-d3e1d411707e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a244c6b-ec6e-4b39-a0ba-03d576044f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a244c6b-ec6e-4b39-a0ba-03d576044f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_375fa024-a956-40cb-906d-46a2a96ac511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_Goodwill_375fa024-a956-40cb-906d-46a2a96ac511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4b33eff9-5512-4e2d-8a79-c2dd7a507e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4b33eff9-5512-4e2d-8a79-c2dd7a507e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f3de1cca-e1f4-45d4-a411-589b5d485a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8ba29ff7-10f1-414e-8d69-880870c3f0b1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f3de1cca-e1f4-45d4-a411-589b5d485a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b75686f4-5fe5-49de-b48a-0b3e9511e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_021d07c0-6e75-4540-97d0-c8b346f502a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b75686f4-5fe5-49de-b48a-0b3e9511e4e8" xlink:to="loc_us-gaap_Liabilities_021d07c0-6e75-4540-97d0-c8b346f502a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9eec6941-52fc-4f17-b8ab-a70da359969f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b75686f4-5fe5-49de-b48a-0b3e9511e4e8" xlink:to="loc_us-gaap_StockholdersEquity_9eec6941-52fc-4f17-b8ab-a70da359969f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b6aa8775-3d37-407f-9c05-bf22aa34d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:to="loc_us-gaap_CommonStockValue_b6aa8775-3d37-407f-9c05-bf22aa34d1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a986512b-b941-434f-bd2d-fa168c2a07f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a986512b-b941-434f-bd2d-fa168c2a07f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_898c0ed6-53ed-488d-8559-7c7002e57067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:to="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_898c0ed6-53ed-488d-8559-7c7002e57067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_64ae83e0-431a-4123-bb48-2c05197b9072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_64ae83e0-431a-4123-bb48-2c05197b9072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cea528e0-f2fe-4307-890b-561e9fdc9b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_165a5fa7-5dd2-4ce8-8f28-2fdd2b957a8f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cea528e0-f2fe-4307-890b-561e9fdc9b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108f561a-4b89-4a17-8abb-63a9b96125c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108f561a-4b89-4a17-8abb-63a9b96125c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_67679d2c-cafb-4300-a81a-9177c2d6986e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_67679d2c-cafb-4300-a81a-9177c2d6986e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1ee9c601-0612-4911-af76-781b86d88b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1ee9c601-0612-4911-af76-781b86d88b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4efaf708-4df7-4342-bc99-10a8c36a5e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:to="loc_us-gaap_InventoryNet_4efaf708-4df7-4342-bc99-10a8c36a5e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a85b49ef-1d6d-4366-98da-02db867b5029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7bfe2e91-17ed-4d12-9c31-234ff782cf02" xlink:to="loc_us-gaap_OtherAssetsCurrent_a85b49ef-1d6d-4366-98da-02db867b5029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1353b24-9755-4fb9-b42c-4bda21cc8fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ffd7412-4963-4ac8-85eb-681b012c8c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1353b24-9755-4fb9-b42c-4bda21cc8fda" xlink:to="loc_us-gaap_LiabilitiesCurrent_2ffd7412-4963-4ac8-85eb-681b012c8c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_6bf03149-cb83-434a-ae5b-6438b84deac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1353b24-9755-4fb9-b42c-4bda21cc8fda" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_6bf03149-cb83-434a-ae5b-6438b84deac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bd82e660-fbf8-4f2b-bfcb-3e4ffb93b411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1353b24-9755-4fb9-b42c-4bda21cc8fda" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bd82e660-fbf8-4f2b-bfcb-3e4ffb93b411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_938bd66e-9afa-4fe7-a512-98664900aa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1353b24-9755-4fb9-b42c-4bda21cc8fda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_938bd66e-9afa-4fe7-a512-98664900aa83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_319f46fb-5374-4f14-9591-fb511818c5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3bd24100-4778-4754-a1dd-04b327aeca9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_319f46fb-5374-4f14-9591-fb511818c5b1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3bd24100-4778-4754-a1dd-04b327aeca9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_938ab9c7-e390-4ea4-9613-736383b2bbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_319f46fb-5374-4f14-9591-fb511818c5b1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_938ab9c7-e390-4ea4-9613-736383b2bbea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_97d6214a-9ec7-4317-8464-640ba3e33f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53e2992a-9d28-4bbb-87ff-69665df04e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_97d6214a-9ec7-4317-8464-640ba3e33f26" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53e2992a-9d28-4bbb-87ff-69665df04e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4f1d89e8-9749-442d-980a-9887c6074596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_97d6214a-9ec7-4317-8464-640ba3e33f26" xlink:to="loc_us-gaap_CostsAndExpenses_4f1d89e8-9749-442d-980a-9887c6074596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_48fa353d-e361-4583-8cfc-3ceb0fef90e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:to="loc_us-gaap_CostOfRevenue_48fa353d-e361-4583-8cfc-3ceb0fef90e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_db63c3d1-3f38-4bba-841f-ed360a6f179f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_db63c3d1-3f38-4bba-841f-ed360a6f179f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca000f26-ec5f-4878-87c8-c68a178419b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca000f26-ec5f-4878-87c8-c68a178419b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_44d1ac9b-ef01-4343-bc4b-b830c66430fc" xlink:href="bmrn-20220331.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_44d1ac9b-ef01-4343-bc4b-b830c66430fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_8bc25c18-b688-4e04-9d23-7991ca793c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5349898-90df-42e7-80cb-3b6ce8c4e437" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_8bc25c18-b688-4e04-9d23-7991ca793c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aec977e6-9772-4bf8-9956-fe9794639292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44553ce4-c29f-4867-b3df-f919c9b2266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aec977e6-9772-4bf8-9956-fe9794639292" xlink:to="loc_us-gaap_OperatingIncomeLoss_44553ce4-c29f-4867-b3df-f919c9b2266b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_975cf4e2-d2b6-4a4a-ae8a-59754b6bd73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aec977e6-9772-4bf8-9956-fe9794639292" xlink:to="loc_us-gaap_InvestmentIncomeInterest_975cf4e2-d2b6-4a4a-ae8a-59754b6bd73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f8147861-c8a9-4e3c-b51a-d0ab28b7e441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aec977e6-9772-4bf8-9956-fe9794639292" xlink:to="loc_us-gaap_InterestExpense_f8147861-c8a9-4e3c-b51a-d0ab28b7e441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_561081f5-b34d-4e93-a2ad-3d37ef74fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aec977e6-9772-4bf8-9956-fe9794639292" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_561081f5-b34d-4e93-a2ad-3d37ef74fc97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_638bbe1c-c191-4ad0-91cb-d7f1da401011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59c9e389-bde0-4a47-b50f-163e7ef40c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_638bbe1c-c191-4ad0-91cb-d7f1da401011" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59c9e389-bde0-4a47-b50f-163e7ef40c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_42dcfb2e-7fa7-4ce4-a182-526314a63f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_638bbe1c-c191-4ad0-91cb-d7f1da401011" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_42dcfb2e-7fa7-4ce4-a182-526314a63f34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0377356b-ebd9-43d4-91ab-cfe211b86f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_NetIncomeLoss_0377356b-ebd9-43d4-91ab-cfe211b86f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4607c833-b974-48df-ad5f-4dee63270d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4607c833-b974-48df-ad5f-4dee63270d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ff8db7cb-c932-4841-98c6-d05e75868557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ff8db7cb-c932-4841-98c6-d05e75868557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cfe9641c-2914-4bc8-9e5d-d3dee6b4c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cfe9641c-2914-4bc8-9e5d-d3dee6b4c045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d72cccc-4681-4a08-b85a-4b8c180ea482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_ShareBasedCompensation_0d72cccc-4681-4a08-b85a-4b8c180ea482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b77d0334-96be-4a4d-ab0f-d472d6c30d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b77d0334-96be-4a4d-ab0f-d472d6c30d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1d9a349d-6eae-458c-8f8a-20bd6dda7069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1d9a349d-6eae-458c-8f8a-20bd6dda7069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_914fb61f-868f-4f24-807b-1b427537feed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_914fb61f-868f-4f24-807b-1b427537feed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_023f1a80-7215-4e46-826a-234e4a356c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_023f1a80-7215-4e46-826a-234e4a356c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_275f04b4-4e41-44b0-9b20-f1ce71c57137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_275f04b4-4e41-44b0-9b20-f1ce71c57137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1bc7683f-712c-4f50-a12d-c3c95985d974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1bc7683f-712c-4f50-a12d-c3c95985d974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_fc51a7a6-cc09-45d8-9b44-3d3199f82989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_fc51a7a6-cc09-45d8-9b44-3d3199f82989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1072be64-c520-4037-9661-ba66787b920c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1072be64-c520-4037-9661-ba66787b920c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4a6b26ec-9c8d-469c-8fc0-111779654e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4a6b26ec-9c8d-469c-8fc0-111779654e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5293f3fb-be9d-4fd9-b604-62a82bd3d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5293f3fb-be9d-4fd9-b604-62a82bd3d2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_eed3f51c-1bd7-4806-9934-5b6c082e2e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86793482-1015-4c9c-989c-b3bc8c47ec71" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_eed3f51c-1bd7-4806-9934-5b6c082e2e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0dae8bdb-2363-47c2-9b90-12a46461b557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0dae8bdb-2363-47c2-9b90-12a46461b557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_65899744-4b92-4b14-9025-7ad6e49d518e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_65899744-4b92-4b14-9025-7ad6e49d518e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4bb7e67a-159b-4970-aabc-9f4082207acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4bb7e67a-159b-4970-aabc-9f4082207acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fccd6754-e786-4b06-8c27-c2f3e561294c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fccd6754-e786-4b06-8c27-c2f3e561294c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_124e0576-e7aa-4df7-9f6d-5d932f4685fd" xlink:href="bmrn-20220331.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68c412b8-6d5e-4e40-9aa9-3ac1c9d8fa13" xlink:to="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_124e0576-e7aa-4df7-9f6d-5d932f4685fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d2552e1-5897-4381-a173-c9600f57dc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e1f86d5-26f1-4894-8cbb-54037d3b959d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d2552e1-5897-4381-a173-c9600f57dc88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e1f86d5-26f1-4894-8cbb-54037d3b959d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f05aecf-59fa-43a0-ad8f-bb85f78a72d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d2552e1-5897-4381-a173-c9600f57dc88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f05aecf-59fa-43a0-ad8f-bb85f78a72d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6e3f3ea9-920f-4f0e-bbfe-6786f0ee26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d2552e1-5897-4381-a173-c9600f57dc88" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6e3f3ea9-920f-4f0e-bbfe-6786f0ee26ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_838042d1-c982-4a2c-8921-824bf31cad8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3d2552e1-5897-4381-a173-c9600f57dc88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_838042d1-c982-4a2c-8921-824bf31cad8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c4b729d-a848-47e5-9e94-059503a20fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_672b4736-9b66-401a-b8c2-fb9d033b0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c4b729d-a848-47e5-9e94-059503a20fb4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_672b4736-9b66-401a-b8c2-fb9d033b0eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8fc323dd-1e9f-4fff-9074-2489de627df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c4b729d-a848-47e5-9e94-059503a20fb4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8fc323dd-1e9f-4fff-9074-2489de627df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_97a674fc-ec12-439f-8c68-07aa21fbfbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c4b729d-a848-47e5-9e94-059503a20fb4" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_97a674fc-ec12-439f-8c68-07aa21fbfbfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_836f6ede-1c5d-4c8c-80da-2b06740a777b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da85d5c0-8746-49ae-bab8-059fc46c3cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_836f6ede-1c5d-4c8c-80da-2b06740a777b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da85d5c0-8746-49ae-bab8-059fc46c3cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be938ca5-5ac3-4b84-b1d3-df7afdeb933b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_836f6ede-1c5d-4c8c-80da-2b06740a777b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be938ca5-5ac3-4b84-b1d3-df7afdeb933b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe63cc42-0ea9-42e6-8320-f151649e42b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_836f6ede-1c5d-4c8c-80da-2b06740a777b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe63cc42-0ea9-42e6-8320-f151649e42b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofInventoryDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d265866f-22f2-446e-9a67-70cf7249254f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5b5f6642-249b-411d-877b-330f7747baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d265866f-22f2-446e-9a67-70cf7249254f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5b5f6642-249b-411d-877b-330f7747baa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_19bde41f-6a66-4632-acdf-714ce617829c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d265866f-22f2-446e-9a67-70cf7249254f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_19bde41f-6a66-4632-acdf-714ce617829c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_98e27e7b-b070-4946-ab50-2a8dc679ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d265866f-22f2-446e-9a67-70cf7249254f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_98e27e7b-b070-4946-ab50-2a8dc679ca43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cbe9c3ba-9d5b-4069-a82b-cd1f37fe2fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0f9e2ba8-5576-4f7a-9f7b-334c55f612ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cbe9c3ba-9d5b-4069-a82b-cd1f37fe2fb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0f9e2ba8-5576-4f7a-9f7b-334c55f612ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_793e4030-1fcd-48b8-b291-9eba4f85ce95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cbe9c3ba-9d5b-4069-a82b-cd1f37fe2fb2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_793e4030-1fcd-48b8-b291-9eba4f85ce95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a05ddf-2d4c-4436-afa8-08dbee8e0297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_553fcd5b-8721-4dba-b123-8a8b6589f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a05ddf-2d4c-4436-afa8-08dbee8e0297" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_553fcd5b-8721-4dba-b123-8a8b6589f66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3339ea35-6274-4789-89be-63087b8711e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a05ddf-2d4c-4436-afa8-08dbee8e0297" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3339ea35-6274-4789-89be-63087b8711e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba467819-38ec-4fc2-a77d-701c469faa28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba467819-38ec-4fc2-a77d-701c469faa28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f8294088-5b0d-4cfd-9144-16eb031e6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f8294088-5b0d-4cfd-9144-16eb031e6a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates_aebb662e-f6b7-4902-8294-f2efbebf9995" xlink:href="bmrn-20220331.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_bmrn_AccruedGovernmentAndOtherRebates_aebb662e-f6b7-4902-8294-f2efbebf9995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_207b095e-44c4-4706-b2d3-d9bea75b9b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_AccruedIncomeTaxes_207b095e-44c4-4706-b2d3-d9bea75b9b7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_c07cb11f-f5e7-4f57-a57e-898013f5b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_c07cb11f-f5e7-4f57-a57e-898013f5b4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_0b7936f5-d13b-4aec-83ef-bc02fc69ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_0b7936f5-d13b-4aec-83ef-bc02fc69ac37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_60671dbd-68b5-4c2b-9670-ba8d68d5c81c" xlink:href="bmrn-20220331.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_60671dbd-68b5-4c2b-9670-ba8d68d5c81c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d8856477-6237-440b-8e3a-e1068fc2b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d8856477-6237-440b-8e3a-e1068fc2b339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dc21b5c-80e2-4b27-807a-94989af61a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dc21b5c-80e2-4b27-807a-94989af61a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_7ba96dc0-9d3c-4f03-9f5f-4334c2a38259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec03747d-4322-4687-ae3d-6b372c1581de" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_7ba96dc0-9d3c-4f03-9f5f-4334c2a38259" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_716eddb2-3c76-444c-a086-a17fa5ed2090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_921fee49-f08b-41fd-b8e9-f4f5c6628307" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_716eddb2-3c76-444c-a086-a17fa5ed2090" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_921fee49-f08b-41fd-b8e9-f4f5c6628307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c2fbc7f2-be98-4fdd-b35b-a40b634a9551" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_716eddb2-3c76-444c-a086-a17fa5ed2090" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_c2fbc7f2-be98-4fdd-b35b-a40b634a9551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f4900207-f2d7-4536-898c-5bd727ac6fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_7ef6f4f5-c62d-4823-bff2-b6143c6f2353" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f4900207-f2d7-4536-898c-5bd727ac6fa4" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_7ef6f4f5-c62d-4823-bff2-b6143c6f2353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_d7cf589a-7fd2-4400-9b99-3a6b3c6573a9" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f4900207-f2d7-4536-898c-5bd727ac6fa4" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_d7cf589a-7fd2-4400-9b99-3a6b3c6573a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofConvertibleDebtDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_e9f48f0c-17ea-4dfa-8ecd-d7ead5a149bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5cc3c3cc-55dd-4ab1-b8ea-710796d97ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_e9f48f0c-17ea-4dfa-8ecd-d7ead5a149bb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5cc3c3cc-55dd-4ab1-b8ea-710796d97ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_79a20412-4434-476d-a9fa-1912d22e2016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_e9f48f0c-17ea-4dfa-8ecd-d7ead5a149bb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_79a20412-4434-476d-a9fa-1912d22e2016" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofInterestExpenseonConvertibleDebtDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a6777603-7d54-4f67-96bd-1f02f3423212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_35eeb10d-90a6-49f7-8873-90fa4d6d013f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_a6777603-7d54-4f67-96bd-1f02f3423212" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_35eeb10d-90a6-49f7-8873-90fa4d6d013f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b277b50e-fa22-478f-bd2c-af7990765e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_a6777603-7d54-4f67-96bd-1f02f3423212" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b277b50e-fa22-478f-bd2c-af7990765e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0d17b71c-a654-4c05-bf6f-3cd6e405f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_a6777603-7d54-4f67-96bd-1f02f3423212" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0d17b71c-a654-4c05-bf6f-3cd6e405f75d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b5e7803-2a04-4622-bce0-6e384853040a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_06fbc547-15cc-49aa-a9b0-bf76422e6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b5e7803-2a04-4622-bce0-6e384853040a" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_06fbc547-15cc-49aa-a9b0-bf76422e6d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_21779065-e51f-4109-aaea-44d9f849dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b5e7803-2a04-4622-bce0-6e384853040a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_21779065-e51f-4109-aaea-44d9f849dafc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_e9b82c15-488b-487e-af9c-0e7aa9f87cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b5e7803-2a04-4622-bce0-6e384853040a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_e9b82c15-488b-487e-af9c-0e7aa9f87cb7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NetIncomePerCommonShareScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_70d52795-a95d-4929-a319-0dba7dcb628a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_76120422-32be-493a-8c8c-29933f268239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_70d52795-a95d-4929-a319-0dba7dcb628a" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_76120422-32be-493a-8c8c-29933f268239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ce14d070-5ed1-40d1-9fbd-c0a710cde846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_70d52795-a95d-4929-a319-0dba7dcb628a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ce14d070-5ed1-40d1-9fbd-c0a710cde846" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bmrn-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="iced75b4cedce4701881e7100b4c621e0_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_529288d9-dae0-423c-8823-1b820035f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_529288d9-dae0-423c-8823-1b820035f0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c59a761f-e3cc-4a5b-b93f-b8c1327847f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_CostOfRevenue_c59a761f-e3cc-4a5b-b93f-b8c1327847f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5e9708d4-363f-4f8c-85c9-54daa4193982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5e9708d4-363f-4f8c-85c9-54daa4193982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_51d0d10f-be0f-41cb-ae7d-9eb9d0515a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_51d0d10f-be0f-41cb-ae7d-9eb9d0515a6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_4de7a346-7b26-4414-940b-0471b4d5a7f8" xlink:href="bmrn-20220331.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_4de7a346-7b26-4414-940b-0471b4d5a7f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2f673234-a22b-48c5-8b1b-58e4a3f09ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2f673234-a22b-48c5-8b1b-58e4a3f09ac5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_792eb407-24a3-489d-8338-426db4ab9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_CostsAndExpenses_792eb407-24a3-489d-8338-426db4ab9f85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76fa1fcc-844e-450a-96b2-43495c4e7098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_OperatingIncomeLoss_76fa1fcc-844e-450a-96b2-43495c4e7098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd20a6ba-7005-4cd2-aa43-ba8fa96265ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd20a6ba-7005-4cd2-aa43-ba8fa96265ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0c92b86e-5799-4c97-8918-b9f7cf6294ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_InterestExpense_0c92b86e-5799-4c97-8918-b9f7cf6294ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_787c6788-6108-4f9d-82f0-447301298b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_787c6788-6108-4f9d-82f0-447301298b63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674b842d-333d-4ec9-b2b5-130d5913eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674b842d-333d-4ec9-b2b5-130d5913eaf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_498f5027-7056-4cde-b9a5-7f70372b5f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_498f5027-7056-4cde-b9a5-7f70372b5f9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d29be4a1-750a-4668-89d0-1d672d2dd78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_NetIncomeLoss_d29be4a1-750a-4668-89d0-1d672d2dd78c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_10d123bc-666c-4cdc-bd67-11514d12a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_EarningsPerShareBasic_10d123bc-666c-4cdc-bd67-11514d12a3f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_73b43845-b120-4d77-add2-22c4fa5209f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_EarningsPerShareDiluted_73b43845-b120-4d77-add2-22c4fa5209f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f032015c-095c-4e6d-9ee4-1aa51ef6af60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f032015c-095c-4e6d-9ee4-1aa51ef6af60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1ef770c-064d-40b4-b271-72d1ab420601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1ef770c-064d-40b4-b271-72d1ab420601" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84e08b28-5c49-4c53-bb4f-9d5f7ff483c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_84e08b28-5c49-4c53-bb4f-9d5f7ff483c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:to="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a9153c07-e69d-4d4f-a229-4f725e2000ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:to="loc_srt_ProductsAndServicesDomain_a9153c07-e69d-4d4f-a229-4f725e2000ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:to="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5cb679da-a178-4509-b7fc-a07d42fedd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:to="loc_us-gaap_ProductMember_5cb679da-a178-4509-b7fc-a07d42fedd97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_34e47ee4-0318-4794-a8f2-5095a570c51f" xlink:href="bmrn-20220331.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:to="loc_bmrn_RoyaltyAndOtherMember_34e47ee4-0318-4794-a8f2-5095a570c51f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i9cc69a18dffe41b095a5bb8f63783296_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_268fcced-92bf-40da-a2ae-3b8c49a23592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_SharesOutstanding_268fcced-92bf-40da-a2ae-3b8c49a23592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_9251df04-5071-4c21-876a-59170cec84b0" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_9251df04-5071-4c21-876a-59170cec84b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e97f2b03-b17f-4664-97d9-f264be0cf553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6fc3b3c-7ffd-44d3-82ff-b5f93c0d5c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_StockholdersEquity_d6fc3b3c-7ffd-44d3-82ff-b5f93c0d5c71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_3bb352c3-54ec-4aa0-a834-584364dc497b" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_3bb352c3-54ec-4aa0-a834-584364dc497b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4eb54464-d4d7-42fa-9b57-83096cbf924e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4eb54464-d4d7-42fa-9b57-83096cbf924e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_d1eb9877-442e-4714-a9b0-7a2d732b6e46" xlink:href="bmrn-20220331.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_d1eb9877-442e-4714-a9b0-7a2d732b6e46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ab081704-d5d9-43aa-824a-0a9dc2d1c3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ab081704-d5d9-43aa-824a-0a9dc2d1c3d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_023bd8dd-e423-49f4-b044-acf8fc48fecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_NetIncomeLoss_023bd8dd-e423-49f4-b044-acf8fc48fecb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2bc9e7d-d05f-4db3-9d6d-0a9da3470e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:to="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33806320-6759-4223-8168-3306cd612c98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:to="loc_us-gaap_EquityComponentDomain_33806320-6759-4223-8168-3306cd612c98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:to="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97a0d051-68c1-4d7f-991e-591884273d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_CommonStockMember_97a0d051-68c1-4d7f-991e-591884273d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0178a421-1588-481a-8315-dd19abb5de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0178a421-1588-481a-8315-dd19abb5de1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_c1a13c30-8a09-4587-89e9-261ae7c88e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_c1a13c30-8a09-4587-89e9-261ae7c88e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3390db5c-e8c8-4508-9c59-5f1a83829d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3390db5c-e8c8-4508-9c59-5f1a83829d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e703358d-0d4f-4acd-8306-9918258d4446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_RetainedEarningsMember_e703358d-0d4f-4acd-8306-9918258d4446" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="extended" id="i72ffe4fa025c4cd89112f6ad0a838004_FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_caa9600a-1b70-4e30-9478-9ba15323b161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_Cash_caa9600a-1b70-4e30-9478-9ba15323b161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f56fffec-8165-46db-99a4-0a0babd952f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f56fffec-8165-46db-99a4-0a0babd952f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_423cf1db-a21e-43b1-bfca-a029a8ff9465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_423cf1db-a21e-43b1-bfca-a029a8ff9465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84518c27-c31e-4fd9-8e60-e4e3b5fd2cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84518c27-c31e-4fd9-8e60-e4e3b5fd2cfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d9cce1f-26f4-4d71-a9f5-822cf869fd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d9cce1f-26f4-4d71-a9f5-822cf869fd87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3abbb7c3-1878-47d8-8323-3160ddb559d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3abbb7c3-1878-47d8-8323-3160ddb559d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91a03ff0-2bd2-412b-898e-2d46aa5764af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91a03ff0-2bd2-412b-898e-2d46aa5764af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8295b21d-abc9-4636-830d-49cf114a2d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8295b21d-abc9-4636-830d-49cf114a2d99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_e090e554-ca48-4044-b6c2-c10ad157dc41" xlink:href="bmrn-20220331.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_e090e554-ca48-4044-b6c2-c10ad157dc41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_9dd27254-9b52-4dd0-a40b-1460bc3740fa" xlink:href="bmrn-20220331.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_9dd27254-9b52-4dd0-a40b-1460bc3740fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7402e585-1b9f-43b4-bcad-354eadd1d47d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:to="loc_srt_RangeMember_7402e585-1b9f-43b4-bcad-354eadd1d47d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:to="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1bd3b56a-f33e-454f-a811-522b7cadddad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:to="loc_srt_MinimumMember_1bd3b56a-f33e-454f-a811-522b7cadddad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dcd5224-a9ad-4bf4-aecf-df97a105f0d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:to="loc_srt_MaximumMember_9dcd5224-a9ad-4bf4-aecf-df97a105f0d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9537d52e-c329-4546-8abb-422357a601a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9537d52e-c329-4546-8abb-422357a601a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a1dc4761-037f-4ebe-8582-1ca3e5c15300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a1dc4761-037f-4ebe-8582-1ca3e5c15300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_373e8fba-4bdb-44e9-819c-92fc2c7756e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_373e8fba-4bdb-44e9-819c-92fc2c7756e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1c320079-ea52-492b-85d4-327d14eff764_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1c320079-ea52-492b-85d4-327d14eff764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_89782408-632c-415b-b641-4e887ea95356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CashMember_89782408-632c-415b-b641-4e887ea95356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9b885e09-8272-49b0-9478-ee14f48faca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9b885e09-8272-49b0-9478-ee14f48faca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_30358c70-e39a-497c-8455-aef1238992ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_30358c70-e39a-497c-8455-aef1238992ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4e222aab-b813-4859-a6bc-585d6f228645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4e222aab-b813-4859-a6bc-585d6f228645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a723a908-a4d7-4528-b6c6-3b5d1649dd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CommercialPaperMember_a723a908-a4d7-4528-b6c6-3b5d1649dd72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_73dd5d32-f5af-4328-a89d-0cb648f30cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_73dd5d32-f5af-4328-a89d-0cb648f30cca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_d87cacb1-117b-4fd2-ba8c-d2af0781dc3b" xlink:href="bmrn-20220331.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_d87cacb1-117b-4fd2-ba8c-d2af0781dc3b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended" id="if9e51f0808b845bc8df9d8bdb011434f_FinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b5ab514d-13e0-4dae-98c6-3e1e59926cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b5ab514d-13e0-4dae-98c6-3e1e59926cbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60e42571-2dbf-4412-b87f-003cce704220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60e42571-2dbf-4412-b87f-003cce704220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember_25f6e4c1-fc92-458b-86c1-6ab3a58aef82" xlink:href="bmrn-20220331.xsd#bmrn_StrategicInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:to="loc_bmrn_StrategicInvestmentMember_25f6e4c1-fc92-458b-86c1-6ab3a58aef82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3f08207-01ba-4e81-811d-a7e89e56e51f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3f08207-01ba-4e81-811d-a7e89e56e51f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f0661018-4dd4-4c58-a104-df23613c366c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f0661018-4dd4-4c58-a104-df23613c366c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails" xlink:type="extended" id="i950b0939caf14ccaa28390a9b9ed9075_SupplementalFinancialStatementsInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a48d05b0-bb58-4718-a135-c0abb8c3f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_InventoryNet_a48d05b0-bb58-4718-a135-c0abb8c3f1ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4e2b34c3-dcfb-4121-9529-68b0c28fd8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_Depreciation_4e2b34c3-dcfb-4121-9529-68b0c28fd8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_654d6f7c-c406-4323-b77a-43ca744bcf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_654d6f7c-c406-4323-b77a-43ca744bcf4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_91ece28c-eb30-4e1f-ac00-39702f2537f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_91ece28c-eb30-4e1f-ac00-39702f2537f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ValoctocogeneRoxaparvovecMember_8728320f-1082-4224-8711-0a9c3b09f8b5" xlink:href="bmrn-20220331.xsd#bmrn_ValoctocogeneRoxaparvovecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:to="loc_bmrn_ValoctocogeneRoxaparvovecMember_8728320f-1082-4224-8711-0a9c3b09f8b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="extended" id="i82e8d8dc80b04ebeb701fd576f63aa94_FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80c03db3-aa62-429a-813d-d31b19cdebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80c03db3-aa62-429a-813d-d31b19cdebeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_deff4835-0d30-4160-8d31-0e22cdef81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_deff4835-0d30-4160-8d31-0e22cdef81ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_88f8404a-0def-454f-9222-37d12bae6bb4" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_88f8404a-0def-454f-9222-37d12bae6bb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_e009d9d1-2b28-4995-ba30-6041eaa468be" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_e009d9d1-2b28-4995-ba30-6041eaa468be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_12bf2ba4-aaa3-4942-9bae-86b72bea35fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_12bf2ba4-aaa3-4942-9bae-86b72bea35fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_633f8afe-5091-45f0-a140-d4dcf43d4699" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_633f8afe-5091-45f0-a140-d4dcf43d4699" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_ce94f706-a0d8-4d21-9334-31ced90bdd3c" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_ce94f706-a0d8-4d21-9334-31ced90bdd3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f06d258d-cdae-4df9-929b-bd3672d91175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f06d258d-cdae-4df9-929b-bd3672d91175" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2be3751b-a991-4afa-8589-be7f0543502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2be3751b-a991-4afa-8589-be7f0543502a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c5a4a837-9d91-4c8f-978f-c3f327e9a915_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c5a4a837-9d91-4c8f-978f-c3f327e9a915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_61fe0a44-2aa1-44c7-ba3c-15d611fe0a5d" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_61fe0a44-2aa1-44c7-ba3c-15d611fe0a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember_c8574c01-f427-4308-99d2-8ea8bcdc70d3" xlink:href="bmrn-20220331.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:to="loc_bmrn_RestrictedInvestmentsMember_c8574c01-f427-4308-99d2-8ea8bcdc70d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7589eff8-7f33-4e15-936b-32a14e275725_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7589eff8-7f33-4e15-936b-32a14e275725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7bc45ab9-5686-4d6d-8b83-9e1d5a95d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7bc45ab9-5686-4d6d-8b83-9e1d5a95d15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac2a7356-6ef8-4ac9-8a04-0cdec0293e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac2a7356-6ef8-4ac9-8a04-0cdec0293e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8433f749-93eb-4991-952e-2156b9e6fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8433f749-93eb-4991-952e-2156b9e6fcd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_905d7561-bc54-404d-bfd4-eaa8850d27d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_905d7561-bc54-404d-bfd4-eaa8850d27d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_d14ee82b-82a0-4de2-a047-7ff2d5c09731" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_d14ee82b-82a0-4de2-a047-7ff2d5c09731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember_4115ebb0-1dcc-479e-bfb2-351ea33ab09e" xlink:href="bmrn-20220331.xsd#bmrn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:to="loc_bmrn_ContingentConsiderationMember_4115ebb0-1dcc-479e-bfb2-351ea33ab09e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" xlink:type="extended" id="i8621427593ea4118a72e26399c86e4d0_FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0aa4a764-70ed-4c5c-bd6c-7044a0963a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0aa4a764-70ed-4c5c-bd6c-7044a0963a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17440925-6cec-4bd1-8e7a-3dfc278b3733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17440925-6cec-4bd1-8e7a-3dfc278b3733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_985292fc-62e4-4253-b1c5-ae8424ecac81" xlink:href="bmrn-20220331.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_985292fc-62e4-4253-b1c5-ae8424ecac81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_114ab2da-dd94-4161-8a85-2d3c96d3733f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_75188cb7-91c5-4e6d-85d1-c0abb0cd552e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_75188cb7-91c5-4e6d-85d1-c0abb0cd552e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember_0b85c8b5-cdf6-4b2a-9ba5-95ca24b7ed7f" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:to="loc_bmrn_ContingentPaymentMember_0b85c8b5-cdf6-4b2a-9ba5-95ca24b7ed7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" xlink:type="extended" id="ia5331fbc6e61467f9fbfcfb16ad4102a_DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_37511830-d3c7-4b5c-9a86-4046c8a46061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_37511830-d3c7-4b5c-9a86-4046c8a46061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_e5e4b1f4-7ce9-49ef-8df7-51067cc27560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_e5e4b1f4-7ce9-49ef-8df7-51067cc27560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:to="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:to="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0273b201-99d4-4c39-8d58-f764355d97ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:to="loc_us-gaap_HedgingDesignationDomain_0273b201-99d4-4c39-8d58-f764355d97ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:to="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_af204b89-db9d-4568-a6a9-b1749fb27e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_af204b89-db9d-4568-a6a9-b1749fb27e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2d0cfb6e-c657-4983-89a9-03e58965aa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:to="loc_us-gaap_NondesignatedMember_2d0cfb6e-c657-4983-89a9-03e58965aa9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail" xlink:type="extended" id="ib6c3b06bb15f4577a637e64d52f9fdab_DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12280edf-2dfe-41b5-9fa9-216cf398804f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12280edf-2dfe-41b5-9fa9-216cf398804f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:to="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_769821a4-4fa4-42c3-935e-3590f701f72e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:to="loc_us-gaap_HedgingDesignationDomain_769821a4-4fa4-42c3-935e-3590f701f72e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:to="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e1b0f33-4327-4558-a5b9-4eb736c91519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e1b0f33-4327-4558-a5b9-4eb736c91519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_3f3a3b57-c3bc-471c-8eaf-01d24b7d0242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:to="loc_us-gaap_NondesignatedMember_3f3a3b57-c3bc-471c-8eaf-01d24b7d0242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f5dc4f54-e34f-4196-b8c0-855f954fce43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f5dc4f54-e34f-4196-b8c0-855f954fce43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_35837dca-d31d-4e75-9f0d-76694faaeef2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:to="loc_us-gaap_PositionDomain_35837dca-d31d-4e75-9f0d-76694faaeef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:to="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_03cbf691-ec2e-4778-bb0b-e0d2be6221b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:to="loc_us-gaap_ShortMember_03cbf691-ec2e-4778-bb0b-e0d2be6221b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_5f040977-3733-4f73-9812-bae27d51a844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:to="loc_us-gaap_LongMember_5f040977-3733-4f73-9812-bae27d51a844" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" xlink:type="extended" id="i38251ab75caa428ea8f18e97bb0d350c_DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14078c97-02ba-4169-9a73-7b70fddf7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14078c97-02ba-4169-9a73-7b70fddf7e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dbf54afa-f4f1-480a-be7f-ce8a02c0ee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dbf54afa-f4f1-480a-be7f-ce8a02c0ee1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:to="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c84bff2d-cc04-48ad-90e1-3c12795bbfbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c84bff2d-cc04-48ad-90e1-3c12795bbfbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3faa2be9-5abf-4767-965e-6ffebc2aed92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3faa2be9-5abf-4767-965e-6ffebc2aed92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_277f0901-8ad5-49a4-9941-35399e90f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_277f0901-8ad5-49a4-9941-35399e90f0d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1ae91d80-2c7f-442c-ae8e-c95c057be0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:to="loc_us-gaap_NondesignatedMember_1ae91d80-2c7f-442c-ae8e-c95c057be0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3873d5d0-9644-4850-8699-d30f7c7614a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3873d5d0-9644-4850-8699-d30f7c7614a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_3d34a58c-3736-4c44-8aa0-9765afd21ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_3d34a58c-3736-4c44-8aa0-9765afd21ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_a7d544ab-40b6-4e63-95b2-a4b123fc636c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_a7d544ab-40b6-4e63-95b2-a4b123fc636c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a653dfc0-4717-4b49-9f65-66b3f320d329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a653dfc0-4717-4b49-9f65-66b3f320d329" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" xlink:type="extended" id="i24f6ac6a0ed04e5480e0a91d79a68e63_DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6779e5ca-d4b2-49bb-9305-cf87d74cbec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6779e5ca-d4b2-49bb-9305-cf87d74cbec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f5f3a5c4-ae91-4d00-927c-595926b2e616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_CostsAndExpenses_f5f3a5c4-ae91-4d00-927c-595926b2e616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b785b000-1692-4493-9f86-3522b5c880c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b785b000-1692-4493-9f86-3522b5c880c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_99aa9cb0-698c-49a5-8ac1-f9f515c384d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_99aa9cb0-698c-49a5-8ac1-f9f515c384d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86026757-fb3f-4724-af62-2cb618f54fbc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:to="loc_srt_ProductsAndServicesDomain_86026757-fb3f-4724-af62-2cb618f54fbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:to="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0d256cf5-81b3-4e00-8260-3f87ff489682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:to="loc_us-gaap_ProductMember_0d256cf5-81b3-4e00-8260-3f87ff489682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_ee02d4c2-cd53-47fb-9687-84c8d55a17ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:to="loc_us-gaap_OperatingExpenseMember_ee02d4c2-cd53-47fb-9687-84c8d55a17ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7ae2ad0e-fd14-44ea-b349-1d853626382b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:to="loc_us-gaap_HedgingDesignationDomain_7ae2ad0e-fd14-44ea-b349-1d853626382b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:to="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1f6cc53c-cd09-46ea-aa15-f9289738a106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1f6cc53c-cd09-46ea-aa15-f9289738a106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_96f24075-fbe4-4a44-8d8b-1a6bf146702e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:to="loc_us-gaap_NondesignatedMember_96f24075-fbe4-4a44-8d8b-1a6bf146702e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e387df95-a155-4e52-860f-5a44e2c04f21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:to="loc_us-gaap_EquityComponentDomain_e387df95-a155-4e52-860f-5a44e2c04f21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:to="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2f58a769-0a47-452c-b1be-fefab5cb10fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2f58a769-0a47-452c-b1be-fefab5cb10fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DebtAdditionalInformationDetail" xlink:type="extended" id="ica426992b7cb40a7a7a99348c29ff104_DebtAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_efe61d5e-e6db-4e0d-878b-794e0c21ca0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_efe61d5e-e6db-4e0d-878b-794e0c21ca0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da16003f-423c-4ea6-9a46-23aa2fd6ba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da16003f-423c-4ea6-9a46-23aa2fd6ba0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_5778b910-d39e-4530-9c4d-fbcf0584c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_LineOfCredit_5778b910-d39e-4530-9c4d-fbcf0584c9ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:to="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_664b67e2-b1e3-42b3-9ef1-411172b1a6c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_664b67e2-b1e3-42b3-9ef1-411172b1a6c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_fbca8ead-400e-4dec-9db8-20a5bcdb3042" xlink:href="bmrn-20220331.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:to="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_fbca8ead-400e-4dec-9db8-20a5bcdb3042" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofConvertibleDebtDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="extended" id="i3546fd43c8274b83ab90ed8c71cf677f_DebtSummaryofConvertibleDebtDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b798ab83-314e-416a-88b1-ab150616d8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b798ab83-314e-416a-88b1-ab150616d8df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0945cb23-3427-43e7-bc6e-3816e689e039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0945cb23-3427-43e7-bc6e-3816e689e039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d24b9a8-a1f0-4a86-95c4-0e4bf3e533ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d24b9a8-a1f0-4a86-95c4-0e4bf3e533ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9ee9550c-32a8-4dfa-bdb2-01c0c0640f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9ee9550c-32a8-4dfa-bdb2-01c0c0640f57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5c5f39a2-8043-4051-a8bb-ac6d79edbdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebt_5c5f39a2-8043-4051-a8bb-ac6d79edbdad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f5907070-ad9f-4b8b-9ce3-999fbda285ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f5907070-ad9f-4b8b-9ce3-999fbda285ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:to="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d22d423c-2d3f-423c-ac99-46a33ddc9059_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d22d423c-2d3f-423c-ac99-46a33ddc9059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_dada4c79-f0c6-4f96-a8e4-bf3fd9b541b0" xlink:href="bmrn-20220331.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_dada4c79-f0c6-4f96-a8e4-bf3fd9b541b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_3583581c-d1b0-45f7-accc-2054487244f6" xlink:href="bmrn-20220331.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_3583581c-d1b0-45f7-accc-2054487244f6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofInterestExpenseonConvertibleDebtDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="extended" id="ifc87fc5ec4af4cc9b0f8fdf3c492e1f0_DebtSummaryofInterestExpenseonConvertibleDebtDetail">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f2303a9d-4204-4ed5-b91f-7bceea6e28a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f2303a9d-4204-4ed5-b91f-7bceea6e28a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c3843cf-2a57-438b-a029-2c48b0a664e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c3843cf-2a57-438b-a029-2c48b0a664e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_66ecc144-9c2b-4e00-b4bf-e4a31dc6ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_66ecc144-9c2b-4e00-b4bf-e4a31dc6ea37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f9f07d9-468a-48aa-9ac6-c471cfea813a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_InterestExpense_2f9f07d9-468a-48aa-9ac6-c471cfea813a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_065a4a8c-700e-46e9-8837-9e458c8f1bac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_065a4a8c-700e-46e9-8837-9e458c8f1bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d080536f-1a89-4852-b6ac-f90e5cb57618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:to="loc_us-gaap_ConvertibleDebtMember_d080536f-1a89-4852-b6ac-f90e5cb57618" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="extended" id="if9741dc1ac7949a183b6b3e19e9b77ee_AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e004e971-5d16-451b-8377-3dc49ffc7dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_StockholdersEquity_e004e971-5d16-451b-8377-3dc49ffc7dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d71ee59a-4576-455e-aa17-1fbc44425ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d71ee59a-4576-455e-aa17-1fbc44425ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_88a43745-1c0c-4a09-947a-061b54922c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_88a43745-1c0c-4a09-947a-061b54922c6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_367a4298-8eef-42f9-8ffc-7848035bd5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_367a4298-8eef-42f9-8ffc-7848035bd5fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57e26ccc-bccf-4928-bed2-37d696ced7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57e26ccc-bccf-4928-bed2-37d696ced7c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0ba61abf-8ab1-49f9-8e19-d3232131b60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2c92a509-4c0f-4796-b990-399887efb433_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:to="loc_us-gaap_EquityComponentDomain_2c92a509-4c0f-4796-b990-399887efb433_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:to="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3643f09e-6287-4c2a-afaf-688ae298a48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3643f09e-6287-4c2a-afaf-688ae298a48e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_87ff027b-6413-4623-9ca0-721e0128c238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_87ff027b-6413-4623-9ca0-721e0128c238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_80e355b2-99f4-46db-a752-bad97e26130d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_80e355b2-99f4-46db-a752-bad97e26130d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" xlink:type="extended" id="ifb7f245c82b2493c90280dee5e23d591_RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d581c78b-2f01-4eb8-9be5-f7131852e2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d581c78b-2f01-4eb8-9be5-f7131852e2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_93ecb044-5500-488d-a079-8f9711f7e240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_93ecb044-5500-488d-a079-8f9711f7e240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_21321fc7-571e-4bb7-9eec-6094cde4322c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_21321fc7-571e-4bb7-9eec-6094cde4322c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f76230ea-0cf0-4c86-a9b9-c72b997ecd56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f76230ea-0cf0-4c86-a9b9-c72b997ecd56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_c71af97e-078d-424a-8566-09319bebf7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_c71af97e-078d-424a-8566-09319bebf7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ad186880-08c0-46c7-900c-142b508b4014_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ad186880-08c0-46c7-900c-142b508b4014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_37cdc152-aebd-4742-b70c-468df90813ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:to="loc_us-gaap_AccountsReceivableMember_37cdc152-aebd-4742-b70c-468df90813ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e1e92d11-c64e-4b29-82cc-9d854366567b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:to="loc_srt_NameOfMajorCustomerDomain_e1e92d11-c64e-4b29-82cc-9d854366567b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:to="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_0b09c199-d50a-4a06-91b4-55f53ac4942f" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomerOneMember_0b09c199-d50a-4a06-91b4-55f53ac4942f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_a74e3d75-9191-4e92-bc7f-92f8d7188506" xlink:href="bmrn-20220331.xsd#bmrn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomerTwoMember_a74e3d75-9191-4e92-bc7f-92f8d7188506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember_30077c29-5826-4c15-8e20-fad9fdd23c30" xlink:href="bmrn-20220331.xsd#bmrn_CustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomersMember_30077c29-5826-4c15-8e20-fad9fdd23c30" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" xlink:type="extended" id="icbf15f5bc8564f5a81096c0d7eda1cb7_RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4691f2c-f032-4c94-9016-e7eb8c6ea4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4691f2c-f032-4c94-9016-e7eb8c6ea4fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:to="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e4bfde3-bb1e-41b2-9118-ba782434a92f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:to="loc_srt_ProductsAndServicesDomain_8e4bfde3-bb1e-41b2-9118-ba782434a92f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:to="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:to="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember_6cc43415-9db8-4fed-a85a-8d36b272614d" xlink:href="bmrn-20220331.xsd#bmrn_ProductFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductFourMember_6cc43415-9db8-4fed-a85a-8d36b272614d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember_198ac7c7-f392-43b4-abbf-0ebc5593d245" xlink:href="bmrn-20220331.xsd#bmrn_ProductTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductTwoMember_198ac7c7-f392-43b4-abbf-0ebc5593d245" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember_3c4eda10-60ae-4a9a-b117-b56dc6a4b67f" xlink:href="bmrn-20220331.xsd#bmrn_ProductThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductThreeMember_3c4eda10-60ae-4a9a-b117-b56dc6a4b67f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember_83f57436-bcaa-4202-9835-d78d3cf657be" xlink:href="bmrn-20220331.xsd#bmrn_ProductSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductSevenMember_83f57436-bcaa-4202-9835-d78d3cf657be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember_52543853-dd08-42ac-bf7c-a69b84f6df7c" xlink:href="bmrn-20220331.xsd#bmrn_ProductSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductSixMember_52543853-dd08-42ac-bf7c-a69b84f6df7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember_0614e168-3410-48b9-9c31-79f17398c242" xlink:href="bmrn-20220331.xsd#bmrn_ProductEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductEightMember_0614e168-3410-48b9-9c31-79f17398c242" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_870a30c2-8914-42c6-a46a-83e9b2b3ca69" xlink:href="bmrn-20220331.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_870a30c2-8914-42c6-a46a-83e9b2b3ca69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_e6510f52-d4a8-417b-9b10-6f825ce78669" xlink:href="bmrn-20220331.xsd#bmrn_ProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductOneMember_e6510f52-d4a8-417b-9b10-6f825ce78669" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_e4b62e74-d333-4ccf-9259-7972ecd0505d" xlink:href="bmrn-20220331.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:to="loc_bmrn_RoyaltyAndOtherMember_e4b62e74-d333-4ccf-9259-7972ecd0505d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_29f00384-85fb-45bc-806c-9bb83c8e5284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_29f00384-85fb-45bc-806c-9bb83c8e5284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_92667062-3835-4206-86d5-cf16776611f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_92667062-3835-4206-86d5-cf16776611f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" xlink:type="extended" id="i0c2b4ad01d9b492ba19c59d76eac71d6_RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdeee4c1-d9db-4ac9-b7ef-4559a054212c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdeee4c1-d9db-4ac9-b7ef-4559a054212c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5728e708-f6a3-4119-8566-6aa579be3056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_5728e708-f6a3-4119-8566-6aa579be3056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_6978953d-7be3-4bb2-8207-a81f464e5893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_6978953d-7be3-4bb2-8207-a81f464e5893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_f79575cf-8ae7-42d4-b2b3-ca925c8b28bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_f79575cf-8ae7-42d4-b2b3-ca925c8b28bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55a74a18-79cc-4e65-8421-5a0992ab33f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:to="loc_srt_ProductsAndServicesDomain_55a74a18-79cc-4e65-8421-5a0992ab33f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:to="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_ae811428-ce77-4cba-a41b-34ccf2a32b8f" xlink:href="bmrn-20220331.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_ae811428-ce77-4cba-a41b-34ccf2a32b8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_d63151fd-bd69-41a4-868f-27f72408308d" xlink:href="bmrn-20220331.xsd#bmrn_ProductOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_bmrn_ProductOneMember_d63151fd-bd69-41a4-868f-27f72408308d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3143ec22-6b21-48df-8411-2662ebbb08f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_us-gaap_ProductMember_3143ec22-6b21-48df-8411-2662ebbb08f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_996b617c-536a-41ca-91da-eed30c2a7f67_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:to="loc_srt_SegmentGeographicalDomain_996b617c-536a-41ca-91da-eed30c2a7f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:to="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0740110d-1f99-4065-873b-85f98f3d8a78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_srt_EuropeMember_0740110d-1f99-4065-873b-85f98f3d8a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f0593b2a-adfc-41d2-ab6b-27b807f4ff7e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_country_US_f0593b2a-adfc-41d2-ab6b-27b807f4ff7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MiddleEastMember_229b0d09-e279-4b08-a419-eb604e2b4fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_us-gaap_MiddleEastMember_229b0d09-e279-4b08-a419-eb604e2b4fa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_c6794879-497f-416c-9c65-3b92edcbacb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_srt_LatinAmericaMember_c6794879-497f-416c-9c65-3b92edcbacb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_12ad436e-ea9a-4fda-92bd-394c7df2c9c0" xlink:href="bmrn-20220331.xsd#bmrn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_bmrn_RestOfWorldMember_12ad436e-ea9a-4fda-92bd-394c7df2c9c0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" xlink:type="extended" id="ia11c7791bf894334862ebfba8e8b5ccd_RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_61a53c8a-6997-4c2b-bb91-3f5cd9a38cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_61a53c8a-6997-4c2b-bb91-3f5cd9a38cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:to="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0781c0e9-16b3-424f-99f4-b2e389557ad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0781c0e9-16b3-424f-99f4-b2e389557ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_969c08bc-ce9d-4ef0-a463-cdf19314e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_969c08bc-ce9d-4ef0-a463-cdf19314e1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a76aecdf-6098-4cf7-b940-e0131c464d48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a76aecdf-6098-4cf7-b940-e0131c464d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c5ed8c0f-c27c-45cd-8d4b-5f9d95db7d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:to="loc_us-gaap_SalesRevenueNetMember_c5ed8c0f-c27c-45cd-8d4b-5f9d95db7d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9636593f-fd23-4cb2-9475-0a7113961427_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:to="loc_srt_NameOfMajorCustomerDomain_9636593f-fd23-4cb2-9475-0a7113961427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:to="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneTwoThreeAndFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:to="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_b4c659bc-d652-4a29-b012-e4cd1462629d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerOneMember_b4c659bc-d652-4a29-b012-e4cd1462629d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_c47c0762-e175-4be5-ad40-d48ccd0fbb3d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerTwoMember_c47c0762-e175-4be5-ad40-d48ccd0fbb3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember_d51c9623-67c9-45a6-8936-08d97467420d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerThreeMember_d51c9623-67c9-45a6-8936-08d97467420d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerFourMember_c23b1060-c76d-4740-9ab0-32ca86c99172" xlink:href="bmrn-20220331.xsd#bmrn_CustomerFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerFourMember_c23b1060-c76d-4740-9ab0-32ca86c99172" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#StockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" xlink:type="extended" id="i02c464db4c1345c0a8f7ba3e460c6969_StockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b46f045e-47ad-4639-afe6-deffe6f058b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b46f045e-47ad-4639-afe6-deffe6f058b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_49d69e57-60fc-4247-8406-f83958ed73e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_49d69e57-60fc-4247-8406-f83958ed73e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6ab3c36b-0f69-4127-9e01-f06a9e709944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_CostOfSalesMember_6ab3c36b-0f69-4127-9e01-f06a9e709944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b48e8f5a-adaf-4422-82d1-434a96317abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b48e8f5a-adaf-4422-82d1-434a96317abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3bce1b7d-b7f3-40e5-8a91-7903089a322c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3bce1b7d-b7f3-40e5-8a91-7903089a322c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NetIncomePerCommonShareScheduleofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="extended" id="i229f9e33d190430aa32585bf4c69adb6_NetIncomePerCommonShareScheduleofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7db7249e-81e6-408c-af4c-58b1acc19405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7db7249e-81e6-408c-af4c-58b1acc19405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_03c42154-7fb0-4383-832f-014f32f590fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_03c42154-7fb0-4383-832f-014f32f590fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da38d5c9-19c6-4a3b-b543-072064e8140d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da38d5c9-19c6-4a3b-b543-072064e8140d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53440ba2-10cb-4365-af69-b1e5d522760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53440ba2-10cb-4365-af69-b1e5d522760c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7f074c07-0cb9-41d3-9692-098645ca137a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7f074c07-0cb9-41d3-9692-098645ca137a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e7e4363-bffa-4e6b-9132-f62210b68b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e7e4363-bffa-4e6b-9132-f62210b68b11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0fb57654-2641-4273-893c-c81df40e047a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_EarningsPerShareBasic_0fb57654-2641-4273-893c-c81df40e047a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c36b0b1b-e915-4ce7-a95e-3f8439d4dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c36b0b1b-e915-4ce7-a95e-3f8439d4dd63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a1f687d9-9a86-4ea7-9d2d-86fee48760d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a1f687d9-9a86-4ea7-9d2d-86fee48760d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cf7e72ef-a82d-4096-9a3a-5b51fba90474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cf7e72ef-a82d-4096-9a3a-5b51fba90474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_1a74bef6-f7ac-4d60-be22-c99fb7e54d8c" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_1a74bef6-f7ac-4d60-be22-c99fb7e54d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_836d5ff4-8f16-4b0e-b0e0-e94461f69871" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_836d5ff4-8f16-4b0e-b0e0-e94461f69871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c46c9fd7-219f-4f98-ae54-f70f631d03d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_RestrictedStockMember_c46c9fd7-219f-4f98-ae54-f70f631d03d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_2337f57f-abd8-4e89-ad6a-5347faadffba" xlink:href="bmrn-20220331.xsd#bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_2337f57f-abd8-4e89-ad6a-5347faadffba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_10dd2f7f-55d8-4fb0-98ab-dcdec210263d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_StockCompensationPlanMember_10dd2f7f-55d8-4fb0-98ab-dcdec210263d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" xlink:type="extended" id="id9aae187b91948f2afed2a2448f841cf_NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e92546a-7cde-489f-aea5-76c0514646d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e92546a-7cde-489f-aea5-76c0514646d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_73383280-8b33-499f-959d-d80fb30f23e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_73383280-8b33-499f-959d-d80fb30f23e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df628dd6-0cfd-415b-b122-d1d62ff4a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df628dd6-0cfd-415b-b122-d1d62ff4a58a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_d8f09fbd-ae7f-445c-bb72-7c8ffd7a99d2" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_d8f09fbd-ae7f-445c-bb72-7c8ffd7a99d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_9dab9e39-f450-42a0-a430-790a1cf288e0" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_9dab9e39-f450-42a0-a430-790a1cf288e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_692af1a8-eb20-4f9e-9864-645d2e39906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_us-gaap_RestrictedStockMember_692af1a8-eb20-4f9e-9864-645d2e39906c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_9a72fd1c-2197-480c-bfd3-2e119ac7aebc" xlink:href="bmrn-20220331.xsd#bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_9a72fd1c-2197-480c-bfd3-2e119ac7aebc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i06f0547ed0d348108c5e0ae9d4a121e7_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_5cfb39ed-cc15-4b56-8955-771093394dc8" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:to="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_5cfb39ed-cc15-4b56-8955-771093394dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b90e61ef-3ff0-4cc3-9cfc-afa302160bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b90e61ef-3ff0-4cc3-9cfc-afa302160bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:to="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_10f245b5-5d88-4e47-a1bc-b924ffb23298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_10f245b5-5d88-4e47-a1bc-b924ffb23298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramMember_8d145877-1c2e-43c7-8304-536c9eba84ba" xlink:href="bmrn-20220331.xsd#bmrn_EarlyStageDevelopmentProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramMember_8d145877-1c2e-43c7-8304-536c9eba84ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1508c9de-3225-447d-b48b-c3f80ebb9c42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1508c9de-3225-447d-b48b-c3f80ebb9c42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember_7d7f9dbb-a72e-441b-b5e6-1d063b84e576" xlink:href="bmrn-20220331.xsd#bmrn_ThirdPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:to="loc_bmrn_ThirdPartyMember_7d7f9dbb-a72e-441b-b5e6-1d063b84e576" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bmrn-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PositionAxis_d980417a-3980-48f1-9a7d-c68eb9038ab1_terseLabel_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position</link:label>
    <link:label id="lab_us-gaap_PositionAxis_label_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionAxis" xlink:to="lab_us-gaap_PositionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_b9e1f835-75cf-4853-bbb7-3c1acadab824_terseLabel_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability, Current</link:label>
    <link:label id="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="bmrn-20220331.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_bmrn_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_dd2d0179-c12f-495e-b3d7-6f258d5674bb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0e0e90cd-d836-4837-9728-2d626f98a616_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ca92c4bb-eaf0-4fb8-b754-587f485270c4_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9fb0cc24-b3b0-4210-ba86-d1eac84c186f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Available for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_9c5168b5-8922-4f4f-99ca-496d00da9719_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_74ae9f23-7a6a-48f6-b3b5-6565b0afceb0_terseLabel_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim</link:label>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_label_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Excluding Product One [Member]</link:label>
    <link:label id="lab_bmrn_ProductsExcludingProductOneMember_documentation_en-US" xlink:label="lab_bmrn_ProductsExcludingProductOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products excluding product one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductsExcludingProductOneMember" xlink:to="lab_bmrn_ProductsExcludingProductOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4702ddff-2aa7-491d-8da0-051080a46859_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ba9bc36b-e3f1-4d61-8d2c-5ee98045be58_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_81572e43-bd27-406f-abdc-1e23460c3e85_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9331925e-26b9-4a21-9096-32c26f938a90_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_90e0902e-aa87-4c75-a1b9-2beda064797b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e6a793a-93a1-4962-90c9-20382cab9218_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramMember_0af5f1ab-46c6-4092-873b-5dedb5ec92cb_terseLabel_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramMember_label_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program [Member]</link:label>
    <link:label id="lab_bmrn_EarlyStageDevelopmentProgramMember_documentation_en-US" xlink:label="lab_bmrn_EarlyStageDevelopmentProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Stage Development Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramMember" xlink:href="bmrn-20220331.xsd#bmrn_EarlyStageDevelopmentProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_EarlyStageDevelopmentProgramMember" xlink:to="lab_bmrn_EarlyStageDevelopmentProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4c586c58-76dc-42d3-9c07-367e8fc7f21f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_90819263-d266-4e74-90af-2c08f417b398_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75cdb2bf-c9da-467a-8d85-0d7b259d0472_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_499816a1-2b0f-428f-a8f9-7eb37579cff6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerFourMember_a563143d-0e12-4799-8d35-8dc1dfd8ff12_terseLabel_en-US" xlink:label="lab_bmrn_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_bmrn_CustomerFourMember_label_en-US" xlink:label="lab_bmrn_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:label id="lab_bmrn_CustomerFourMember_documentation_en-US" xlink:label="lab_bmrn_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerFourMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomerFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerFourMember" xlink:to="lab_bmrn_CustomerFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_c8b8e73a-de5b-4f37-8af8-576de025ce7c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added taxes payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_387f282d-c693-432d-8b8f-6d75f78167e1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_edfbcd9d-0978-4737-b784-86fa78507723_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_65e856ec-d4db-4f56-a287-de816fccd379_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ThirdPartyMember_05c81ff8-350a-401e-818e-acd7b58d737a_terseLabel_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party</link:label>
    <link:label id="lab_bmrn_ThirdPartyMember_label_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party [Member]</link:label>
    <link:label id="lab_bmrn_ThirdPartyMember_documentation_en-US" xlink:label="lab_bmrn_ThirdPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember" xlink:href="bmrn-20220331.xsd#bmrn_ThirdPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ThirdPartyMember" xlink:to="lab_bmrn_ThirdPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_9bf76650-4668-45d7-88ae-4ffaf659907c_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f1379648-96f6-435f-bad8-49383ea86db2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1032a46a-12de-4d80-aa80-1f3936f3482d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MiddleEastMember_ed7e96f0-3875-41e2-8eae-c063f7f093d6_terseLabel_en-US" xlink:label="lab_us-gaap_MiddleEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Middle East</link:label>
    <link:label id="lab_us-gaap_MiddleEastMember_label_en-US" xlink:label="lab_us-gaap_MiddleEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Middle East [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MiddleEastMember" xlink:to="lab_us-gaap_MiddleEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e43d7d1-3bc5-45c8-b373-855e7e5d919e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0cd849ff-6236-4efe-bf53-ae64f7ed68c1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6c5e5f09-6c4c-4f8c-92c2-5a1ebc3c06df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_66f5f2dd-bd2e-45b6-b0af-e380efbfc673_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fb73f91-b873-4e21-ad57-2e5bef9a3023_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_09694b7f-76da-4747-b43c-8211c4d78c6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_bd3e05d5-e5ad-4edf-8b06-c07b26441174_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_7dceb94b-db5e-46a5-82bf-de5aeb8ec718_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of nonfinancial assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_e4de5fd4-df9a-4471-ba04-17d23ffae220_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_label_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_documentation_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:href="bmrn-20220331.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:to="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_f6cc82f8-88d5-4de5-961b-a817a52004a9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfa59c16-fd17-4d2a-bbc3-b69bf47a4040_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_591779b2-fc84-4986-8758-e60dc878c251_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;current&#160;assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_138e3e15-ee42-4168-9d2c-02f0eb4ad116_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4b5e231c-3648-4eaf-a195-5f4160519855_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of potentially issuable shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_015de5c1-a8f0-427c-9e2d-bccb19734d46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b8f61ac3-7f64-420e-a2bc-adbd9e41db78_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_b2d3ba85-1bbc-4766-8d83-936e99f43662_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_0e4ba847-fa53-4ee4-8c5a-a11f95e1aaa2_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Segment Reporting Disclosure [Text Block]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and segment reporting disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:to="lab_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_728cdf4d-89c9-41df-83ac-bcf16f8aabd5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bb6cd048-c9de-40d5-a9c2-b1bf7f0e1829_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_f499cecb-61e7-4dbc-a2c8-038cc869ee2b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed by Sanofi</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentConsiderationMember_bcf768d2-5c76-443c-b251-3c596911edbc_terseLabel_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bmrn_ContingentConsiderationMember_label_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_bmrn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_bmrn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember" xlink:href="bmrn-20220331.xsd#bmrn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentConsiderationMember" xlink:to="lab_bmrn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_6d9cc4b6-e23d-4989-b04f-24cb6d7bb044_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7fb27c19-ec97-4266-af32-69e56c3a7809_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8d0303a2-431d-4154-a220-c96714b389ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9a624b34-7c7b-4881-9aac-8d367d6901e3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c1d83509-bfe2-4f9d-a434-8c797eeac1d4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5b883514-0911-4651-88e8-12e1b6ee833e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of awards under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_57d834b5-7c7f-4ed5-86c0-6ba7ee10d73c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_55e70ae8-9a4a-42e7-8de5-f44582be6c00_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_14180e6c-cb08-40bf-865a-85f736fb8d64_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ee46dfad-62ac-496d-a863-ca4c95a6c5e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97a2e00c-2758-4100-80ff-391fd0c0c3ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StrategicInvestmentMember_3ec60941-5c34-4441-8d6d-4b8326d3c0c7_terseLabel_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment</link:label>
    <link:label id="lab_bmrn_StrategicInvestmentMember_label_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment [Member]</link:label>
    <link:label id="lab_bmrn_StrategicInvestmentMember_documentation_en-US" xlink:label="lab_bmrn_StrategicInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember" xlink:href="bmrn-20220331.xsd#bmrn_StrategicInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StrategicInvestmentMember" xlink:to="lab_bmrn_StrategicInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f85d7eb5-1497-431d-af1d-91c1a6f57805_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_68131f91-cd72-4fc2-817b-ba32d6b4e403_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c9d12c26-01b8-467d-8bc3-e11c9ae678c6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_a96252f8-606f-42d8-aef1-a91fe829ea96_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomersMember_6bd0f8c0-a682-4791-91c1-6a941807b922_terseLabel_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers</link:label>
    <link:label id="lab_bmrn_CustomersMember_label_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers [Member]</link:label>
    <link:label id="lab_bmrn_CustomersMember_documentation_en-US" xlink:label="lab_bmrn_CustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomersMember" xlink:to="lab_bmrn_CustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_b89c4dc2-e75b-4163-b536-73086ba4b5be_terseLabel_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term marketable securities maturity period</link:label>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities Maturity Period</link:label>
    <link:label id="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:href="bmrn-20220331.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:to="lab_bmrn_LongTermMarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2aed9059-8f6d-4a55-9285-ce2c794f495f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5cc01377-e691-47b7-9cba-7eceda586ef9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_25cf8706-8203-4c0b-8d79-7492e3a42dd7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense capitalized to inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_8c2155cd-b122-47b0-a99a-539c6a5bf3b2_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_label_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Line Items]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesLineItems_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems" xlink:to="lab_bmrn_ScheduleOfInterestExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_5acb1067-78b5-4083-9257-38ff15eb2bf2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_765e7ecc-19ee-4afa-925f-5de553115f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_349d5cb0-0149-4b3d-9600-2c2fdc9f4466_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayments of financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_d5a432f2-0a13-4ecc-838b-1429450e6c6a_terseLabel_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of nonfinancial assets</link:label>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_label_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Nonfinancial Assets</link:label>
    <link:label id="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets_documentation_en-US" xlink:label="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Nonfinancial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:href="bmrn-20220331.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:to="lab_bmrn_ProceedsFromSaleOfNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerOneTwoThreeAndFourMember_0af54ea5-d120-4320-b0c6-b93a9c3441b3_terseLabel_en-US" xlink:label="lab_bmrn_CustomerOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A, B, C, &amp; D</link:label>
    <link:label id="lab_bmrn_CustomerOneTwoThreeAndFourMember_label_en-US" xlink:label="lab_bmrn_CustomerOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One, Two, Three, And Four [Member]</link:label>
    <link:label id="lab_bmrn_CustomerOneTwoThreeAndFourMember_documentation_en-US" xlink:label="lab_bmrn_CustomerOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One, Two, Three, And Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoThreeAndFourMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneTwoThreeAndFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember" xlink:to="lab_bmrn_CustomerOneTwoThreeAndFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_073c6be0-7b4d-4ad7-a2f7-408d7a24f897_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_117377bc-8a16-4786-8de7-9bacee150d53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses as reported</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8561bd26-33a7-4607-b74f-ec4d6618b2c5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE, BASIC (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_338c0d44-c1a7-4ced-ab50-b6c69537b147_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_02960c66-7361-4316-8dbe-037e9bec577c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e6eb257-184f-49ac-adae-b72d0cdd9e38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities remeasured</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74ab675a-be63-4681-bc65-c280f5a3b326_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration as of December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ab854c9-7320-4d5b-82ea-e24da80cd58b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration as of September 30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_31d5f3aa-ce4a-4040-bb5d-18ebed8db67f_terseLabel_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_label_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments [Member]</link:label>
    <link:label id="lab_bmrn_RestrictedInvestmentsMember_documentation_en-US" xlink:label="lab_bmrn_RestrictedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember" xlink:href="bmrn-20220331.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestrictedInvestmentsMember" xlink:to="lab_bmrn_RestrictedInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_99900535-7e4f-4a7e-af77-bedc75f90477_verboseLabel_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other current liabilities</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Current Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities current fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherLiabilitiesCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7a74f42a-8c80-4e63-85bb-aade4dacc314_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Net Product Revenues Based on Patient Location</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3912a86d-c841-4129-a93b-09970ecfcecf_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_acecad8e-3ed8-48e3-96ae-3757c2cefa6c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_4c0ff477-a4ac-47f1-867b-d2969a27fc01_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ValoctocogeneRoxaparvovecMember_64b0cd9a-9bf0-4585-af2c-964028f92ec9_terseLabel_en-US" xlink:label="lab_bmrn_ValoctocogeneRoxaparvovecMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valoctocogene Roxaparvovec</link:label>
    <link:label id="lab_bmrn_ValoctocogeneRoxaparvovecMember_label_en-US" xlink:label="lab_bmrn_ValoctocogeneRoxaparvovecMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valoctocogene Roxaparvovec [Member]</link:label>
    <link:label id="lab_bmrn_ValoctocogeneRoxaparvovecMember_documentation_en-US" xlink:label="lab_bmrn_ValoctocogeneRoxaparvovecMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valoctocogene Roxaparvovec</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ValoctocogeneRoxaparvovecMember" xlink:href="bmrn-20220331.xsd#bmrn_ValoctocogeneRoxaparvovecMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ValoctocogeneRoxaparvovecMember" xlink:to="lab_bmrn_ValoctocogeneRoxaparvovecMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_db772252-3253-4480-ae37-e26c9c9cc874_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a7a36e4a-fcd3-4368-ab98-232a1ce63f3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6bd1c963-9a64-45be-b9ef-ea91ebb90fad_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial assets, Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_34c50446-c8e1-47d4-be77-5fa07ccba245_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6d24497d-992d-45e6-9188-56bf641834df_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Price&#160;in Active Markets For Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d1f6bc8-0bce-4135-a341-d7daf99cd68c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_09e6a40e-2929-41ff-a47a-ab6d5d0592cf_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange (gain) loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_f1618906-3ea9-4d81-ba07-024df35e51cf_terseLabel_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty and other revenues</link:label>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_label_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty And Other [Member]</link:label>
    <link:label id="lab_bmrn_RoyaltyAndOtherMember_documentation_en-US" xlink:label="lab_bmrn_RoyaltyAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember" xlink:href="bmrn-20220331.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RoyaltyAndOtherMember" xlink:to="lab_bmrn_RoyaltyAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_998ddbb7-7733-4a65-84cc-bffd5cc9c97c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7624fbf8-a361-4122-b4b0-0a03fd8adba8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_1aeea674-38a5-428d-936f-227d787acf2d_terseLabel_en-US" xlink:label="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable under the 2027 Notes</link:label>
    <link:label id="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_label_en-US" xlink:label="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
    <link:label id="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_documentation_en-US" xlink:label="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due Two Thousand Twenty Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7b45e934-41ed-4929-b39d-56fda48dbfe1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c6268a5b-f9c3-4d70-8089-69cad8a1bfe8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1f54460f-7f56-42f1-a31a-6a61b329476a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e1db2282-f95a-4a02-af6f-fe7593841fe3_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_76c5ac69-1fad-43af-84af-aa2981cb26fb_terseLabel_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign and other</link:label>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_label_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government And Other Debt Securities [Member]</link:label>
    <link:label id="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_documentation_en-US" xlink:label="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government and other debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:href="bmrn-20220331.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:to="lab_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_46c65c98-dc20-4c68-b215-709d5e542237_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerOneMember_df6e23b9-f7e8-4a87-94a8-a66ed8f542f1_verboseLabel_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_fb159930-6823-45c5-bcf7-ae2a0d38d1ef_terseLabel_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_label_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_bmrn_CustomerOneMember_documentation_en-US" xlink:label="lab_bmrn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerOneMember" xlink:to="lab_bmrn_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a3007af-aa67-4fc2-96bb-cba48ccfeb0b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_ec786383-06f0-460c-8d94-fb9aae8389b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_018a13e8-60bc-40f8-a321-7f9cb23e076a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6583c938-f1ac-4911-9f16-5eaa33291e1b_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c947cca4-9aa6-4ff0-a4a3-5d4272d3a51f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_9eb80c0c-34c5-48b2-9f53-df615abab971_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c14f3068-076f-471d-9915-bd4a5cce8d04_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c63d1c2d-6018-425d-b135-c95c6b77d621_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a6771b2c-b605-4f3c-859c-4d4b547a7129_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIssuedEmployeeStockTrust_7941d4d5-24b1-4174-a07f-f98feabcd6fb_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)</link:label>
    <link:label id="lab_us-gaap_CommonStockIssuedEmployeeStockTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued, Employee Stock Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:to="lab_us-gaap_CommonStockIssuedEmployeeStockTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_824a7079-2d9e-4167-aac9-a04a3e04bf23_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding amount</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_12f6a71f-63ce-4e99-8e5b-447ae1441d2f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_2d49c2e3-9448-482f-8398-7bca0ab8f283_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial liabilities, Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e9a4a252-d981-4669-8c7f-0570b905bfab_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5735acaf-8c42-421c-8ccb-19b5c35e0c60_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19302369-8c6c-4f57-a2ed-e06d243d9a33_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_72243f29-ab5e-4f5c-9f6e-dfba6a330759_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_918cb153-2825-4001-8139-0ed3483b4f87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dd86a4d4-0e8c-4805-8825-18ba2c8126e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_404ba48b-abb1-4cdd-9147-81ed125e5130_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6f439c7f-4be8-421b-b2fe-6f59f3dcde13_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5f1bdb2b-ae9e-4f34-96ed-f1a4f471cb62_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3c71176d-2b66-493e-9354-d0cb37581813_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_436aa959-5f99-4fe7-bed2-7391f3252b19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Stock Held By NQDC</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation, Share-based Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:to="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7216a530-0ff5-4e15-bb08-4ca8c8d6d145_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c24be0d3-8379-45ee-9dcb-a5c145be4e71_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c59a469c-328d-41bb-a657-764f17523247_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Product Revenues by Product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6cb46a96-e45b-4827-83fe-ce25ab5b5e28_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_c18ceb8c-2f74-4c94-aca2-f27b2c6ee77d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Expense on Debt</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_28599424-246e-4d3c-8e1b-a0fe5f888913_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 500,000,000 shares authorized; 184,901,764 and 183,912,514 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_faa3619d-ce9f-43f1-aae8-ae5add7e9f9d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_36eea859-06c6-4599-90b5-676a7b01be24_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c6f195ac-98ce-49ef-831b-baa4048c8aa6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6dd228d7-28a1-488c-ada8-2dca757193e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8ff87a7f-71a2-45a1-9cdc-f93dfb401cfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2cb63760-4451-4ed9-8faa-d829fc06ee41_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_4292ef3c-28b2-4d2c-87be-12eb21d97a22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_3d954c4b-7e9f-4aba-a403-e8b7566478e3_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortMember_80cf01bc-1be0-4578-87d3-598c58a14076_terseLabel_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell</link:label>
    <link:label id="lab_us-gaap_ShortMember_label_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortMember" xlink:to="lab_us-gaap_ShortMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_a75c8fa8-3858-4eb9-99e8-ede6e22bd1c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c556ef2b-7fd4-4c44-b586-95b65f8dd8aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3f4914e3-1fc5-45af-b7f3-be0da1da1168_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_1b0b6fa1-9e2e-423d-9fce-f87dccd2467c_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_115f0b93-64bf-4368-ac6d-8f860e86f892_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_372ca7a2-98be-4721-b7ff-3ff84e8fb655_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_RestOfWorldMember_bfd0de39-cead-47de-b0c2-7ddb4b7380d6_terseLabel_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_bmrn_RestOfWorldMember_label_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_bmrn_RestOfWorldMember_documentation_en-US" xlink:label="lab_bmrn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember" xlink:href="bmrn-20220331.xsd#bmrn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_RestOfWorldMember" xlink:to="lab_bmrn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_a8773484-adcd-47ff-911c-3cffe45f93f6_verboseLabel_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other non-current assets</link:label>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Noncurrent Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets noncurrent fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherAssetsNoncurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_8055f9a5-3190-4895-a4f5-b20dc7f7b4ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_89d75c49-df3b-4b9e-823c-d7976dbfbdac_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_130aba39-d262-4f68-a64e-0dd761cd94f8_terseLabel_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.599% Senior Subordinated Convertible Notes Due in August 2024</link:label>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:href="bmrn-20220331.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:to="lab_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ccd624da-5fd0-40be-acc0-7c1555b81bf5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85cd9c0d-155f-4d10-a15c-7d52fb637387_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e2ad491-4a75-4de5-b904-a3b29115447f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1814bd23-6445-46b9-97dd-e1152658f825_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_992fd86e-4100-47e3-b16a-a2a25371e343_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bf8b5f9a-4d60-4b15-af72-262e7c3a9ae7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6accd412-53a5-4284-aae9-4bb1a94b0c03_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_70134454-95d0-437c-a67c-d3d9a2b959eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f0bf56c-75a0-4d99-b979-5a96d1912402_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6eb07002-a038-46df-85bc-e72f856367d3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2ac9ba69-38a4-4144-a70d-aed3aa67302d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8f2c7114-c250-4c32-acee-3ac110bacb17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_e59d4f25-a80d-4d7f-8096-de91cd1f3f00_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_10a39ccd-924f-4992-a390-c8717acec084_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Line Items]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Line Items]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and geographic information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:to="lab_bmrn_ConcentrationRiskAndGeographicInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_243dd500-c797-4185-ac21-a7d3acd4cf02_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentPaymentMember_3d05f2a1-0d72-43f7-b1af-7ff7da1e1ce4_terseLabel_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment</link:label>
    <link:label id="lab_bmrn_ContingentPaymentMember_label_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment [Member]</link:label>
    <link:label id="lab_bmrn_ContingentPaymentMember_documentation_en-US" xlink:label="lab_bmrn_ContingentPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentPaymentMember" xlink:to="lab_bmrn_ContingentPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_02ec7b0f-4b8e-43ee-9c37-a91a69ca7ff4_terseLabel_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</link:label>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_label_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones</link:label>
    <link:label id="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_documentation_en-US" xlink:label="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:to="lab_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2139488e-0fd4-449e-85f9-988bb747a19c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_035674ae-df81-4a13-b504-9b7e30f7e4b3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_af314ce7-ad35-4f6a-87bd-3e679ac78eaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ffa3df9f-9cca-458d-893e-28bab60af885_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_f3d4c17b-a832-4d9f-b062-89e6a2b0099d_terseLabel_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans (in shares)</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_label_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_documentation_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value new issues net excess tax benefit tax deficiency, shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:to="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b981b511-8d51-45c0-ab6e-bd5d56b48bee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_2c4394a1-b7c1-4830-89d0-cbafc7dd74b5_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_856c4acd-6960-4c78-a8c7-50f571c08987_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6b0c173d-fe47-4bf5-b06c-9d2c0a77926c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4e6e01a-37b0-4afd-8640-46a69cf363b7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dce2834f-68de-4276-91fd-75ed9fd6ce4a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e5945e02-18fc-4357-a097-3ecb2f193ecf_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense, net of amounts capitalized into inventory</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_4fdd5d40-58f5-4eba-81c0-7bc5e807f4a5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed by Company</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_450170c9-2e79-4cf2-b48e-d038195e6659_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3ad0e1b0-99f8-4daa-98b6-477101a8cbd2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7f1eabd5-203d-4c88-93a9-dac31ab1c021_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_2b713ab5-9f46-4609-b935-c91684a7aa29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_534a80a4-2389-4cfe-8f2c-7ccc8b138b9d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d2fae47e-f120-4738-89e3-403812fffdf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_3d154136-5610-4651-95e3-a2acdae26676_terseLabel_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities related to fixed assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_label_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets</link:label>
    <link:label id="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_documentation_en-US" xlink:label="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:href="bmrn-20220331.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:to="lab_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec9f785b-4bef-43bf-8fb8-03160fc84f1a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_67e95e59-b28e-4165-b343-2a2aa4158eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_79ab2036-934e-4227-adb3-2f879375850a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a3c3834-d285-4ed5-b98c-38837d9f61d7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_63c2811c-f5f9-4901-8665-87914bc3159b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e658eff8-1be3-40e3-b3f0-15c35f549bca_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_e149a241-1a8f-4763-9802-321c103b02e6_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_label_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Interest Expenses [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfInterestExpensesTable_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expenses table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable" xlink:to="lab_bmrn_ScheduleOfInterestExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_005bd553-b703-40ab-96a0-44e38a019154_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0585f039-c323-417a-b0b7-dfb459960e90_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_312e5abc-05ab-4261-b438-47594bea59f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6309b9f5-ff40-4de4-ad9b-1acfd5469279_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0cd7ab13-7119-4dad-810e-02131dfc9382_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ca8c9137-4e16-49a0-9fa1-7108abcce6c5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11ded8c2-77b1-4188-bfdd-31549b8dd961_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d2a18e8f-6f0c-4c74-8e18-c3d7bc0eb0b7_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated As Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_c5710d55-594d-4ea2-9b10-9ff1f4ba0478_terseLabel_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NQDC Plan assets</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_label_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Deferred Compensation Plan Assets [Member]</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_documentation_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified deferred compensation plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:to="lab_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1c895b73-76a6-4e63-bd33-e4c3b1752d54_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_a7b67979-a893-45fe-8a8f-a2ae4ca66e23_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Interest expense, net of tax, on convertible notes</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6671ce4a-d457-4217-b57e-31b97f742707_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b197e2af-dc83-4919-95d1-35b9ec1ca061_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8fe9b5ac-442b-4d1a-b967-c58ff526697e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3ef1144e-7d8a-48d4-88c4-250ae45e5a19_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_eb6e1e12-992a-49c0-91c3-fed74715caa4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a096a729-4e22-4f51-96c5-799a6061dfd1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_d1731301-4473-45fa-8549-b06da26d894b_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense on convertible debt</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_8ae245ee-7935-456d-975a-efb7d17c3f7b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0f65f698-6c95-401b-b6d7-42ee12c11d30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b565a571-9401-49a9-8ec2-a08334e64426_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_84160c4d-152d-42ea-88d8-89cad684ceff_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company&#8217;s common stock held by the NQDC</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_090c3981-a81c-41e4-ad6e-807be4d8d0cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fc5d7a52-1aa4-4340-bbc2-8243cdbf20bd_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerTwoMember_383e68cd-0862-45c2-9f08-fe5443675b39_verboseLabel_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_1feda2dc-d3b2-48f2-b1e5-6c394d85984e_terseLabel_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_label_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_bmrn_CustomerTwoMember_documentation_en-US" xlink:label="lab_bmrn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerTwoMember" xlink:to="lab_bmrn_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_56205993-9ce4-4a17-848a-06bb15f2a6ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_397051e4-e806-4cdf-87b0-177c148bf76f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_cf4b9f81-2151-4775-b545-7dc34b15b1fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_132d002c-6a5d-406f-a588-a04a671fa099_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b4c466ac-ed7c-4ba0-9238-5f822a553f42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_5fddf883-b6f9-4c2a-abba-c68a90c852e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivatives Designated as Hedging Instruments Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b92f971a-dca9-454c-a03c-7c3c07315fbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_079e8700-9e30-4de1-ae76-a2edd71f8c33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_33cc5f55-4ae9-4f93-b29c-25b38855017a_verboseLabel_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other current assets</link:label>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Current Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets current fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_749b6728-3ac6-495e-9bde-719e367f69ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible debt, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_f791aa24-a0ee-4ae6-a548-a20b76ab89de_terseLabel_en-US" xlink:label="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock potentially issuable for ESPP purchases</link:label>
    <link:label id="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuable To Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable for employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:href="bmrn-20220331.xsd#bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:to="lab_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_92b23e4e-20a8-480f-9d17-dbc1c95e669f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_648d10ce-8645-47c4-b6d3-b43482f25965_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_00602ba6-f2c7-4ba9-b03a-f6d5d470cb4d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a4693391-ebf3-482d-9f1b-87cd07d51e56_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3ae98ed5-54df-4006-b74a-b7af938f85e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductFourMember_38abf32e-731b-4835-a172-fba3e37849c4_terseLabel_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vimizim</link:label>
    <link:label id="lab_bmrn_ProductFourMember_label_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Four [Member]</link:label>
    <link:label id="lab_bmrn_ProductFourMember_documentation_en-US" xlink:label="lab_bmrn_ProductFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 4 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductFourMember" xlink:to="lab_bmrn_ProductFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1753a528-41b7-4eb9-81d0-2e7fbbe07714_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7e616ca0-3001-432b-8df2-71348d9915fd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_20f3b3a9-14a9-44ab-a451-ab09dcde0f89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_606bee5c-8bc3-4971-96bd-91e39362a315_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_572f7e45-b026-4fdc-a31f-0fa295760af3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_47001f55-a335-4b69-bc66-adf8efdce314_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_659ff4b7-5cd7-4a71-9885-bc7c5d516244_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_21f809c9-1159-4a6d-8ea7-5540a79c6634_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_f0a7af2a-1afb-4ef4-8711-f1d7e1dd921c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d6349a24-bf54-4340-b6ca-707c13d6a7c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_40745a1d-42dc-4909-bac4-3fb9838be4f6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fe5a3019-c618-4b0c-85b6-3dd4da1f22f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_162cafc7-0ca8-463e-87d5-e888ec508d24_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d8ab4fb-f2ab-4276-8927-0bf7eba54c96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_12fea07b-4ec8-44fc-8242-320824a92451_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_63bad468-bab3-4fa2-a28d-2515088a750f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_55d87dcb-8eda-408a-85bf-46a73db77a16_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_59f9f81d-7a0f-4cfb-a90b-f114779a96b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_6c4113bd-59d5-4c31-a9f6-a7747c77718b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_58bd1ae8-e3ff-40f6-a142-8c775356aaf2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Product Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_143f6dee-edf4-4338-8643-8b7b00a7895c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_dd3e7917-9e79-4243-855f-4f7d0a02b9c7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount on convertible notes</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_9c71b0d0-9264-4ce3-b1f3-a71676984a97_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term convertible debt, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_912dd274-20b4-4def-af57-0fd747812e44_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net of unamortized discount and deferred offering costs</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d9f4b202-b441-4457-8cea-43f56d98f43c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a554d4cc-56a6-4d48-9e2a-2817a9fe9e2b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e77bc46b-67bd-49ed-8689-d72518250d66_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductTwoMember_4122f59f-5fd0-4fed-8c6c-477e73084bb9_terseLabel_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Naglazyme</link:label>
    <link:label id="lab_bmrn_ProductTwoMember_label_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Two [Member]</link:label>
    <link:label id="lab_bmrn_ProductTwoMember_documentation_en-US" xlink:label="lab_bmrn_ProductTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductTwoMember" xlink:to="lab_bmrn_ProductTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d2d51024-9ee5-48c2-94c0-900e0b861968_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0fc24283-47c1-4f46-9f2d-7e98ba0ee45e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_3cfe91ad-8593-466f-af22-61e63a9b4a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of fixed-rate convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2e92a2f5-65ec-4fc2-89c7-280873379c7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a73c0dd7-3014-4135-92dd-07a823d65568_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_56ed5aa2-85fb-4604-851b-6111c4129400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9566fb11-3968-4dcf-ac00-66629f08b495_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_b2327cb1-68a1-4b1a-bef4-facb98464661_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_4db1a5eb-891b-412f-a4cf-c4afb6f85ccb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) Recognized in Earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_649dbfe5-65a1-4abc-b2e4-540b284dc2a9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ad0cbc21-20fa-4d08-89ff-b1ac691833fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2c7857d3-82f0-4c31-a2d0-81e3eb121a70_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2984668b-7ba9-46f1-87ee-f75de6551935_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_af357bfb-2e99-4557-a8ae-ef270a75e134_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductSevenMember_9375cea7-56c9-4816-ac2e-35105228df56_terseLabel_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palynziq</link:label>
    <link:label id="lab_bmrn_ProductSevenMember_label_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Seven [Member]</link:label>
    <link:label id="lab_bmrn_ProductSevenMember_documentation_en-US" xlink:label="lab_bmrn_ProductSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 7 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductSevenMember" xlink:to="lab_bmrn_ProductSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_fae4bcc4-c0cf-4227-ad2b-f9c0615f7c42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fb74da78-9e62-4d3d-8476-7015d9ce5fe9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current-period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_adbe7d98-0f3f-410d-a868-6fd6902b4b56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_fc7ff07c-7a28-4132-b2fd-48f7c636c1d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_15adaf5c-880a-4fd3-bea5-e3068eeabbe6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ea18e9db-b1f5-401f-877f-7f9edc97ec0f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_339c6144-547a-41a2-ab8a-268bf9d1b8c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_c99f5dc3-f819-44e1-9dce-860888c140f7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dd232820-cc9d-4fe1-af1d-456ad614ad1d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9d7c6d77-f73f-4ba1-9e5e-f88f3a85722a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_09700eed-fbc9-4ac3-8025-06db9677d2e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8c44c9ef-4e1b-4791-8496-d63f95b0ad23_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6bdbca44-1de3-4b8f-91bf-450576dbd2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_db15abdb-2b6e-43db-953e-cfa61058d88a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductThreeMember_83eefd95-cbf1-4dbd-abc8-d183aba10811_terseLabel_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kuvan</link:label>
    <link:label id="lab_bmrn_ProductThreeMember_label_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Three [Member]</link:label>
    <link:label id="lab_bmrn_ProductThreeMember_documentation_en-US" xlink:label="lab_bmrn_ProductThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductThreeMember" xlink:to="lab_bmrn_ProductThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_07b9b428-01d0-4f49-a4b4-dac64b452cd6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_de8e9a50-632d-4715-a499-8555b15b0ced_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes stated rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_70dbca92-72ee-4d6a-a952-eda0c371a967_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract_aad7aa24-5180-45fa-ad07-0227cad87f82_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Abstract]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Abstract]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and geographic information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:to="lab_bmrn_ConcentrationRiskAndGeographicInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_5fb915ab-c81d-48fa-b99c-f6e5b7e828eb_verboseLabel_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans, net of tax</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_label_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency</link:label>
    <link:label id="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_documentation_en-US" xlink:label="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value new issues net excess tax benefit tax deficiency.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:to="lab_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_76a077c9-6ae2-4382-b4b9-0f31b8ea7765_terseLabel_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable" xlink:to="lab_bmrn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ae6f7b2-35f0-4fdf-9ee8-10691bf3e958_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_0115e3a1-7d8b-48bc-b7b8-48626fa2c0aa_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_137e302a-f9b0-4181-a3b5-95611403e9be_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_81eb12e2-7bb3-4468-99cc-615debd99302_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts&#160;payable&#160;and accrued&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_03c29575-67d6-4002-816b-44246a4d120d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_88d2e6c4-38bd-45fb-88fb-69108078fe2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_8403ad8e-af2b-40c8-9f6d-992ee67ca25b_terseLabel_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset amortization and contingent consideration</link:label>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_label_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization And Contingent Consideration</link:label>
    <link:label id="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration_documentation_en-US" xlink:label="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:href="bmrn-20220331.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:to="lab_bmrn_IntangibleAssetAmortizationAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d3d5d65c-686f-4063-a233-3c93a76100fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_f9298b36-5762-4337-aa65-239133297f2e_terseLabel_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Table]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_label_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk And Geographic Information [Table]</link:label>
    <link:label id="lab_bmrn_ConcentrationRiskAndGeographicInformationTable_documentation_en-US" xlink:label="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk and geographic information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:to="lab_bmrn_ConcentrationRiskAndGeographicInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ed4543aa-0a4b-4d19-9023-448b08f4eec7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_ee609dbc-919b-429f-ac75-12ba81fdf430_terseLabel_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates payable</link:label>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_bmrn_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates" xlink:href="bmrn-20220331.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AccruedGovernmentAndOtherRebates" xlink:to="lab_bmrn_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b530d83f-4b14-4ccc-90a0-e2fbc56d00e0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93193e7d-3dd6-4e41-b7f3-1f930291ef8b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_83948dfc-20c2-4b8d-99b7-02238e1e1325_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE, DILUTED (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_894af9b7-de16-459f-82c3-dea5364a8f56_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_33f744e1-f8bb-45ee-b117-9c822174c03e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6e2d7073-730f-45ff-b62a-8e56d90cd5f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_9d13b5bc-f601-44e7-b218-332acbfcbf72_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_c8eded1a-ff57-49e6-a6d0-7ca3aad191a0_verboseLabel_en-US" xlink:label="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable under the 2024 Notes</link:label>
    <link:label id="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due Two Thousand Twenty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" xlink:to="lab_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_18162d53-8249-416d-9f3e-9ec6751de28a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd448448-59a4-4043-ae4d-0ecbde8b8971_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d541966b-f932-4460-b33f-64d0870333cc_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_0d65c1f9-a573-4997-97dd-9a4a40e64729_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d5ee72f2-b134-475c-92bb-ab5b9a3e6120_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_93683803-438c-484b-9da0-5dd5704d6c7e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ae2f1948-2e1f-4cd5-a1e6-c6aaed7eba51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_68448e7e-d39f-4794-8193-dd7802632278_terseLabel_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2018 Credit Facility</link:label>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_label_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]</link:label>
    <link:label id="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_documentation_en-US" xlink:label="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving two thousand eighteen credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:href="bmrn-20220331.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:to="lab_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_20184123-de51-4cbc-9a06-dc4e408536d8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b8d76746-eaf5-4cde-91b4-e4867685d13a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_33fcd8dd-a8e4-4c9d-b3a1-38cbc24cf168_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1282e449-6118-4a81-8f97-e241066476cc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_950da9be-7f92-4b9a-93b4-2d5cebf764ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c4765545-9997-43a9-99d5-fb492396c5c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI attributable to parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_075ef1a2-2c8f-4192-af4b-1a084aaa88d9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_9f4a32cb-c2d1-4037-934b-3e7aec074d30_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_001a444e-eddf-49af-8a09-eab00ce58c16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_57ecc526-74bc-4d16-9323-84854c8b7139_terseLabel_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NQDC Plan liability</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_label_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Deferred Compensation Plan Liability [Member]</link:label>
    <link:label id="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_documentation_en-US" xlink:label="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified deferred compensation plan liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:to="lab_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_bace2566-d310-4207-bf5f-5ccc559b84a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_0b1f19da-75b7-44f3-81b1-655dec2fa834_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongMember_daa5261a-0d51-49e7-be3b-d4d467fd9a31_terseLabel_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase</link:label>
    <link:label id="lab_us-gaap_LongMember_label_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongMember" xlink:to="lab_us-gaap_LongMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b1886ca8-eeed-44c8-b9e6-9782b899e99a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_41a00dad-c0bc-43f8-9f84-10691ede64f0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_a3e1099f-677a-4939-a85b-ceeb5be30e22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c16a3749-1287-4dae-ab76-36f849271bd9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_611042da-2cc3-4af6-b905-0c666a6aa789_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b9bd7b6-dd3f-40de-baaa-cc70a79bd91e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductSixMember_223a2bda-a9a8-475e-b004-f0323c513d6c_terseLabel_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brineura</link:label>
    <link:label id="lab_bmrn_ProductSixMember_label_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Six [Member]</link:label>
    <link:label id="lab_bmrn_ProductSixMember_documentation_en-US" xlink:label="lab_bmrn_ProductSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductSixMember" xlink:to="lab_bmrn_ProductSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_4e024dad-1e32-4474-bb9b-3a9de52dc0e2_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before &#160;&#160;&#160;&#160; reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_5f5d8dea-7ea2-4543-958a-24642384c6d0_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_23acd289-9439-443f-a403-5bbec1ff0286_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property Plant and Equipment Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3d1e7f1f-457f-48f8-9c34-c3b5d7ba4c1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_5a61b362-4744-4207-b3ef-ed0004cebb4e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_595d24b9-3168-4f5d-82de-4ef4468c9f14_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a06f288f-8afb-430a-b1b6-ec93edba7d4a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e21dc584-d7de-4e22-ad2d-93b8bde3b1ba_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4ba456dc-f763-4ae2-9d77-8694f3a79701_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a9378e38-cab4-4362-887d-0a46bc340b49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_880e10f1-d7e2-4fdc-880c-5b169dba6cf2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7687aac5-5274-4bb0-997e-9b4b96ac669e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d961cc0a-9b3c-434e-a2cf-c666cfb9fe40_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_44f054ee-78f5-44e8-a763-c265c1d68155_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Foreign Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6222c345-0a89-4982-ad46-b27f009e23e3_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_09812d43-d4fe-43e0-9fca-af09637ef148_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_ec2903d6-fd7c-49f8-9e22-733e422a9288_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_380945de-2d3b-44fd-8303-486b52805c12_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_87a07239-01f6-4d22-bf55-7952504f5a30_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_2d52395b-b8a6-41f0-bd75-ac7cc2d14b98_verboseLabel_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange remeasurement of Euro denominated contingent consideration</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_label_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement</link:label>
    <link:label id="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_documentation_en-US" xlink:label="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:href="bmrn-20220331.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:to="lab_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ee992107-51c0-4445-be05-ccd79412dd57_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_4386d0ed-ba59-4c7a-9abb-8be04b7bdefc_terseLabel_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_bmrn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems" xlink:to="lab_bmrn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_0ec5e7a1-dfba-4f08-a446-3ed6c42fe7a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a92f30d-ab29-475e-9450-74789fc2d631_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b840d93e-1496-4263-85c6-4bec0f7060e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6c237956-01c1-4cc4-929f-f7e08b3e1b4d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d70662a5-217e-48e1-961e-67189fb14738_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c963faf2-aa97-405e-b2e7-3c7f01cc40e5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Product Revenue Concentrations Attributed to Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_023331bb-15fc-4afe-b56b-d843166e839e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4f735043-e2ad-47a1-bb16-217603174804_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6f8b1dfb-1dc8-4f8d-87be-af07c09a085b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33048b72-c819-401f-abe2-ecdf7a266a7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_efbe3036-a314-4fd0-8876-37d7be548f92_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: gain (loss) reclassified from AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_f44c8120-b4c6-4139-a37f-2bcbd9425aa0_verboseLabel_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of other non-current liabilities</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_label_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Noncurrent Fair Value Disclosure</link:label>
    <link:label id="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities noncurrent fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:to="lab_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_48b42749-1d87-4334-a800-55530dffb893_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fe65fb03-548a-42ca-bd43-75140b8934f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_f3192732-695f-490c-8f22-5214b2388b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9eff1703-9c9f-450a-b986-cb489c62972a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_df565cd7-bd8d-4d4f-b8ca-2bb4d563754f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets remeasured</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_377c1f47-3ca3-473b-b309-fdfdf207208e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f30507e3-fffd-4724-9420-b13c59d857ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e3dd1cc9-4ba8-405d-9988-33348a9c945c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_8033b65b-ce10-4c22-8759-924c83798967_negatedTerseLabel_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock held by the NQDC</link:label>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_label_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</link:label>
    <link:label id="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_documentation_en-US" xlink:label="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:href="bmrn-20220331.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:to="lab_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ada684ec-341c-433b-98af-04d5b3e51350_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7e9f39f7-e30a-4dcc-9fce-ef6e5afa5e0a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ef3247bf-ae98-41e6-a9c6-4b000a1f68fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_57296a2c-c8f7-4983-9b30-0b38fc65ffcb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_09202c0b-ea0f-4752-b494-1deffd54d360_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4e72bb33-f020-4bd3-9234-bff9b0ef4ad5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_dfb8c25e-7ac2-4f5b-b822-149cf591fd00_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_faac1d59-9bfb-44ca-a578-41f9224e20a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_1e1a65d4-7ad8-48d1-bf69-85833c36b624_terseLabel_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Senior Subordinated Convertible Notes Due in May 2027</link:label>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_label_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]</link:label>
    <link:label id="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_documentation_en-US" xlink:label="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Senior Subordinated Convertible Notes Due in May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:href="bmrn-20220331.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:to="lab_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b790f33d-74cd-4446-9910-83b5b506416d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_519a34c5-06f3-431e-ba4a-10ca7fc669be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c73d4ee-6e5e-44ff-b74b-7081482ad58b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_085324c2-78d9-4142-9dfe-a953cdb6fa63_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_998aa8eb-f3ee-4fb3-8090-3a8120c30fcd_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments and other minimum contractual obligations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_44209e52-9f31-43c6-a22a-c483564ec8a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8acc3c66-e9fa-4f1e-b82a-96ad91020488_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_adcd6c7e-dfb2-45d7-ba19-7e0362b81426_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0d144491-d96e-41e7-b049-eb4ed5999036_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_c0a0e05a-7eac-454c-999c-39c09ebcb7db_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PositionDomain_12720c55-a222-4faf-a4cb-42bc41023b33_terseLabel_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position</link:label>
    <link:label id="lab_us-gaap_PositionDomain_label_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionDomain" xlink:to="lab_us-gaap_PositionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1fbb1565-1359-49db-9ad9-7b525cd35ed1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5ff70143-c0db-4e68-82ac-7b5c17157f4a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount net of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_95a0d2ee-c59c-40d3-9f63-706f8517269d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a25af2cb-0d55-4c3c-a628-4c2be7f94dc4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e36bfe19-230a-4623-8a8d-8945c0793ea0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f8ef27cb-8b5c-4f98-a0ff-91cf7622cf04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0bbede7f-88df-4d07-8272-3ed21d38d05e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductEightMember_bfaa62ee-6ab9-42cd-a7a4-2bff46c80f2c_terseLabel_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voxzogo</link:label>
    <link:label id="lab_bmrn_ProductEightMember_label_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Eight [Member]</link:label>
    <link:label id="lab_bmrn_ProductEightMember_documentation_en-US" xlink:label="lab_bmrn_ProductEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductEightMember" xlink:to="lab_bmrn_ProductEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_9b5c3bae-372b-402c-8733-18c0a7bdc0bb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f3fdff73-9636-4457-9435-fc76d3bcb1c8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_42ada410-ae0f-4905-86a5-c9b63ec87bb1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_1aa3262f-9ab7-421d-a0ec-76d637b4ddbc_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_fa2382cc-66dd-4490-a7da-a172dead4b9d_terseLabel_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities maturity period</link:label>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities Maturity Period</link:label>
    <link:label id="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:href="bmrn-20220331.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:to="lab_bmrn_ShortTermMarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ProductOneMember_2620409f-680d-49d4-84ec-b19f63c3cb06_terseLabel_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aldurazyme</link:label>
    <link:label id="lab_bmrn_ProductOneMember_label_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product One [Member]</link:label>
    <link:label id="lab_bmrn_ProductOneMember_documentation_en-US" xlink:label="lab_bmrn_ProductOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember" xlink:href="bmrn-20220331.xsd#bmrn_ProductOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ProductOneMember" xlink:to="lab_bmrn_ProductOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2afc9fc9-1448-4de9-9061-34453c324808_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_a138657f-c32c-4376-bbcb-26b6788c116a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_34391e9d-c86f-49dd-972a-365b1af2586e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f6ffb989-5c4b-4c04-b0ae-eb9fae2f281b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7c136db5-433b-4407-983e-fefba6c62057_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_98fe56e4-0145-4daf-8374-f1862727cf7e_terseLabel_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:label id="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_documentation_en-US" xlink:label="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="lab_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_0f6e3435-aa76-4987-b1c4-7e81d1660b62_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2abfba4-4c2d-49a7-992e-0e1dd3ca34e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ba793592-f491-4ced-86c3-2a8dbb42a3fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Carrying Amount of Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_a6eafac7-43c8-43fd-b262-3c61966c7bf4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued operating expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_860514ba-8963-4402-b075-442951adebb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_9c8adac3-aee0-4771-b259-e49ed1ddef03_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bmrn_CustomerThreeMember_6ea02412-8b6e-4bec-92bc-f567bf889f66_terseLabel_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_bmrn_CustomerThreeMember_label_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_bmrn_CustomerThreeMember_documentation_en-US" xlink:label="lab_bmrn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember" xlink:href="bmrn-20220331.xsd#bmrn_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bmrn_CustomerThreeMember" xlink:to="lab_bmrn_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_ae3ccc5b-58d8-42a0-9384-777084353bef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d2fa7cf2-978a-4bed-b84d-f626758d6883_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bmrn-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2b768e3a-e534-4f53-b7af-5d04d5fa1961,g:310f7190-7051-4981-9b34-1a8e19c7f639-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com/role/CoverPage" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_621f2b95-666b-49f0-b574-777c5203ff88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentType_621f2b95-666b-49f0-b574-777c5203ff88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_92fc4bf1-6353-4ba5-bd55-e9e878e2d495" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentQuarterlyReport_92fc4bf1-6353-4ba5-bd55-e9e878e2d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_22bc0fdf-aeae-4f6d-8ad2-de7cf4a41e35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentPeriodEndDate_22bc0fdf-aeae-4f6d-8ad2-de7cf4a41e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ae5dba44-3fc3-4e75-a847-9721f9695e76" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentTransitionReport_ae5dba44-3fc3-4e75-a847-9721f9695e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e481c2b6-43e0-4f97-b6d9-96cc12e9653a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityFileNumber_e481c2b6-43e0-4f97-b6d9-96cc12e9653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c4e72ff-1765-4766-b81d-96a83bcb2c02" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityRegistrantName_1c4e72ff-1765-4766-b81d-96a83bcb2c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0482f022-f9bd-4c81-8807-4aebc7824377" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0482f022-f9bd-4c81-8807-4aebc7824377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4e587814-6d92-4b4a-b993-75aafc9548c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityTaxIdentificationNumber_4e587814-6d92-4b4a-b993-75aafc9548c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a5c52a74-0db6-4ea7-a703-edbceb072283" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityAddressAddressLine1_a5c52a74-0db6-4ea7-a703-edbceb072283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_900843d5-7edc-46f1-a6a2-a0eb52c7caab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityAddressCityOrTown_900843d5-7edc-46f1-a6a2-a0eb52c7caab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8d5a25ca-72ae-4941-8ac3-b64b1d2ef9f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityAddressStateOrProvince_8d5a25ca-72ae-4941-8ac3-b64b1d2ef9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a96c038a-86ee-48c6-92e5-a266ce4f856b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityAddressPostalZipCode_a96c038a-86ee-48c6-92e5-a266ce4f856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b669df85-d170-4b68-9580-7dcaf08f5d75" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_CityAreaCode_b669df85-d170-4b68-9580-7dcaf08f5d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_934cadf5-e89a-4ba3-805f-8c264bbe79ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_LocalPhoneNumber_934cadf5-e89a-4ba3-805f-8c264bbe79ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6faa0a8a-d01e-44cc-b2ca-723752c683e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_Security12bTitle_6faa0a8a-d01e-44cc-b2ca-723752c683e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_265ddb48-d4fd-418f-bb89-ebfcd29a7c08" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_TradingSymbol_265ddb48-d4fd-418f-bb89-ebfcd29a7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cf6ffabb-ddb3-49d6-acbf-b6ac3e6f546d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_SecurityExchangeName_cf6ffabb-ddb3-49d6-acbf-b6ac3e6f546d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_405efaaa-2d9f-4e63-b6d2-db253604d3eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityCurrentReportingStatus_405efaaa-2d9f-4e63-b6d2-db253604d3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dc3abc05-0944-4695-8683-5ca3dce4e555" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityInteractiveDataCurrent_dc3abc05-0944-4695-8683-5ca3dce4e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_026275b3-8f0c-4dd5-b24e-4bf1dcabdb78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityFilerCategory_026275b3-8f0c-4dd5-b24e-4bf1dcabdb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8dfa2493-d8f5-40e5-b6a5-1092d6b1374f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntitySmallBusiness_8dfa2493-d8f5-40e5-b6a5-1092d6b1374f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d067d1da-b572-4062-a287-1062e4f5bd84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityEmergingGrowthCompany_d067d1da-b572-4062-a287-1062e4f5bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2e1b81c7-a5b5-4ddc-8aef-5e6aa81654d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityShellCompany_2e1b81c7-a5b5-4ddc-8aef-5e6aa81654d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6e3eca83-f22b-438a-a5ce-98d0ed70ba9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6e3eca83-f22b-438a-a5ce-98d0ed70ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d5d17207-df81-4224-8d34-fb11c9097b6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_AmendmentFlag_d5d17207-df81-4224-8d34-fb11c9097b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_965874d6-08ab-4ee7-874d-676f046c6c1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentFiscalYearFocus_965874d6-08ab-4ee7-874d-676f046c6c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3d98b4d0-694b-4fac-9379-46496cb7a200" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3d98b4d0-694b-4fac-9379-46496cb7a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0c16a192-6695-441c-9311-4346f06a27bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_EntityCentralIndexKey_0c16a192-6695-441c-9311-4346f06a27bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_aa18744b-9f1b-4c67-9fd4-c02ff6de596b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3301902-3a85-4427-a86d-04a2b07aa579" xlink:to="loc_dei_CurrentFiscalYearEndDate_aa18744b-9f1b-4c67-9fd4-c02ff6de596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5439e57e-6d68-4edd-a954-909759902597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6dfaebd5-cc38-4c5e-824a-6d6781ee3adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5439e57e-6d68-4edd-a954-909759902597" xlink:to="loc_us-gaap_AssetsAbstract_6dfaebd5-cc38-4c5e-824a-6d6781ee3adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6dfaebd5-cc38-4c5e-824a-6d6781ee3adb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abeeb4a4-496b-4bcc-880d-46c616e23522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abeeb4a4-496b-4bcc-880d-46c616e23522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4cd451e9-33bc-437b-acd1-3c0cbfa6cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4cd451e9-33bc-437b-acd1-3c0cbfa6cf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d443145a-a1c1-40ac-84fa-f830d64ae587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d443145a-a1c1-40ac-84fa-f830d64ae587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e3c60257-96a9-4c57-bf54-43128950adca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_InventoryNet_e3c60257-96a9-4c57-bf54-43128950adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_30ef0411-f752-4083-b486-e8f492aeee01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_OtherAssetsCurrent_30ef0411-f752-4083-b486-e8f492aeee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_53f79647-0b7f-45e6-aa88-73b76d74671d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11d99dc8-5af9-4266-b40e-36a1cdb4c17a" xlink:to="loc_us-gaap_AssetsCurrent_53f79647-0b7f-45e6-aa88-73b76d74671d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6dfaebd5-cc38-4c5e-824a-6d6781ee3adb" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5d22299a-eae2-4b2a-b3b7-1d493391d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5d22299a-eae2-4b2a-b3b7-1d493391d5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_251ef95c-880d-429b-ac4f-47467e677e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_251ef95c-880d-429b-ac4f-47467e677e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5383f481-326b-44f4-ad8b-16a623a0cc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5383f481-326b-44f4-ad8b-16a623a0cc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4cfaa7d8-f75d-4e79-93ab-220f4dc55fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_Goodwill_4cfaa7d8-f75d-4e79-93ab-220f4dc55fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6c3c469c-ad51-4878-aca9-31db3e9ef04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6c3c469c-ad51-4878-aca9-31db3e9ef04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c78f4a7e-1a77-44de-8e13-bcd3e0033475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4effbc0b-31df-4bd7-a81a-4ec265dbf410" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c78f4a7e-1a77-44de-8e13-bcd3e0033475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f2d339cf-d281-4ed0-b2e0-201bd7c0e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6dfaebd5-cc38-4c5e-824a-6d6781ee3adb" xlink:to="loc_us-gaap_Assets_f2d339cf-d281-4ed0-b2e0-201bd7c0e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5439e57e-6d68-4edd-a954-909759902597" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d7f1a35d-3628-461b-bd65-8fcf7f1a0767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d7f1a35d-3628-461b-bd65-8fcf7f1a0767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8bfb3a89-3ea3-487e-9765-9ca98ab61f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d7f1a35d-3628-461b-bd65-8fcf7f1a0767" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8bfb3a89-3ea3-487e-9765-9ca98ab61f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_71404732-fc3e-439a-b91d-703ff80b0190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d7f1a35d-3628-461b-bd65-8fcf7f1a0767" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_71404732-fc3e-439a-b91d-703ff80b0190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5faed7d3-3939-44b4-aced-14cda4dcebf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d7f1a35d-3628-461b-bd65-8fcf7f1a0767" xlink:to="loc_us-gaap_LiabilitiesCurrent_5faed7d3-3939-44b4-aced-14cda4dcebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_91e608fc-0367-4cae-b5a1-82c94ed10d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_91e608fc-0367-4cae-b5a1-82c94ed10d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8f21e0ae-1696-4c3f-bd12-398d23554b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_91e608fc-0367-4cae-b5a1-82c94ed10d6b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8f21e0ae-1696-4c3f-bd12-398d23554b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dcabfafb-9c96-43f1-93f6-abe2249784a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_91e608fc-0367-4cae-b5a1-82c94ed10d6b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dcabfafb-9c96-43f1-93f6-abe2249784a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_223c241e-15fe-479d-a820-126320d8da7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_91e608fc-0367-4cae-b5a1-82c94ed10d6b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_223c241e-15fe-479d-a820-126320d8da7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_13d00aa2-2856-4b93-aa55-ccdbd55a90ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:to="loc_us-gaap_Liabilities_13d00aa2-2856-4b93-aa55-ccdbd55a90ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dbcf1ca1-be77-4a41-84da-848bc3045667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_CommonStockValue_dbcf1ca1-be77-4a41-84da-848bc3045667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ad5fe5f1-f1c8-425a-9644-55c0b202d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ad5fe5f1-f1c8-425a-9644-55c0b202d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_a2e6ddaa-412a-4897-b3f7-e943c32f75f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIssuedEmployeeStockTrust"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_CommonStockIssuedEmployeeStockTrust_a2e6ddaa-412a-4897-b3f7-e943c32f75f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d6e2cb2a-4cd0-46a3-bfdd-551d5e745607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d6e2cb2a-4cd0-46a3-bfdd-551d5e745607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26be4d18-1012-4685-b338-5538ead27b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26be4d18-1012-4685-b338-5538ead27b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dfce5256-c800-422e-8de5-acd2abc1a301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ac118ac-5e55-443b-90d8-39fbef68738c" xlink:to="loc_us-gaap_StockholdersEquity_dfce5256-c800-422e-8de5-acd2abc1a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_71595a40-d58f-4f2a-a680-bfc569fc36ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13d321a7-a142-402d-9e9d-96b1b8bc6ce2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_71595a40-d58f-4f2a-a680-bfc569fc36ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f789dbb7-359c-4e31-b102-5d2b17761918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_34027d92-0034-4e05-8599-f989e709177f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f789dbb7-359c-4e31-b102-5d2b17761918" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_34027d92-0034-4e05-8599-f989e709177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0fba3e8e-4bb6-4156-bdf2-9e6c632f9599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f789dbb7-359c-4e31-b102-5d2b17761918" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0fba3e8e-4bb6-4156-bdf2-9e6c632f9599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3adb07d1-97a2-41ae-9388-3131a51f2cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f789dbb7-359c-4e31-b102-5d2b17761918" xlink:to="loc_us-gaap_CommonStockSharesIssued_3adb07d1-97a2-41ae-9388-3131a51f2cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_07947bfb-a72c-42d5-8205-65bb65b2fe32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f789dbb7-359c-4e31-b102-5d2b17761918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_07947bfb-a72c-42d5-8205-65bb65b2fe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8e77fd2b-62b2-412e-9fed-fff623492080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8e77fd2b-62b2-412e-9fed-fff623492080" xlink:to="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:to="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a9153c07-e69d-4d4f-a229-4f725e2000ca" xlink:to="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5cb679da-a178-4509-b7fc-a07d42fedd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:to="loc_us-gaap_ProductMember_5cb679da-a178-4509-b7fc-a07d42fedd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_34e47ee4-0318-4794-a8f2-5095a570c51f" xlink:href="bmrn-20220331.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b69bea14-c790-4134-8199-c4c591ac80a0" xlink:to="loc_bmrn_RoyaltyAndOtherMember_34e47ee4-0318-4794-a8f2-5095a570c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4dff827e-081f-4333-922d-1b20ce514416" xlink:to="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_529288d9-dae0-423c-8823-1b820035f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_929e3871-fab3-4903-a638-1c653debefd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_529288d9-dae0-423c-8823-1b820035f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c59a761f-e3cc-4a5b-b93f-b8c1327847f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_CostOfRevenue_c59a761f-e3cc-4a5b-b93f-b8c1327847f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5e9708d4-363f-4f8c-85c9-54daa4193982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5e9708d4-363f-4f8c-85c9-54daa4193982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_51d0d10f-be0f-41cb-ae7d-9eb9d0515a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_51d0d10f-be0f-41cb-ae7d-9eb9d0515a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_4de7a346-7b26-4414-940b-0471b4d5a7f8" xlink:href="bmrn-20220331.xsd#bmrn_IntangibleAssetAmortizationAndContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_bmrn_IntangibleAssetAmortizationAndContingentConsideration_4de7a346-7b26-4414-940b-0471b4d5a7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2f673234-a22b-48c5-8b1b-58e4a3f09ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2f673234-a22b-48c5-8b1b-58e4a3f09ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_792eb407-24a3-489d-8338-426db4ab9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9735fcc-09d5-402a-a87b-e7d7a126202b" xlink:to="loc_us-gaap_CostsAndExpenses_792eb407-24a3-489d-8338-426db4ab9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76fa1fcc-844e-450a-96b2-43495c4e7098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_OperatingIncomeLoss_76fa1fcc-844e-450a-96b2-43495c4e7098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd20a6ba-7005-4cd2-aa43-ba8fa96265ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd20a6ba-7005-4cd2-aa43-ba8fa96265ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0c92b86e-5799-4c97-8918-b9f7cf6294ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_InterestExpense_0c92b86e-5799-4c97-8918-b9f7cf6294ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_787c6788-6108-4f9d-82f0-447301298b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_787c6788-6108-4f9d-82f0-447301298b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674b842d-333d-4ec9-b2b5-130d5913eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674b842d-333d-4ec9-b2b5-130d5913eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_498f5027-7056-4cde-b9a5-7f70372b5f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_498f5027-7056-4cde-b9a5-7f70372b5f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d29be4a1-750a-4668-89d0-1d672d2dd78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_NetIncomeLoss_d29be4a1-750a-4668-89d0-1d672d2dd78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_10d123bc-666c-4cdc-bd67-11514d12a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_EarningsPerShareBasic_10d123bc-666c-4cdc-bd67-11514d12a3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_73b43845-b120-4d77-add2-22c4fa5209f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_EarningsPerShareDiluted_73b43845-b120-4d77-add2-22c4fa5209f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f032015c-095c-4e6d-9ee4-1aa51ef6af60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f032015c-095c-4e6d-9ee4-1aa51ef6af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1ef770c-064d-40b4-b271-72d1ab420601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1ef770c-064d-40b4-b271-72d1ab420601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84e08b28-5c49-4c53-bb4f-9d5f7ff483c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_332b95bd-448b-4531-b6f4-037208e84447" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_84e08b28-5c49-4c53-bb4f-9d5f7ff483c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_14e625dc-8690-43fa-818d-4fe6e819e83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_14e625dc-8690-43fa-818d-4fe6e819e83e" xlink:to="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33806320-6759-4223-8168-3306cd612c98" xlink:to="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97a0d051-68c1-4d7f-991e-591884273d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_CommonStockMember_97a0d051-68c1-4d7f-991e-591884273d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0178a421-1588-481a-8315-dd19abb5de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0178a421-1588-481a-8315-dd19abb5de1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_c1a13c30-8a09-4587-89e9-261ae7c88e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_c1a13c30-8a09-4587-89e9-261ae7c88e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3390db5c-e8c8-4508-9c59-5f1a83829d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3390db5c-e8c8-4508-9c59-5f1a83829d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e703358d-0d4f-4acd-8306-9918258d4446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c2e719a-a733-4e60-9aaf-f38a3d91c072" xlink:to="loc_us-gaap_RetainedEarningsMember_e703358d-0d4f-4acd-8306-9918258d4446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_17f82389-44b7-44f2-a207-0f9f788e88d7" xlink:to="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_783859ec-3d73-4f05-a0e2-a5175cd2303b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_268fcced-92bf-40da-a2ae-3b8c49a23592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_SharesOutstanding_268fcced-92bf-40da-a2ae-3b8c49a23592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_9251df04-5071-4c21-876a-59170cec84b0" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares_9251df04-5071-4c21-876a-59170cec84b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e97f2b03-b17f-4664-97d9-f264be0cf553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_SharesOutstanding_e97f2b03-b17f-4664-97d9-f264be0cf553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6fc3b3c-7ffd-44d3-82ff-b5f93c0d5c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_StockholdersEquity_d6fc3b3c-7ffd-44d3-82ff-b5f93c0d5c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_3bb352c3-54ec-4aa0-a834-584364dc497b" xlink:href="bmrn-20220331.xsd#bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency_3bb352c3-54ec-4aa0-a834-584364dc497b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4eb54464-d4d7-42fa-9b57-83096cbf924e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4eb54464-d4d7-42fa-9b57-83096cbf924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_d1eb9877-442e-4714-a9b0-7a2d732b6e46" xlink:href="bmrn-20220331.xsd#bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan_d1eb9877-442e-4714-a9b0-7a2d732b6e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ab081704-d5d9-43aa-824a-0a9dc2d1c3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ab081704-d5d9-43aa-824a-0a9dc2d1c3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_023bd8dd-e423-49f4-b044-acf8fc48fecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_NetIncomeLoss_023bd8dd-e423-49f4-b044-acf8fc48fecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2bc9e7d-d05f-4db3-9d6d-0a9da3470e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cffbdf5-fa8c-43a4-acb3-5df4cdcafff4" xlink:to="loc_us-gaap_StockholdersEquity_e2bc9e7d-d05f-4db3-9d6d-0a9da3470e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5f76a6ab-eab3-4c78-837a-5b5a4369942e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5f76a6ab-eab3-4c78-837a-5b5a4369942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b501b95-c4be-4c80-907e-4d87c549a70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5f76a6ab-eab3-4c78-837a-5b5a4369942e" xlink:to="loc_us-gaap_NetIncomeLoss_6b501b95-c4be-4c80-907e-4d87c549a70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5f76a6ab-eab3-4c78-837a-5b5a4369942e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cf5af840-0e44-465c-a146-871c0b948de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cf5af840-0e44-465c-a146-871c0b948de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6cedad27-fb57-4e38-8d34-5a932dd75e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6cedad27-fb57-4e38-8d34-5a932dd75e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e0b06514-e46e-4dda-bd96-5113cfa2b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e0b06514-e46e-4dda-bd96-5113cfa2b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f1466461-bc41-40e2-8cdf-3f715bbe1723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_ShareBasedCompensation_f1466461-bc41-40e2-8cdf-3f715bbe1723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f327901d-9f6c-42cf-8343-5e485c402785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f327901d-9f6c-42cf-8343-5e485c402785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4a4a6354-ebe1-45e8-a736-92cf5f9592e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4a4a6354-ebe1-45e8-a736-92cf5f9592e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d96a4968-0bf4-4b03-bcee-cc0de6b8566a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d96a4968-0bf4-4b03-bcee-cc0de6b8566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a43f78bf-f6e2-421f-86ec-0cb621a5313e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a43f78bf-f6e2-421f-86ec-0cb621a5313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dc2c1117-ed85-4961-b9d1-b3f21c5c7f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dc2c1117-ed85-4961-b9d1-b3f21c5c7f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f15fe7f9-664c-434d-b8a6-84578f1df17f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b09ac88-86f7-473e-a896-b89724b243e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5b09ac88-86f7-473e-a896-b89724b243e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_59386838-5857-470a-ab67-6a48407e0cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_59386838-5857-470a-ab67-6a48407e0cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42454759-4791-42d2-bcaa-42ef5067f22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_42454759-4791-42d2-bcaa-42ef5067f22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9b462bc9-aa34-46f4-b9bc-fc6b537caa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9b462bc9-aa34-46f4-b9bc-fc6b537caa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_958807a3-4b45-4918-9aa3-574e745e44b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_958807a3-4b45-4918-9aa3-574e745e44b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_732518cc-ffa2-4613-9e94-3b6bf0d84da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dcb84f9-5c4d-4324-9971-90dd88e585f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_732518cc-ffa2-4613-9e94-3b6bf0d84da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a4067fc-adca-4677-9bbd-5fe5f45737db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5f76a6ab-eab3-4c78-837a-5b5a4369942e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a4067fc-adca-4677-9bbd-5fe5f45737db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5829398c-864c-4ad5-80b2-2f7225445587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5829398c-864c-4ad5-80b2-2f7225445587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0b5394b8-370c-4ade-ab74-9a05e138f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0b5394b8-370c-4ade-ab74-9a05e138f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_71275405-bb09-4d38-8c48-2b8c30385cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_71275405-bb09-4d38-8c48-2b8c30385cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_d2fa1928-4762-4ee2-8670-357a1d6ed341" xlink:href="bmrn-20220331.xsd#bmrn_ProceedsFromSaleOfNonfinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_bmrn_ProceedsFromSaleOfNonfinancialAssets_d2fa1928-4762-4ee2-8670-357a1d6ed341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0aa1168f-7d2d-4092-906a-26b08de40650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0aa1168f-7d2d-4092-906a-26b08de40650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_beeca6e5-4cbe-406c-941a-af729313d285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4b12878c-b32c-44db-813a-01d8b86c9e96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_beeca6e5-4cbe-406c-941a-af729313d285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cf001b3d-35b8-4080-afa7-534163f1a7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cf001b3d-35b8-4080-afa7-534163f1a7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ec97d676-adeb-4344-8ed9-70b499251245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ec97d676-adeb-4344-8ed9-70b499251245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_352dfed1-8c3c-46e7-aaa6-00d8c468880e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_352dfed1-8c3c-46e7-aaa6-00d8c468880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31c463ed-0120-4b63-a499-d733cf211752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_43d452da-ddec-40e8-b316-6d65cb437558" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31c463ed-0120-4b63-a499-d733cf211752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c1e0fc4d-1641-48d2-adf8-55cbf06e7b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c1e0fc4d-1641-48d2-adf8-55cbf06e7b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c713c1e5-df60-42c6-87dd-a4f7bdecf769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c713c1e5-df60-42c6-87dd-a4f7bdecf769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_e6746e1f-785a-4340-85de-22597aeab24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_e6746e1f-785a-4340-85de-22597aeab24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83899c74-5951-4aa4-a1d2-e93c970f01c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_e6746e1f-785a-4340-85de-22597aeab24a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83899c74-5951-4aa4-a1d2-e93c970f01c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9295106-2344-4e22-bdc6-aef69f94b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_e6746e1f-785a-4340-85de-22597aeab24a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9295106-2344-4e22-bdc6-aef69f94b18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a53f9ef2-1d80-43a3-8492-13c70b6b09b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a53f9ef2-1d80-43a3-8492-13c70b6b09b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_2c988dd0-71ae-4ddb-9785-9176d4c865a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a53f9ef2-1d80-43a3-8492-13c70b6b09b7" xlink:to="loc_us-gaap_IncomeTaxesPaid_2c988dd0-71ae-4ddb-9785-9176d4c865a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_67d94e6f-eadf-4489-8fbc-c3835d434e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a53f9ef2-1d80-43a3-8492-13c70b6b09b7" xlink:to="loc_us-gaap_InterestPaidNet_67d94e6f-eadf-4489-8fbc-c3835d434e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_412e5f47-1e12-495f-9138-bc47f63e4102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1b7be187-9d53-49a2-b14d-57db2d9b5e78" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_412e5f47-1e12-495f-9138-bc47f63e4102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_ee745c4b-a700-494e-b921-fed0ecc88ade" xlink:href="bmrn-20220331.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_412e5f47-1e12-495f-9138-bc47f63e4102" xlink:to="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets_ee745c4b-a700-494e-b921-fed0ecc88ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_5a32af39-f67c-476a-af7f-537678d30d92" xlink:href="bmrn-20220331.xsd#bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_412e5f47-1e12-495f-9138-bc47f63e4102" xlink:to="loc_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets_5a32af39-f67c-476a-af7f-537678d30d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bmrn-20220331.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bb2bd0e-3cad-4a77-a6df-a8d81b57a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d88a1256-362a-4623-a596-f93be0066ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bb2bd0e-3cad-4a77-a6df-a8d81b57a83d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d88a1256-362a-4623-a596-f93be0066ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bmrn-20220331.xsd#BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_42015572-43bf-4987-8621-895f61c3ab6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b6fd697c-98f2-4261-8ab7-11326da1737c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42015572-43bf-4987-8621-895f61c3ab6c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b6fd697c-98f2-4261-8ab7-11326da1737c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_da1e064b-b565-4b4b-8701-5d9242ae3c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42015572-43bf-4987-8621-895f61c3ab6c" xlink:to="loc_us-gaap_UseOfEstimates_da1e064b-b565-4b4b-8701-5d9242ae3c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_45841b76-fbe8-43af-8f99-409486bc18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42015572-43bf-4987-8621-895f61c3ab6c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_45841b76-fbe8-43af-8f99-409486bc18b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f076e9b9-5c43-45d7-b263-03de11798af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8b076a0b-89ba-444e-930e-63017d8d797b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f076e9b9-5c43-45d7-b263-03de11798af4" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8b076a0b-89ba-444e-930e-63017d8d797b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eebfdc89-b438-4d92-a167-4c228650e375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_663faeb7-d271-4031-961d-f1282a74b7e7" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eebfdc89-b438-4d92-a167-4c228650e375" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock_663faeb7-d271-4031-961d-f1282a74b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8daadf9b-1230-482f-b144-4a4eae4876e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8daadf9b-1230-482f-b144-4a4eae4876e8" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7402e585-1b9f-43b4-bcad-354eadd1d47d" xlink:to="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1bd3b56a-f33e-454f-a811-522b7cadddad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:to="loc_srt_MinimumMember_1bd3b56a-f33e-454f-a811-522b7cadddad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dcd5224-a9ad-4bf4-aecf-df97a105f0d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2ef88b85-a6d9-483d-9108-f622e2bcc3c3" xlink:to="loc_srt_MaximumMember_9dcd5224-a9ad-4bf4-aecf-df97a105f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9537d52e-c329-4546-8abb-422357a601a6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a1dc4761-037f-4ebe-8582-1ca3e5c15300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a1dc4761-037f-4ebe-8582-1ca3e5c15300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_373e8fba-4bdb-44e9-819c-92fc2c7756e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cb925a2-3192-4c5b-b136-f8cd933fece1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_373e8fba-4bdb-44e9-819c-92fc2c7756e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1c320079-ea52-492b-85d4-327d14eff764" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_89782408-632c-415b-b641-4e887ea95356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CashMember_89782408-632c-415b-b641-4e887ea95356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9b885e09-8272-49b0-9478-ee14f48faca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9b885e09-8272-49b0-9478-ee14f48faca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_30358c70-e39a-497c-8455-aef1238992ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_30358c70-e39a-497c-8455-aef1238992ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4e222aab-b813-4859-a6bc-585d6f228645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4e222aab-b813-4859-a6bc-585d6f228645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a723a908-a4d7-4528-b6c6-3b5d1649dd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_CommercialPaperMember_a723a908-a4d7-4528-b6c6-3b5d1649dd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_73dd5d32-f5af-4328-a89d-0cb648f30cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_73dd5d32-f5af-4328-a89d-0cb648f30cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_d87cacb1-117b-4fd2-ba8c-d2af0781dc3b" xlink:href="bmrn-20220331.xsd#bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c407284a-5976-47fb-add6-5e33b7136ac6" xlink:to="loc_bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember_d87cacb1-117b-4fd2-ba8c-d2af0781dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_b8f6f124-c357-4567-a023-ed027305da58" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_caa9600a-1b70-4e30-9478-9ba15323b161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_Cash_caa9600a-1b70-4e30-9478-9ba15323b161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f56fffec-8165-46db-99a4-0a0babd952f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f56fffec-8165-46db-99a4-0a0babd952f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_423cf1db-a21e-43b1-bfca-a029a8ff9465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_423cf1db-a21e-43b1-bfca-a029a8ff9465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84518c27-c31e-4fd9-8e60-e4e3b5fd2cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_84518c27-c31e-4fd9-8e60-e4e3b5fd2cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d9cce1f-26f4-4d71-a9f5-822cf869fd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d9cce1f-26f4-4d71-a9f5-822cf869fd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3abbb7c3-1878-47d8-8323-3160ddb559d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3abbb7c3-1878-47d8-8323-3160ddb559d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91a03ff0-2bd2-412b-898e-2d46aa5764af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91a03ff0-2bd2-412b-898e-2d46aa5764af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8295b21d-abc9-4636-830d-49cf114a2d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8295b21d-abc9-4636-830d-49cf114a2d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_e090e554-ca48-4044-b6c2-c10ad157dc41" xlink:href="bmrn-20220331.xsd#bmrn_ShortTermMarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_bmrn_ShortTermMarketableSecuritiesMaturityPeriod_e090e554-ca48-4044-b6c2-c10ad157dc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_9dd27254-9b52-4dd0-a40b-1460bc3740fa" xlink:href="bmrn-20220331.xsd#bmrn_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_436cc485-8023-4699-91d4-0dc4f106e5e2" xlink:to="loc_bmrn_LongTermMarketableSecuritiesMaturityPeriod_9dd27254-9b52-4dd0-a40b-1460bc3740fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_608b2cac-0e5a-4209-93f2-98b1ecea0cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_608b2cac-0e5a-4209-93f2-98b1ecea0cf5" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_60e42571-2dbf-4412-b87f-003cce704220" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_StrategicInvestmentMember_25f6e4c1-fc92-458b-86c1-6ab3a58aef82" xlink:href="bmrn-20220331.xsd#bmrn_StrategicInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8cb1c2f2-ac18-431c-bb08-9cd5fc5a471a" xlink:to="loc_bmrn_StrategicInvestmentMember_25f6e4c1-fc92-458b-86c1-6ab3a58aef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3f08207-01ba-4e81-811d-a7e89e56e51f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f0661018-4dd4-4c58-a104-df23613c366c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_38772cdd-4ed4-4002-9f9b-e4674c8d7f17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f0661018-4dd4-4c58-a104-df23613c366c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_a0e8fb46-3e99-44a8-9aa5-e5afaae14cd5" xlink:to="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b5ab514d-13e0-4dae-98c6-3e1e59926cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_278bb348-92e0-4c7a-81f8-c480b7f20738" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b5ab514d-13e0-4dae-98c6-3e1e59926cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d420669-80ed-45a6-a2d6-7eef2ebdc5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8bc12ee3-cdc4-46ad-bae6-7088344920e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d420669-80ed-45a6-a2d6-7eef2ebdc5f2" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8bc12ee3-cdc4-46ad-bae6-7088344920e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161adc36-be81-4bbc-b2c3-a9c158acd52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b22d8fe4-15f5-4853-b182-e71b624eb730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161adc36-be81-4bbc-b2c3-a9c158acd52b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b22d8fe4-15f5-4853-b182-e71b624eb730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d33d46dd-f148-449a-928e-2c9e7fa496a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161adc36-be81-4bbc-b2c3-a9c158acd52b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d33d46dd-f148-449a-928e-2c9e7fa496a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_266aa6ab-6c90-4f30-a29f-877d6e37ac7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161adc36-be81-4bbc-b2c3-a9c158acd52b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_266aa6ab-6c90-4f30-a29f-877d6e37ac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c860533d-0b0d-41cd-ae3d-2016af136689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161adc36-be81-4bbc-b2c3-a9c158acd52b" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c860533d-0b0d-41cd-ae3d-2016af136689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofInventoryDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5c8490c-f2db-4064-a984-dd81248d5d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2b335872-9836-421b-b0cf-8a4427ce63d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5c8490c-f2db-4064-a984-dd81248d5d71" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2b335872-9836-421b-b0cf-8a4427ce63d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f9ee17ed-09eb-4971-8a3d-eaea78f89893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5c8490c-f2db-4064-a984-dd81248d5d71" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f9ee17ed-09eb-4971-8a3d-eaea78f89893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1333d927-d2e9-422b-adf8-4e4a00e3585e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5c8490c-f2db-4064-a984-dd81248d5d71" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1333d927-d2e9-422b-adf8-4e4a00e3585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ce44f1ca-ba7a-49f6-93c7-170ebd70e3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5c8490c-f2db-4064-a984-dd81248d5d71" xlink:to="loc_us-gaap_InventoryNet_ce44f1ca-ba7a-49f6-93c7-170ebd70e3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2099d00a-d9ce-402f-b0b0-21023cb936cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2099d00a-d9ce-402f-b0b0-21023cb936cd" xlink:to="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_91ece28c-eb30-4e1f-ac00-39702f2537f9" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ValoctocogeneRoxaparvovecMember_8728320f-1082-4224-8711-0a9c3b09f8b5" xlink:href="bmrn-20220331.xsd#bmrn_ValoctocogeneRoxaparvovecMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_999d3f19-b8c0-4a70-839d-56ae15c05fc5" xlink:to="loc_bmrn_ValoctocogeneRoxaparvovecMember_8728320f-1082-4224-8711-0a9c3b09f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_ebe4efcc-f851-45f8-bf67-ad978a9e6140" xlink:to="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a48d05b0-bb58-4718-a135-c0abb8c3f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_InventoryNet_a48d05b0-bb58-4718-a135-c0abb8c3f1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4e2b34c3-dcfb-4121-9529-68b0c28fd8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_Depreciation_4e2b34c3-dcfb-4121-9529-68b0c28fd8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_654d6f7c-c406-4323-b77a-43ca744bcf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_126a22f3-2238-48f6-afc7-c1e66ef9efe2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_654d6f7c-c406-4323-b77a-43ca744bcf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_808e595a-3b43-4164-b93c-1cc3a8393bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a5ddf-ee7c-42c8-9c8f-7e689d48c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_808e595a-3b43-4164-b93c-1cc3a8393bf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a5ddf-ee7c-42c8-9c8f-7e689d48c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_37852c98-a7bd-43c5-8855-c1fadab25494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_808e595a-3b43-4164-b93c-1cc3a8393bf1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_37852c98-a7bd-43c5-8855-c1fadab25494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f27baca2-3a21-49d6-a1ab-5383b6cdcc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_808e595a-3b43-4164-b93c-1cc3a8393bf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f27baca2-3a21-49d6-a1ab-5383b6cdcc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0754a9d0-dadb-4528-805e-b82c31137479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_295e46aa-ea6d-456e-ba59-4aa9f9a8d8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0754a9d0-dadb-4528-805e-b82c31137479" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_295e46aa-ea6d-456e-ba59-4aa9f9a8d8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2ce9b3b0-2864-46a5-b3c8-f772d50198a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0754a9d0-dadb-4528-805e-b82c31137479" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2ce9b3b0-2864-46a5-b3c8-f772d50198a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69d1bc59-b2be-424a-b203-1f034e5b9020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0754a9d0-dadb-4528-805e-b82c31137479" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69d1bc59-b2be-424a-b203-1f034e5b9020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_07861ca8-69e9-477a-b3a7-36d76f940c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_07861ca8-69e9-477a-b3a7-36d76f940c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3e889b96-35a6-4e93-8dee-431c4d2b68a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3e889b96-35a6-4e93-8dee-431c4d2b68a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_AccruedGovernmentAndOtherRebates_e9beded0-d829-463c-9124-dfb30706ffcd" xlink:href="bmrn-20220331.xsd#bmrn_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_bmrn_AccruedGovernmentAndOtherRebates_e9beded0-d829-463c-9124-dfb30706ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_b211ec06-8b41-48f9-a3c4-8698e233af39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_b211ec06-8b41-48f9-a3c4-8698e233af39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_ce444083-db8b-450d-a25e-0d56fa6582b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_ce444083-db8b-450d-a25e-0d56fa6582b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_97c58073-7497-4eb0-9635-1cb48948e169" xlink:href="bmrn-20220331.xsd#bmrn_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_bmrn_OperatingAndFinanceLeaseLiabilityCurrent_97c58073-7497-4eb0-9635-1cb48948e169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_7cadf3e2-5d5f-4e02-8e30-2e926db1d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_7cadf3e2-5d5f-4e02-8e30-2e926db1d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_9487d842-0bd7-446f-a4b8-ddefc113aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_AccruedIncomeTaxes_9487d842-0bd7-446f-a4b8-ddefc113aa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c12c796f-f200-4dd9-9193-2ce9ef0a0f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c12c796f-f200-4dd9-9193-2ce9ef0a0f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_085289af-37f5-4b5b-a81f-2b99c002fd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_085289af-37f5-4b5b-a81f-2b99c002fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7d18fb3b-53d1-4e2b-acd9-d19d1ff37e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28a2b925-181f-4d1f-b11b-fbdf1a0c443b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7d18fb3b-53d1-4e2b-acd9-d19d1ff37e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7e19498f-3934-4431-8225-663a7d45ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_fb142303-79f3-4f79-9652-c1f701b2c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7e19498f-3934-4431-8225-663a7d45ee02" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_fb142303-79f3-4f79-9652-c1f701b2c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a43128e8-8f09-4f9f-a71f-fbf75618305c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8433b7c9-a41b-4af5-b6a9-c7c51d932ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a43128e8-8f09-4f9f-a71f-fbf75618305c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8433b7c9-a41b-4af5-b6a9-c7c51d932ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_00a750d2-0e2f-48f0-8620-7fe1b785a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a43128e8-8f09-4f9f-a71f-fbf75618305c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_00a750d2-0e2f-48f0-8620-7fe1b785a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9271ba30-56b2-484b-a01e-6da7b5bb5c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9271ba30-56b2-484b-a01e-6da7b5bb5c0b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1eddcfa4-9bdb-4ff2-87e9-2e13165b0264" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2be3751b-a991-4afa-8589-be7f0543502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d38cbc36-6a02-4e6e-88f5-10d406453d17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2be3751b-a991-4afa-8589-be7f0543502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5a4a837-9d91-4c8f-978f-c3f327e9a915" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_61fe0a44-2aa1-44c7-ba3c-15d611fe0a5d" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanAssetsMember_61fe0a44-2aa1-44c7-ba3c-15d611fe0a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestrictedInvestmentsMember_c8574c01-f427-4308-99d2-8ea8bcdc70d3" xlink:href="bmrn-20220331.xsd#bmrn_RestrictedInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cc039d10-1c34-4469-b854-4d1c2eb60cee" xlink:to="loc_bmrn_RestrictedInvestmentsMember_c8574c01-f427-4308-99d2-8ea8bcdc70d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7589eff8-7f33-4e15-936b-32a14e275725" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7bc45ab9-5686-4d6d-8b83-9e1d5a95d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7bc45ab9-5686-4d6d-8b83-9e1d5a95d15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac2a7356-6ef8-4ac9-8a04-0cdec0293e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac2a7356-6ef8-4ac9-8a04-0cdec0293e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8433f749-93eb-4991-952e-2156b9e6fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a8e4694-58a2-4cf4-a6b0-30689fbaa704" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8433f749-93eb-4991-952e-2156b9e6fcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_905d7561-bc54-404d-bfd4-eaa8850d27d6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_d14ee82b-82a0-4de2-a047-7ff2d5c09731" xlink:href="bmrn-20220331.xsd#bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:to="loc_bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember_d14ee82b-82a0-4de2-a047-7ff2d5c09731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentConsiderationMember_4115ebb0-1dcc-479e-bfb2-351ea33ab09e" xlink:href="bmrn-20220331.xsd#bmrn_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf492f45-bfe2-4919-846f-6f6a194ce156" xlink:to="loc_bmrn_ContingentConsiderationMember_4115ebb0-1dcc-479e-bfb2-351ea33ab09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee4bb088-647e-454e-bcd9-889756863927" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80c03db3-aa62-429a-813d-d31b19cdebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_80c03db3-aa62-429a-813d-d31b19cdebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_deff4835-0d30-4160-8d31-0e22cdef81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_deff4835-0d30-4160-8d31-0e22cdef81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_88f8404a-0def-454f-9222-37d12bae6bb4" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherAssetsCurrentFairValueDisclosure_88f8404a-0def-454f-9222-37d12bae6bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_e009d9d1-2b28-4995-ba30-6041eaa468be" xlink:href="bmrn-20220331.xsd#bmrn_OtherAssetsNoncurrentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherAssetsNoncurrentFairValueDisclosure_e009d9d1-2b28-4995-ba30-6041eaa468be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_12bf2ba4-aaa3-4942-9bae-86b72bea35fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_12bf2ba4-aaa3-4942-9bae-86b72bea35fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_633f8afe-5091-45f0-a140-d4dcf43d4699" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesCurrentFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherLiabilitiesCurrentFairValueDisclosure_633f8afe-5091-45f0-a140-d4dcf43d4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_ce94f706-a0d8-4d21-9334-31ced90bdd3c" xlink:href="bmrn-20220331.xsd#bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure_ce94f706-a0d8-4d21-9334-31ced90bdd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f06d258d-cdae-4df9-929b-bd3672d91175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76de283b-46f7-47b5-bde1-fabf7ab978ab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f06d258d-cdae-4df9-929b-bd3672d91175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4316a130-e895-4c45-b487-377d1924ce23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4316a130-e895-4c45-b487-377d1924ce23" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75188cb7-91c5-4e6d-85d1-c0abb0cd552e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentMember_0b85c8b5-cdf6-4b2a-9ba5-95ca24b7ed7f" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef84a979-6f80-43b8-8e7d-511389d2d999" xlink:to="loc_bmrn_ContingentPaymentMember_0b85c8b5-cdf6-4b2a-9ba5-95ca24b7ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ad84ca7f-a25c-43de-9c19-ba780e1b36d8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_51cd69cd-4ae5-467b-b2cf-715e04f64632" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0aa4a764-70ed-4c5c-bd6c-7044a0963a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0aa4a764-70ed-4c5c-bd6c-7044a0963a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17440925-6cec-4bd1-8e7a-3dfc278b3733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17440925-6cec-4bd1-8e7a-3dfc278b3733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_985292fc-62e4-4253-b1c5-ae8424ecac81" xlink:href="bmrn-20220331.xsd#bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement_985292fc-62e4-4253-b1c5-ae8424ecac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_114ab2da-dd94-4161-8a85-2d3c96d3733f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e90b07ea-8ee9-4177-a024-ed09a9ddd929" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_114ab2da-dd94-4161-8a85-2d3c96d3733f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eafbc222-da58-4859-874f-c6b89e3bd89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d6ee327c-c86a-4307-a3f0-f753bd8eb4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eafbc222-da58-4859-874f-c6b89e3bd89b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d6ee327c-c86a-4307-a3f0-f753bd8eb4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b154e1a8-bd77-4166-bf8b-4c4c29791f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_aead2520-d35d-498b-84a2-663e92668b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b154e1a8-bd77-4166-bf8b-4c4c29791f11" xlink:to="loc_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_aead2520-d35d-498b-84a2-663e92668b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5cf6299d-0980-43ec-be6c-2a6527f46473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b154e1a8-bd77-4166-bf8b-4c4c29791f11" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5cf6299d-0980-43ec-be6c-2a6527f46473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_3b07f8e3-2346-445a-b112-c618f0bc675c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b154e1a8-bd77-4166-bf8b-4c4c29791f11" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_3b07f8e3-2346-445a-b112-c618f0bc675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c0b4978a-f216-449b-8186-d86058c6dade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c0b4978a-f216-449b-8186-d86058c6dade" xlink:to="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:to="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0273b201-99d4-4c39-8d58-f764355d97ef" xlink:to="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_af204b89-db9d-4568-a6a9-b1749fb27e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_af204b89-db9d-4568-a6a9-b1749fb27e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2d0cfb6e-c657-4983-89a9-03e58965aa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f9d1c0f-fcef-4c95-98c9-3859ecb95c14" xlink:to="loc_us-gaap_NondesignatedMember_2d0cfb6e-c657-4983-89a9-03e58965aa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8ec7669e-d4d1-4687-95eb-7911103aa1a5" xlink:to="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_37511830-d3c7-4b5c-9a86-4046c8a46061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_37511830-d3c7-4b5c-9a86-4046c8a46061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_e5e4b1f4-7ce9-49ef-8df7-51067cc27560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_33cc3e4e-6191-4111-af92-d25bcd1fb613" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_e5e4b1f4-7ce9-49ef-8df7-51067cc27560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_95571b7d-9320-46da-95f5-ee92af09148b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_95571b7d-9320-46da-95f5-ee92af09148b" xlink:to="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_769821a4-4fa4-42c3-935e-3590f701f72e" xlink:to="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e1b0f33-4327-4558-a5b9-4eb736c91519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e1b0f33-4327-4558-a5b9-4eb736c91519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_3f3a3b57-c3bc-471c-8eaf-01d24b7d0242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_26852df9-05f9-4a5f-a658-b7319325e896" xlink:to="loc_us-gaap_NondesignatedMember_3f3a3b57-c3bc-471c-8eaf-01d24b7d0242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_269dbe5c-1ba3-4c5a-85b1-b5abf19322ba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f5dc4f54-e34f-4196-b8c0-855f954fce43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e657ac92-07cf-420a-940e-a3f73589cd53" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f5dc4f54-e34f-4196-b8c0-855f954fce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PositionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionAxis_35837dca-d31d-4e75-9f0d-76694faaeef2" xlink:to="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_03cbf691-ec2e-4778-bb0b-e0d2be6221b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:to="loc_us-gaap_ShortMember_03cbf691-ec2e-4778-bb0b-e0d2be6221b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_5f040977-3733-4f73-9812-bae27d51a844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_c65d0e9e-6d66-4c68-ad34-3d530d26790f" xlink:to="loc_us-gaap_LongMember_5f040977-3733-4f73-9812-bae27d51a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5ba7ba8b-d79e-4ff6-8ed8-1b40322a0578" xlink:to="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12280edf-2dfe-41b5-9fa9-216cf398804f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a3cd93eb-b5c3-4edc-a6fe-025af34da9de" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12280edf-2dfe-41b5-9fa9-216cf398804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_49d66821-ff84-4650-ad3a-803bd7ee362a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_49d66821-ff84-4650-ad3a-803bd7ee362a" xlink:to="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c84bff2d-cc04-48ad-90e1-3c12795bbfbf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3faa2be9-5abf-4767-965e-6ffebc2aed92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a567dee-ed2e-4a21-973a-628b34318581" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3faa2be9-5abf-4767-965e-6ffebc2aed92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a46f86c6-c11d-47c1-a7a5-dd1491a3d8f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_277f0901-8ad5-49a4-9941-35399e90f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_277f0901-8ad5-49a4-9941-35399e90f0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1ae91d80-2c7f-442c-ae8e-c95c057be0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_76af83be-35d5-42e3-b6d1-c7c85f786408" xlink:to="loc_us-gaap_NondesignatedMember_1ae91d80-2c7f-442c-ae8e-c95c057be0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d74067b6-3fa8-44b5-bce4-8d8ec0b7890a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3873d5d0-9644-4850-8699-d30f7c7614a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3873d5d0-9644-4850-8699-d30f7c7614a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_3d34a58c-3736-4c44-8aa0-9765afd21ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_3d34a58c-3736-4c44-8aa0-9765afd21ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_a7d544ab-40b6-4e63-95b2-a4b123fc636c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_a7d544ab-40b6-4e63-95b2-a4b123fc636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a653dfc0-4717-4b49-9f65-66b3f320d329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12e6a738-5a79-4e81-ac07-c801b7055e54" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a653dfc0-4717-4b49-9f65-66b3f320d329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ef97eed2-9e82-4ca4-bed0-dcda8c785cb3" xlink:to="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14078c97-02ba-4169-9a73-7b70fddf7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14078c97-02ba-4169-9a73-7b70fddf7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dbf54afa-f4f1-480a-be7f-ce8a02c0ee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f06489d1-9a07-4397-bc9f-0dddd3df75bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dbf54afa-f4f1-480a-be7f-ce8a02c0ee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d1e937c-eb1b-41d0-ad89-4c465d433551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d1e937c-eb1b-41d0-ad89-4c465d433551" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_86026757-fb3f-4724-af62-2cb618f54fbc" xlink:to="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0d256cf5-81b3-4e00-8260-3f87ff489682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_83ce8339-5fc5-4a4b-8d75-e4e68a0291a2" xlink:to="loc_us-gaap_ProductMember_0d256cf5-81b3-4e00-8260-3f87ff489682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7b15cfc-0536-49b7-bd5b-41bf9c9796e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_ee02d4c2-cd53-47fb-9687-84c8d55a17ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3090f6df-9f00-4fb8-a957-c59440eb62f6" xlink:to="loc_us-gaap_OperatingExpenseMember_ee02d4c2-cd53-47fb-9687-84c8d55a17ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7ae2ad0e-fd14-44ea-b349-1d853626382b" xlink:to="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1f6cc53c-cd09-46ea-aa15-f9289738a106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1f6cc53c-cd09-46ea-aa15-f9289738a106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_96f24075-fbe4-4a44-8d8b-1a6bf146702e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6f876d31-7413-48b3-876c-e8efb690bcd8" xlink:to="loc_us-gaap_NondesignatedMember_96f24075-fbe4-4a44-8d8b-1a6bf146702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e387df95-a155-4e52-860f-5a44e2c04f21" xlink:to="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2f58a769-0a47-452c-b1be-fefab5cb10fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_310d446e-b346-4ca7-b183-3cb1fde7a4e7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2f58a769-0a47-452c-b1be-fefab5cb10fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_042a2801-6f6c-48da-b1b2-476838dc4832" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6779e5ca-d4b2-49bb-9305-cf87d74cbec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6779e5ca-d4b2-49bb-9305-cf87d74cbec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f5f3a5c4-ae91-4d00-927c-595926b2e616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_CostsAndExpenses_f5f3a5c4-ae91-4d00-927c-595926b2e616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b785b000-1692-4493-9f86-3522b5c880c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b785b000-1692-4493-9f86-3522b5c880c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_99aa9cb0-698c-49a5-8ac1-f9f515c384d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5037cf3c-83cd-40d6-b756-33e63e72fbe9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_99aa9cb0-698c-49a5-8ac1-f9f515c384d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBT" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bc443767-863c-484b-934c-b03eba4af9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_3bba39e3-989d-491f-a256-6ddaa30e7d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bc443767-863c-484b-934c-b03eba4af9a8" xlink:to="loc_us-gaap_LongTermDebtTextBlock_3bba39e3-989d-491f-a256-6ddaa30e7d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DEBTTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4c388e4-5b72-4498-85e4-2ea84607e3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_5bed8341-d9dc-4d44-9261-d5c09d0137ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4c388e4-5b72-4498-85e4-2ea84607e3e6" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_5bed8341-d9dc-4d44-9261-d5c09d0137ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f619101b-0e83-46be-9a37-ba2f5583f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4c388e4-5b72-4498-85e4-2ea84607e3e6" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f619101b-0e83-46be-9a37-ba2f5583f0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DebtAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d3e2dce-8bd3-480d-94e4-45bd98f75675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d3e2dce-8bd3-480d-94e4-45bd98f75675" xlink:to="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:to="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_664b67e2-b1e3-42b3-9ef1-411172b1a6c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_fbca8ead-400e-4dec-9db8-20a5bcdb3042" xlink:href="bmrn-20220331.xsd#bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_daf322d9-b06d-4023-a0f9-28b3b38d831a" xlink:to="loc_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember_fbca8ead-400e-4dec-9db8-20a5bcdb3042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0296270b-515d-4358-b939-74c28567823d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_efe61d5e-e6db-4e0d-878b-794e0c21ca0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_efe61d5e-e6db-4e0d-878b-794e0c21ca0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da16003f-423c-4ea6-9a46-23aa2fd6ba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da16003f-423c-4ea6-9a46-23aa2fd6ba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_5778b910-d39e-4530-9c4d-fbcf0584c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52b592d8-0b6b-4c77-9af5-039a1c8de154" xlink:to="loc_us-gaap_LineOfCredit_5778b910-d39e-4530-9c4d-fbcf0584c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofConvertibleDebtDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7cd8732d-469d-488c-a7c2-5f5d1eb96a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7cd8732d-469d-488c-a7c2-5f5d1eb96a05" xlink:to="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:to="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d22d423c-2d3f-423c-ac99-46a33ddc9059" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_dada4c79-f0c6-4f96-a8e4-bf3fd9b541b0" xlink:href="bmrn-20220331.xsd#bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:to="loc_bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member_dada4c79-f0c6-4f96-a8e4-bf3fd9b541b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_3583581c-d1b0-45f7-accc-2054487244f6" xlink:href="bmrn-20220331.xsd#bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e81b3fb6-9725-45af-af3f-74df4ed7dbea" xlink:to="loc_bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember_3583581c-d1b0-45f7-accc-2054487244f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3810b43a-6072-4632-9a93-4ad6cc288958" xlink:to="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b798ab83-314e-416a-88b1-ab150616d8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b798ab83-314e-416a-88b1-ab150616d8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0945cb23-3427-43e7-bc6e-3816e689e039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0945cb23-3427-43e7-bc6e-3816e689e039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d24b9a8-a1f0-4a86-95c4-0e4bf3e533ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d24b9a8-a1f0-4a86-95c4-0e4bf3e533ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9ee9550c-32a8-4dfa-bdb2-01c0c0640f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9ee9550c-32a8-4dfa-bdb2-01c0c0640f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5c5f39a2-8043-4051-a8bb-ac6d79edbdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebt_5c5f39a2-8043-4051-a8bb-ac6d79edbdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f5907070-ad9f-4b8b-9ce3-999fbda285ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95cd171b-828f-4850-b0d9-dd4650e3eb17" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f5907070-ad9f-4b8b-9ce3-999fbda285ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#DebtSummaryofInterestExpenseonConvertibleDebtDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74614728-a5a7-4da6-b7d4-ed186ff6afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74614728-a5a7-4da6-b7d4-ed186ff6afb7" xlink:to="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_065a4a8c-700e-46e9-8837-9e458c8f1bac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d080536f-1a89-4852-b6ac-f90e5cb57618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d6844e50-64f6-41a1-a124-16e1e4c98b5c" xlink:to="loc_us-gaap_ConvertibleDebtMember_d080536f-1a89-4852-b6ac-f90e5cb57618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:href="bmrn-20220331.xsd#bmrn_ScheduleOfInterestExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesTable_4905d56f-3c95-41aa-b14e-6b6ed7cd534e" xlink:to="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f2303a9d-4204-4ed5-b91f-7bceea6e28a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f2303a9d-4204-4ed5-b91f-7bceea6e28a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c3843cf-2a57-438b-a029-2c48b0a664e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c3843cf-2a57-438b-a029-2c48b0a664e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_66ecc144-9c2b-4e00-b4bf-e4a31dc6ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_66ecc144-9c2b-4e00-b4bf-e4a31dc6ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f9f07d9-468a-48aa-9ac6-c471cfea813a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ScheduleOfInterestExpensesLineItems_699a2a4f-f657-433d-8b72-9ed30f77f221" xlink:to="loc_us-gaap_InterestExpense_2f9f07d9-468a-48aa-9ac6-c471cfea813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bmrn-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa511da5-8dd8-44fc-aed7-0b08ce4fb479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5991576e-54f7-477a-a012-20878bf0fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa511da5-8dd8-44fc-aed7-0b08ce4fb479" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5991576e-54f7-477a-a012-20878bf0fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db8b9105-e0cf-40b2-a744-1ac41a6bdc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2d275385-2b10-4450-8258-36c0844e9901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db8b9105-e0cf-40b2-a744-1ac41a6bdc68" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2d275385-2b10-4450-8258-36c0844e9901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_de032ffd-eb0c-4c01-b8ca-b56d86f2efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_de032ffd-eb0c-4c01-b8ca-b56d86f2efa1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c92a509-4c0f-4796-b990-399887efb433" xlink:to="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3643f09e-6287-4c2a-afaf-688ae298a48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3643f09e-6287-4c2a-afaf-688ae298a48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_87ff027b-6413-4623-9ca0-721e0128c238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_87ff027b-6413-4623-9ca0-721e0128c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_80e355b2-99f4-46db-a752-bad97e26130d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60c4fefe-8622-4e03-b600-49e4b0e919b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_80e355b2-99f4-46db-a752-bad97e26130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_cec21545-8ce0-4213-b005-73e3ad610909" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e88a566-2353-4345-9933-3ef171cf1249" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e004e971-5d16-451b-8377-3dc49ffc7dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_StockholdersEquity_e004e971-5d16-451b-8377-3dc49ffc7dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d71ee59a-4576-455e-aa17-1fbc44425ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d71ee59a-4576-455e-aa17-1fbc44425ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_88a43745-1c0c-4a09-947a-061b54922c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_88a43745-1c0c-4a09-947a-061b54922c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_367a4298-8eef-42f9-8ffc-7848035bd5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_367a4298-8eef-42f9-8ffc-7848035bd5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57e26ccc-bccf-4928-bed2-37d696ced7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57e26ccc-bccf-4928-bed2-37d696ced7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0ba61abf-8ab1-49f9-8e19-d3232131b60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6851c52f-b42d-43a2-b77e-736898b20cc7" xlink:to="loc_us-gaap_StockholdersEquity_0ba61abf-8ab1-49f9-8e19-d3232131b60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="bmrn-20220331.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_70c37626-3e24-409b-9fb7-82972f71c651" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_3654707d-842b-4b55-b715-be8477ab587b" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_70c37626-3e24-409b-9fb7-82972f71c651" xlink:to="loc_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock_3654707d-842b-4b55-b715-be8477ab587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_2dfea356-24bd-4027-959e-b419561966ed" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_dccc1b0a-818b-4da6-a8de-dd3db30e8424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_2dfea356-24bd-4027-959e-b419561966ed" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_dccc1b0a-818b-4da6-a8de-dd3db30e8424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6a11be2a-b470-454e-b2e9-5110067eeeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_2dfea356-24bd-4027-959e-b419561966ed" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6a11be2a-b470-454e-b2e9-5110067eeeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f9975dde-35bd-46e0-a679-dc5e16ec35b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_2dfea356-24bd-4027-959e-b419561966ed" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f9975dde-35bd-46e0-a679-dc5e16ec35b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_13db4b46-8642-4e4d-b238-27aa61c458ba" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_13db4b46-8642-4e4d-b238-27aa61c458ba" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f76230ea-0cf0-4c86-a9b9-c72b997ecd56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_c71af97e-078d-424a-8566-09319bebf7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6ea081f9-c60e-464f-8c37-5e4c9f26d48d" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_c71af97e-078d-424a-8566-09319bebf7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ad186880-08c0-46c7-900c-142b508b4014" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_37cdc152-aebd-4742-b70c-468df90813ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a380d5-a8b8-48f8-9961-7c43bd872ff6" xlink:to="loc_us-gaap_AccountsReceivableMember_37cdc152-aebd-4742-b70c-468df90813ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e1e92d11-c64e-4b29-82cc-9d854366567b" xlink:to="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_0b09c199-d50a-4a06-91b4-55f53ac4942f" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomerOneMember_0b09c199-d50a-4a06-91b4-55f53ac4942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_a74e3d75-9191-4e92-bc7f-92f8d7188506" xlink:href="bmrn-20220331.xsd#bmrn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomerTwoMember_a74e3d75-9191-4e92-bc7f-92f8d7188506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomersMember_30077c29-5826-4c15-8e20-fad9fdd23c30" xlink:href="bmrn-20220331.xsd#bmrn_CustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_07bcac9f-3140-4141-a0f4-d5c2f17527e1" xlink:to="loc_bmrn_CustomersMember_30077c29-5826-4c15-8e20-fad9fdd23c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationTable_f39f210a-89c9-4320-acb9-f7c170d5a35c" xlink:to="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d581c78b-2f01-4eb8-9be5-f7131852e2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d581c78b-2f01-4eb8-9be5-f7131852e2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_93ecb044-5500-488d-a079-8f9711f7e240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_93ecb044-5500-488d-a079-8f9711f7e240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_21321fc7-571e-4bb7-9eec-6094cde4322c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationLineItems_cc0e4441-375c-466e-8964-c14ecc8b9da4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_21321fc7-571e-4bb7-9eec-6094cde4322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_d6489ab4-fd31-4275-aa16-061999bfeab3" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_d6489ab4-fd31-4275-aa16-061999bfeab3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:to="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e4bfde3-bb1e-41b2-9118-ba782434a92f" xlink:to="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:to="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductFourMember_6cc43415-9db8-4fed-a85a-8d36b272614d" xlink:href="bmrn-20220331.xsd#bmrn_ProductFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductFourMember_6cc43415-9db8-4fed-a85a-8d36b272614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductTwoMember_198ac7c7-f392-43b4-abbf-0ebc5593d245" xlink:href="bmrn-20220331.xsd#bmrn_ProductTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductTwoMember_198ac7c7-f392-43b4-abbf-0ebc5593d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductThreeMember_3c4eda10-60ae-4a9a-b117-b56dc6a4b67f" xlink:href="bmrn-20220331.xsd#bmrn_ProductThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductThreeMember_3c4eda10-60ae-4a9a-b117-b56dc6a4b67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSevenMember_83f57436-bcaa-4202-9835-d78d3cf657be" xlink:href="bmrn-20220331.xsd#bmrn_ProductSevenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductSevenMember_83f57436-bcaa-4202-9835-d78d3cf657be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductSixMember_52543853-dd08-42ac-bf7c-a69b84f6df7c" xlink:href="bmrn-20220331.xsd#bmrn_ProductSixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductSixMember_52543853-dd08-42ac-bf7c-a69b84f6df7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductEightMember_0614e168-3410-48b9-9c31-79f17398c242" xlink:href="bmrn-20220331.xsd#bmrn_ProductEightMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductEightMember_0614e168-3410-48b9-9c31-79f17398c242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_870a30c2-8914-42c6-a46a-83e9b2b3ca69" xlink:href="bmrn-20220331.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_870a30c2-8914-42c6-a46a-83e9b2b3ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_e6510f52-d4a8-417b-9b10-6f825ce78669" xlink:href="bmrn-20220331.xsd#bmrn_ProductOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_4084823c-2365-4917-9225-ffdfd9c6b0e7" xlink:to="loc_bmrn_ProductOneMember_e6510f52-d4a8-417b-9b10-6f825ce78669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RoyaltyAndOtherMember_e4b62e74-d333-4ccf-9259-7972ecd0505d" xlink:href="bmrn-20220331.xsd#bmrn_RoyaltyAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4a47d0a-c749-4e0b-bc9b-f63c6c42b54c" xlink:to="loc_bmrn_RoyaltyAndOtherMember_e4b62e74-d333-4ccf-9259-7972ecd0505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_9c109fff-49bb-45aa-a83b-e1cce8c7e0f8" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_29f00384-85fb-45bc-806c-9bb83c8e5284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_29f00384-85fb-45bc-806c-9bb83c8e5284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_92667062-3835-4206-86d5-cf16776611f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_12458fdd-ede1-4581-8b97-5de11de6732e" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_92667062-3835-4206-86d5-cf16776611f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_56e93b8e-29b8-4435-8e73-69f64a9353d4" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4691f2c-f032-4c94-9016-e7eb8c6ea4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_874389ce-10ad-4623-a3a2-230fed32758f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4691f2c-f032-4c94-9016-e7eb8c6ea4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_c6f43e18-b49b-4db6-932a-46b3d06dc029" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_c6f43e18-b49b-4db6-932a-46b3d06dc029" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_5728e708-f6a3-4119-8566-6aa579be3056" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_6978953d-7be3-4bb2-8207-a81f464e5893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_6978953d-7be3-4bb2-8207-a81f464e5893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_f79575cf-8ae7-42d4-b2b3-ca925c8b28bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_94409c8e-b853-45e3-a1d8-fd5e9d349954" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_f79575cf-8ae7-42d4-b2b3-ca925c8b28bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_55a74a18-79cc-4e65-8421-5a0992ab33f5" xlink:to="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductsExcludingProductOneMember_ae811428-ce77-4cba-a41b-34ccf2a32b8f" xlink:href="bmrn-20220331.xsd#bmrn_ProductsExcludingProductOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_bmrn_ProductsExcludingProductOneMember_ae811428-ce77-4cba-a41b-34ccf2a32b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ProductOneMember_d63151fd-bd69-41a4-868f-27f72408308d" xlink:href="bmrn-20220331.xsd#bmrn_ProductOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_bmrn_ProductOneMember_d63151fd-bd69-41a4-868f-27f72408308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3143ec22-6b21-48df-8411-2662ebbb08f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb1ba9a2-d6b7-4f9a-8653-67b3c2b44c6b" xlink:to="loc_us-gaap_ProductMember_3143ec22-6b21-48df-8411-2662ebbb08f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_996b617c-536a-41ca-91da-eed30c2a7f67" xlink:to="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0740110d-1f99-4065-873b-85f98f3d8a78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_srt_EuropeMember_0740110d-1f99-4065-873b-85f98f3d8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f0593b2a-adfc-41d2-ab6b-27b807f4ff7e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_country_US_f0593b2a-adfc-41d2-ab6b-27b807f4ff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MiddleEastMember_229b0d09-e279-4b08-a419-eb604e2b4fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MiddleEastMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_us-gaap_MiddleEastMember_229b0d09-e279-4b08-a419-eb604e2b4fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_c6794879-497f-416c-9c65-3b92edcbacb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_srt_LatinAmericaMember_c6794879-497f-416c-9c65-3b92edcbacb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_RestOfWorldMember_12ad436e-ea9a-4fda-92bd-394c7df2c9c0" xlink:href="bmrn-20220331.xsd#bmrn_RestOfWorldMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a867c3d-a3c9-49bc-b613-9b70dc46bfc3" xlink:to="loc_bmrn_RestOfWorldMember_12ad436e-ea9a-4fda-92bd-394c7df2c9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_013ee770-21ee-4803-af83-f026c024222b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdeee4c1-d9db-4ac9-b7ef-4559a054212c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68441e85-2a2b-4c4e-b100-89a7bcc81a3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdeee4c1-d9db-4ac9-b7ef-4559a054212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_b67f569e-7c3b-4bc9-bfe3-954b7c792f68" xlink:href="bmrn-20220331.xsd#bmrn_ConcentrationRiskAndGeographicInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_ConcentrationRiskAndGeographicInformationAbstract_b67f569e-7c3b-4bc9-bfe3-954b7c792f68" xlink:to="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0781c0e9-16b3-424f-99f4-b2e389557ad3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_969c08bc-ce9d-4ef0-a463-cdf19314e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9b71956e-564d-487f-b3bc-92ce7c3fb8fb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_969c08bc-ce9d-4ef0-a463-cdf19314e1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a76aecdf-6098-4cf7-b940-e0131c464d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c5ed8c0f-c27c-45cd-8d4b-5f9d95db7d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c648bcb-5b0a-4853-962b-9937db128139" xlink:to="loc_us-gaap_SalesRevenueNetMember_c5ed8c0f-c27c-45cd-8d4b-5f9d95db7d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9636593f-fd23-4cb2-9475-0a7113961427" xlink:to="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneTwoThreeAndFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5a5618d0-b467-42a9-9899-fbb47ff554a9" xlink:to="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerOneMember_b4c659bc-d652-4a29-b012-e4cd1462629d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerOneMember_b4c659bc-d652-4a29-b012-e4cd1462629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerTwoMember_c47c0762-e175-4be5-ad40-d48ccd0fbb3d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerTwoMember_c47c0762-e175-4be5-ad40-d48ccd0fbb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerThreeMember_d51c9623-67c9-45a6-8936-08d97467420d" xlink:href="bmrn-20220331.xsd#bmrn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerThreeMember_d51c9623-67c9-45a6-8936-08d97467420d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CustomerFourMember_c23b1060-c76d-4740-9ab0-32ca86c99172" xlink:href="bmrn-20220331.xsd#bmrn_CustomerFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CustomerOneTwoThreeAndFourMember_924ee394-e7b2-4585-927a-5eb710338f57" xlink:to="loc_bmrn_CustomerFourMember_c23b1060-c76d-4740-9ab0-32ca86c99172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_50138378-e4c8-47e8-b525-212b0d961e43" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_61a53c8a-6997-4c2b-bb91-3f5cd9a38cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d02de30c-94a6-4424-aefe-458cc3ece294" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_61a53c8a-6997-4c2b-bb91-3f5cd9a38cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bmrn-20220331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0c90175-3d73-485d-9054-1594f2c45084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_98e44862-f47a-4dd3-bf0c-289c3be3f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0c90175-3d73-485d-9054-1594f2c45084" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_98e44862-f47a-4dd3-bf0c-289c3be3f8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b246d7d-eaa1-42cd-9e0a-69be8541bcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_91954984-fe8e-4686-8a76-1f2eb2213b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b246d7d-eaa1-42cd-9e0a-69be8541bcaa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_91954984-fe8e-4686-8a76-1f2eb2213b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#StockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d01aecf0-a1b6-4b8f-8416-6221acc53f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d01aecf0-a1b6-4b8f-8416-6221acc53f08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49d69e57-60fc-4247-8406-f83958ed73e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6ab3c36b-0f69-4127-9e01-f06a9e709944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_CostOfSalesMember_6ab3c36b-0f69-4127-9e01-f06a9e709944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b48e8f5a-adaf-4422-82d1-434a96317abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b48e8f5a-adaf-4422-82d1-434a96317abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3bce1b7d-b7f3-40e5-8a91-7903089a322c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a3998cf4-e0ab-4d93-a9e2-207be563d0cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3bce1b7d-b7f3-40e5-8a91-7903089a322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b0de61-733b-4a84-902f-9d24c5a726b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b46f045e-47ad-4639-afe6-deffe6f058b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1db82961-c238-4a4b-8c51-c7b766793415" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b46f045e-47ad-4639-afe6-deffe6f058b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd1e7ccb-df18-49a6-a672-ed13d398ef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_71ec6bb1-e448-456c-b451-4922002fc27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd1e7ccb-df18-49a6-a672-ed13d398ef4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_71ec6bb1-e448-456c-b451-4922002fc27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NETINCOMEPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_29e9cd65-9fec-490a-b2b4-a9c4e9435d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7b131381-9401-43d7-b0da-7fe867409f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29e9cd65-9fec-490a-b2b4-a9c4e9435d4f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7b131381-9401-43d7-b0da-7fe867409f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NETINCOMEPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8f6b8848-bdeb-41f1-8309-9f0e94090100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_289f825f-e740-496e-9c07-c3cdfa25ff8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f6b8848-bdeb-41f1-8309-9f0e94090100" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_289f825f-e740-496e-9c07-c3cdfa25ff8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d2df68c2-8018-4db0-ac30-c4da4e0faf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f6b8848-bdeb-41f1-8309-9f0e94090100" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d2df68c2-8018-4db0-ac30-c4da4e0faf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NetIncomePerCommonShareScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd85cbb2-ce4d-49a7-95a7-53a6184bf17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd85cbb2-ce4d-49a7-95a7-53a6184bf17c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1f687d9-9a86-4ea7-9d2d-86fee48760d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cf7e72ef-a82d-4096-9a3a-5b51fba90474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cf7e72ef-a82d-4096-9a3a-5b51fba90474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_1a74bef6-f7ac-4d60-be22-c99fb7e54d8c" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_1a74bef6-f7ac-4d60-be22-c99fb7e54d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_836d5ff4-8f16-4b0e-b0e0-e94461f69871" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_836d5ff4-8f16-4b0e-b0e0-e94461f69871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c46c9fd7-219f-4f98-ae54-f70f631d03d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_RestrictedStockMember_c46c9fd7-219f-4f98-ae54-f70f631d03d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_2337f57f-abd8-4e89-ad6a-5347faadffba" xlink:href="bmrn-20220331.xsd#bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_2337f57f-abd8-4e89-ad6a-5347faadffba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_10dd2f7f-55d8-4fb0-98ab-dcdec210263d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7eaf370d-021f-444c-bf6b-e4ad344df7d9" xlink:to="loc_us-gaap_StockCompensationPlanMember_10dd2f7f-55d8-4fb0-98ab-dcdec210263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_797e6b18-f135-4e14-b7cb-de2422c3dab5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7db7249e-81e6-408c-af4c-58b1acc19405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7db7249e-81e6-408c-af4c-58b1acc19405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_03c42154-7fb0-4383-832f-014f32f590fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_03c42154-7fb0-4383-832f-014f32f590fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da38d5c9-19c6-4a3b-b543-072064e8140d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38cbe327-14be-443d-934d-7b589262da60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da38d5c9-19c6-4a3b-b543-072064e8140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53440ba2-10cb-4365-af69-b1e5d522760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5d4953a1-1da3-462e-a4c1-7a83b6a9321c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53440ba2-10cb-4365-af69-b1e5d522760c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7f074c07-0cb9-41d3-9692-098645ca137a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a514a0a-b1d9-4b79-aaa9-470e9d221562" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7f074c07-0cb9-41d3-9692-098645ca137a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e7e4363-bffa-4e6b-9132-f62210b68b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e7e4363-bffa-4e6b-9132-f62210b68b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0fb57654-2641-4273-893c-c81df40e047a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_EarningsPerShareBasic_0fb57654-2641-4273-893c-c81df40e047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c36b0b1b-e915-4ce7-a95e-3f8439d4dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aed14bfc-3493-47ba-8cee-afe8d23276e5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c36b0b1b-e915-4ce7-a95e-3f8439d4dd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a6d5c6f1-2fb0-4271-aa2f-f895d75032aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a6d5c6f1-2fb0-4271-aa2f-f895d75032aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73383280-8b33-499f-959d-d80fb30f23e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df628dd6-0cfd-415b-b122-d1d62ff4a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df628dd6-0cfd-415b-b122-d1d62ff4a58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_d8f09fbd-ae7f-445c-bb72-7c8ffd7a99d2" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember_d8f09fbd-ae7f-445c-bb72-7c8ffd7a99d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_9dab9e39-f450-42a0-a430-790a1cf288e0" xlink:href="bmrn-20220331.xsd#bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember_9dab9e39-f450-42a0-a430-790a1cf288e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_692af1a8-eb20-4f9e-9864-645d2e39906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_us-gaap_RestrictedStockMember_692af1a8-eb20-4f9e-9864-645d2e39906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_9a72fd1c-2197-480c-bfd3-2e119ac7aebc" xlink:href="bmrn-20220331.xsd#bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_591cd540-3ea5-4436-a8c6-c988d10109df" xlink:to="loc_bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember_9a72fd1c-2197-480c-bfd3-2e119ac7aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fdb372-1f16-4848-bba3-f83acef4f842" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e92546a-7cde-489f-aea5-76c0514646d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df54d2f8-49b6-45a7-9399-7f69ca88bf10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e92546a-7cde-489f-aea5-76c0514646d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bmrn-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5b55d95-8c18-44cb-927c-8a22f0a571cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ee95534-3c73-4096-8b09-aa0bcd09d88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5b55d95-8c18-44cb-927c-8a22f0a571cc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ee95534-3c73-4096-8b09-aa0bcd09d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="bmrn-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e497652d-b248-4e61-8e7f-98afaff35582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e497652d-b248-4e61-8e7f-98afaff35582" xlink:to="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10f245b5-5d88-4e47-a1bc-b924ffb23298" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_EarlyStageDevelopmentProgramMember_8d145877-1c2e-43c7-8304-536c9eba84ba" xlink:href="bmrn-20220331.xsd#bmrn_EarlyStageDevelopmentProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_416fbe07-fa41-424f-ad70-257521ccbc9e" xlink:to="loc_bmrn_EarlyStageDevelopmentProgramMember_8d145877-1c2e-43c7-8304-536c9eba84ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1508c9de-3225-447d-b48b-c3f80ebb9c42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ThirdPartyMember_7d7f9dbb-a72e-441b-b5e6-1d063b84e576" xlink:href="bmrn-20220331.xsd#bmrn_ThirdPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3b430c7f-5662-4907-92c8-6dbbc7322468" xlink:to="loc_bmrn_ThirdPartyMember_7d7f9dbb-a72e-441b-b5e6-1d063b84e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:href="bmrn-20220331.xsd#bmrn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesTable_7105d123-1185-44a8-bef7-6ab2273732b5" xlink:to="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_5cfb39ed-cc15-4b56-8955-771093394dc8" xlink:href="bmrn-20220331.xsd#bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:to="loc_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones_5cfb39ed-cc15-4b56-8955-771093394dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b90e61ef-3ff0-4cc3-9cfc-afa302160bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bmrn_CommitmentsAndContingenciesLineItems_92f3ff41-f94f-4d9a-8a7d-27a81fa610a7" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b90e61ef-3ff0-4cc3-9cfc-afa302160bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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MHX>5F+J57"NQ$.1&RZSV>.3DZ[1W<W:7C1RLBK'%UQ'0IR!7&Q.Z6C5'AJ$
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2>?HKH;=?     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979032584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioMarin Pharmaceutical Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 Lindaro Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Rafael<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-6700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,995,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979308056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 605,440<span></span>
</td>
<td class="nump">$ 587,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">450,798<span></span>
</td>
<td class="nump">426,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">430,147<span></span>
</td>
<td class="nump">373,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">786,356<span></span>
</td>
<td class="nump">776,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">121,283<span></span>
</td>
<td class="nump">110,442<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,394,024<span></span>
</td>
<td class="nump">2,274,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">462,827<span></span>
</td>
<td class="nump">507,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,039,544<span></span>
</td>
<td class="nump">1,035,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">374,251<span></span>
</td>
<td class="nump">388,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">196,199<span></span>
</td>
<td class="nump">196,199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,446,676<span></span>
</td>
<td class="nump">1,449,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">149,186<span></span>
</td>
<td class="nump">151,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,062,707<span></span>
</td>
<td class="nump">6,003,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">426,418<span></span>
</td>
<td class="nump">491,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">48,232<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">490,418<span></span>
</td>
<td class="nump">539,822<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long-term convertible debt, net</a></td>
<td class="nump">1,080,061<span></span>
</td>
<td class="nump">1,079,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">100,913<span></span>
</td>
<td class="nump">98,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,671,392<span></span>
</td>
<td class="nump">1,732,585<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 500,000,000 shares authorized; 184,901,764 and 183,912,514 shares issued and outstanding, respectively</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">5,206,287<span></span>
</td>
<td class="nump">5,191,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockIssuedEmployeeStockTrust', window );">Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)</a></td>
<td class="num">(9,389)<span></span>
</td>
<td class="num">(9,689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(877)<span></span>
</td>
<td class="nump">14,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(804,891)<span></span>
</td>
<td class="num">(925,689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,391,315<span></span>
</td>
<td class="nump">4,270,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 6,062,707<span></span>
</td>
<td class="nump">$ 6,003,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockIssuedEmployeeStockTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123585891&amp;loc=d3e19833-108362<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockIssuedEmployeeStockTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984526424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">184,901,764<span></span>
</td>
<td class="nump">183,912,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">184,901,764<span></span>
</td>
<td class="nump">183,912,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984138904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 519,359<span></span>
</td>
<td class="nump">$ 486,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">116,965<span></span>
</td>
<td class="nump">120,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">160,836<span></span>
</td>
<td class="nump">148,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">194,619<span></span>
</td>
<td class="nump">174,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_IntangibleAssetAmortizationAndContingentConsideration', window );">Intangible asset amortization and contingent consideration</a></td>
<td class="nump">17,612<span></span>
</td>
<td class="nump">17,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="num">(108,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">382,032<span></span>
</td>
<td class="nump">460,944<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME FROM OPERATIONS</a></td>
<td class="nump">137,327<span></span>
</td>
<td class="nump">25,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,806)<span></span>
</td>
<td class="num">(3,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME BEFORE INCOME TAXES</a></td>
<td class="nump">134,187<span></span>
</td>
<td class="nump">23,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">13,389<span></span>
</td>
<td class="nump">5,857<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME</a></td>
<td class="nump">$ 120,798<span></span>
</td>
<td class="nump">$ 17,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">NET INCOME PER SHARE, BASIC (in dollars per share)</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">NET INCOME PER SHARE, DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">183,990<span></span>
</td>
<td class="nump">181,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">194,886<span></span>
</td>
<td class="nump">184,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE INCOME</a></td>
<td class="nump">$ 105,489<span></span>
</td>
<td class="nump">$ 38,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">505,525<span></span>
</td>
<td class="nump">467,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember', window );">Royalty and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,834<span></span>
</td>
<td class="nump">$ 18,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_IntangibleAssetAmortizationAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_IntangibleAssetAmortizationAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980289768">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Company Stock Held By NQDC</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,106,002<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 4,993,407<span></span>
</td>
<td class="num">$ (9,839)<span></span>
</td>
<td class="num">$ (16,139)<span></span>
</td>
<td class="num">$ (861,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency', window );">Issuances under equity incentive plans, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="num">(29,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan', window );">Common stock held by the NQDC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,371<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,371<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,162,010<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">5,010,619<span></span>
</td>
<td class="num">(9,558)<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
<td class="num">(844,238)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">183,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares', window );">Issuances under equity incentive plans (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">184,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,270,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">5,191,502<span></span>
</td>
<td class="num">(9,689)<span></span>
</td>
<td class="nump">14,432<span></span>
</td>
<td class="num">(925,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency', window );">Issuances under equity incentive plans, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="num">(33,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan', window );">Common stock held by the NQDC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,798<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,391,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 5,206,287<span></span>
</td>
<td class="num">$ (9,389)<span></span>
</td>
<td class="num">$ (877)<span></span>
</td>
<td class="num">$ (804,891)<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues net excess tax benefit tax deficiency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues net excess tax benefit tax deficiency, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980287912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 120,798<span></span>
</td>
<td class="nump">$ 17,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27,343<span></span>
</td>
<td class="nump">27,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investments</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">47,833<span></span>
</td>
<td class="nump">49,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="num">(108,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="num">(6,887)<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">700<span></span>
</td>
<td class="num">(871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(54,813)<span></span>
</td>
<td class="nump">40,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="num">(6,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(8,011)<span></span>
</td>
<td class="nump">42,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(78,143)<span></span>
</td>
<td class="num">(72,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(45,431)<span></span>
</td>
<td class="nump">113,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(28,817)<span></span>
</td>
<td class="num">(25,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="nump">155,818<span></span>
</td>
<td class="nump">194,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(147,361)<span></span>
</td>
<td class="num">(237,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ProceedsFromSaleOfNonfinancialAssets', window );">Proceeds from sale of nonfinancial assets</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(1,858)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">87,782<span></span>
</td>
<td class="num">(70,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercises of awards under equity incentive plans</a></td>
<td class="nump">8,235<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(32,949)<span></span>
</td>
<td class="num">(29,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal repayments of financing leases</a></td>
<td class="num">(566)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(25,280)<span></span>
</td>
<td class="num">(24,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">18,164<span></span>
</td>
<td class="nump">18,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">587,276<span></span>
</td>
<td class="nump">649,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">605,440<span></span>
</td>
<td class="nump">667,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets', window );">Decrease in accounts payable and accrued liabilities related to fixed assets</a></td>
<td class="num">(2,481)<span></span>
</td>
<td class="num">(12,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets', window );">Increase (decrease) in accounts payable and accrued liabilities related to intangible assets</a></td>
<td class="num">$ (637)<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ProceedsFromSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Nonfinancial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ProceedsFromSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281981961912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#8217;s portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2022 or any other period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022, as compared to the significant accounting policies disclosed in Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three months ended March&#160;31, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of significance or potential significance to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281981954904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities were classified as available-for-sale at March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,077,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,531,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,320)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,519,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1">one</span></span> and five years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#8217;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div>The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#8217;s strategic investments was $16.5 million. These investments were recorded in Other Assets in the Company&#8217;s Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984199656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</a></td>
<td class="text">SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Balance Sheet Information </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,110&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,356&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,669&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory as of March&#160;31, 2022, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $11.3 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the first quarter of 2022, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec by the European Medicines Agency had been significantly reduced and the Company expects to realize economic benefit in the future. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings and correspondence with the relevant regulatory authorities following the submission of the additional two-year follow-up safety and efficacy data requested by the regulatory agencies in the third quarter of 2020, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, and commercialization and marketplace trends.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#8217;s policies on inventory produced prior to regulatory approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,780,711&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(741,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense, net of amounts capitalized into inventory, for the three months ended March&#160;31, 2022 and March&#160;31, 2021 was $11.7 million and $12.5 million, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible Assets, Net consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(304,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Statement of Comprehensive Income Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on Sale of Nonfinancial Assets, Net in the first quarter of 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the FDA in connection with the U.S. approval of Voxzogo. As a result of the PRV sale, the Company recognized a $108.0&#160;million net gain on sale of nonfinancial assets in the Company's Consolidated Statement of Comprehensive Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982115496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Business Overview and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021.&#160;Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note 6 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The restricted investments at March&#160;31, 2022 and December&#160;31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the three months ended March&#160;31, 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982023048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</a></td>
<td class="text">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange forward contracts (forward contracts) to protect against the reduction in value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to one year, nine months. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to three months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#8217;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company expects to reclassify unrealized gains of $7.6 million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982160456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#8217;s convertible debt:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,080,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,101,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The fair value of the Company&#8217;s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s convertible debt consisted of the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 10 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#8217;s convertible debt.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0&#160;million which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of March&#160;31, 2022, there were no amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982096232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,225)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,309)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,264)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,945)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For additional discussion of reclassifications from AOCI see Note 5 &#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Derivative Instruments and Hedging Strategies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982031176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationAbstract', window );"><strong>Concentration Risk And Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock', window );">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</a></td>
<td class="text">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates total Net Product Revenues by product.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#8217;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#8217;s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.026%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middle East</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for 21% and 14% of the Company&#8217;s March&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021, when two customers accounted for 28% and 16% of the accounts receivable balance, respectively. As of March&#160;31, 2022, and December&#160;31, 2021, the accounts receivable balance for Sanofi included $61.4 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#8217; financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the three months ended March&#160;31, 2022 and 2021, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and the Company anticipates a continued impact due to COVID-19 on its financial results in 2022. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment could affect the Company&#8217;s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company&#8217;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and geographic information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and segment reporting disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982162488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. Compensation expense included in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:&#160;</span></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $5.2 million and $4.4 million was capitalized into inventory for the three months ended March&#160;31, 2022 and 2021, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281981952376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER COMMON SHARE</a></td>
<td class="text">NET INCOME PER COMMON SHARE<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#8217;s Employee Share Purchase Plan (ESPP), unvested RSUs, the Company&#8217;s common stock held by the NQDC and contingent issuances of common stock related to the Company&#8217;s convertible debt.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):</span></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on convertible notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company&#8217;s common stock held by the NQDC</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands):</span></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982020360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#8217;s general </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company was subject to contingent payments considered reasonably possible of $788.5 million, including $389.0 million related to an early stage development program licensed from a third party in the fourth quarter of 2021 and $225.0 million related to an early stage development program licensed from a third party in the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;D activities. These amounts are included as R&amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services, production services and facility construction services. As of March&#160;31, 2022, such commitments were estimated at approximately $117.5 million, all of which were short-term. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982985672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2022 or any other period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company&#8217;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three months ended March&#160;31, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of significance or potential significance to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982116616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,077,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,531,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,320)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,519,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Company&#8217;s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1">one</span></span> and five years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281983425400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,110&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,356&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,669&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment Net</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, Plant and Equipment, Net consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,780,711&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(741,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(720,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible Assets, Net consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(304,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency exchange forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982029032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021.&#160;Other than the Company&#8217;s fixed-rate convertible debt disclosed in Note 6 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of March&#160;31, 2022 or December&#160;31, 2021.</span><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The restricted investments at March&#160;31, 2022 and December&#160;31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs</a></td>
<td class="text">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in the fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281983069080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Summary of Derivatives Designated as Hedging Instruments Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company&#8217;s derivatives outstanding as of the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value Carrying Amount of Derivatives</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company&#8217;s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.976%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts&#160;payable&#160;and accrued&#160;liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982047672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Convertible Debt</a></td>
<td class="text">The following table summarizes information regarding the Company&#8217;s convertible debt:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount net of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,080,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,079,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed-rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed-rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,101,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The fair value of the Company&#8217;s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Overview and Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense on Debt</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company&#8217;s convertible debt consisted of the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984233128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,225)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,309)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,264)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,139)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>&#160;&#160;&#160;&#160; reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,945)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982984328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationAbstract', window );"><strong>Concentration Risk And Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Net Product Revenues by Product</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates total Net Product Revenues by product.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voxzogo</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty and other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Total Net Product Revenues Based on Patient Location</a></td>
<td class="text">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.026%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middle East</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Sanofi</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Net Product Revenue Concentrations Attributed to Largest Customers</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company&#8217;s total Net Product Revenues attributed to the Company&#8217;s largest customers for the periods presented.&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and geographic information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281982145048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">Compensation expense included in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984201080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):</span></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest expense, net of tax, on convertible notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company&#8217;s common stock held by the NQDC</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per common share, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands):</span></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281975254728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,531,139<span></span>
</td>
<td class="nump">$ 1,523,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12,320)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">1,519,065<span></span>
</td>
<td class="nump">1,521,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">605,440<span></span>
</td>
<td class="nump">587,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">450,798<span></span>
</td>
<td class="nump">426,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">462,827<span></span>
</td>
<td class="nump">507,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">441,957<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">441,957<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">441,957<span></span>
</td>
<td class="nump">301,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,089,182<span></span>
</td>
<td class="nump">1,222,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12,320)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">1,077,108<span></span>
</td>
<td class="nump">1,220,491<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">163,483<span></span>
</td>
<td class="nump">286,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">450,798<span></span>
</td>
<td class="nump">426,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">462,827<span></span>
</td>
<td class="nump">507,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">160,485<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">160,485<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">160,485<span></span>
</td>
<td class="nump">285,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">585,315<span></span>
</td>
<td class="nump">584,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9,815)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">575,562<span></span>
</td>
<td class="nump">582,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">240,777<span></span>
</td>
<td class="nump">200,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">334,785<span></span>
</td>
<td class="nump">381,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">237,962<span></span>
</td>
<td class="nump">224,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,059)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">235,950<span></span>
</td>
<td class="nump">224,631<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">155,716<span></span>
</td>
<td class="nump">146,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">80,234<span></span>
</td>
<td class="nump">78,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,518<span></span>
</td>
<td class="nump">68,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">50,508<span></span>
</td>
<td class="nump">68,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">47,510<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">51,822<span></span>
</td>
<td class="nump">56,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(414)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">51,409<span></span>
</td>
<td class="nump">56,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">9,451<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">47,624<span></span>
</td>
<td class="nump">47,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Foreign and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term Marketable Securities</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Marketable Securities</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod', window );">Long term marketable securities maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ShortTermMarketableSecuritiesMaturityPeriod', window );">Short term marketable securities maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod', window );">Long term marketable securities maturity period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_LongTermMarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_LongTermMarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ShortTermMarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term marketable securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ShortTermMarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281983049912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember', window );">Strategic Investment | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Strategic investments fair value</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984145480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Statements Information - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 92,110<span></span>
</td>
<td class="nump">$ 80,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">402,319<span></span>
</td>
<td class="nump">415,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">291,927<span></span>
</td>
<td class="nump">281,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 786,356<span></span>
</td>
<td class="nump">$ 776,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980562904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Statements Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 786,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 776,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense, net of amounts capitalized into inventory</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of nonfinancial assets, net</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=bmrn_ValoctocogeneRoxaparvovecMember', window );">Valoctocogene Roxaparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=bmrn_ValoctocogeneRoxaparvovecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=bmrn_ValoctocogeneRoxaparvovecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281983403160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,780,711<span></span>
</td>
<td class="nump">$ 1,756,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(741,167)<span></span>
</td>
<td class="num">(720,574)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,039,544<span></span>
</td>
<td class="nump">$ 1,035,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979018680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Statements Information - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 678,601<span></span>
</td>
<td class="nump">$ 677,350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(304,350)<span></span>
</td>
<td class="num">(288,698)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net carrying value</a></td>
<td class="nump">$ 374,251<span></span>
</td>
<td class="nump">$ 388,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980429416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued operating expenses</a></td>
<td class="nump">$ 187,810<span></span>
</td>
<td class="nump">$ 193,003<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">127,938<span></span>
</td>
<td class="nump">204,446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_AccruedGovernmentAndOtherRebates', window );">Accrued rebates payable</a></td>
<td class="nump">56,295<span></span>
</td>
<td class="nump">47,987<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties payable</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">15,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Foreign currency exchange forward contracts</a></td>
<td class="nump">12,716<span></span>
</td>
<td class="nump">6,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OperatingAndFinanceLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">10,829<span></span>
</td>
<td class="nump">10,464<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Value added taxes payable</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued income taxes</a></td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other</a></td>
<td class="nump">6,055<span></span>
</td>
<td class="nump">4,108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 426,418<span></span>
</td>
<td class="nump">$ 491,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281978283960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted&#160;Price&#160;in Active Markets For Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Financial assets remeasured</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liabilities remeasured</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">24,900,000<span></span>
</td>
<td class="nump">26,869,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">27,759,000<span></span>
</td>
<td class="nump">28,912,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">66,859,000<span></span>
</td>
<td class="nump">50,275,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,096,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">89,246,000<span></span>
</td>
<td class="nump">89,371,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">22,387,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">64,000,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">24,900,000<span></span>
</td>
<td class="nump">26,869,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">27,759,000<span></span>
</td>
<td class="nump">28,912,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">25,246,000<span></span>
</td>
<td class="nump">25,972,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2) | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">22,387,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable Inputs (Level 2) | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">64,000,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities, Total</a></td>
<td class="nump">64,000,000<span></span>
</td>
<td class="nump">63,399,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3) | NQDC Plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3) | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure', window );">Fair value of other current liabilities</a></td>
<td class="nump">64,000,000<span></span>
</td>
<td class="nump">48,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure', window );">Fair value of other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">22,387,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">22,387,000<span></span>
</td>
<td class="nump">23,929,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsCurrentFairValueDisclosure', window );">Fair value of other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">2,513,000<span></span>
</td>
<td class="nump">2,940,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments | Significant&#160;Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">2,513,000<span></span>
</td>
<td class="nump">2,940,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure', window );">Fair value of other non-current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets current fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherAssetsNoncurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets noncurrent fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherAssetsNoncurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherLiabilitiesCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other liabilities current fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherLiabilitiesCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other liabilities noncurrent fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_NonqualifiedDeferredCompensationPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_NonqualifiedDeferredCompensationPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bmrn_RestrictedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bmrn_RestrictedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984243864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) - Contingent Payment<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration as of December 31, 2020</a></td>
<td class="nump">$ 63,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in the fair value of contingent consideration</a></td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement', window );">Foreign exchange remeasurement of Euro denominated contingent consideration</a></td>
<td class="num">(1,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration as of September 30, 2021</a></td>
<td class="nump">$ 64,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bmrn_ContingentPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281983271400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Strategies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions</a></td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated As Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity of derivatives</a></td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity of derivatives</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980411752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail) - Forward Foreign Exchange Contracts - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated As Hedging Instruments | Sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 650,302<span></span>
</td>
<td class="nump">$ 740,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated As Hedging Instruments | Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">147,206<span></span>
</td>
<td class="nump">183,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">98,800<span></span>
</td>
<td class="nump">113,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 3,565<span></span>
</td>
<td class="nump">$ 31,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_ShortMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_ShortMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_LongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_LongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979058792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="nump">$ 22,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Derivatives Designated As Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">24,502<span></span>
</td>
<td class="nump">22,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">15,654<span></span>
</td>
<td class="nump">6,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Derivatives Designated As Hedging Instruments | Other&#160;current&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">20,763<span></span>
</td>
<td class="nump">17,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Derivatives Designated As Hedging Instruments | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Derivatives Designated As Hedging Instruments | Accounts&#160;payable&#160;and accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Derivatives Designated As Hedging Instruments | Other&#160;long-term&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Not Designated as Hedging Instrument | Other&#160;current&#160;assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Not Designated as Hedging Instrument | Accounts&#160;payable&#160;and accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281978721784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 519,359<span></span>
</td>
<td class="nump">$ 486,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">382,032<span></span>
</td>
<td class="nump">460,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gains (Losses) Recognized in Earnings</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expenses as reported | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</a></td>
<td class="num">(1,379)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">505,525<span></span>
</td>
<td class="nump">467,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Cash Flow Hedging Gains (Losses) Reclassified into Earnings</a></td>
<td class="nump">$ 5,572<span></span>
</td>
<td class="num">$ (2,757)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980531336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value of equity component</a></td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember', window );">The 2018 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980272552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Convertible Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">1,080,061<span></span>
</td>
<td class="nump">$ 1,079,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt, net</a></td>
<td class="nump">1,080,061<span></span>
</td>
<td class="nump">1,079,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 1,101,981<span></span>
</td>
<td class="nump">$ 1,146,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member', window );">1.25% Senior Subordinated Convertible Notes Due in May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes stated rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount net of deferred offering costs</a></td>
<td class="num">(10,465)<span></span>
</td>
<td class="num">(10,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">589,535<span></span>
</td>
<td class="nump">589,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 604,758<span></span>
</td>
<td class="nump">$ 625,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember', window );">0.599% Senior Subordinated Convertible Notes Due in August 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes stated rate</a></td>
<td class="nump">0.599%<span></span>
</td>
<td class="nump">0.599%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes</a></td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount net of deferred offering costs</a></td>
<td class="num">(4,474)<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes, net of unamortized discount and deferred offering costs</a></td>
<td class="nump">490,526<span></span>
</td>
<td class="nump">490,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Total fair value of fixed-rate convertible debt</a></td>
<td class="nump">$ 497,223<span></span>
</td>
<td class="nump">$ 521,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980566168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Summary of Interest Expense on Convertible Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfInterestExpensesLineItems', window );"><strong>Schedule Of Interest Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense on convertible debt</a></td>
<td class="nump">$ 3,806<span></span>
</td>
<td class="nump">$ 3,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ScheduleOfInterestExpensesLineItems', window );"><strong>Schedule Of Interest Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest expense</a></td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of discount on convertible notes</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense on convertible debt</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ScheduleOfInterestExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of interest expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ScheduleOfInterestExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980309896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 4,270,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,106,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before &#160;&#160;&#160;&#160; reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,499)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,383<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current-period other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,391,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,162,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before &#160;&#160;&#160;&#160; reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,225)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current-period other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,418)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Available for-Sale Debt Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before &#160;&#160;&#160;&#160; reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,274)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Less: gain (loss) reclassified from AOCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,383<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current-period other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,891)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,264)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI attributable to parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">14,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (877)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,004<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281978254264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating business segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 430,147<span></span>
</td>
<td class="nump">$ 373,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bmrn_CustomersMember', window );">Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 61,400<span></span>
</td>
<td class="nump">$ 67,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems', window );"><strong>Concentration Risk And Geographic Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ConcentrationRiskAndGeographicInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk and geographic information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ConcentrationRiskAndGeographicInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979353592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 519,359<span></span>
</td>
<td class="nump">$ 486,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">505,525<span></span>
</td>
<td class="nump">467,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductFourMember', window );">Vimizim | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">183,059<span></span>
</td>
<td class="nump">158,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductTwoMember', window );">Naglazyme | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">128,031<span></span>
</td>
<td class="nump">107,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductThreeMember', window );">Kuvan | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">59,337<span></span>
</td>
<td class="nump">70,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductSevenMember', window );">Palynziq | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">54,885<span></span>
</td>
<td class="nump">54,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductSixMember', window );">Brineura | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">36,173<span></span>
</td>
<td class="nump">27,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductEightMember', window );">Voxzogo | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">19,658<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember', window );">Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Marketed by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">481,143<span></span>
</td>
<td class="nump">417,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember', window );">Aldurazyme | Marketed by Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">24,382<span></span>
</td>
<td class="nump">50,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember', window );">Royalty and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 13,834<span></span>
</td>
<td class="nump">$ 18,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281975079144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 519,359<span></span>
</td>
<td class="nump">$ 486,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">505,525<span></span>
</td>
<td class="nump">467,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">481,143<span></span>
</td>
<td class="nump">417,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">156,832<span></span>
</td>
<td class="nump">148,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">150,815<span></span>
</td>
<td class="nump">155,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Middle East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">65,607<span></span>
</td>
<td class="nump">15,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">62,544<span></span>
</td>
<td class="nump">59,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">45,345<span></span>
</td>
<td class="nump">38,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember', window );">Marketed by Sanofi | Aldurazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 24,382<span></span>
</td>
<td class="nump">$ 50,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductsExcludingProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmrn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmrn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bmrn_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bmrn_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980244072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) - Customer Concentration Risk - Net Product Revenue<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A, B, C, &amp; D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneTwoThreeAndFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneTwoThreeAndFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bmrn_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bmrn_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281975036200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 47,833<span></span>
</td>
<td class="nump">$ 49,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">6,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">17,190<span></span>
</td>
<td class="nump">17,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 26,317<span></span>
</td>
<td class="nump">$ 25,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281984223032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense capitalized to inventory</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281975228232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Common Share - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income, basic</a></td>
<td class="nump">$ 120,798<span></span>
</td>
<td class="nump">$ 17,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: Interest expense, net of tax, on convertible notes</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net Income, diluted</a></td>
<td class="nump">$ 123,561<span></span>
</td>
<td class="nump">$ 17,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">183,990<span></span>
</td>
<td class="nump">181,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">194,886<span></span>
</td>
<td class="nump">184,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per common share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per common share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember', window );">Common stock issuable under the 2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">4,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember', window );">Common stock issuable under the 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember', window );">Common stock potentially issuable for ESPP purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">The Company&#8217;s common stock held by the NQDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281979423512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">10,927<span></span>
</td>
<td class="nump">18,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">6,206<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember', window );">Common stock issuable under the 2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember', window );">Common stock issuable under the 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember', window );">Common stock potentially issuable for ESPP purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of potentially issuable shares (in shares)</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140281980622616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones', window );">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</a></td>
<td class="nump">$ 788.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments and other minimum contractual obligations</a></td>
<td class="nump">$ 117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember', window );">Early Stage Development Program | Third Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones', window );">Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389.0<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>bmrn-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bmrn="http://www.bmrn.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20220331.xsd" xlink:type="simple"/>
    <context id="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibaa05a7fa135456a8fe312c91de5e0ee_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i5017a08d58224e19b728357a77f28248_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63654500f0694941a974905d3087a5ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9964555943664f0cb773a445f771d126_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if87ec807037b48a1827df1aaa0055934_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:RoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if973bfa7c942477d8a27516ba36f112e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1c36f51afd949d2922a9403458ff14e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88e39e6909554b2fb8708ff366791343_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3672150712a44391a3ca9ba235561a68_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib209ba21e10b4555b66a335b31afd83c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4b01dbbc2904243b9407a39a5cd814d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idabde523660c4e0bb4175d419336ec3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i36be7b3ebd4244dd822037d737ee85c5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id953c96ff17c4c53bb75b4fa1aed178e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic83218bf734f4322a2d42769d9866f47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b7832f66eca4ae3aadf7917fe918857_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f86851fcae34ae2a4d65e7a6c993a18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7be8e4176b874e8ebabfd30bfa5f25d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8922e4d2b913460fbd96bbc32f58fb8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2ce4e8fcc10349509bc910ed5fc7d1f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i17e50effa4c044d1a1f56b02b147b183_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65140d9974ff4879ad2575de4f85ba00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c04fe803925410fb3dc8389bd8d71b8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ae5076ed26c4e069af93432359b1543_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e7db0e866934747a0ef27975afd832f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3649606ceb74fcf8df8cc4b91928646_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3dc492906fa645578549b49d3cf4ce75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i837ed5d736814a3bbeb99f71701e965d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie11e992c2c33410da4c7f9aa950bb1c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id48ead339f954703bef2ad6408f75e1d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7810dda9d65495381e007327ae9c35c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i003577bf2fb84683baafc0afbded1f79_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9bebefd2f4b14a17ad7eff862468738f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f0fe85c7e614d609da901db5e3fa4de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if8037f34da784a8da052f3d100568fdc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i475042e9abf7443a90e179783dd443f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iad4fc146174c44dfac7293154917c0cd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i43f4e3af7d5541438a52d3a255447f9a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16b20b1e79404e219e16bb43665c85f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19740758cf5742bd95d6aa74d07388eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06655e4513d7439fb94059adafe0bba4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9adf0006647246c1a686f4e093f0039b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i376acb983838406dafef8389effeae4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib088395ca9b54cd5ab2856cb12431e57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadebcf821247497ba93eafb227624346_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie54c42f5d5ad4f02b10f1329b8e06482_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id952376c72fe492898bd2bb8f3c2ba18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fd980138ba04ea4aa0bf850eba714f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ca8e30ed951424daed017118d432eef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:StrategicInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9569970b087c446aaf59bf7e94224bd2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">bmrn:ValoctocogeneRoxaparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i11cc1a5725ab4723b0462ef1a3028473_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67c5cd0a2b524859bbb3035e15216170_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ice4c0ea303bc4617bff30b97f3119d8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idac071ae2357499a807f15a7c6d7c22d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibea9395534ba42e3a0190935fdfbb79d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id06e40f8e2ee4cf4a3d50677fc6227a2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie67fb8408fad4a14a69938859aaf1ffe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie5bd403d599a4cae83b4124e73e69e92_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7a5305ac356c4dae82b317efba8e3eed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1af36fbb7aca467c8d91640910e44cbf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifeee18ee6d494c7790cf41fe0038c831_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id262761c1fad424b90e86b74ae146097_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie98efc0e12da4354a0d424854f64af5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic1a1cedc9eed4bfab32ee8743471c711_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia462eb49aaaf40e997e1a56cd4ffe090_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i478e66d57d4645caa9b700a5fd1ef8eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4cd46ba90ab490ab24b52d5a3097a86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7475279edad54e10a67e1ba4a06c239c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9059f91d0ea641c8a3ca5f6af90239be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:NonqualifiedDeferredCompensationPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e1bbedcd77d4d4e9132645838dec1f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86b2a564c9924e1593e108f04e0e05fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d27016ee9414a53ac394d4ec7659333_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bmrn:RestrictedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a2b5c574e4b4548be514c50e602f6fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i018f94a349524435963ac9c426ebd9da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea8e222c468d40d181487297a7c0cbd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f6783e8d375468bb371c65e2e9858b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id40b5097a4704fd29443d8189ff20cfc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e3c8c6419414c7397306df2567d9a10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e3e175895dd4eddaf85bea4d5710175_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id8702f41faa34d58a58f591cc29c5186_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bmrn:ContingentPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i24a67b5f17b74d8d875e70d77ac24e0a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fb2fa6470f64208b9cca9caed841242_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i10323adbf43747cc8e67c4d6d61a7601_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2d9103e14e34a25a637947fb0294c86_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ied746eb100554a6386b2c27894ffc0e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i693b3a7b97e1437ebca5874be75ea456_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia82a5008ad32467abe48f8d161ab8af8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73022b6d871f47e28feede850e27c229_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16e5ec0991924f7c96ecf3ccf3bb217f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a0d508ddf7e40db989b324877ca4949_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic28b615c8a794db39d946b9acae01f69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27917553b8fd4dfbac5fe095c7b4bde6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic06dfaccfdbe46caac6458766a03b73f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf7f9f8463ea496caae776a4ddbd016b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i021baed86234498eaefce274645b825b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd9174aac2384a699993569e2b6eb445_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i84f2f900f6b144a0975d6dc3d49144ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5618c6fb44d74a64909673a57923b8ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3985bd1ab09f4ea0bbe878344b3713b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1adb2627443a447f8c92c839abeda3a7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i482d5788d5874458a97a7e25c5406e22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i125b9e8420b44a9498f4af3776f779da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d039887887e460290fb9430275f52d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5119ab19f704add84d831075c4fe20f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0b30d6f7853643148004a14e6c5d0fdb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c517e48e00e4becb6f7ce5b1310c741_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf3fbdd624724d3d85d457df11a2b0ec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6aa52acc498d4cdab18b97d9c59c01b9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id59ded9cd6c34aa1968e85dc2a793158_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0331cf243884e099d67f815a061dcd2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9d1bc8295d14eccb284c5835c6f2c82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a61fb3318b44b2ba23a29e3998e0700_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="id8cf35d33be44d27a7f0d3b047d0f271_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e3059cd10734ed783cd2d2634b0d82b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99b1717d96134283ae50ccf10e9f13ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2c3fc76077b46a996c89411439fc65e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d46d1b4201e4019aa70b698c03d7415_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3f51f53032a84b1b89b05ca56aa74445_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i840b2f2e120540f98c612afa3ec823f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b4c4bfebe294de7b1a98930ea9835b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id01504b7547d48c29809551d9fa94665_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic74a170ac59147cca285f25489fe3660_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddc468e5fd8a42e2b1558768f37e6571_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56ef15ea138648cca1e80f4d3e259dc9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica5c489de8f841848c2154b45041d920_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i491df707a2b5489fb420d6bc1f228e19_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i89eb3a13235f4740a02e03ada4aacecf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie708c87270e9415c898a4aeae0af25bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i895d2189edd943fdadd1d2c44e8fa735_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id4d78c3903b24697b01c59cc20ff5358_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20640d60dab64a039c473a7175a0a267_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i594041ae57af40ccab0c62019799787e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b892fdeb6e14ef287c0f6a538ac8c13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib1103deb96054b26b048779411774904_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b9f090883124d2198ad6215aa997c28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0ff03d00b5648269908ec5e62655bb4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id742c4f384be442b8fca74da0bbbaa4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f4557550c4f422393773b243642092c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib8f201c2b5d348ee8cef94eeee757986_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9306ad4c27064a6b9826f59953cafc24_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a14de3abadb40778471e66184af280a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74ff7532c1ae49528158820bb4da4aea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iecad8ebdb8c244bd98a2afd89bba0a2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cdbd316d31b4d1cab319df9d84f7f77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bmrn:ProductsExcludingProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmrn:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23782facb41e4a0394006d0c61111460_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21c33100f90b40bca71ded15376adfcb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5e5f24d472d4e82b55a8346cd4fc93b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fdf37db79194886b085e0309823a025_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1bf584b76688449d949ae03ea7a23992_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4f6c8323762a4a68a579e56d15514782_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ief8a05482b8a475f87dfd720c5c6b2f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21f73aa86157436b89f7042549ab2cdf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoThreeAndFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6e84ec89b6c4d8ea066d35c5ace7603_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneTwoThreeAndFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4519e269765428dbc66faaaa2646940_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb6f40e5c0bf4422a0a81cb722132751_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5407662ac25040bf8b124d95a9d5af58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5da3b672cc79498eb14a326a63d8c950_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4d5c38e0f09439dbdf86382f3b59459_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae90bf0fe46c464d9eb1ead18b979c57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bmrn:CustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19465b1578ec4dd28c910af817bceab3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03cdf675716d437c964339c1910bdbdc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f0fd632f5fd41e287a0b11cae9cbeca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i008d8298bf11412ba45a7ea365cc12cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b0087b7e6ba4593890bb5c30ab38817_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4910a2e24b7045899f96c49194daa7f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie33737b08299431889d37d12a1d70178_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85312ddaf862450190f331615f114ab7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i530302b04890455682f0ab0adc4d162e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib721cab6f4a2424680bcabdd246154df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id99beaf0bac24ae7a8e8559e31363de0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i275d3e6c3fa2449e9f081a92e87e1c21_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bad4330064641499986ec8dd304acef_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bmrn:ThirdPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bmrn:EarlyStageDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>bmrn:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV8yLTEtMS0xLTQ1NDQx_4525c2fa-2830-4bd5-a9a5-c131707d1925">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV8zLTEtMS0xLTQ1NDQx_a5339ace-1181-41d1-b636-4c74b5c289bc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV80LTEtMS0xLTQ1NDQx_764558ad-a65c-4eb9-b026-fdebc1177d95">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV81LTEtMS0xLTQ1NDQx_79f2cdf9-1f8d-43b6-b13a-fbf434761ea7">0001048477</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83L2ZyYWc6MjRkMGEyNjVjY2M1NGRhNDhmYWU3OGQxOWQxZGZkNjUvdGFibGU6YjQ0MDQ3MmE2MjU5NGRjZWIzMzEwY2VmZTk5ZTE1NDkvdGFibGVyYW5nZTpiNDQwNDcyYTYyNTk0ZGNlYjMzMTBjZWZlOTllMTU0OV82LTEtMS0xLTQ1NDQx_df993a8f-9130-4e85-afc4-49e4b1dd913d">--12-31</dei:CurrentFiscalYearEndDate>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="ie54c42f5d5ad4f02b10f1329b8e06482_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525">P1Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="id952376c72fe492898bd2bb8f3c2ba18_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1">P1Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <dei:DocumentType
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMjU_49568a7d-995a-468d-9beb-700fb7202f3a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6OWVjNzk1MGNmMGZiNGM1MGI0NjliOTk5ZDJjYWVhZTAvdGFibGVyYW5nZTo5ZWM3OTUwY2YwZmI0YzUwYjQ2OWI5OTlkMmNhZWFlMF8wLTAtMS0xLTQ1NDQx_6e35cafc-1c64-4293-8323-cbe006549a00">true</dei:DocumentQuarterlyReport>
    <dei:DocumentQuarterlyReport
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6OWVjNzk1MGNmMGZiNGM1MGI0NjliOTk5ZDJjYWVhZTAvdGFibGVyYW5nZTo5ZWM3OTUwY2YwZmI0YzUwYjQ2OWI5OTlkMmNhZWFlMF8wLTAtMS0xLTQ1NDQx_f9cb8620-bdfe-4232-8acb-549a82123cc3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yMTE_deaca2d5-a9ef-4f74-bd3b-2ed3c208f1ef">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YzQzNTM2NDQyMjNkNDEyZjhkODJjOTM2NWI5ZmMxNmIvdGFibGVyYW5nZTpjNDM1MzY0NDIyM2Q0MTJmOGQ4MmM5MzY1YjlmYzE2Yl8wLTAtMS0xLTQ1NDQx_2112a309-fa83-4b92-b473-6c2086c19a2a">false</dei:DocumentTransitionReport>
    <dei:DocumentTransitionReport
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YzQzNTM2NDQyMjNkNDEyZjhkODJjOTM2NWI5ZmMxNmIvdGFibGVyYW5nZTpjNDM1MzY0NDIyM2Q0MTJmOGQ4MmM5MzY1YjlmYzE2Yl8wLTAtMS0xLTQ1NDQx_d1437d1f-15b0-4573-bd1a-48d9f97bee08">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8zMjE_ee62d3dc-f1d3-474e-8aeb-4e291485a84b">000-26727</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8zNjU_81d80d55-a67c-4f15-9797-b2804ea5185b">BioMarin Pharmaceutical Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTAtMS0xLTQ1NDQx_5e00c763-875f-44e6-8fe6-0597b04ed1a7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTAtMS0xLTQ1NDQx_71a6dc3f-d688-4597-8249-65241935e5e6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTMtMS0xLTQ1NDQx_1eec61c3-9da2-4d0b-bc9f-5ffc48fe958b">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8wLTMtMS0xLTQ1NDQx_5adaf7dd-348c-4b31-890c-17b64a0eef51">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTAtMS0xLTQ1NDQx_53bbf259-ccaf-4381-ba9a-56ab07502274">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTAtMS0xLTQ1NDQx_ca27083b-5acd-4d34-b7a5-34a95cba12df">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTEtMS0xLTQ1NDQx_29b0c8cd-6f86-4d22-a28b-93d9ca51c7a7">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTEtMS0xLTQ1NDQx_c651cf8c-409c-42da-a2f6-6c5fd5f7bfb2">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTItMS0xLTQ1NDQx_31ffc0f2-0918-49c3-b83b-3c3060d04bfb">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTItMS0xLTQ1NDQx_aa58eae4-ef9a-4c42-9835-3f7bb7d17b05">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTMtMS0xLTQ1NDQx_89546f9e-3aec-4a29-acb5-a8c967c7e901">94901</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6ZWU3MzI3ZGRjZjNjNDY0Nzk5MTQ1ODNmMzUxOWE0MWYvdGFibGVyYW5nZTplZTczMjdkZGNmM2M0NjQ3OTkxNDU4M2YzNTE5YTQxZl8zLTMtMS0xLTQ1NDQx_ccb6d38a-13d4-4838-b005-0ad453234c56">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV80Njk_d8095216-72f6-48ea-8b02-42515f76432b">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV80NzM_ee8dcf15-66ec-428a-b1cb-2c3cdcbbaf5d">506-6700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTAtMS0xLTQ1NDQx_b7b684ad-dd19-4da6-a51c-903ac47b037a">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTAtMS0xLTQ1NDQx_bfb011f9-e22a-4e62-8e14-623fa1a7d68e">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTItMS0xLTQ1NDQx_44dff287-0a28-4db4-801c-bf6d4af6387e">BMRN</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTItMS0xLTQ1NDQx_eab252d4-a669-4a06-a055-2e2def4e946f">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTQtMS0xLTQ1NDQx_2e438fe7-6ba1-4da5-8cb7-724f2e801e81">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6MTUzMzZhNGQwNGI0NGEzMjkxYmEyMDI2ZjYzNWEwODkvdGFibGVyYW5nZToxNTMzNmE0ZDA0YjQ0YTMyOTFiYTIwMjZmNjM1YTA4OV8xLTQtMS0xLTQ1NDQx_b7c7d84e-c4aa-4fdc-ac4a-7e74bb4c463e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMDE5_1d9160cd-5700-442d-8d6b-c3e11c2c6395">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8xMzQ3_9b30b03c-5c37-4097-88e5-400b9c0659f4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8wLTAtMS0xLTQ1NDQx_1e8800a8-7157-45d7-896a-1b74e6e14304">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8yLTYtMS0xLTQ1NDQx_b0589e76-82a4-4edb-a65c-92c0c90a38c1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGFibGU6YmJkNzM1ZDY1ZWI5NGE2NWE1NDk2NTk0ZDg3ZTRjODUvdGFibGVyYW5nZTpiYmQ3MzVkNjVlYjk0YTY1YTU0OTY1OTRkODdlNGM4NV8zLTItMS0xLTQ1NDQx_beeb09ac-a324-489f-903e-408217ee8239">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yMDg3_dfbb5022-6e24-4865-8040-1d2840afd2ff">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibaa05a7fa135456a8fe312c91de5e0ee_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xL2ZyYWc6Njk2MDg3YWNhOTVmNDkzZGIyZGVjYzEzYmY2NjU4ODkvdGV4dHJlZ2lvbjo2OTYwODdhY2E5NWY0OTNkYjJkZWNjMTNiZjY2NTg4OV8yNzQ4Nzc5MDcxODg5_3fe5ddf6-481a-4bcb-82cb-c4098cc95826"
      unitRef="shares">184995348</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0xLTEtMS00NTQ0MQ_c6756d2a-10f9-4bdb-a8d9-73def0774916"
      unitRef="usd">605440000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a"
      unitRef="usd">587276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0xLTEtMS00NTQ0MQ_8da3b357-18ee-4f4c-92cd-47b26706a7b6"
      unitRef="usd">450798000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0xLTEtMS00NTQ0MQ_60885410-639c-42da-a5fc-6a169ced1f35"
      unitRef="usd">430147000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e"
      unitRef="usd">373399000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0xLTEtMS00NTQ0MQ_08f0705e-0096-4da0-a210-f9eb90df692d"
      unitRef="usd">786356000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1"
      unitRef="usd">776669000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0xLTEtMS00NTQ0MQ_e94d98be-711a-4a4d-9773-2befda3c8015"
      unitRef="usd">121283000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018"
      unitRef="usd">110442000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0xLTEtMS00NTQ0MQ_b88c7bbf-b47c-4d68-b295-6c65f7c502ad"
      unitRef="usd">2394024000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87"
      unitRef="usd">2274385000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMS0xLTEtNDU0NDE_0ce2b0f0-d422-43df-9f9e-19dc4e66041b"
      unitRef="usd">462827000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMS0xLTEtNDU0NDE_c7435ce6-b859-4204-a473-89df7ecee70f"
      unitRef="usd">1039544000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21"
      unitRef="usd">1035461000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMS0xLTEtNDU0NDE_d5592dc1-26cf-4c7b-887d-3cfbf2c0617c"
      unitRef="usd">374251000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603"
      unitRef="usd">388652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMS0xLTEtNDU0NDE_634ceccb-754b-4475-b916-84931ff8311f"
      unitRef="usd">196199000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6"
      unitRef="usd">196199000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMS0xLTEtNDU0NDE_f584c110-2d57-48eb-a4da-e2abec956d67"
      unitRef="usd">1446676000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65"
      unitRef="usd">1449075000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMS0xLTEtNDU0NDE_9d9945fa-e013-4349-a657-1228b36dd4f4"
      unitRef="usd">149186000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f"
      unitRef="usd">151760000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMS0xLTEtNDU0NDE_0e94a408-aa06-4bfc-8e9a-ed85c9ffcaca"
      unitRef="usd">6062707000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a"
      unitRef="usd">6003325000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMS0xLTEtNDU0NDE_eba05f30-6ec4-44fd-b8b4-429c420b3292"
      unitRef="usd">426418000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6"
      unitRef="usd">491590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMS0xLTEtNDU0NDE_dee859ff-58a1-4d59-bc74-362cc070b755"
      unitRef="usd">64000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b"
      unitRef="usd">48232000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMS0xLTEtNDU0NDE_e408e6e2-02d4-4885-ba73-5a9793dcb7f1"
      unitRef="usd">490418000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8"
      unitRef="usd">539822000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMS0xLTEtNDU0NDE_0031927e-6fb3-4179-8797-1b5edf20fd0e"
      unitRef="usd">1080061000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5"
      unitRef="usd">1079077000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMS0xLTEtNDU0NDE_c92ec190-7f53-4f98-b22a-1e92534752bc"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a"
      unitRef="usd">15167000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMS0xLTEtNDU0NDE_e1e79e06-8b00-4f26-aaf5-f57509511d20"
      unitRef="usd">100913000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101"
      unitRef="usd">98519000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMS0xLTEtNDU0NDE_3632270c-e871-424b-81a8-30c6acdf1a58"
      unitRef="usd">1671392000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a"
      unitRef="usd">1732585000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8xOA_a33fd101-fbf4-476f-852f-11d99544ac33"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8xOA_ce8fa225-5885-4ac4-b1a3-8a53fe8771c4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8zMg_34c74f2d-ac46-4411-9a99-f3d0a62f7e50"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl8zMg_d2a99c68-746f-412c-a5fd-a96e260e9cc8"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl81NA_765c49f3-23ca-44c0-a4f8-c6f158e7c25c"
      unitRef="shares">184901764</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl81NA_a4a6b11b-5fb1-49bf-8783-1d90a981f29f"
      unitRef="shares">184901764</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl82MQ_667081be-534e-491e-9538-8675f6619513"
      unitRef="shares">183912514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMC0xLTEtNDU0NDEvdGV4dHJlZ2lvbjpkNDZjNWE2Mjk1ZGQ0OThhYjE3YmRkNTc5Njk2NTNjMl82MQ_e6c6ea5e-f4df-4de8-9c73-148739385561"
      unitRef="shares">183912514</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMS0xLTEtNDU0NDE_c6db3604-0528-4880-a1e7-12ef2c81d9e4"
      unitRef="usd">185000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33"
      unitRef="usd">184000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMS0xLTEtNDU0NDE_a71aa71a-5873-4ed3-bf5a-d5e48a85c0ac"
      unitRef="usd">5206287000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7"
      unitRef="usd">5191502000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockIssuedEmployeeStockTrust
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMS0xLTEtNDU0NDE_2dd5b88b-74a3-4fcd-91e3-1a2c8df83bc6"
      unitRef="usd">9389000</us-gaap:CommonStockIssuedEmployeeStockTrust>
    <us-gaap:CommonStockIssuedEmployeeStockTrust
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5"
      unitRef="usd">9689000</us-gaap:CommonStockIssuedEmployeeStockTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMS0xLTEtNDU0NDE_eaaf5c7f-bfff-4fe9-8473-e48bc10268fd"
      unitRef="usd">-877000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1"
      unitRef="usd">14432000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMS0xLTEtNDU0NDE_229b1f9a-372b-4128-87c6-c7d12e690e53"
      unitRef="usd">-804891000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe"
      unitRef="usd">-925689000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMS0xLTEtNDU0NDE_78018010-b69b-4080-8e69-513d64305457"
      unitRef="usd">4391315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11"
      unitRef="usd">4270740000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMS0xLTEtNDU0NDE_1714fb0f-af1e-4414-9183-d729161c212a"
      unitRef="usd">6062707000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756"
      unitRef="usd">6003325000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMy01LTEtMS00NTQ0MQ_54b39845-1aed-4dd0-bd76-d63baddf7f8f"
      unitRef="usd">505525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMy03LTEtMS00NTQ0MQ_9f382898-ee37-4c3a-b8f2-231fed618a3a"
      unitRef="usd">467769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if87ec807037b48a1827df1aaa0055934_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNC01LTEtMS00NTQ0MQ_31641286-64b0-46df-8e1e-dd5aa815d48f"
      unitRef="usd">13834000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNC03LTEtMS00NTQ0MQ_6b1769e4-98fb-42a5-bc1b-28311f686f53"
      unitRef="usd">18261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNS01LTEtMS00NTQ0MQ_4266404b-defe-46aa-a3da-659e90055e63"
      unitRef="usd">519359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNS03LTEtMS00NTQ0MQ_b655aecb-0b26-4ba6-816d-5c228e1285e3"
      unitRef="usd">486030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNy01LTEtMS00NTQ0MQ_bd19bc6c-e3f4-44b1-a5de-f20e118a9c4f"
      unitRef="usd">116965000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfNy03LTEtMS00NTQ0MQ_cb88a9f1-d1d0-472b-ba5d-8b8106430566"
      unitRef="usd">120166000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOC01LTEtMS00NTQ0MQ_a6e835a5-2792-41a8-89aa-be84eae6460e"
      unitRef="usd">160836000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOC03LTEtMS00NTQ0MQ_efd1dbfb-8a32-4d2d-b594-72fc5428bd78"
      unitRef="usd">148725000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOS01LTEtMS00NTQ0MQ_8b889101-e803-4139-b425-1244800e26a8"
      unitRef="usd">194619000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfOS03LTEtMS00NTQ0MQ_fc3242f2-9e34-4e45-b330-ffec136d9011"
      unitRef="usd">174318000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bmrn:IntangibleAssetAmortizationAndContingentConsideration
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTAtNS0xLTEtNDU0NDE_f53f7d2b-09f0-477a-8d20-466ae8d4ff24"
      unitRef="usd">17612000</bmrn:IntangibleAssetAmortizationAndContingentConsideration>
    <bmrn:IntangibleAssetAmortizationAndContingentConsideration
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTAtNy0xLTEtNDU0NDE_e3bf69c5-69f4-4404-9a8a-18fd2ee71e3c"
      unitRef="usd">17735000</bmrn:IntangibleAssetAmortizationAndContingentConsideration>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTEtNS0xLTEtNDU0NDE_90cdd34b-7f8e-43e2-aa50-03ad343ab47b"
      unitRef="usd">108000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTEtNy0xLTEtNDU0NDE_8fd8ec5a-7e73-44ce-9a15-d656ff750258"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:CostsAndExpenses
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTItNS0xLTEtNDU0NDE_ebfe8f82-9f26-4168-b790-5d4b3f12a626"
      unitRef="usd">382032000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTItNy0xLTEtNDU0NDE_192eed73-94cc-4188-ae31-cb2198a8f5dc"
      unitRef="usd">460944000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTMtNS0xLTEtNDU0NDE_33c3e09b-b9c4-433d-95ba-f6ef588f81b7"
      unitRef="usd">137327000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTMtNy0xLTEtNDU0NDE_64e9f2fb-7e1c-436c-8559-33cb8673e7e5"
      unitRef="usd">25086000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTYtNS0xLTEtNDU0NDE_b07e8d3f-f8b9-481b-a479-4b928e05aa94"
      unitRef="usd">1820000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTYtNy0xLTEtNDU0NDE_7e39da3f-176a-4d87-b114-5fae4e9b113b"
      unitRef="usd">2439000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTctNS0xLTEtNDU0NDE_1bff763e-ec6c-4011-b4a0-fc18380c44e8"
      unitRef="usd">3806000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTctNy0xLTEtNDU0NDE_b060b941-9646-47fe-ab74-ff7a91ab098a"
      unitRef="usd">3804000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTgtNS0xLTEtNDU0NDE_ec7ceb16-98ed-41d8-9b0d-df1edddfefa4"
      unitRef="usd">-1154000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTgtNy0xLTEtNDU0NDE_ab673383-5484-4541-a0be-b56e86fc6c1f"
      unitRef="usd">-493000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTktNS0xLTEtNDU0NDE_4bcea9c7-4a72-42d7-841f-d7395d80f886"
      unitRef="usd">134187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMTktNy0xLTEtNDU0NDE_a9f06b16-62f0-4389-bd9d-a9d690bed7d6"
      unitRef="usd">23228000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjAtNS0xLTEtNDU0NDE_e0a653b5-aae4-46bd-bfce-37be3c86c3d8"
      unitRef="usd">13389000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjAtNy0xLTEtNDU0NDE_bc2831c4-735d-4f53-a121-304e5fbda370"
      unitRef="usd">5857000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjEtNS0xLTEtNDU0NDE_08e62fc9-1967-44cc-a49c-6d50f35b5b1a"
      unitRef="usd">120798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjEtNy0xLTEtNDU0NDE_82be69fa-c26d-4db2-bad4-96231e388b98"
      unitRef="usd">17371000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjItNS0xLTEtNDU0NDE_155f3ccb-8a01-4adb-b555-892bb39ac45a"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjItNy0xLTEtNDU0NDE_26879a00-78c7-4fb5-ad87-bb459747a302"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjMtNS0xLTEtNDU0NDE_43f70aec-a3b5-41ae-8ad7-2a6d210dedf2"
      unitRef="usdPerShare">0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjMtNy0xLTEtNDU0NDE_7dd5b9d1-7dbe-4af4-9a9c-fc1c84bb7bb8"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjQtNS0xLTEtNDU0NDE_3570fd3d-f94d-4b09-b1d4-08b27cff00f3"
      unitRef="shares">183990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjQtNy0xLTEtNDU0NDE_78ad95bc-24ab-44f6-86ca-19a2cfe0545d"
      unitRef="shares">181772000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjUtNS0xLTEtNDU0NDE_738ca209-9530-4c6e-bea0-9e3d35028d44"
      unitRef="shares">194886000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjUtNy0xLTEtNDU0NDE_2e566349-2d5f-4da3-ac55-8c57040fefd9"
      unitRef="shares">184365000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjctNS0xLTEtNDU0NDE_499c1dc1-f808-4278-8a9b-bcf64e0b87d4"
      unitRef="usd">105489000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yMi9mcmFnOjIyZDNjYmQzMzNhMjQxN2JhOGI4MjZjMTFkMzAxY2E1L3RhYmxlOmI5ZjViNzhmYTRjNTQzNGM5NGM5YmIzNTRmZGQ0MGFmL3RhYmxlcmFuZ2U6YjlmNWI3OGZhNGM1NDM0Yzk0YzliYjM1NGZkZDQwYWZfMjctNy0xLTEtNDU0NDE_c92d6738-07e6-4b90-8c06-e88eb7f7dd7f"
      unitRef="usd">38514000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="if973bfa7c942477d8a27516ba36f112e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711"
      unitRef="shares">183913000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="if1c36f51afd949d2922a9403458ff14e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3"
      unitRef="shares">181741000</us-gaap:SharesOutstanding>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares
      contextRef="i88e39e6909554b2fb8708ff366791343_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNC01LTEtMS00NTQ0MQ_35a7c3c4-6ed3-4df8-b367-fc147c239a6f"
      unitRef="shares">989000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares
      contextRef="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNC03LTEtMS00NTQ0MQ_9f0a6d3b-38b5-4314-9123-c89d3e4b370d"
      unitRef="shares">930000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares>
    <us-gaap:SharesOutstanding
      contextRef="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNi01LTEtMS00NTQ0MQ_435f6ce3-e4ce-4267-b432-30930a1b35be"
      unitRef="shares">184902000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i3672150712a44391a3ca9ba235561a68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfNi03LTEtMS00NTQ0MQ_a858f21c-88ae-4624-b8f3-9f2cf25ffebc"
      unitRef="shares">182671000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66"
      unitRef="usd">4270740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib209ba21e10b4555b66a335b31afd83c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c"
      unitRef="usd">4106002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if973bfa7c942477d8a27516ba36f112e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62"
      unitRef="usd">184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1c36f51afd949d2922a9403458ff14e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda"
      unitRef="usd">182000</us-gaap:StockholdersEquity>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i88e39e6909554b2fb8708ff366791343_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTEtNS0xLTEtNDU0NDE_2f744a65-8198-41d2-a940-a2c579b87d11"
      unitRef="usd">1000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i9d4f41ec28bc4610ab18e7033a10f841_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTEtNy0xLTEtNDU0NDE_cf44c91e-8458-4611-bf06-d44a94b47652"
      unitRef="usd">1000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <us-gaap:StockholdersEquity
      contextRef="iaa7e2c4ac2064228ae818bc0a03a211f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTItNS0xLTEtNDU0NDE_70d32c0c-94ad-4da2-abd6-5271bcdf8bd0"
      unitRef="usd">185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3672150712a44391a3ca9ba235561a68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTItNy0xLTEtNDU0NDE_b96905e4-1d8d-463d-b30a-b38995b1b0f6"
      unitRef="usd">183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4b01dbbc2904243b9407a39a5cd814d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682"
      unitRef="usd">5191502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idabde523660c4e0bb4175d419336ec3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe"
      unitRef="usd">4993407000</us-gaap:StockholdersEquity>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTUtNS0xLTEtNDU0NDE_873791d3-f2c7-4117-a279-b47afda7d186"
      unitRef="usd">-33633000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
      contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTUtNy0xLTEtNDU0NDE_6ddcc1da-496c-4b1d-8a69-e390e93d5c3c"
      unitRef="usd">-29916000</bmrn:StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTYtNS0xLTEtNDU0NDE_3027673f-dd26-4bf2-81f8-3cc9e922ea67"
      unitRef="usd">48718000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTYtNy0xLTEtNDU0NDE_e83e0f6c-af68-4380-ab9d-c88fbc3c6510"
      unitRef="usd">47409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i12f678c63ab04cc5a30c15a4884c45ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTgtNS0xLTEtNDU0NDE_41674897-1e07-4e38-a020-127e0cee2956"
      unitRef="usd">300000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i1b8505a9684f48389d6e661b829ea049_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTgtNy0xLTEtNDU0NDE_3a724ab5-f03c-476c-bf4f-180467e07045"
      unitRef="usd">281000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <us-gaap:StockholdersEquity
      contextRef="i36be7b3ebd4244dd822037d737ee85c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTktNS0xLTEtNDU0NDE_4b226f13-2a5e-436b-ac72-49febcc95957"
      unitRef="usd">5206287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id953c96ff17c4c53bb75b4fa1aed178e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTktNy0xLTEtNDU0NDE_4a4190ca-ef87-419f-984f-84520f254011"
      unitRef="usd">5010619000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic83218bf734f4322a2d42769d9866f47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62"
      unitRef="usd">-9689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b7832f66eca4ae3aadf7917fe918857_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50"
      unitRef="usd">-9839000</us-gaap:StockholdersEquity>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i2f86851fcae34ae2a4d65e7a6c993a18_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjctNS0xLTEtNDU0NDE_ba1a4dee-8c8c-4014-95e5-791b62fcbaff"
      unitRef="usd">-300000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan
      contextRef="i7be8e4176b874e8ebabfd30bfa5f25d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjctNy0xLTEtNDU0NDE_6f27233e-1f22-4351-8f3b-44103b351a7a"
      unitRef="usd">-281000</bmrn:AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan>
    <us-gaap:StockholdersEquity
      contextRef="i8922e4d2b913460fbd96bbc32f58fb8a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjgtNS0xLTEtNDU0NDE_9c2c6b74-0169-44c9-8484-ea32dd36c166"
      unitRef="usd">-9389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ce4e8fcc10349509bc910ed5fc7d1f0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjgtNy0xLTEtNDU0NDE_2815d10a-3528-466e-bade-fe7abb32ade8"
      unitRef="usd">-9558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17e50effa4c044d1a1f56b02b147b183_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127"
      unitRef="usd">14432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65140d9974ff4879ad2575de4f85ba00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623"
      unitRef="usd">-16139000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3c04fe803925410fb3dc8389bd8d71b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzItNS0xLTEtNDU0NDE_344dff68-86d4-442e-ac6e-dbcfe200cd12"
      unitRef="usd">-15309000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ae5076ed26c4e069af93432359b1543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzItNy0xLTEtNDU0NDE_e91443af-ee64-4c3e-be7b-52a5c2515dd8"
      unitRef="usd">21143000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i4e7db0e866934747a0ef27975afd832f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzMtNS0xLTEtNDU0NDE_0f1ee247-db08-4e0c-a377-c98178e6fbcf"
      unitRef="usd">-877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3649606ceb74fcf8df8cc4b91928646_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzMtNy0xLTEtNDU0NDE_cdf24450-3470-427b-aedf-f52125b68bb1"
      unitRef="usd">5004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dc492906fa645578549b49d3cf4ce75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b"
      unitRef="usd">-925689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i837ed5d736814a3bbeb99f71701e965d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac"
      unitRef="usd">-861609000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie11e992c2c33410da4c7f9aa950bb1c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzctNS0xLTEtNDU0NDE_c2e88b57-d4aa-4cca-9aff-a7456408df17"
      unitRef="usd">120798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id48ead339f954703bef2ad6408f75e1d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzctNy0xLTEtNDU0NDE_07d5cbae-801b-42e9-a7a5-a63765e60fba"
      unitRef="usd">17371000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="ia7810dda9d65495381e007327ae9c35c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzgtNS0xLTEtNDU0NDE_4d480ab9-ddd9-4d15-8671-80f37d6312d6"
      unitRef="usd">-804891000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i003577bf2fb84683baafc0afbded1f79_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzgtNy0xLTEtNDU0NDE_f70cea95-2a8c-441f-a6d4-22ea5cc0b8c3"
      unitRef="usd">-844238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzktNS0xLTEtNDU0NDE_06e15b13-004b-492c-8555-6b91c01a9281"
      unitRef="usd">4391315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzktNy0xLTEtNDU0NDE_a6c9cbea-9378-4dfd-92f9-8e92d2d4f964"
      unitRef="usd">4162010000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMy0xLTEtMS00NTQ0MQ_18167e18-d36d-4ca6-aed1-da0b3b83dab4"
      unitRef="usd">120798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMy0zLTEtMS00NTQ0MQ_b963076f-b3de-4ffb-873e-c113a06cc60a"
      unitRef="usd">17371000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNS0xLTEtMS00NTQ0MQ_18fab828-f851-43c6-96d1-70ffae3bafdd"
      unitRef="usd">27343000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNS0zLTEtMS00NTQ0MQ_06950263-9a9a-4a3e-8852-2bfdae24cd0a"
      unitRef="usd">27983000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNi0xLTEtMS00NTQ0MQ_2d39bde4-c2e1-47a5-a3b9-553f3a358eed"
      unitRef="usd">1033000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNi0zLTEtMS00NTQ0MQ_64b832cc-0cfc-491e-8fd9-674bcf91c976"
      unitRef="usd">1043000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNy0xLTEtMS00NTQ0MQ_26b0e016-49cf-4a8d-ae66-bb1633c160c4"
      unitRef="usd">-1652000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNy0zLTEtMS00NTQ0MQ_ac785c81-8ef0-4723-8686-6b08d7b721f7"
      unitRef="usd">-673000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOC0xLTEtMS00NTQ0MQ_ee93df28-4599-43f0-bdd8-68884fc1ae8c"
      unitRef="usd">47833000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOC0zLTEtMS00NTQ0MQ_820f75ac-7393-4be4-b37c-455277089490"
      unitRef="usd">49503000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOS0xLTEtMS00NTQ0MQ_b033bbe7-c4b1-4686-b2dc-13eac48ea131"
      unitRef="usd">108000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfOS0zLTEtMS00NTQ0MQ_ed45f6df-57a8-4fe0-8597-8b53d530ddb1"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTEtMS0xLTEtNDU0NDE_c45e26d8-6518-4c88-add3-85dc911c91cd"
      unitRef="usd">4800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTEtMy0xLTEtNDU0NDE_f181fc1d-cdaa-4670-85be-7f8545d9ce53"
      unitRef="usd">3335000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTItMS0xLTEtNDU0NDE_2ab6881f-4b7a-416e-841e-bd735919596b"
      unitRef="usd">6887000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTItMy0xLTEtNDU0NDE_aca6eba2-97e2-41a6-9312-34ae977925c2"
      unitRef="usd">-3950000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTMtMS0xLTEtNDU0NDE_e28bfffe-98e0-46a5-8570-fd830ee926db"
      unitRef="usd">1989000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTMtMy0xLTEtNDU0NDE_d2b6e664-a87a-4681-99da-b96d0904240d"
      unitRef="usd">2255000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTQtMS0xLTEtNDU0NDE_f9b6abc9-d334-4e80-9c28-fbe5136b72bf"
      unitRef="usd">-700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTQtMy0xLTEtNDU0NDE_3c0f6d62-4661-4fda-8bf7-39fbb0669d75"
      unitRef="usd">871000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTYtMS0xLTEtNDU0NDE_9437f756-9c42-4756-8526-9527dab8213b"
      unitRef="usd">54813000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTYtMy0xLTEtNDU0NDE_c86a82c9-5bcb-45b7-bcdb-97721bb75f93"
      unitRef="usd">-40294000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTctMS0xLTEtNDU0NDE_351f422c-b77c-492e-97ca-be922d01b563"
      unitRef="usd">-1125000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTctMy0xLTEtNDU0NDE_d0729c57-a1b5-4e96-9d61-14eca9a4610a"
      unitRef="usd">6425000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTgtMS0xLTEtNDU0NDE_58ef50f2-2d26-4da7-beb9-53baef863851"
      unitRef="usd">8011000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTgtMy0xLTEtNDU0NDE_13c0dbee-8a7c-471f-93c0-669fc573b73f"
      unitRef="usd">-42784000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTktMS0xLTEtNDU0NDE_d1a6dc75-4821-4178-b13c-b57e711f0063"
      unitRef="usd">-1440000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMTktMy0xLTEtNDU0NDE_5edea341-080d-47b8-9b73-aeb208cf4dbb"
      unitRef="usd">-1617000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjAtMS0xLTEtNDU0NDE_1bcf071a-12b4-4d26-b676-5fa7390ac358"
      unitRef="usd">-78143000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjAtMy0xLTEtNDU0NDE_48172d51-6e29-444b-9fca-55b400a89d2f"
      unitRef="usd">-72304000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjEtMS0xLTEtNDU0NDE_90c038fd-6db1-4da0-8940-5a7b087ec645"
      unitRef="usd">1710000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjEtMy0xLTEtNDU0NDE_0ca035e1-3368-49a0-a907-2da51cfc86fe"
      unitRef="usd">2304000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjItMS0xLTEtNDU0NDE_9e3ecc96-e759-48da-8ff6-79c82c2491c8"
      unitRef="usd">-45431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjItMy0xLTEtNDU0NDE_3256de5d-bb39-4c2c-bb18-42b2a4321ba7"
      unitRef="usd">113512000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjQtMS0xLTEtNDU0NDE_be371b14-bf09-4b8e-a317-f9860fbff7a0"
      unitRef="usd">28817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjQtMy0xLTEtNDU0NDE_18b1845c-4851-4604-9f0d-a98973019841"
      unitRef="usd">25507000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjUtMS0xLTEtNDU0NDE_98c4a1d2-351c-4d05-8bda-b100d99f9e86"
      unitRef="usd">155818000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjUtMy0xLTEtNDU0NDE_d4f26021-d01a-4efb-a2e6-4b18cbb285d3"
      unitRef="usd">194637000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjYtMS0xLTEtNDU0NDE_299a983f-751c-4993-8674-128156c07083"
      unitRef="usd">147361000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjYtMy0xLTEtNDU0NDE_f2484cfb-1eb1-4939-9edd-40c2904b8d32"
      unitRef="usd">237171000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <bmrn:ProceedsFromSaleOfNonfinancialAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjctMS0xLTEtNDU0NDE_38b9ac9d-ff37-49ab-91b6-55df800c0b20"
      unitRef="usd">110000000</bmrn:ProceedsFromSaleOfNonfinancialAssets>
    <bmrn:ProceedsFromSaleOfNonfinancialAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjctMy0xLTEtNDU0NDE_c75be8b5-a0a9-4387-8112-9a756f120582"
      unitRef="usd">0</bmrn:ProceedsFromSaleOfNonfinancialAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjgtMS0xLTEtNDU0NDE_10ae6fad-1788-41c9-8598-242413134bef"
      unitRef="usd">1858000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMjgtMy0xLTEtNDU0NDE_f846e825-12dc-4e8b-b16d-e44914ad4dc7"
      unitRef="usd">2747000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzEtMS0xLTEtNDU0NDE_7f4d54f0-42b2-41db-a608-04d93bbbacf5"
      unitRef="usd">87782000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzEtMy0xLTEtNDU0NDE_bd2e6009-deb8-48d2-8fb3-199f41a130bf"
      unitRef="usd">-70788000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzMtMS0xLTEtNDU0NDE_44f9c2cd-452c-490f-8c02-d03c5c191f1b"
      unitRef="usd">8235000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzMtMy0xLTEtNDU0NDE_ffcf03f6-f6af-4d0f-8a42-fe929bd9bd9a"
      unitRef="usd">5817000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzQtMS0xLTEtNDU0NDE_e11193c9-a679-489f-9d96-9ecf7a7e383f"
      unitRef="usd">32949000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzQtMy0xLTEtNDU0NDE_cdbc5f3d-3a6c-44b8-a8fa-20c59c9743e7"
      unitRef="usd">29097000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzktMS0xLTEtNDU0NDE_8aac57f5-44d3-48f1-89a7-7f43bb560050"
      unitRef="usd">566000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfMzktMy0xLTEtNDU0NDE_5b5475ad-f515-4469-a1ad-a9e6757f129b"
      unitRef="usd">1084000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDEtMS0xLTEtNDU0NDE_49c59555-654a-4bad-a7ab-4c920d3c8c20"
      unitRef="usd">-25280000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDEtMy0xLTEtNDU0NDE_fac0deaf-8216-4160-8e39-3d0e2ce18a63"
      unitRef="usd">-24364000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDItMS0xLTEtNDU0NDE_57389b3d-7c3d-4307-b9dc-6c7835499705"
      unitRef="usd">1093000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDItMy0xLTEtNDU0NDE_3d99300c-1c97-4547-af90-24d6a304b7cc"
      unitRef="usd">-205000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDMtMS0xLTEtNDU0NDE_c931db81-5c21-4c04-b27c-bf45a309ce07"
      unitRef="usd">18164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDMtMy0xLTEtNDU0NDE_83d9a503-ab4e-498c-94c6-4a7f8d058292"
      unitRef="usd">18155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDUtMS0xLTEtNDU0NDE_0ad326eb-45b5-48c9-948f-1c5bbbb21a37"
      unitRef="usd">587276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib209ba21e10b4555b66a335b31afd83c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDUtMy0xLTEtNDU0NDE_bf29f7c5-8a5a-484d-8d58-70209db9f365"
      unitRef="usd">649158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDYtMS0xLTEtNDU0NDE_40efa4bd-2381-4006-9c08-39ff4b5a20ab"
      unitRef="usd">605440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i92f6be262c6c4e51bf32b7a84eb3ea35_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDYtMy0xLTEtNDU0NDE_97b58d00-2bad-46ee-ab4a-fcc82696f903"
      unitRef="usd">667313000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDgtMS0xLTEtNDU0NDE_bc6ae781-01b9-41c9-b63e-e62043127df8"
      unitRef="usd">1316000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDgtMy0xLTEtNDU0NDE_ec9233d7-9cb7-40b5-9faf-e64a827a7373"
      unitRef="usd">2998000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDktMS0xLTEtNDU0NDE_a5791472-b1f9-4e79-842e-108379f580fe"
      unitRef="usd">1422000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNDktMy0xLTEtNDU0NDE_007c2d4b-cea8-431f-a7bb-931dd145cf06"
      unitRef="usd">1465000</us-gaap:InterestPaidNet>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTEtMS0xLTEtNDU0NDE_c048b232-b40b-47e2-817d-cd94fa4f094b"
      unitRef="usd">-2481000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTEtMy0xLTEtNDU0NDE_90018bbf-9995-4f43-a6ef-23a586f39166"
      unitRef="usd">-12795000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTItMS0xLTEtNDU0NDE_c2baaac7-052e-4cfe-accc-ece1b924061f"
      unitRef="usd">-637000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets>
    <bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yOC9mcmFnOjViOTljMjdjNjdiYTQ3ODI5YzllZDE2ODQ5YzUwN2ZjL3RhYmxlOmQxOTljNTljY2Y0OTQ1ZDliOGY2N2E4YWI2Y2MzY2JhL3RhYmxlcmFuZ2U6ZDE5OWM1OWNjZjQ5NDVkOWI4ZjY3YThhYjZjYzNjYmFfNTItMy0xLTEtNDU0NDE_4f19246b-0b12-4d33-9687-68bf2816d66e"
      unitRef="usd">1298000</bmrn:SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzYzOA_441abd6e-de47-4d34-8cc8-3bbd64e4fc78">BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#x2019;s portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2022 or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates may change materially in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Management performed an evaluation of the Company&#x2019;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2022, as compared to the significant accounting policies disclosed in Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three months ended March&#160;31, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzYzOQ_f3bb459a-436e-466c-a2d8-65aa8c2905b2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2022 or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzY0MA_7073eaca-e618-48f0-81f1-c5f8c0164b9b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates may change materially in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Management performed an evaluation of the Company&#x2019;s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8zNC9mcmFnOmY4NDNkNDdmNWU3MTRlOTRhMzA2YWVjYzMzMjVmZTRkL3RleHRyZWdpb246Zjg0M2Q0N2Y1ZTcxNGU5NGEzMDZhZWNjMzMyNWZlNGRfMjc0ODc3OTA3NzY0MQ_721a41c7-fb03-407b-b92d-2e4d4ae523e0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three months ended March&#160;31, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTM5MQ_f0505037-0be6-416d-80bf-a7b8fb107286">FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All marketable securities were classified as available-for-sale at March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,089,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,077,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,531,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,519,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,222,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;The Company&#x2019;s long-term marketable securities mature between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1"&gt;one&lt;/span&gt;&lt;/span&gt; and five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security&#x2019;s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.&lt;/span&gt;&lt;/div&gt;The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the Company&#x2019;s strategic investments was $16.5 million. These investments were recorded in Other Assets in the Company&#x2019;s Condensed Consolidated Balance Sheets.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTM5Mg_6a99c76b-5420-4315-a104-82f2e35502e8">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,089,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,077,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,531,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,519,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,222,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;The Company&#x2019;s long-term marketable securities mature between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_5dea40cc-0424-4935-b96c-ba6895f32525"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDEw_6f8cc625-b806-46a8-8274-ce3615fb3fa1"&gt;one&lt;/span&gt;&lt;/span&gt; and five years.&lt;/span&gt;&lt;/div&gt;</bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock>
    <us-gaap:Cash
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xLTEtMS00NTQ0MQ_4f72d025-5cd5-4867-b562-3c1b5361ff97"
      unitRef="usd">441957000</us-gaap:Cash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0zLTEtMS00NTQ0MQ_6b21946a-5519-403a-a913-2fea8c7c5575"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy01LTEtMS00NTQ0MQ_11aa3617-8f7e-4949-85e2-ce951cd95bf9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy03LTEtMS00NTQ0MQ_87505b2a-dc49-439a-867b-3153c13bcce7"
      unitRef="usd">441957000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy05LTEtMS00NTQ0MQ_ec18d321-ef05-4d52-9404-80ee9a6c895a"
      unitRef="usd">441957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xMS0xLTEtNDU0NDE_25d29991-161a-434b-afef-f9212b0a71d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4d9b92fb50b84a28af3f7e3165cfe9a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMy0xMy0xLTEtNDU0NDE_2904e8f1-8d28-4270-9cd5-8b4fe906f870"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xLTEtMS00NTQ0MQ_60fa5cb0-1cf3-4634-8af0-92c0c7f4d282"
      unitRef="usd">160485000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0zLTEtMS00NTQ0MQ_7157b71f-9567-4a95-97c6-875f91bbf564"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi01LTEtMS00NTQ0MQ_91fcbc59-1486-404b-b707-fec2c167788b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi03LTEtMS00NTQ0MQ_ae937c9d-a9f8-4d31-9244-0bdb13c13c18"
      unitRef="usd">160485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi05LTEtMS00NTQ0MQ_da34cea0-2da6-49f1-b5f2-e2cb54172914"
      unitRef="usd">160485000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xMS0xLTEtNDU0NDE_85cc7d1e-0dda-4f48-a43a-9ae983b3a3e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9bebefd2f4b14a17ad7eff862468738f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNi0xMy0xLTEtNDU0NDE_d782d0e0-e11e-4340-82d1-d1ba6d919082"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xLTEtMS00NTQ0MQ_2163c0ab-3e05-435d-bddf-fc138c0cf0e1"
      unitRef="usd">585315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0zLTEtMS00NTQ0MQ_d2ca7275-bb6d-4df2-af0b-df15a1956348"
      unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy01LTEtMS00NTQ0MQ_ac833e70-7eee-4221-8621-28c87f2caede"
      unitRef="usd">9815000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy03LTEtMS00NTQ0MQ_0115afbf-2658-48ba-98fd-f77f7069f0c7"
      unitRef="usd">575562000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy05LTEtMS00NTQ0MQ_94a8da40-f5e0-4bc2-a770-8199aa850746"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xMS0xLTEtNDU0NDE_63f622b9-4c5d-4b0f-b6d1-739640be28c1"
      unitRef="usd">240777000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2f0fe85c7e614d609da901db5e3fa4de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfNy0xMy0xLTEtNDU0NDE_39d4b0ce-812c-4b0c-94e0-39091548db77"
      unitRef="usd">334785000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xLTEtMS00NTQ0MQ_7c0d1d05-0b71-46d4-aa7c-c587b335c0d5"
      unitRef="usd">237962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0zLTEtMS00NTQ0MQ_26fb4326-2ac3-46fb-ab3e-e02495e82d3a"
      unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC01LTEtMS00NTQ0MQ_bc2c5fe0-fb25-48d3-9571-5bf0bb07b468"
      unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC03LTEtMS00NTQ0MQ_829d453f-bee4-49dc-9d5e-e671b3fa017e"
      unitRef="usd">235950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC05LTEtMS00NTQ0MQ_a3c3fab0-e428-4a52-8941-7610292eb007"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xMS0xLTEtNDU0NDE_35404d8f-fe97-479c-b2a5-0e9b29fb3879"
      unitRef="usd">155716000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if8037f34da784a8da052f3d100568fdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOC0xMy0xLTEtNDU0NDE_1b0d1d0b-b735-4289-aafd-6ac6f5cbbbb1"
      unitRef="usd">80234000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xLTEtMS00NTQ0MQ_02492387-3179-4807-9efb-a5b6730e29f2"
      unitRef="usd">50518000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0zLTEtMS00NTQ0MQ_1eebaba7-8ec1-4458-9b08-9e4a453dee3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS01LTEtMS00NTQ0MQ_e094056c-eb5c-4c97-b59c-97570aba2ab8"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS03LTEtMS00NTQ0MQ_56da068c-46a6-4cbb-a8ee-101c16ea4d59"
      unitRef="usd">50508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS05LTEtMS00NTQ0MQ_dde1b1a2-181e-4cab-8356-65d63da85682"
      unitRef="usd">2998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xMS0xLTEtNDU0NDE_a6820c59-571e-4f41-9eab-2f0b69ca2ae6"
      unitRef="usd">47510000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i475042e9abf7443a90e179783dd443f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfOS0xMy0xLTEtNDU0NDE_7265ee85-93e7-4a5d-a68f-f1a620b98c59"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMS0xLTEtNDU0NDE_c94c32f6-b800-4540-980c-1c59b80251a9"
      unitRef="usd">51822000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMy0xLTEtNDU0NDE_fab0d376-06f5-4961-ac29-4d8e697b01dc"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtNS0xLTEtNDU0NDE_a95a9ed4-d810-4377-8494-1409406b2951"
      unitRef="usd">414000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtNy0xLTEtNDU0NDE_f2710f33-0113-48c0-9014-6397e3c83de2"
      unitRef="usd">51409000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtOS0xLTEtNDU0NDE_a156cfce-36be-4787-879b-d700806e0a48"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMTEtMS0xLTQ1NDQx_38053745-4282-4e02-9712-1e41e2baeb45"
      unitRef="usd">3785000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i306cc2d6c64340a99d27f2fb97cc4bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTAtMTMtMS0xLTQ1NDQx_caabfd5b-d857-4d30-a4da-8b2553cc8846"
      unitRef="usd">47624000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMS0xLTEtNDU0NDE_91e005f7-028c-4645-bb79-8c9f965a8f0f"
      unitRef="usd">3080000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMy0xLTEtNDU0NDE_67d1b9a7-9e52-43f6-a1d1-928e758771d2"
      unitRef="usd">136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtNS0xLTEtNDU0NDE_9eccb108-400f-492f-b9c4-99168a8d238a"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtNy0xLTEtNDU0NDE_66e28ce6-fc74-4737-a5fd-5889374b764d"
      unitRef="usd">3194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtOS0xLTEtNDU0NDE_41b7404d-d8e9-456b-8cbb-fc3b55ce495d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMTEtMS0xLTQ1NDQx_a55fe8fd-c1f3-414d-ab32-c6bf1856d281"
      unitRef="usd">3010000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iad4fc146174c44dfac7293154917c0cd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTEtMTMtMS0xLTQ1NDQx_2b6569e7-7dda-4467-9e6c-3ad94e08a485"
      unitRef="usd">184000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMS0xLTEtNDU0NDE_f60339a6-6843-4a28-941b-fe7fd7618987"
      unitRef="usd">1089182000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMy0xLTEtNDU0NDE_a5a94339-477d-40b0-846f-a5d78d846280"
      unitRef="usd">246000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItNS0xLTEtNDU0NDE_f7cdd0c8-2df7-4b00-ac53-b9d31b146d88"
      unitRef="usd">12320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItNy0xLTEtNDU0NDE_caab1b6e-ee38-4ad7-8cec-2fd3d600021f"
      unitRef="usd">1077108000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItOS0xLTEtNDU0NDE_f97712a3-4dbf-4997-8323-aca3cc4ce02f"
      unitRef="usd">163483000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMTEtMS0xLTQ1NDQx_c7a84e7f-e296-4ea7-87bf-caf896f756c3"
      unitRef="usd">450798000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i43f4e3af7d5541438a52d3a255447f9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTItMTMtMS0xLTQ1NDQx_a93fa255-5470-4a80-bd1c-654c65bc1d96"
      unitRef="usd">462827000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMS0xLTEtNDU0NDE_32e8f063-40ae-4ac3-ab0c-afabbfa3d571"
      unitRef="usd">1531139000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMy0xLTEtNDU0NDE_cf001c6a-29c9-4720-9f3d-e223fcaca4d3"
      unitRef="usd">246000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtNS0xLTEtNDU0NDE_2457b1a2-d70a-4018-bf25-f85b0186f841"
      unitRef="usd">12320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtNy0xLTEtNDU0NDE_faaae260-8af5-430d-862a-d3cfc57e19a8"
      unitRef="usd">1519065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtOS0xLTEtNDU0NDE_110f1cfd-3ab8-4be6-9b98-d1b13d8921fc"
      unitRef="usd">605440000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMTEtMS0xLTQ1NDQx_d9f58451-ebcb-4c9c-a6c4-38490b30e96d"
      unitRef="usd">450798000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjAwNGQwMGNkODZjNDQzNmNhNzBlYTI2ZGI1Yzg1NjNiL3RhYmxlcmFuZ2U6MDA0ZDAwY2Q4NmM0NDM2Y2E3MGVhMjZkYjVjODU2M2JfMTMtMTMtMS0xLTQ1NDQx_06345c87-9a18-414d-853e-b3096e7070b6"
      unitRef="usd">462827000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:Cash
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xLTEtMS00NTQ0MQ_d99b40a5-2b5d-4b64-8da5-cb1d99c481ad"
      unitRef="usd">301177000</us-gaap:Cash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0zLTEtMS00NTQ0MQ_dcdfef2d-8722-4e67-b971-7c9a4db18203"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy01LTEtMS00NTQ0MQ_580ba105-5251-4fee-8545-b200a8c902a4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy03LTEtMS00NTQ0MQ_96aec560-5ba9-4abb-9057-3224ed9adf19"
      unitRef="usd">301177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy05LTEtMS00NTQ0MQ_5e2060cc-1909-4cb5-9353-005bdc485046"
      unitRef="usd">301177000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xMS0xLTEtNDU0NDE_fb31557f-6f50-4b10-9504-77a95f704824"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i16b20b1e79404e219e16bb43665c85f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMy0xMy0xLTEtNDU0NDE_245b95bb-4515-4cb0-ab29-19b198bb34f5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xLTEtMS00NTQ0MQ_3c5f528d-1bd8-414e-87ac-b53b3be1d4ec"
      unitRef="usd">285099000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0zLTEtMS00NTQ0MQ_3e2c0407-a9c2-4ba4-86a7-1432f734b016"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi01LTEtMS00NTQ0MQ_f041b863-ee5a-4f06-be42-851f96030e20"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi03LTEtMS00NTQ0MQ_09099f55-da25-4e21-9847-d9add84609d3"
      unitRef="usd">285099000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi05LTEtMS00NTQ0MQ_0c49a157-6881-4829-8067-a986f162c66b"
      unitRef="usd">285099000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xMS0xLTEtNDU0NDE_dbbc1291-6134-42db-a1bb-a474583102ee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia409d65b4cdd44d9aa3ade7c9957f14f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNi0xMy0xLTEtNDU0NDE_179d83fd-457b-462c-b391-cace7bee1279"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xLTEtMS00NTQ0MQ_66e1656f-2c01-4796-85ba-83507dabfd6a"
      unitRef="usd">584000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0zLTEtMS00NTQ0MQ_1f8819ec-ef07-4e8d-b3e6-cdc2b896f790"
      unitRef="usd">386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy01LTEtMS00NTQ0MQ_54795d56-b616-4c34-858b-be03a94ee373"
      unitRef="usd">2086000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy03LTEtMS00NTQ0MQ_5dc3af72-e963-40fe-a12a-49d085305f70"
      unitRef="usd">582300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy05LTEtMS00NTQ0MQ_3696ab75-9b77-4520-9c96-a353bb6a7190"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xMS0xLTEtNDU0NDE_0f161aab-e9bb-4802-88c1-88cdc55439a2"
      unitRef="usd">200304000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i19740758cf5742bd95d6aa74d07388eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfNy0xMy0xLTEtNDU0NDE_b81d9248-ea38-40a5-ab24-bd0f1ef50ab0"
      unitRef="usd">381996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xLTEtMS00NTQ0MQ_0fb0c7b7-b9f0-456a-a25d-08b4038592f0"
      unitRef="usd">224774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0zLTEtMS00NTQ0MQ_600ddaea-a02e-40c7-b76b-d1cfd78ab3dc"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS01LTEtMS00NTQ0MQ_dba688cd-0d4a-4376-94e8-ee897fa33cb9"
      unitRef="usd">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS03LTEtMS00NTQ0MQ_4310f972-9bae-4120-8498-d17d39341344"
      unitRef="usd">224631000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS05LTEtMS00NTQ0MQ_c9918e99-bed7-4c70-8be0-021d414c028d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xMS0xLTEtNDU0NDE_832149a3-7450-4b3b-bb0b-5d7e2c8d69b0"
      unitRef="usd">146421000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i06655e4513d7439fb94059adafe0bba4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfOS0xMy0xLTEtNDU0NDE_57bdd425-122d-46f4-84e9-3b783c0cf534"
      unitRef="usd">78210000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMS0xLTEtNDg3NTk_6e16cb29-561b-4d6b-8835-2ef429ccedba"
      unitRef="usd">68384000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMy0xLTEtNDg3NTk_f47bf1ce-b925-4ac5-a50f-b56fa814c315"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNS0xLTEtNDg3NTk_ae0d0e1d-f73c-42b2-9bf2-f547daf9f212"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNy0xLTEtNDg3NTk_713e1be4-bc42-4345-8d66-72522382225a"
      unitRef="usd">68384000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtOS0xLTEtNDg3NTk_88ac4964-0df0-40b8-a8bf-3db4d2385a4c"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTEtMS0xLTQ4NzU5_516021c4-9463-467f-9a7a-f57a01f63943"
      unitRef="usd">67384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9adf0006647246c1a686f4e093f0039b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTMtMS0xLTQ4NzU5_973a69f4-2b7c-411f-8f08-6d332790ac02"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMS0xLTEtNDU0NDE_5e189d75-a5fa-43b6-872b-808e6bf659f4"
      unitRef="usd">56936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMy0xLTEtNDU0NDE_82d438a1-ee06-4621-ad81-24018ebbded9"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNS0xLTEtNDU0NDE_fd5104f0-6b0b-449c-9880-d15534b68e0a"
      unitRef="usd">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtNy0xLTEtNDU0NDE_88af5a02-e98a-49f4-98e7-8c5ea91d0aa0"
      unitRef="usd">56851000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtOS0xLTEtNDU0NDE_d0e74895-af44-4259-99f9-0bd870cc5df2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTEtMS0xLTQ1NDQx_76548112-5770-4d96-869f-0a41e0ebbf44"
      unitRef="usd">9451000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8b0a3f3f87bb4f97a9ce05a69cfdfff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTAtMTMtMS0xLTQ1NDQx_b608a99a-2a75-4960-bb05-3e1a53ad9652"
      unitRef="usd">47400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMS0xLTEtNDU0NDE_35ffde7d-2477-4af6-8f86-bfbe7a2178db"
      unitRef="usd">3097000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMy0xLTEtNDU0NDE_77a5e59e-dde7-4695-bb52-09d94ecb22d7"
      unitRef="usd">141000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtNS0xLTEtNDU0NDE_4b42cfbf-c96d-4fe1-a3b8-d4d01a42e140"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtNy0xLTEtNDU0NDE_c0874878-dd49-447e-a820-56d47439a832"
      unitRef="usd">3226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtOS0xLTEtNDU0NDE_3f061074-c983-4581-9f9e-0cb67d7d2c17"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMTEtMS0xLTQ1NDQx_9cb3ed4f-46eb-4e2f-8842-acdd8f691ece"
      unitRef="usd">3039000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i376acb983838406dafef8389effeae4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTEtMTMtMS0xLTQ1NDQx_321f2e36-d7ea-4a5d-9cdc-e46f974d7bb3"
      unitRef="usd">187000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMS0xLTEtNDU0NDE_2f52c625-a93c-443e-ac2d-7629a93df8a2"
      unitRef="usd">1222290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMy0xLTEtNDU0NDE_d9765520-7f7a-43f6-aec7-4bccb8945a29"
      unitRef="usd">719000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItNS0xLTEtNDU0NDE_7b2f2f2b-9cc2-4843-aacd-176c805af2ac"
      unitRef="usd">2518000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItNy0xLTEtNDU0NDE_7755e1e1-d11b-4410-bfab-326f1ff7b60b"
      unitRef="usd">1220491000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItOS0xLTEtNDU0NDE_a7067699-578a-42a2-a852-2347f9b21b59"
      unitRef="usd">286099000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMTEtMS0xLTQ1NDQx_73419e10-5021-4e3b-838a-fee534964cd5"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib088395ca9b54cd5ab2856cb12431e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTItMTMtMS0xLTQ1NDQx_90ae6e35-aaa1-4166-ab62-4d9c86e6b9e5"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMS0xLTEtNDU0NDE_5d2c8693-5699-4cc3-b7de-d0ea8af10458"
      unitRef="usd">1523467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMy0xLTEtNDU0NDE_b588bec7-4c3a-4613-8752-bb420393ebf8"
      unitRef="usd">719000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtNS0xLTEtNDU0NDE_4e206acb-29c8-49e3-81e8-859f36035c34"
      unitRef="usd">2518000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtNy0xLTEtNDU0NDE_230e22d1-b776-4079-97a4-c07eac05c89c"
      unitRef="usd">1521668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtOS0xLTEtNDU0NDE_152c1bf5-d7f4-4403-baae-88198deac09e"
      unitRef="usd">587276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMTEtMS0xLTQ1NDQx_82d1dd47-d753-411e-b9ad-5637de6173c4"
      unitRef="usd">426599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RhYmxlOjliYTE3YjE1ZTNlODQ5NTI4MWQ1YzJiZDJlZGVhZjM5L3RhYmxlcmFuZ2U6OWJhMTdiMTVlM2U4NDk1MjgxZDVjMmJkMmVkZWFmMzlfMTMtMTMtMS0xLTQ1NDQx_050ee5c1-f895-43d9-bf53-5b167716be27"
      unitRef="usd">507793000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <bmrn:ShortTermMarketableSecuritiesMaturityPeriod
      contextRef="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMzMz_278bea95-cda7-4718-a23c-50fbcd1ef547">P1Y</bmrn:ShortTermMarketableSecuritiesMaturityPeriod>
    <bmrn:ShortTermMarketableSecuritiesMaturityPeriod
      contextRef="iadebcf821247497ba93eafb227624346_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMzMz_a4d09fd9-ed90-4ac2-903f-b6497850ec32">P1Y</bmrn:ShortTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i0598d40bd8f14ad4ae8871e71c8350d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDE3_3b03ee9a-cf1f-4779-94e3-4a8875f5d5da">P5Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <bmrn:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="iadebcf821247497ba93eafb227624346_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfNDE3_4c8c71e9-89ba-4231-838f-c3a9cb25beac">P5Y</bmrn:LongTermMarketableSecuritiesMaturityPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8fd980138ba04ea4aa0bf850eba714f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTI2Mg_4c440d78-ab59-4681-ae15-d427b951821b"
      unitRef="usd">16500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i6ca8e30ed951424daed017118d432eef_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80Ni9mcmFnOjUwYWUyMGNmMjQ2YjQyYzI5NDlhNGUwYzg5MDU4ZjlkL3RleHRyZWdpb246NTBhZTIwY2YyNDZiNDJjMjk0OWE0ZTBjODkwNThmOWRfMTI2Mg_f749d2cf-710c-45cd-b548-893a2013e826"
      unitRef="usd">16500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzNA_221e7947-25f6-4bbb-b061-32caf28eeed3">SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplemental Balance Sheet Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory as of March&#160;31, 2022, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $11.3 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the first quarter of 2022, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec by the European Medicines Agency had been significantly reduced and the Company expects to realize economic benefit in the future. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings and correspondence with the relevant regulatory authorities following the submission of the additional two-year follow-up safety and efficacy data requested by the regulatory agencies in the third quarter of 2020, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, and commercialization and marketplace trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#x2019;s policies on inventory produced prior to regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment, Net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,780,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(741,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,039,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,035,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation expense, net of amounts capitalized into inventory, for the three months ended March&#160;31, 2022 and March&#160;31, 2021 was $11.7 million and $12.5 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible Assets, Net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(304,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts Payable and Accrued Liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value added taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplemental Statement of Comprehensive Income Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gain on Sale of Nonfinancial Assets, Net in the first quarter of 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the FDA in connection with the U.S. approval of Voxzogo. As a result of the PRV sale, the Company recognized a $108.0&#160;million net gain on sale of nonfinancial assets in the Company's Consolidated Statement of Comprehensive Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzMg_0be37cea-e89d-4ec7-9914-d063402676a9">&lt;div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMS0xLTEtMS00NTQ0MQ_bb783ed1-535a-46c4-8614-603c6273e10b"
      unitRef="usd">92110000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMS0zLTEtMS00NTQ0MQ_044d39c9-9b9f-41da-8b91-22b20aacb6cc"
      unitRef="usd">80269000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMi0xLTEtMS00NTQ0MQ_fdaf6b40-365c-4dcc-876c-dd02dd24a52e"
      unitRef="usd">402319000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMi0zLTEtMS00NTQ0MQ_f2be163f-10a7-46af-80ee-1a24b4227ab9"
      unitRef="usd">415261000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMy0xLTEtMS00NTQ0MQ_3b4fcdf4-d638-44d2-b25e-a5c14a610d05"
      unitRef="usd">291927000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfMy0zLTEtMS00NTQ0MQ_11f9e2a5-642c-4afa-bd77-1630384d78e8"
      unitRef="usd">281139000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfNC0xLTEtMS00NTQ0MQ_331275e7-d2c7-401e-bfdc-d93518e1b1b3"
      unitRef="usd">786356000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmI4YjI0MWNlNTg0ZTQyZTFhYjZmOWU1MjBlNjYyMjQ3L3RhYmxlcmFuZ2U6YjhiMjQxY2U1ODRlNDJlMWFiNmY5ZTUyMGU2NjIyNDdfNC0zLTEtMS00NTQ0MQ_07e9d002-bcfb-468e-a78d-72890cfb2d24"
      unitRef="usd">776669000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9569970b087c446aaf59bf7e94224bd2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY0OTI2NzQ0Nzc1OQ_93b70dc4-cd68-4402-8f28-92e27944b775"
      unitRef="usd">11300000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzOQ_2a8e4479-7bb0-4d84-b4ad-29e3963e564b">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment, Net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,780,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(741,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(720,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,039,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,035,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMS0xLTEtMS00NTQ0MQ_151cf821-557a-4830-b084-1116e7273569"
      unitRef="usd">1780711000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMS0zLTEtMS00NTQ0MQ_20c71c41-6456-46e6-979c-1e32b784b9bb"
      unitRef="usd">1756035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMi0xLTEtMS00NTQ0MQ_cf5031bc-0e7c-403c-b5bd-db46ac0f7187"
      unitRef="usd">741167000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMi0zLTEtMS00NTQ0MQ_8f064e3b-f888-4f1c-af55-b6207ce18234"
      unitRef="usd">720574000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMy0xLTEtMS00NTQ0MQ_3f9ce954-575d-4c7e-ace3-101e56c2eba5"
      unitRef="usd">1039544000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOmQyNjFjM2YxMmRlMjQzZDRiNDg4OTdlNDZhYjY0YTIyL3RhYmxlcmFuZ2U6ZDI2MWMzZjEyZGUyNDNkNGI0ODg5N2U0NmFiNjRhMjJfMy0zLTEtMS00NTQ0MQ_72691516-e99d-4d05-82cb-965bc9674335"
      unitRef="usd">1035461000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY1NQ_e3a7f5a6-74ea-48c8-988e-7865e0a50d67"
      unitRef="usd">11700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTY0OTI2NzQ0NDgwNA_5d246303-d9ce-4c86-a403-96a2e33e3d58"
      unitRef="usd">12500000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzMw_1b3ce909-e8fb-46df-b7f4-c7caaaa87fd5">Intangible Assets, Net consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;678,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(304,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMS0xLTEtMS00NTQ0MQ_e477e628-4350-4d76-9e71-cb4e305227f7"
      unitRef="usd">678601000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMS0zLTEtMS00NTQ0MQ_4a3d2d71-b09f-4abc-b358-72bcb7672f54"
      unitRef="usd">677350000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMi0xLTEtMS00NTQ0MQ_bb9035a4-2897-406c-8bbe-50b738cb9009"
      unitRef="usd">304350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMi0zLTEtMS00NTQ0MQ_535fe139-5d50-4bb5-b9cd-7e4ab84fdb21"
      unitRef="usd">288698000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMy0xLTEtMS00NTQ0MQ_d1ed0f25-eeb1-4fe6-aef1-3576e90409d3"
      unitRef="usd">374251000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjMxY2NiYjVlNjM0ZDQ1MTk4N2Q0NzM3Mjk2YzJkYzQ4L3RhYmxlcmFuZ2U6MzFjY2JiNWU2MzRkNDUxOTg3ZDQ3MzcyOTZjMmRjNDhfMy0zLTEtMS00NTQ0MQ_289916d2-c747-4656-92f7-9d11b3a65e0f"
      unitRef="usd">388652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMTkzNg_0e5676dc-8fc1-4ad1-becd-96868f5b6301">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts Payable and Accrued Liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued rebates payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value added taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMS0xLTEtMS00NTQ0MQ_3bf365ee-5035-4073-9814-0b58514c0677"
      unitRef="usd">187810000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMS0zLTEtMS00NTQ0MQ_c44847cb-f52a-4853-8723-d77ce25a428a"
      unitRef="usd">193003000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMi0xLTEtMS00NTQ0MQ_2dca9c56-75b0-44ee-916c-a8636b27a87f"
      unitRef="usd">127938000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMi0zLTEtMS00NTQ0MQ_3bffec36-1d97-485b-b2d0-343a47433eb4"
      unitRef="usd">204446000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bmrn:AccruedGovernmentAndOtherRebates
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMy0xLTEtMS00NTQ0MQ_2cb5b367-b9f7-4885-b4ea-8fda873255af"
      unitRef="usd">56295000</bmrn:AccruedGovernmentAndOtherRebates>
    <bmrn:AccruedGovernmentAndOtherRebates
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMy0zLTEtMS00NTQ0MQ_f60d264a-7b06-44aa-8702-14d088838f0f"
      unitRef="usd">47987000</bmrn:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNC0xLTEtMS00NTQ0MQ_69418ad5-271c-45a3-8c81-2f145d06be7c"
      unitRef="usd">16026000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNC0zLTEtMS00NTQ0MQ_a311af88-c624-46e4-8648-0f2f931b0e54"
      unitRef="usd">15215000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNi0xLTEtMS00NTQ0MQ_4ffe5aa9-ed66-4a65-a9e2-e72c99e325f0"
      unitRef="usd">12716000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNi0zLTEtMS00NTQ0MQ_43c59116-da1f-475c-a685-c2dbcb0de581"
      unitRef="usd">6263000</us-gaap:DerivativeLiabilitiesCurrent>
    <bmrn:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNS0xLTEtMS00NTQ0MQ_c3276693-ed5d-4de5-936e-4b8242c0a510"
      unitRef="usd">10829000</bmrn:OperatingAndFinanceLeaseLiabilityCurrent>
    <bmrn:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNS0zLTEtMS00NTQ0MQ_4a2e3196-62a7-4d31-8587-5d46f4941189"
      unitRef="usd">10464000</bmrn:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNy0xLTEtMS00NTQ0MQ_a0283a45-5539-4980-82f3-cfa1f5a08d4d"
      unitRef="usd">5096000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfNy0zLTEtMS00NTQ0MQ_db279cb4-b80b-42fa-8e11-51f5f4432487"
      unitRef="usd">1935000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOC0xLTEtMS00NTQ0MQ_c54bf2b9-c1c4-44bd-b087-07e8e874bcd0"
      unitRef="usd">3347000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOC0zLTEtMS00NTQ0MQ_87c6183e-dd5e-463d-ac30-c1cc48c551b0"
      unitRef="usd">1213000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0xLTEtMS01MTg4OA_1dc994c5-af54-46ce-9632-f5628dbf8fe6"
      unitRef="usd">306000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0zLTEtMS01MTg4OA_989879ae-f66d-4099-8860-7e483f090e09"
      unitRef="usd">6956000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0xLTEtMS00NTQ0MQ_6c50e91d-d9ea-44b4-b704-5da63906e493"
      unitRef="usd">6055000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfOS0zLTEtMS00NTQ0MQ_2ec3f720-6bdd-45df-9d66-efef6952d509"
      unitRef="usd">4108000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMTAtMS0xLTEtNDU0NDE_e2a72322-2397-49aa-8b69-6356085e07c2"
      unitRef="usd">426418000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RhYmxlOjUxMWFlNjBlZTc5OTRjNTk5ZWRhYTQyNTllYTUwMDk4L3RhYmxlcmFuZ2U6NTExYWU2MGVlNzk5NGM1OTllZGFhNDI1OWVhNTAwOThfMTAtMy0xLTEtNDU0NDE_c6002b3c-16f2-4b66-9091-755242ddc0c2"
      unitRef="usd">491590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV80OS9mcmFnOjA0MGZlNjNjNTkzNTRjODJiZDhhZjgzMzJhNWM3NTA5L3RleHRyZWdpb246MDQwZmU2M2M1OTM1NGM4MmJkOGFmODMzMmE1Yzc1MDlfMjE5OTAyMzI2MDA3Ng_da77f89a-0748-4cb0-b803-f502c01b0bd3"
      unitRef="usd">108000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE5Mg_07860636-b8a6-4194-926c-864e031076bc">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013; Business Overview and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021.&#160;Other than the Company&#x2019;s fixed-rate convertible debt disclosed in Note 6 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The restricted investments at March&#160;31, 2022 and December&#160;31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange remeasurement of Euro denominated contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE4Nw_bbbc3f81-5350-4e01-aa0c-b98833a5d6cc">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021.&#160;Other than the Company&#x2019;s fixed-rate convertible debt disclosed in Note 6 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NQDC Plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The restricted investments at March&#160;31, 2022 and December&#160;31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i11cc1a5725ab4723b0462ef1a3028473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_1073be44-8ae5-4f52-8f1a-14f64d7067ac"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i67c5cd0a2b524859bbb3035e15216170_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_697efc28-cd4e-417a-b329-778744ce8cd7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i11cc1a5725ab4723b0462ef1a3028473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_95fb2baa-a1b2-4324-b0fd-0955a0525980"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i67c5cd0a2b524859bbb3035e15216170_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfNjIz_96644de1-d0e7-466a-bb14-0c7eb5df7310"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="ice4c0ea303bc4617bff30b97f3119d8a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC0yLTEtMS00NTQ0MQ_32abf80d-8f7a-4c1a-b1e0-0d8b1dd09f87"
      unitRef="usd">2859000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="idac071ae2357499a807f15a7c6d7c22d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC00LTEtMS00NTQ0MQ_a3d98e62-a524-43b1-be11-a89db3e47743"
      unitRef="usd">0</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNC02LTEtMS00NTQ0MQ_03e085ce-ec9e-442f-b3b5-5890eba5d6aa"
      unitRef="usd">2859000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ice4c0ea303bc4617bff30b97f3119d8a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy0yLTEtMS00NTQ0MQ_23787584-2182-47cb-ae65-f89399ccbd83"
      unitRef="usd">22387000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="idac071ae2357499a807f15a7c6d7c22d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy00LTEtMS00NTQ0MQ_b8922acd-609f-4589-95f1-62b4c657352b"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i82c05b9ecc824a7bab4fb71036ba39dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfNy02LTEtMS00NTQ0MQ_0c0648ca-69ba-4743-b305-58320c6461da"
      unitRef="usd">22387000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ibea9395534ba42e3a0190935fdfbb79d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC0yLTEtMS00NTQ0MQ_84a31a84-d92c-465c-b2d4-f792ea5c8c85"
      unitRef="usd">2513000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="id06e40f8e2ee4cf4a3d50677fc6227a2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC00LTEtMS00NTQ0MQ_693a4f1b-1dd3-4684-be31-23b2f59019f9"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ie67fb8408fad4a14a69938859aaf1ffe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOC02LTEtMS00NTQ0MQ_21b1e65e-b4d4-427a-a44c-5f94f1dc4da1"
      unitRef="usd">2513000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS0yLTEtMS00NTQ0MQ_70dba730-7512-4015-8dd1-d43cfba24518"
      unitRef="usd">24900000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS00LTEtMS00NTQ0MQ_65bcbd63-2f7f-46d4-92a8-3979ebabb56e"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfOS02LTEtMS00NTQ0MQ_0078ef9f-1069-4a65-a96d-049a93634547"
      unitRef="usd">24900000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtMi0xLTEtNDU0NDE_eb5ecd11-4916-4b21-90aa-a76c5f11d57f"
      unitRef="usd">27759000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtNC0xLTEtNDU0NDE_cb83f729-ba08-4dd6-82ab-67b2dcd4689d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTAtNi0xLTEtNDU0NDE_2a74acc1-d6e9-476d-9b23-4315308cc6ef"
      unitRef="usd">27759000</us-gaap:AssetsFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ifeee18ee6d494c7790cf41fe0038c831_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtMi0xLTEtNDU0NDE_e7f3c1d2-7710-4dc1-97c1-45bb1749db7e"
      unitRef="usd">2859000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="id262761c1fad424b90e86b74ae146097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtNC0xLTEtNDU0NDE_c587b482-c101-4d50-b36c-f8d545f4096a"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ie98efc0e12da4354a0d424854f64af5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTMtNi0xLTEtNDU0NDE_f0f93bf8-4b99-4e45-a653-2be282021513"
      unitRef="usd">2859000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ic1a1cedc9eed4bfab32ee8743471c711_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtMi0xLTEtNDU0NDE_78863775-5fcf-411c-9aa6-89d6da3e1f9d"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ia462eb49aaaf40e997e1a56cd4ffe090_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtNC0xLTEtNDU0NDE_cb7029f8-997c-4cbd-9047-0b29c8b5d4db"
      unitRef="usd">64000000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i478e66d57d4645caa9b700a5fd1ef8eb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTQtNi0xLTEtNDU0NDE_32eb5358-5c0f-40d6-a110-693c3f9700d4"
      unitRef="usd">64000000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtMi0xLTEtNDU0NDE_28e216d0-98aa-4029-809f-8afa68676859"
      unitRef="usd">2859000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtNC0xLTEtNDU0NDE_45f28e7f-45d0-442d-9467-56df137ab08f"
      unitRef="usd">64000000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTUtNi0xLTEtNDU0NDE_3ec27114-481e-4e67-b6db-10efe8aaf7f5"
      unitRef="usd">66859000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="ifeee18ee6d494c7790cf41fe0038c831_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctMi0xLTEtNDU0NDE_487db7a2-98e0-4dba-bdbf-551a6af7f54e"
      unitRef="usd">22387000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="id262761c1fad424b90e86b74ae146097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctNC0xLTEtNDU0NDE_b2812c41-0251-40d5-ae05-a2ba191e5cad"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="ie98efc0e12da4354a0d424854f64af5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMTctNi0xLTEtNDU0NDE_a4e88312-fdd8-450d-95a0-f610fc7931d5"
      unitRef="usd">22387000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie5bd403d599a4cae83b4124e73e69e92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtMi0xLTEtNDU0NDE_aa703837-3ff6-45ca-b3f8-6d41a34f88ff"
      unitRef="usd">25246000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7a5305ac356c4dae82b317efba8e3eed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtNC0xLTEtNDU0NDE_b561e5ba-821a-4a92-aebf-952fccb0e951"
      unitRef="usd">64000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1af36fbb7aca467c8d91640910e44cbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOmQ5ZmZkNTgxNDZmMTRlNTZhMjJjMjQ5ZjZmYTc3MzQ2L3RhYmxlcmFuZ2U6ZDlmZmQ1ODE0NmYxNGU1NmEyMmMyNDlmNmZhNzczNDZfMjAtNi0xLTEtNDU0NDE_a3a20478-ce82-43e7-8b2f-041d5b6b965c"
      unitRef="usd">89246000</us-gaap:LiabilitiesFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="id4cd46ba90ab490ab24b52d5a3097a86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC0zLTEtMS00NTQ0MQ_750547e6-9aee-4afa-99d9-4af90824886a"
      unitRef="usd">2043000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i7475279edad54e10a67e1ba4a06c239c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC01LTEtMS00NTQ0MQ_3fa20f3d-f8c7-4044-8711-85dcb94c67d2"
      unitRef="usd">0</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsCurrentFairValueDisclosure
      contextRef="i9059f91d0ea641c8a3ca5f6af90239be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfNC03LTEtMS00NTQ0MQ_1b7b082f-5b83-4ae1-8a09-93b8bc7014b6"
      unitRef="usd">2043000</bmrn:OtherAssetsCurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="id4cd46ba90ab490ab24b52d5a3097a86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC0zLTEtMS00NTQ0MQ_c2dda3c3-b944-4680-92a6-5f0985f620a6"
      unitRef="usd">23929000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i7475279edad54e10a67e1ba4a06c239c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC01LTEtMS00NTQ0MQ_1cdba1a2-2610-4e53-9c3c-eac8d978bc1c"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i9059f91d0ea641c8a3ca5f6af90239be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOC03LTEtMS00NTQ0MQ_bc47b224-37db-4ef7-9fd2-9c525c55905d"
      unitRef="usd">23929000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i5e1bbedcd77d4d4e9132645838dec1f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS0zLTEtMS00NTQ0MQ_69fe7320-3f86-4ea2-9af3-d4240cb39ee0"
      unitRef="usd">2940000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i86b2a564c9924e1593e108f04e0e05fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS01LTEtMS00NTQ0MQ_7cbd79d6-e586-481f-a149-51578e6f8b33"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i9d27016ee9414a53ac394d4ec7659333_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfOS03LTEtMS00NTQ0MQ_24be4c54-1117-451e-a3e3-bbe636401b23"
      unitRef="usd">2940000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtMy0xLTEtNDU0NDE_f7ea6ed8-3cde-44a6-a610-8300b65a263c"
      unitRef="usd">26869000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtNS0xLTEtNDU0NDE_19ea1253-7368-4bac-8362-504f343cc031"
      unitRef="usd">0</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <bmrn:OtherAssetsNoncurrentFairValueDisclosure
      contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTEtNy0xLTEtNDU0NDE_bdffa70d-2126-401a-9284-a55b1e861b25"
      unitRef="usd">26869000</bmrn:OtherAssetsNoncurrentFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItMy0xLTEtNDU0NDE_268e2e9b-51ce-47ab-9126-166fba93cd88"
      unitRef="usd">28912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItNS0xLTEtNDU0NDE_842ba45e-77a5-40ef-a967-9f687f37d7a1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTItNy0xLTEtNDU0NDE_fb6d248c-bbe1-47c3-a182-e737380dcedc"
      unitRef="usd">28912000</us-gaap:AssetsFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtMy0xLTEtNDU0NDE_1da15873-7d6e-4aa3-b717-68613b0d1ccd"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i018f94a349524435963ac9c426ebd9da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtNS0xLTEtNDU0NDE_a55bbad8-b660-4cf3-af34-40127164b3d4"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="iea8e222c468d40d181487297a7c0cbd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTUtNy0xLTEtNDU0NDE_1cf14f2d-72a0-40f9-8b98-4a688701ecb4"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i9f6783e8d375468bb371c65e2e9858b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtMy0xLTEtNDU0NDE_cdd784ef-aaaf-45ff-97b3-3884c2bff97d"
      unitRef="usd">0</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="id40b5097a4704fd29443d8189ff20cfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtNS0xLTEtNDU0NDE_94a59982-659a-44ca-ac88-e8fc0deebfc5"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i5e3c8c6419414c7397306df2567d9a10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTYtNy0xLTEtNDU0NDE_440465bb-1588-4c84-9469-22d9b5cd0898"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctMy0xLTEtNDU0NDE_c27a4b2c-f276-4ad8-8a83-8e4be39f23c4"
      unitRef="usd">2043000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctNS0xLTEtNDU0NDE_89d4f0d4-e8ba-4e76-9eef-52299af3a5af"
      unitRef="usd">48232000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesCurrentFairValueDisclosure
      contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTctNy0xLTEtNDU0NDE_123990cd-6886-49c5-972d-258ef901c913"
      unitRef="usd">50275000</bmrn:OtherLiabilitiesCurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="id5e751fba4cd4c2fb0a9a3dff628db11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktMy0xLTEtNDU0NDE_7907db74-1d91-4beb-98e2-39e5aaeec6fe"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i018f94a349524435963ac9c426ebd9da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktNS0xLTEtNDU0NDE_7a2a2dff-99c4-4dd6-9ea0-9b0984202dad"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="iea8e222c468d40d181487297a7c0cbd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMTktNy0xLTEtNDU0NDE_3b210bd8-8f77-4152-a42b-a497983d7100"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i9f6783e8d375468bb371c65e2e9858b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtMy0xLTEtNDU0NDE_cbde504c-cbd7-4c2b-9e5c-800bae7dcdd6"
      unitRef="usd">0</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="id40b5097a4704fd29443d8189ff20cfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtNS0xLTEtNDU0NDE_a95253ad-a306-4373-9e35-a12561859cf6"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i5e3c8c6419414c7397306df2567d9a10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjAtNy0xLTEtNDU0NDE_9585abcf-48a9-429a-af6f-9b85b9720c8e"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtMy0xLTEtNDU0NDE_8dd67e03-0a5b-45d0-902f-022d85adb69b"
      unitRef="usd">23929000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtNS0xLTEtNDU0NDE_52dfbdcb-185a-4aed-8868-f721d36d5fbc"
      unitRef="usd">15167000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure
      contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjEtNy0xLTEtNDU0NDE_da914f3d-dec3-4c5d-a202-df69c970ac35"
      unitRef="usd">39096000</bmrn:OtherLiabilitiesNoncurrentFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if9e892e0bc7d4f3f89a846bc8f1bc326_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItMy0xLTEtNDU0NDE_19ba8020-91b2-4303-b1a6-47343422ef89"
      unitRef="usd">25972000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4a2b5c574e4b4548be514c50e602f6fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItNS0xLTEtNDU0NDE_d91e2ea8-03e4-46c4-a702-df04705a3d21"
      unitRef="usd">63399000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3f26a3a0f54447e5bbfa03a26c5ad2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjdhMDU1OTVmZGU2NDRiNzY4ODBkZjQzZDk1MzZiZjRhL3RhYmxlcmFuZ2U6N2EwNTU5NWZkZTY0NGI3Njg4MGRmNDNkOTUzNmJmNGFfMjItNy0xLTEtNDU0NDE_31ca2359-7f91-4ae4-8ff0-0d655d32b3d2"
      unitRef="usd">89371000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RleHRyZWdpb246NWRhZjE4NzNhZDJhNDNjNjkxNjQzMDQxZDliNDc3YjlfMTE4OA_000c38a4-a2b7-4625-b612-67b84e6f6583">Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange remeasurement of Euro denominated contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2e3e175895dd4eddaf85bea4d5710175_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMC0xLTEtMS00NTQ0MQ_157ae862-d9be-4dc2-9297-17fe0a5393cf"
      unitRef="usd">63399000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMS0xLTEtMS00NTQ0MQ_63936dd9-303a-467e-a6eb-cf0cdb8284a6"
      unitRef="usd">1989000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement
      contextRef="i46949838bb0d477994f27f2d1c6dce3e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMi0xLTEtMS00NTQ0MQ_b99b8f5c-91fa-4552-886d-abc66a54736c"
      unitRef="usd">-1388000</bmrn:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id8702f41faa34d58a58f591cc29c5186_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81Mi9mcmFnOjVkYWYxODczYWQyYTQzYzY5MTY0MzA0MWQ5YjQ3N2I5L3RhYmxlOjMyYTU1NWNhMGEyNzQ2MjBiMzRlZmFlMGQ5MGU5MDRmL3RhYmxlcmFuZ2U6MzJhNTU1Y2EwYTI3NDYyMGIzNGVmYWUwZDkwZTkwNGZfMy0xLTEtMS00NTQ0MQ_50133a87-ff36-42c3-b2ba-185c7b21c4f3"
      unitRef="usd">64000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxNQ_8a298d7f-6959-4f16-bda2-26b9fb82139b">DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange forward contracts (forward contracts) to protect against the reduction in value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to one year, nine months. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to three months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company&#x2019;s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate notional amounts for the Company&#x2019;s derivatives outstanding as of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value carrying amounts of the Company&#x2019;s derivatives, as classified within the fair value hierarchy, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;For additional discussion of fair value measurements, see Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues as reported&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses as reported&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company expects to reclassify unrealized gains of $7.6 million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i24a67b5f17b74d8d875e70d77ac24e0a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfNDcz_11118d39-154e-4a5d-97d8-4bd4478aacb5">P1Y9M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfNzcw_1f9c0384-56da-46ac-bd4c-8ecab369d33d">P3M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxMQ_9f60ddd4-58cc-4d4d-8c25-a367de985497">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate notional amounts for the Company&#x2019;s derivatives outstanding as of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6fb2fa6470f64208b9cca9caed841242_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMi0xLTEtMS00NTQ0MQ_02460b57-8463-49d5-88cc-0876fe00cac1"
      unitRef="usd">650302000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i10323adbf43747cc8e67c4d6d61a7601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMi0zLTEtMS00NTQ0MQ_bf458bf8-35cd-4108-aeb4-ee5b0583afd8"
      unitRef="usd">740667000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia2d9103e14e34a25a637947fb0294c86_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMy0xLTEtMS00NTQ0MQ_565a3122-6a14-4498-afbc-3a2fac1e7be2"
      unitRef="usd">147206000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ied746eb100554a6386b2c27894ffc0e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfMy0zLTEtMS00NTQ0MQ_20775108-b09b-490c-aaf8-fdb42ce35bdb"
      unitRef="usd">183256000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i693b3a7b97e1437ebca5874be75ea456_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNi0xLTEtMS00NTQ0MQ_b0281739-d83e-4611-bce0-e8601829e0dc"
      unitRef="usd">98800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia82a5008ad32467abe48f8d161ab8af8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNi0zLTEtMS00NTQ0MQ_6841c87c-44a8-41c2-8163-06cda086ad0b"
      unitRef="usd">113257000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i73022b6d871f47e28feede850e27c229_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNy0xLTEtMS00NTQ0MQ_826b596f-3ab2-4b7d-9b19-2619205fe0de"
      unitRef="usd">3565000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i16e5ec0991924f7c96ecf3ccf3bb217f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjM1MzY3Y2I1NjlmZDRmY2Q5NzJiNzdjNDA0NDRhOTMzL3RhYmxlcmFuZ2U6MzUzNjdjYjU2OWZkNGZjZDk3MmI3N2M0MDQ0NGE5MzNfNy0zLTEtMS00NTQ0MQ_e48bc032-c00c-4964-b4e3-d0f38a367694"
      unitRef="usd">31068000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIxMw_803743d2-8f6f-45ef-bbb1-d9a655da3b00">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value carrying amounts of the Company&#x2019;s derivatives, as classified within the fair value hierarchy, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability Derivatives - Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts&#160;payable&#160;and accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Derivatives Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;For additional discussion of fair value measurements, see Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3a0d508ddf7e40db989b324877ca4949_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMy0xLTEtMS00NTQ0MQ_9eacc1b4-ad8c-46a1-bb28-2b547dc5f0f5"
      unitRef="usd">20763000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic28b615c8a794db39d946b9acae01f69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMy0zLTEtMS00NTQ0MQ_e074d842-72f6-4d27-8c32-dfeaa03f7ae0"
      unitRef="usd">17357000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i27917553b8fd4dfbac5fe095c7b4bde6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNC0xLTEtMS00NTQ0MQ_594b13ae-d4a0-4c9c-917a-e95574657e1e"
      unitRef="usd">3739000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic06dfaccfdbe46caac6458766a03b73f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNC0zLTEtMS00NTQ0MQ_a8ee0037-3ae2-4a2c-95a7-06b4f647715e"
      unitRef="usd">4991000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibf7f9f8463ea496caae776a4ddbd016b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNS0xLTEtMS00NTQ0MQ_fbde6bfd-da57-47d8-82c3-809e0201f4ac"
      unitRef="usd">24502000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i021baed86234498eaefce274645b825b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfNS0zLTEtMS00NTQ0MQ_a6fad16f-b99b-45d2-98e0-03c193df746d"
      unitRef="usd">22348000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibd9174aac2384a699993569e2b6eb445_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOC0xLTEtMS00NTQ0MQ_23451751-f785-41a8-9aec-01975610c18f"
      unitRef="usd">12670000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i84f2f900f6b144a0975d6dc3d49144ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOC0zLTEtMS00NTQ0MQ_a2af7fa0-7da7-40ab-af95-7d9b6bccdac9"
      unitRef="usd">5487000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5618c6fb44d74a64909673a57923b8ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOS0xLTEtMS00NTQ0MQ_41a6448d-6271-4468-b8ac-c5f10f599cd6"
      unitRef="usd">2984000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3985bd1ab09f4ea0bbe878344b3713b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfOS0zLTEtMS00NTQ0MQ_509fa542-1cbf-467d-9b83-5ccb49d89313"
      unitRef="usd">1378000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibf7f9f8463ea496caae776a4ddbd016b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTAtMS0xLTEtNDU0NDE_0a31cf50-adc6-4ae9-83ff-3283c4c2002a"
      unitRef="usd">15654000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i021baed86234498eaefce274645b825b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTAtMy0xLTEtNDU0NDE_a3651e1b-8c22-4d44-9185-e023a34a1ecb"
      unitRef="usd">6865000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1adb2627443a447f8c92c839abeda3a7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTQtMS0xLTEtNDU0NDE_d7d6c313-7ac3-41f0-8f81-0394bc07e2ab"
      unitRef="usd">98000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i482d5788d5874458a97a7e25c5406e22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTQtMy0xLTEtNDU0NDE_d17a777e-79c9-40cb-a3ee-3025f676b8a3"
      unitRef="usd">427000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i125b9e8420b44a9498f4af3776f779da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTgtMS0xLTEtNDU0NDE_9157f81c-af45-4692-9a13-aba9814dd198"
      unitRef="usd">46000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3d039887887e460290fb9430275f52d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMTgtMy0xLTEtNDU0NDE_7c509c61-6c1a-4f9c-a034-a5e3aa5a2e1a"
      unitRef="usd">776000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjItMS0xLTEtNDU0NDE_7af95e13-e9bf-4759-9c88-76a52f7b09dc"
      unitRef="usd">24600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjItMy0xLTEtNDU0NDE_e1710900-ef13-4ff1-acce-1b304608d8a6"
      unitRef="usd">22775000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjMtMS0xLTEtNDU0NDE_432825df-b73a-4703-b50e-3c98e3403625"
      unitRef="usd">15700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOmFmMDg5ODFmMDFhNTQzMmViMTM4ZTJhMTkyMWMyNmExL3RhYmxlcmFuZ2U6YWYwODk4MWYwMWE1NDMyZWIxMzhlMmExOTIxYzI2YTFfMjMtMy0xLTEtNDU0NDE_7e277982-af2f-41e1-a052-0cdec15c3298"
      unitRef="usd">7641000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMjIwOQ_4735723f-5316-4d6e-95e9-947483fd3882">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash Flow Hedging Gains (Losses) &lt;br/&gt;Reclassified into Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues as reported&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses as reported&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains (Losses) Recognized in Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC0xLTEtMS00NTQ0MQ_9875c97f-2f7d-4833-ac47-8eb4a23508cb"
      unitRef="usd">505525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib5119ab19f704add84d831075c4fe20f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC0zLTEtMS00NTQ0MQ_99e0d7b7-d2c2-4430-b8f3-d8f3f7f43692"
      unitRef="usd">5572000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC01LTEtMS00NTQ0MQ_23240146-33bf-41a6-b58c-c72f99dfe38d"
      unitRef="usd">467769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i0b30d6f7853643148004a14e6c5d0fdb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNC03LTEtMS00NTQ0MQ_efe5218e-7b57-41d5-91ad-937c438fbe63"
      unitRef="usd">-2757000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:CostsAndExpenses
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS0xLTEtMS00NTQ0MQ_954d5577-3686-4a08-8b24-b8d40796e2a7"
      unitRef="usd">382032000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7c517e48e00e4becb6f7ce5b1310c741_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS0zLTEtMS00NTQ0MQ_b038c1c1-6f15-4e33-b802-ce15aba4c099"
      unitRef="usd">-1379000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:CostsAndExpenses
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS01LTEtMS00NTQ0MQ_1c1b2622-c5c4-4f73-88fc-8d0936383647"
      unitRef="usd">460944000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="icf3fbdd624724d3d85d457df11a2b0ec_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfNS03LTEtMS00NTQ0MQ_9d8d3219-c017-41fa-b2d3-f2c6e1f9a40b"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfOC0zLTEtMS00NTQ0MQ_edaeb304-1158-4e1d-9c84-21afd35f9dd0"
      unitRef="usd">1292000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6aa52acc498d4cdab18b97d9c59c01b9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RhYmxlOjJhY2Y1NDAzOWVhMzRhODlhODFhM2I1OGEzMTc0OGE5L3RhYmxlcmFuZ2U6MmFjZjU0MDM5ZWEzNGE4OWE4MWEzYjU4YTMxNzQ4YTlfOC03LTEtMS00NTQ0MQ_eaa2d614-23c6-4aaa-83ee-e1c8e9ebceb3"
      unitRef="usd">4269000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81NS9mcmFnOmY1Zjk2MzMyNWQxNzQxNDg5NWE3N2EzMmI1MTNmNmY4L3RleHRyZWdpb246ZjVmOTYzMzI1ZDE3NDE0ODk1YTc3YTMyYjUxM2Y2ZjhfMTk1MA_a3dc2951-5f4f-4c9b-92e2-9370183b3eee"
      unitRef="usd">7600000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc1OA_79cbacd7-0000-4fc1-8f81-bb15f048c0c3">DEBT&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company&#x2019;s convertible debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total convertible debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,080,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of fixed-rate convertible debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total fair value of fixed-rate convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,101,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The fair value of the Company&#x2019;s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense on the Company&#x2019;s convertible debt consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of discount on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 10 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 for additional information related to the Company&#x2019;s convertible debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0&#160;million which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes.&#160;The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of March&#160;31, 2022, there were no amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTYx_16fd4442-c357-4c0a-8926-62b02025521e"
      unitRef="usd">1100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc2MA_59d3859f-7b56-4515-b239-e6a485aebc79">The following table summarizes information regarding the Company&#x2019;s convertible debt:&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized discount net of deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total convertible debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,080,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,079,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value of fixed-rate convertible debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total fair value of fixed-rate convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,101,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The fair value of the Company&#x2019;s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Overview and Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjNkMzczYTk3ZDdkMzRmZjM4MjlkOGU4ODMxZWNlMDA4XzQ_372e102e-8f10-4374-b9e8-0ac6ae9f728d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id0331cf243884e099d67f815a061dcd2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjNkMzczYTk3ZDdkMzRmZjM4MjlkOGU4ODMxZWNlMDA4XzQ_66e6c854-339a-4c46-bd7d-bb4aeb26ced2"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id0331cf243884e099d67f815a061dcd2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0xLTEtMS00NTQ0MQ_d63c35b1-20a5-4d05-b90c-cc391d804873"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMS0zLTEtMS00NTQ0MQ_afe235d9-8c0a-4e65-b79c-32d9beb83ee7"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id0331cf243884e099d67f815a061dcd2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMi0xLTEtMS00NTQ0MQ_21515feb-70f7-4373-bf10-2393e3271750"
      unitRef="usd">10465000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMi0zLTEtMS00NTQ0MQ_e71d8182-3dc4-4f11-8c94-6b29a8a2c44f"
      unitRef="usd">10971000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="id0331cf243884e099d67f815a061dcd2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMy0xLTEtMS00NTQ0MQ_3980b374-e7ca-4935-a2f6-c546f6ef61ee"
      unitRef="usd">589535000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMy0zLTEtMS00NTQ0MQ_68db228f-8de1-46ed-ba9b-ae7cf073e89b"
      unitRef="usd">589029000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjIwNTM3MDk5MTZmYTRlZDRhN2MzODRjYTgyOWQxOTE0XzQ_5488deaa-888a-46dc-bfb0-4436478145ed"
      unitRef="number">0.00599</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0wLTEtMS00NTQ0MS90ZXh0cmVnaW9uOjIwNTM3MDk5MTZmYTRlZDRhN2MzODRjYTgyOWQxOTE0XzQ_c79344cb-8d08-4409-a40c-b21dd4826b21"
      unitRef="number">0.00599</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0xLTEtMS00NTQ0MQ_31b2ebaf-9bc1-474a-96f9-1f73b80be05f"
      unitRef="usd">495000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNS0zLTEtMS00NTQ0MQ_a535eab7-9107-46c4-b7ce-038239264bda"
      unitRef="usd">495000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNi0xLTEtMS00NTQ0MQ_4c2d90b7-218a-435e-8403-3899abe5ce49"
      unitRef="usd">4474000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNi0zLTEtMS00NTQ0MQ_0f18b940-cebe-436b-b821-5553a3ea79ae"
      unitRef="usd">4952000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNy0xLTEtMS00NTQ0MQ_2b9e4723-aff4-4363-85dc-2b2bf7f8f1b6"
      unitRef="usd">490526000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfNy0zLTEtMS00NTQ0MQ_21763353-00aa-4722-b4dc-79324e82ddbe"
      unitRef="usd">490048000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfOS0xLTEtMS00NTQ0MQ_e512a572-2f45-4193-8820-16696f91a1bf"
      unitRef="usd">1080061000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfOS0zLTEtMS00NTQ0MQ_a93d0698-a3c2-4663-bf57-12ec2bdc4d18"
      unitRef="usd">1079077000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="id0331cf243884e099d67f815a061dcd2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTItMS0xLTEtNDU0NDE_dfb6f355-7b75-4f0f-9f7a-20928d349106"
      unitRef="usd">604758000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="id59ded9cd6c34aa1968e85dc2a793158_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTItMy0xLTEtNDU0NDE_4778d231-6410-4422-aad4-4b976bf63e1e"
      unitRef="usd">625122000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="if9d1bc8295d14eccb284c5835c6f2c82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTMtMS0xLTEtNDU0NDE_c4d34bda-5c02-427a-abe6-52880a61ab48"
      unitRef="usd">497223000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i996fc39458ef4d55b3cb8c33ea4d6385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTMtMy0xLTEtNDU0NDE_8ba9b96e-e627-4468-923d-4be20ac1c825"
      unitRef="usd">521082000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTQtMS0xLTEtNDU0NDE_3c3f70b1-a592-49f5-8238-c970a950dca2"
      unitRef="usd">1101981000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i63654500f0694941a974905d3087a5ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjE4Mzc4MDMzN2NjMTRjNjQ5ODU1MTU3OWUwMDE4MzRhL3RhYmxlcmFuZ2U6MTgzNzgwMzM3Y2MxNGM2NDk4NTUxNTc5ZTAwMTgzNGFfMTQtMy0xLTEtNDU0NDE_008fd81c-69b7-4ded-bfe0-f2c89068cf57"
      unitRef="usd">1146204000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTc2Mw_1de6a6dc-7d9f-41ad-887e-93dba88220c9">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense on the Company&#x2019;s convertible debt consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of discount on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMi01LTEtMS00NTQ0MQ_3fc9358a-b12e-4689-b4f6-318b686b0a07"
      unitRef="usd">2616000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMi03LTEtMS00NTQ0MQ_43a6f7ea-5cdf-4c4b-ae79-c63ef889e4a8"
      unitRef="usd">2616000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMy01LTEtMS00NTQ0MQ_79d52430-62e1-4a51-aa45-e26d1b658554"
      unitRef="usd">836000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfMy03LTEtMS00NTQ0MQ_dc0663d5-6245-46de-b770-67cd309c0882"
      unitRef="usd">834000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNC01LTEtMS00NTQ0MQ_d635a963-74ba-4206-bb5a-d515e668534c"
      unitRef="usd">148000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNC03LTEtMS00NTQ0MQ_c1f45995-85e8-402a-8480-0e3e22bd0bb4"
      unitRef="usd">148000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpense
      contextRef="i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNS01LTEtMS00NTQ0MQ_0a479330-2bd3-4343-bc39-9b20f978e339"
      unitRef="usd">3600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0140a347dcf549bc89ebb73fff140a19_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RhYmxlOjk4MTFiOWQ0YzJhYjQyMDg5ZTNkZjExNDg5MTQyY2ExL3RhYmxlcmFuZ2U6OTgxMWI5ZDRjMmFiNDIwODllM2RmMTE0ODkxNDJjYTFfNS03LTEtMS00NTQ0MQ_5e0e2391-f49c-4fb3-8b48-c71f1d0fae64"
      unitRef="usd">3598000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9a61fb3318b44b2ba23a29e3998e0700_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTA4OA_d54569c9-80f6-40cc-aa01-ef125a647cfa"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="id8cf35d33be44d27a7f0d3b047d0f271_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV81OC9mcmFnOmU4MWEyNjhlNDgzMTQ3ODM5MmZjNzhhNzNkODZhZDM1L3RleHRyZWdpb246ZTgxYTI2OGU0ODMxNDc4MzkyZmM3OGE3M2Q4NmFkMzVfMTU5OA_1bd26540-154e-4458-b431-d0a5811d0cf1"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RleHRyZWdpb246YjkyYjg3ZWJiNmRmNGM2OGFhZGFiZThkMmU3ODllZjFfNDQ2_977aac50-0a67-43e4-afe4-726d905f18ec">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on Cash&lt;br/&gt;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on&lt;br/&gt;Available for-Sale&lt;br/&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;&#160;&#160;&#160;&#160; reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on Cash&lt;br/&gt;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on&lt;br/&gt;Available for-Sale&lt;br/&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;&#160;&#160;&#160;&#160; reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For additional discussion of reclassifications from AOCI see Note 5 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivative Instruments and Hedging Strategies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RleHRyZWdpb246YjkyYjg3ZWJiNmRmNGM2OGFhZGFiZThkMmU3ODllZjFfNDUw_4337e36c-67df-4668-bd0d-1e447754c2af">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on Cash&lt;br/&gt;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on&lt;br/&gt;Available for-Sale&lt;br/&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;&#160;&#160;&#160;&#160; reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on Cash&lt;br/&gt;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;br/&gt;(Losses) on&lt;br/&gt;Available for-Sale&lt;br/&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before&lt;br/&gt;&#160;&#160;&#160;&#160; reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: gain (loss) reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AOCI balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i5e3059cd10734ed783cd2d2634b0d82b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi0xLTEtMS00NTQ0MQ_a1b967dc-ace2-4684-9bc2-3a9f8b4a129e"
      unitRef="usd">15805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99b1717d96134283ae50ccf10e9f13ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi0zLTEtMS00NTQ0MQ_4ffa53d3-7d7e-4281-af7f-1d0c9819d205"
      unitRef="usd">-1373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17e50effa4c044d1a1f56b02b147b183_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMi03LTEtMS00NTQ0MQ_9d73fb43-fadd-48e1-8204-cfe829b31301"
      unitRef="usd">14432000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy0xLTEtMS00NTQ0MQ_92d41021-d552-4370-9489-f548bdda470c"
      unitRef="usd">-3225000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy0zLTEtMS00NTQ0MQ_595451bb-1195-4a26-95d0-459b4efeb31b"
      unitRef="usd">-10274000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfMy03LTEtMS00NTQ0MQ_7ef21d19-f3a0-436a-8e17-e87df91d73d9"
      unitRef="usd">-13499000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC0xLTEtMS00NTQ0MQ_803b89d9-83bd-4c7a-b5d1-cf953da162fa"
      unitRef="usd">4193000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC0zLTEtMS00NTQ0MQ_1e1aa4fb-e311-4e7d-bf4f-52b7342dee41"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNC03LTEtMS00NTQ0MQ_1c2b49da-1c72-4f9f-b7ac-94ddb33a7988"
      unitRef="usd">4193000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS0xLTEtMS00NTQ0MQ_259f36a1-3a27-4b73-a1f9-671cb294d55c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS0zLTEtMS00NTQ0MQ_06198eb7-175b-4b5e-b935-022e0b0c2df6"
      unitRef="usd">-2383000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNS03LTEtMS00NTQ0MQ_5739eb2d-1811-4be2-a253-1bb3a51e7804"
      unitRef="usd">-2383000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id20cef047b0247b3ad12f7246dd0a108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi0xLTEtMS00NTQ0MQ_5c58e35f-72ac-4c51-8025-e63d49d8d17a"
      unitRef="usd">-7418000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie9e1e5c2db6148c2b71d24cefc4ecf78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi0zLTEtMS00NTQ0MQ_d74cd268-7ef8-4ec3-81c9-f2e8b5018b13"
      unitRef="usd">-7891000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNi03LTEtMS00NTQ0MQ_e17d13f7-9142-4bdc-ab5d-6584e6ec45d0"
      unitRef="usd">-15309000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ie2c3fc76077b46a996c89411439fc65e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy0xLTEtMS00NTQ0MQ_bf489644-7ba2-48c5-85e0-f8ade36363e0"
      unitRef="usd">8387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d46d1b4201e4019aa70b698c03d7415_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy0zLTEtMS00NTQ0MQ_5aba5235-60fa-463e-b6ea-f9925af93072"
      unitRef="usd">-9264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e7db0e866934747a0ef27975afd832f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOjFiY2MzYjdhNzY2MDQ1NjM5YTYyMTRhNzA0ZTU3MTFhL3RhYmxlcmFuZ2U6MWJjYzNiN2E3NjYwNDU2MzlhNjIxNGE3MDRlNTcxMWFfNy03LTEtMS00NTQ0MQ_0fff3cef-8da0-4b08-ba53-30371a345dbb"
      unitRef="usd">-877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f51f53032a84b1b89b05ca56aa74445_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi0xLTEtMS00NTQ0MQ_a647c71b-66d2-41e5-ae09-e86e0b1a788e"
      unitRef="usd">-20028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i840b2f2e120540f98c612afa3ec823f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi0zLTEtMS00NTQ0MQ_23013fb7-e777-4e9d-ab54-d530bda20ece"
      unitRef="usd">3889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65140d9974ff4879ad2575de4f85ba00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMi03LTEtMS00NTQ0MQ_9dd5edbb-3b52-427a-b358-11d6bd4cad77"
      unitRef="usd">-16139000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy0xLTEtMS00NTQ0MQ_c8dab8f0-a5a3-4572-a97a-f98014167c09"
      unitRef="usd">19893000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy0zLTEtMS00NTQ0MQ_b34692f4-95f6-413d-a4b7-2af3200c4691"
      unitRef="usd">-1945000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfMy03LTEtMS00NTQ0MQ_90c19534-e489-4e41-93e0-5f41a8e825b5"
      unitRef="usd">17948000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC0xLTEtMS00NTQ0MQ_c6cd8107-8252-4152-9660-a1a93f6424b2"
      unitRef="usd">-2752000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC0zLTEtMS00NTQ0MQ_c4ce5212-1081-4de9-8b08-bb21cb279183"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNC03LTEtMS00NTQ0MQ_7c924852-a4c7-4abe-bf4b-5a9d3738fc9c"
      unitRef="usd">-2752000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS0xLTEtMS00NTQ0MQ_6e475122-073e-4aa3-b402-80afc338e8e0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS0zLTEtMS00NTQ0MQ_8feceaae-5f75-4f92-a354-6007a527fc43"
      unitRef="usd">-443000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNS03LTEtMS00NTQ0MQ_b48c19bc-1934-4f71-8466-54ff211f5846"
      unitRef="usd">-443000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3529ef3770684bc6b36c73c745ff110a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi0xLTEtMS00NTQ0MQ_1ce9bb32-4ca0-409e-a546-97f7fd8d4dfa"
      unitRef="usd">22645000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib0e98a397b9b4ff6bd77db6f48573896_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi0zLTEtMS00NTQ0MQ_ad6f1070-11a0-4ee2-94d7-5a8aebc6679c"
      unitRef="usd">-1502000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNi03LTEtMS00NTQ0MQ_29d96e8a-d559-4616-a0cb-55490d67842e"
      unitRef="usd">21143000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i3b4c4bfebe294de7b1a98930ea9835b9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy0xLTEtMS00NTQ0MQ_3367f6ba-fb5f-4234-8583-f8b7ba51acd2"
      unitRef="usd">2617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id01504b7547d48c29809551d9fa94665_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy0zLTEtMS00NTQ0MQ_0f5144b6-ef00-4e89-8fff-47280fa422e2"
      unitRef="usd">2387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3649606ceb74fcf8df8cc4b91928646_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82MS9mcmFnOmI5MmI4N2ViYjZkZjRjNjhhYWRhYmU4ZDJlNzg5ZWYxL3RhYmxlOmRiZjVkNTZhNmEwMTRjZjQ4MjljZWRkMzM2NmE0ZjBlL3RhYmxlcmFuZ2U6ZGJmNWQ1NmE2YTAxNGNmNDgyOWNlZGQzMzY2YTRmMGVfNy03LTEtMS00NTQ0MQ_0ee49a34-d08c-4566-be2f-bf82e2ae9d9c"
      unitRef="usd">5004000</us-gaap:StockholdersEquity>
    <bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQzNw_c6125b46-416a-4aca-a41f-1012b48ec4cc">REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table disaggregates total Net Product Revenues by product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues by product:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vimizim&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Naglazyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Kuvan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Palynziq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brineura&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Voxzogo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aldurazyme net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;486,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company&#x2019;s Net Product Revenues within the regions below may have a material adverse effect on the Company&#x2019;s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Middle East&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aldurazyme net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table illustrates the percentage of the Company&#x2019;s total Net Product Revenues attributed to the Company&#x2019;s largest customers for the periods presented.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On a consolidated basis, two customers accounted for 21% and 14% of the Company&#x2019;s March&#160;31, 2022 accounts receivable balance, respectively, compared to December&#160;31, 2021, when two customers accounted for 28% and 16% of the accounts receivable balance, respectively. As of March&#160;31, 2022, and December&#160;31, 2021, the accounts receivable balance for Sanofi included $61.4 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers&#x2019; financial condition and requires prepayments in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the three months ended March&#160;31, 2022 and 2021, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and the Company anticipates a continued impact due to COVID-19 on its financial results in 2022. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is mindful that conditions in the current macroeconomic environment could affect the Company&#x2019;s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company&#x2019;s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.&lt;/span&gt;&lt;/div&gt;</bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY0OTI2NzQ0ODUwNg_69eac079-c990-4937-b7b0-57399ef712c9"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQ0Mg_3ab6bb3d-1fb9-458c-897f-fed3e4c23bc4">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table disaggregates total Net Product Revenues by product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenues by product:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vimizim&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Naglazyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Kuvan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Palynziq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brineura&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Voxzogo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aldurazyme net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;486,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic74a170ac59147cca285f25489fe3660_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMy01LTEtMS00NTQ0MQ_8906ef14-bac7-470b-99b3-9e3f80c3761a"
      unitRef="usd">183059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddc468e5fd8a42e2b1558768f37e6571_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMy03LTEtMS00NTQ0MQ_282d2a5c-12c5-4094-a4a5-6ca166b220f7"
      unitRef="usd">158298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56ef15ea138648cca1e80f4d3e259dc9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNC01LTEtMS00NTQ0MQ_9ceff8cb-eb6c-4141-afd6-68f0a5160213"
      unitRef="usd">128031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica5c489de8f841848c2154b45041d920_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNC03LTEtMS00NTQ0MQ_31e0d814-9e74-427b-abd8-6556cdedbb87"
      unitRef="usd">107336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i491df707a2b5489fb420d6bc1f228e19_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNS01LTEtMS00NTQ0MQ_be500fc9-dbef-4afe-88c1-5f18726ee32d"
      unitRef="usd">59337000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89eb3a13235f4740a02e03ada4aacecf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNS03LTEtMS00NTQ0MQ_3ceeb12c-a27b-4197-a478-658ed5d8a498"
      unitRef="usd">70763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie708c87270e9415c898a4aeae0af25bd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNi01LTEtMS00NTQ0MQ_e965b79b-20b0-4947-8ae1-dc0da345c69e"
      unitRef="usd">54885000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i895d2189edd943fdadd1d2c44e8fa735_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNi03LTEtMS00NTQ0MQ_dea9c83c-fa87-4ba2-abc4-d54e501de434"
      unitRef="usd">54038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4d78c3903b24697b01c59cc20ff5358_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNy01LTEtMS00NTQ0MQ_666cba5d-24d2-4e44-a66c-8a1e1db33978"
      unitRef="usd">36173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20640d60dab64a039c473a7175a0a267_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfNy03LTEtMS00NTQ0MQ_35018147-330d-4f14-a0f2-ab4b418e540c"
      unitRef="usd">27325000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i594041ae57af40ccab0c62019799787e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfOC01LTEtMS00NTQ0MQ_879b479b-7ea2-478a-bb4d-fd5619a928bc"
      unitRef="usd">19658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b892fdeb6e14ef287c0f6a538ac8c13_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfOC03LTEtMS00NTQ0MQ_6863c844-19a5-4d6a-bacf-b9dfeaf04327"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1103deb96054b26b048779411774904_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTAtNS0xLTEtNDU0NDE_6c6478fe-1d9a-4e11-9224-ee7581841e1e"
      unitRef="usd">481143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTAtNy0xLTEtNDU0NDE_6c7683c4-f87a-42f5-a507-ccc0bd0839ab"
      unitRef="usd">417760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTEtNS0xLTEtNDU0NDE_769c5627-307e-4b7b-8844-dce05df594b1"
      unitRef="usd">24382000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTEtNy0xLTEtNDU0NDE_a8ec6110-89f0-49b7-9468-13cf048784a9"
      unitRef="usd">50009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNS0xLTEtNDU0NDE_7b91a65a-579a-4a64-88be-bbf68ad5799e"
      unitRef="usd">505525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNy0xLTEtNDU0NDE_c40ff62c-c8e2-472a-aaa7-dc3a012fad5f"
      unitRef="usd">467769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if87ec807037b48a1827df1aaa0055934_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNS0xLTEtNTEwMTM_7ec9cb8a-0e1f-4aa4-9b78-3cda581d90f3"
      unitRef="usd">13834000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4614f93f2cb544778d4948368a64a5a4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTItNy0xLTEtNTEwMTM_eb0981b4-eb3d-4b2f-87f7-f06d3677efa7"
      unitRef="usd">18261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTMtNS0xLTEtNTEwMTM_0bc393ee-ba35-4878-a835-646ca94e4431"
      unitRef="usd">519359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjRhNTJmNGU4NGQ3MjRmMGM4NTEyMDFhZGQyZTczNTBjL3RhYmxlcmFuZ2U6NGE1MmY0ZTg0ZDcyNGYwYzg1MTIwMWFkZDJlNzM1MGNfMTMtNy0xLTEtNTEwMTM_2aa1bf94-2d99-40cd-9c59-885034a017c5"
      unitRef="usd">486030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQ0NA_e93e9cf6-4ee1-44c8-954f-827b9b8fb8d8">The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Middle East&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues marketed by the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;481,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aldurazyme net product revenues marketed by Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b9f090883124d2198ad6215aa997c28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi01LTEtMS01NDMwOQ_36d6ecf6-411a-4e08-aa4f-fe017447f371"
      unitRef="usd">156832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0ff03d00b5648269908ec5e62655bb4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi03LTEtMS01NDMwOQ_0c9e350d-4515-4c86-bdeb-b3640fd60149"
      unitRef="usd">148872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id742c4f384be442b8fca74da0bbbaa4e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi01LTEtMS00NTQ0MQ_315f08c5-6770-4bc8-8d6c-af821ae70167"
      unitRef="usd">150815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f4557550c4f422393773b243642092c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfMi03LTEtMS00NTQ0MQ_63ddefbd-ecf5-4b87-96e5-cfea69cb39eb"
      unitRef="usd">155064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8f201c2b5d348ee8cef94eeee757986_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC01LTEtMS01NDI3Ng_b0978954-6f1a-4363-861c-781b3ccebac0"
      unitRef="usd">65607000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9306ad4c27064a6b9826f59953cafc24_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC03LTEtMS01NDI3Ng_389f808f-3058-4109-82f9-fc389b8e7b64"
      unitRef="usd">15559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a14de3abadb40778471e66184af280a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC01LTEtMS00NTQ0MQ_71bb2988-6464-4afc-837c-271e9b5d1c76"
      unitRef="usd">62544000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74ff7532c1ae49528158820bb4da4aea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNC03LTEtMS00NTQ0MQ_41788225-2aba-4f3a-a724-6c579c2d59fb"
      unitRef="usd">59705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecad8ebdb8c244bd98a2afd89bba0a2e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNS01LTEtMS00NTQ0MQ_0d4cfa7b-8718-4386-a608-2a694889cd4c"
      unitRef="usd">45345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cdbd316d31b4d1cab319df9d84f7f77_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNS03LTEtMS00NTQ0MQ_82ebf015-072b-4899-8e3c-8efd27957028"
      unitRef="usd">38560000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1103deb96054b26b048779411774904_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNi01LTEtMS00NTQ0MQ_4658ef6c-b64d-486f-b319-33f6b52079c4"
      unitRef="usd">481143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ef88630ab1d478ab596aca3dc4b9639_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNi03LTEtMS00NTQ0MQ_c67473a2-5e45-460b-b180-4e6c9b0b386d"
      unitRef="usd">417760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d37c6b20af94e39a50ed4a1f0ccaf4a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNy01LTEtMS00NTQ0MQ_1c2a51dd-6d70-43c2-ba85-d3043b95de4f"
      unitRef="usd">24382000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i566e660b9b5646bc8af6eb3d02d41692_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfNy03LTEtMS00NTQ0MQ_62a17b41-0e7f-4a2e-8bcd-1dca518b8a86"
      unitRef="usd">50009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a0b42502c494bb086615adb5f41fedc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfOC01LTEtMS00NTQ0MQ_b723fc9f-ed62-488f-ab09-f86921cb9c17"
      unitRef="usd">505525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9964555943664f0cb773a445f771d126_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjM1YTY3NDA2NjZiMDRhZDliMDAwMzdhMmFhZjZiNmI2L3RhYmxlcmFuZ2U6MzVhNjc0MDY2NmIwNGFkOWIwMDAzN2EyYWFmNmI2YjZfOC03LTEtMS00NTQ0MQ_57345b1f-a749-485d-b623-512c2ed774f9"
      unitRef="usd">467769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfNDQzOA_fc4586ff-997c-42f5-8cba-d2d8728f872b">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table illustrates the percentage of the Company&#x2019;s total Net Product Revenues attributed to the Company&#x2019;s largest customers for the periods presented.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i23782facb41e4a0394006d0c61111460_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMi01LTEtMS00NTQ0MQ_3af21d70-6565-41e7-93d4-a2bee404c072"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21c33100f90b40bca71ded15376adfcb_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMi03LTEtMS00NTQ0MQ_d9e8cffa-3adf-4a79-8524-e726fe86a401"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie5e5f24d472d4e82b55a8346cd4fc93b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMy01LTEtMS00NTQ0MQ_0545e860-cd0f-483c-a5fe-b65cc47f8c94"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6fdf37db79194886b085e0309823a025_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfMy03LTEtMS00NTQ0MQ_c1f71391-4c40-4222-8fb8-a17949b0885e"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1bf584b76688449d949ae03ea7a23992_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNC01LTEtMS00NTQ0MQ_aaa2415c-381e-438a-ac99-2d681d9dc6a2"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4f6c8323762a4a68a579e56d15514782_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNC03LTEtMS00NTQ0MQ_8c930eb3-6799-43f1-89e3-31dc2465ecff"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief8a05482b8a475f87dfd720c5c6b2f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS01LTEtMS00OTAyNQ_8099f1bf-11ec-472a-bac0-b6fdc61fcdbd"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21f73aa86157436b89f7042549ab2cdf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS03LTEtMS00OTAyNQ_eed8a20b-67a2-48b5-889c-17032e33eaca"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS01LTEtMS00NTQ0MQ_57fb6fb1-876f-4462-9b1d-f8ba0eca5059"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6e84ec89b6c4d8ea066d35c5ace7603_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RhYmxlOjQwODM4YjdlYzlhNTRkNGJiMWNjMzZlN2Q2NmQ0Y2EyL3RhYmxlcmFuZ2U6NDA4MzhiN2VjOWE1NGQ0YmIxY2MzNmU3ZDY2ZDRjYTJfNS03LTEtMS00NTQ0MQ_3d451dc4-9b76-4ecd-94fa-8977f058695a"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie4519e269765428dbc66faaaa2646940_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY1Nw_d60516a7-d7a8-4bd5-9eda-b714e5030f15"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb6f40e5c0bf4422a0a81cb722132751_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTY2NA_c611dd6d-97e7-4ce2-a3be-d8b6a9a9845c"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5407662ac25040bf8b124d95a9d5af58_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTc3OA_406507a1-4f7a-450f-8030-f1702274fa25"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5da3b672cc79498eb14a326a63d8c950_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTc4NQ_572abef9-9736-4e48-afe4-f341a11ab648"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic4d5c38e0f09439dbdf86382f3b59459_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTkwOQ_2c08ef9a-2f8f-4016-a8fa-f793e888ec79"
      unitRef="usd">61400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iae90bf0fe46c464d9eb1ead18b979c57_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82NC9mcmFnOmVkOTNmNjBkMzcyNTQ2MDZiZTI4YWRhYWM4ZmI5ZmY5L3RleHRyZWdpb246ZWQ5M2Y2MGQzNzI1NDYwNmJlMjhhZGFhYzhmYjlmZjlfMTkxNg_715c5b0a-82d1-4e1e-9628-ddd1e51161e3"
      unitRef="usd">67900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfNDg4_dc060c71-73ef-4073-9559-43168dc0884e">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. Compensation expense included in the Company&#x2019;s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation of $5.2 million and $4.4 million was capitalized into inventory for the three months ended March&#160;31, 2022 and 2021, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfNDkw_0a590d6a-144e-4345-b2d3-178a9df512ff">Compensation expense included in the Company&#x2019;s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19465b1578ec4dd28c910af817bceab3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMi01LTEtMS00NTQ0MQ_05e5306b-b3a2-49a3-85df-ae6442248681"
      unitRef="usd">4326000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03cdf675716d437c964339c1910bdbdc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMi03LTEtMS00NTQ0MQ_bce01f85-115f-45a6-b964-ad576a4382df"
      unitRef="usd">6481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f0fd632f5fd41e287a0b11cae9cbeca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMy01LTEtMS00NTQ0MQ_e45ac6bb-e52d-4e47-b3cf-d28f0cbc4707"
      unitRef="usd">17190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i008d8298bf11412ba45a7ea365cc12cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfMy03LTEtMS00NTQ0MQ_4b709d77-0bb2-4328-9685-f6146d34e5c3"
      unitRef="usd">17517000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b0087b7e6ba4593890bb5c30ab38817_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNC01LTEtMS00NTQ0MQ_7ea4e08b-2e00-44a7-8862-2b53fa4e1b92"
      unitRef="usd">26317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4910a2e24b7045899f96c49194daa7f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNC03LTEtMS00NTQ0MQ_60b13511-9778-4b2e-bf8f-d3d550b15331"
      unitRef="usd">25505000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNS01LTEtMS00NTQ0MQ_179e6f85-688d-40c4-aa4b-193e2aa57cf8"
      unitRef="usd">47833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RhYmxlOjJhMjhlMWUxMmM1NzRjYmRiYTdhNWEzZWU4OTIzZGI2L3RhYmxlcmFuZ2U6MmEyOGUxZTEyYzU3NGNiZGJhN2E1YTNlZTg5MjNkYjZfNS03LTEtMS00NTQ0MQ_4d47471e-74e1-43c8-9d34-7987df78111a"
      unitRef="usd">49503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfMTY0OTI2NzQ0MjYyMQ_8b2ff151-9756-43c8-af73-f4dd3842de18"
      unitRef="usd">5200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV82Ny9mcmFnOjEwODQwYzk0ZDY2ZjQ4ZWFiMzhhM2RkZDdiNzBmMGRmL3RleHRyZWdpb246MTA4NDBjOTRkNjZmNDhlYWIzOGEzZGRkN2I3MGYwZGZfMTY0OTI2NzQ0MjYyOQ_6850328f-bf73-4e87-b9bb-efa7963a7dce"
      unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyNA_31fbba7e-2693-4d29-a390-1c5ea85c0a9a">NET INCOME PER COMMON SHARE&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company&#x2019;s Employee Share Purchase Plan (ESPP), unvested RSUs, the Company&#x2019;s common stock held by the NQDC and contingent issuances of common stock related to the Company&#x2019;s convertible debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest expense, net of tax, on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock potentially issuable for ESPP purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The Company&#x2019;s common stock held by the NQDC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock potentially issuable for ESPP purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyMA_691adc95-f02d-42d0-bf53-daade779fc67">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest expense, net of tax, on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock potentially issuable for ESPP purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The Company&#x2019;s common stock held by the NQDC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMy01LTEtMS00NTQ0MQ_4cda4003-dffa-4c1a-8d4f-2694f5936717"
      unitRef="usd">120798000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMy03LTEtMS00NTQ0MQ_087cb9d2-c673-4cc9-962e-6de875bd885a"
      unitRef="usd">17371000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNC01LTEtMS00NTQ0MQ_f1f3c4a3-0092-4d37-982b-c2731da92d04"
      unitRef="usd">2763000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNC03LTEtMS00NTQ0MQ_c43cf07b-2194-4358-bb9f-e2c872793603"
      unitRef="usd">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNS01LTEtMS00NTQ0MQ_8cd7f5b8-7e67-4026-bb92-26b85a3f8a10"
      unitRef="usd">123561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNS03LTEtMS00NTQ0MQ_22e106ac-e5db-4631-b03b-7c2e93fa5d24"
      unitRef="usd">17371000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNy01LTEtMS00NTQ0MQ_9686dc07-bf24-4752-bb37-3c777db52e11"
      unitRef="shares">183990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfNy03LTEtMS00NTQ0MQ_ddcab8ee-33fd-4dbf-89c8-96413faa2e45"
      unitRef="shares">181772000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfOS01LTEtMS00NTQ0MQ_d57bf0db-f2b8-4a05-a790-68d328f34fe6"
      unitRef="shares">564000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ie33737b08299431889d37d12a1d70178_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfOS03LTEtMS00NTQ0MQ_384eb2de-86b1-4369-9441-7c3431d1827e"
      unitRef="shares">1010000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i85312ddaf862450190f331615f114ab7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTAtNS0xLTEtNDU0NDE_c8d0ad95-1894-4060-8d1a-cf0659cd9b14"
      unitRef="shares">4365000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTAtNy0xLTEtNDU0NDE_cbcd323f-0534-4738-bca4-aa79637b8454"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTEtNS0xLTEtNDU0NDE_0e422fbe-4ac6-4b12-b75b-d1f626259cad"
      unitRef="shares">3970000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i530302b04890455682f0ab0adc4d162e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTEtNy0xLTEtNDU0NDE_d046868c-dd6d-4092-8734-3b39832324f1"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTMtNS0xLTEtNDU0NDE_45bf6ea8-b9a7-4056-a56b-68102b1a7e2a"
      unitRef="shares">1517000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTMtNy0xLTEtNDU0NDE_5f4069f9-2856-4c2b-a80b-1a4d7193d4d7"
      unitRef="shares">1031000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTQtNS0xLTEtNDU0NDE_b7f9952d-bdd3-4d5d-a532-949fd2a1d7ea"
      unitRef="shares">307000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTQtNy0xLTEtNDU0NDE_a2ec6f41-65a8-4b45-b808-bdc1f0f2f302"
      unitRef="shares">359000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ib721cab6f4a2424680bcabdd246154df_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTUtNS0xLTEtNDU0NDE_7d893b1f-baef-4519-8c1b-34ede5f2885c"
      unitRef="shares">173000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="id99beaf0bac24ae7a8e8559e31363de0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTUtNy0xLTEtNDU0NDE_c339c5a0-725c-494d-b9d1-67efa4f5ca22"
      unitRef="shares">193000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTYtNS0xLTEtNDU0NDE_f73a6eb0-f237-40e2-8925-6204540585ea"
      unitRef="shares">194886000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTYtNy0xLTEtNDU0NDE_5c773e15-f714-4f35-a056-d361dc9ea0a4"
      unitRef="shares">184365000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTctNS0xLTEtNDU0NDE_ab6114f0-0270-4da8-acd7-01a0a3b02f8a"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTctNy0xLTEtNDU0NDE_9d11de9c-cf04-4893-9efe-30f029b8b4b4"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTgtNS0xLTEtNDU0NDE_504a33ee-1e6f-4a33-b3c3-c5f9eaa09781"
      unitRef="usdPerShare">0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOjJjNjhmZDY4NDc4NzQ2ZjFiMGVkZmU3ODFjOTQxNTRlL3RhYmxlcmFuZ2U6MmM2OGZkNjg0Nzg3NDZmMWIwZWRmZTc4MWM5NDE1NGVfMTgtNy0xLTEtNDU0NDE_eeacf975-8785-4d7c-937c-2d7f13a979e2"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RleHRyZWdpb246ZmQ3YzAxMDNhOTg3NDA5MmIwZjBlZjAwNDdiNzgxMzRfMTMyMg_89d4850c-a5b6-4bf2-a7ca-3349bedf1775">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable under the 2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock potentially issuable for ESPP purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icdfe7e839e1f41a6b5df04ff15f7ca4a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfMi01LTEtMS00NTQ0MQ_2e5e6f59-e3cf-4609-b99f-a317eaf3cbf9"
      unitRef="shares">6206000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie33737b08299431889d37d12a1d70178_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfMi03LTEtMS00NTQ0MQ_59db6042-ed37-47c4-a73c-2885c1fed6fe"
      unitRef="shares">6217000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85312ddaf862450190f331615f114ab7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC01LTEtMS00Nzk2NA_99e8e50b-0ac6-4c66-8a46-7d94585f0d40"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1ef251580625448999d25baa3bba5e6e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC03LTEtMS00Nzk2NA_7cb6f960-90a4-4617-b19a-b681d80edb88"
      unitRef="shares">4365000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0abd91aeaae64fe5b8f6a9b60fe7f1ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC01LTEtMS00NTQ0MQ_8e4817aa-6ba6-428d-8578-b723259123f6"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i530302b04890455682f0ab0adc4d162e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNC03LTEtMS00NTQ0MQ_86c16ef6-d2e7-4cf8-a651-aadebd74d301"
      unitRef="shares">3970000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2db5f4313ae646e693c8d4d22e499c01_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNi01LTEtMS00NTQ0MQ_9c32d3ed-d810-4b3e-9bc2-267dd344f08e"
      unitRef="shares">4463000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ffe431db60947e0a53f78ff2493b80d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNi03LTEtMS00NTQ0MQ_b49f310a-89a4-4ecb-88e9-0b843ae7a409"
      unitRef="shares">3920000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61dd49ec6234a5abfe1d6ed2e71f854_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNy01LTEtMS00NTQ0MQ_ca9a51f0-15a4-40f2-81c4-c4f3fcce700c"
      unitRef="shares">258000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i515fdc5ceb1644808e5cc2ffbaf4db11_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfNy03LTEtMS00NTQ0MQ_0448d083-46d3-4d02-b2b2-5633ba5215f1"
      unitRef="shares">301000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfOS01LTEtMS00NTQ0MQ_83f323cf-26de-417e-b064-a3df3feb95a3"
      unitRef="shares">10927000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1813b76e056243b68b7170cec5efe3dc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83MC9mcmFnOmZkN2MwMTAzYTk4NzQwOTJiMGYwZWYwMDQ3Yjc4MTM0L3RhYmxlOmI5M2IwM2UzMTU5NjQxNGJiZDU2MGU1MTJjYWM4YmFjL3RhYmxlcmFuZ2U6YjkzYjAzZTMxNTk2NDE0YmJkNTYwZTUxMmNhYzhiYWNfOS03LTEtMS00NTQ0MQ_010a23e9-db87-49a8-ba0b-ac690e2180e4"
      unitRef="shares">18773000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMjMwNQ_aa319ef1-aefe-441b-8b50-69ad8b78f7d9">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company&#x2019;s general &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company was subject to contingent payments considered reasonably possible of $788.5 million, including $389.0 million related to an early stage development program licensed from a third party in the fourth quarter of 2021 and $225.0 million related to an early stage development program licensed from a third party in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses experts and laboratories at universities and other institutions to perform certain R&amp;amp;D activities. These amounts are included as R&amp;amp;D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;amp;D services, production services and facility construction services. As of March&#160;31, 2022, such commitments were estimated at approximately $117.5 million, all of which were short-term. The Company has also licensed technology, for which it is required to pay royalties upon future sales, subject to certain annual minimums.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfNzEx_cb20c67f-3a4b-4489-819b-0846ec27340d"
      unitRef="usd">788500000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="i275d3e6c3fa2449e9f081a92e87e1c21_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMTY0OTI2NzQ0NTIyNg_21a16422-79b4-4dab-9854-dbeb1aa8bc54"
      unitRef="usd">389000000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
      contextRef="i2bad4330064641499986ec8dd304acef_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMTY0OTI2NzQ0NTIyMg_79acc10b-441a-4e53-8b53-211a69270861"
      unitRef="usd">225000000</bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i5017a08d58224e19b728357a77f28248_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV83My9mcmFnOjMwYzkzN2UxMDQ1MzRkMzg5NmMxZWU4NGJiZjNjMDc5L3RleHRyZWdpb246MzBjOTM3ZTEwNDUzNGQzODk2YzFlZTg0YmJmM2MwNzlfMjE2MQ_5858ab24-365a-4a10-a74a-93786fd604b2"
      unitRef="usd">117500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.02pt">December&#160;31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjktMy0xLTEtNDU0NDE_8b90f8e9-e5ea-4b69-9df0-95fa9d611e33"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTYtMy0xLTEtNDU0NDE_d278207c-8834-4581-a9ef-612ecda0033a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzAtMy0xLTEtNDU0NDE_a9154295-7ac8-48ad-a3ac-f12b96660aa7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfOC0zLTEtMS00NTQ0MQ_e96d7a94-af0e-4114-a29b-e4538bfe1f87"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjYtMy0xLTEtNDU0NDE_de5208c2-6fb5-4997-909c-7dc1ad884101"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjUtMy0xLTEtNDU0NDE_c9ad5fb1-8613-4078-ae00-1fa6d709e24a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNC0zLTEtMS00NTQ0MQ_d0357bbe-760b-4a98-988a-2402ce44982f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTUtMy0xLTEtNDU0NDE_64247f2b-c6df-4b41-b4a2-cbe0a14f8f3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzQtMy0xLTEtNDU0NDE_9474b9ba-b9ca-40d8-b86a-4e9b02c78c11"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNy0zLTEtMS00NTQ0MQ_fcdbde65-2d57-4631-bafc-c04b8cc90018"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTItMy0xLTEtNDU0NDE_9fb8c8cb-a5d0-4126-b491-be968bc03603"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjEtMy0xLTEtNDU0NDE_7ad3db07-191d-4757-a5c8-9aeeda0c5cd8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzItMy0xLTEtNDU0NDE_d8913c55-1293-4060-bdf4-5ef5b6567fe1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzEtMy0xLTEtNDU0NDE_49bdb069-b24d-423a-be1c-aea7329cd6e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTQtMy0xLTEtNDU0NDE_b77f0f47-fa03-4d72-b407-3859296a6d65"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjQtMy0xLTEtNDU0NDE_d8816b08-01c9-44fa-99f2-36fd6208d0e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTAtMy0xLTEtNDU0NDE_40a1d698-e2d6-49b8-aa63-d04770dcd947"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTMtMy0xLTEtNDU0NDE_650db0e7-8eaf-42d0-836b-4490976617c6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMy0zLTEtMS00NTQ0MQ_145da41e-a647-473d-b9cf-0b5874cb079a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNS0zLTEtMS00NTQ0MQ_9cde392e-591e-490d-b05f-bc1b364ab49e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzMtMy0xLTEtNDU0NDE_6fd4c65f-c13b-468a-8883-9e1378c95dbe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjctMy0xLTEtNDU0NDE_95bb4ad0-2683-43e6-a786-9ac68e9cbd6a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfNi0zLTEtMS00NTQ0MQ_a111fa4e-493f-4233-8fa7-301d499024f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMjAtMy0xLTEtNDU0NDE_5a0ab262-86d0-4453-9d69-78e2db7e539b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMzUtMy0xLTEtNDU0NDE_0790c3bd-ef0a-42ca-bc26-ee19c01b6756"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTEtMy0xLTEtNDU0NDE_092d9521-4a90-4604-a05f-57908f10ad21"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RhYmxlOmFmNzNiNTQyNDNhNjQ1YTA4ZGYzZjBlOWY5OTk3YjEyL3RhYmxlcmFuZ2U6YWY3M2I1NDI0M2E2NDVhMDhkZjNmMGU5Zjk5OTdiMTJfMTktMy0xLTEtNDU0NDE_baabce4e-29da-418f-ac05-c2faf811acd6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8xOS9mcmFnOjJkOWI3ZTUzYjc3NDRlYzNiODhjNDM4ZDI3M2FmZTI0L3RleHRyZWdpb246MmQ5YjdlNTNiNzc0NGVjM2I4OGM0MzhkMjczYWZlMjRfMzk3_dd6cf4d6-f570-4603-a73d-7445a73251b6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;25, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNy0xLTEtNDU0NDE_9a5f08b8-c922-4eaa-a435-783b99cf6623"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNS0xLTEtNDU0NDE_0ca541ed-c80f-407b-88ca-b32b6b775d62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNy0xLTEtNDU0NDE_e54e8744-0d7b-4c31-a493-ebe85904bafe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy01LTEtMS00NTQ0MQ_883321bd-6fe2-4597-9d9d-daf1e846c711"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNS0xLTEtNDU0NDE_668ac248-c009-43a9-a655-18c6f945d77b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC01LTEtMS00NTQ0MQ_3a7bc1eb-e934-472d-a4a3-43347f5a4c66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzAtNS0xLTEtNDU0NDE_3a76ee7f-2862-4d6d-bba2-7ffd6e4ad127"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNy0xLTEtNDU0NDE_78037784-0f29-414d-9cbd-cb56b4cb5d50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMy03LTEtMS00NTQ0MQ_27550c6f-24ca-4359-aed0-cc9603b467c3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMzUtNy0xLTEtNDU0NDE_ba146d1b-9e1f-4887-b0eb-ae0d6f5f7fac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTAtNy0xLTEtNDU0NDE_a3d5996f-3a7d-4f7f-931e-f56ae2c2adda"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMjYtNS0xLTEtNDU0NDE_54e92283-2625-4a4f-9548-702e8fec8b62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfMTQtNS0xLTEtNDU0NDE_e87b8b8e-7fae-41a9-9992-b7efb4b56682"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RhYmxlOmFmYzM1YjVmYmVlNDQ3NTFhMjY4NzI1ZDRmNTRmNWFmL3RhYmxlcmFuZ2U6YWZjMzViNWZiZWU0NDc1MWEyNjg3MjVkNGY1NGY1YWZfOC03LTEtMS00NTQ0MQ_d138f437-6977-468c-9723-0995c265c03c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmNkMmI5NGIwNTE3MjQ5MmE5ZmZmYzAxNjNjY2FmY2MxL3NlYzpjZDJiOTRiMDUxNzI0OTJhOWZmZmMwMTYzY2NhZmNjMV8yNS9mcmFnOjFlZWFiYmYxZjNhYTRjZjliZjE2ZTY3MTFkNWQ1ZTE1L3RleHRyZWdpb246MWVlYWJiZjFmM2FhNGNmOWJmMTZlNjcxMWQ1ZDVlMTVfNDU4_5dfd086b-d25b-4dc2-9525-d4ae2afb4ebe"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR6_<F.(-4##..79OU!MB\YQ;:[R+*_*Q[)P&$9O*&^"Z78=V7:/3K)-M+*U
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MC5T-.@R;F[4Y+YJ<P8&<7[$<H- _08$7!#WPV>OP.<DZN/\<[H+[K@1!5X+
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M(=($P/Y:"/TT,1VN^Z E_P!02P,$%     @ 6&B=5-!8TF^6!0  FA0  !@
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M2AG \ZT0\G6@7E =1X[^!5!+ P04    " !8:)U4.!+PQXL&  "5&P  &
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M<VV2@XRM"6A8,12%E#/()]JV@XG6;<XEOFQ;U12S;G?1MAO:EFK7K2XE5MC
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MOP'E)PE?9Q\([GF2\" [7#$*ZR<,X/Z2\^3Y1 Q0?HD[_1]02P,$%     @
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MLY,1_C$.(S5 2_P2_*DZND9*E8>B^*UNILNSDT AXAE/I9J"P<^>CWF6J9D
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M4B4 [U=%(5]OU *'_T8X_Q]02P,$%     @ 6&B=5"BF.HY%"   =!4  !@
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M_?HZY+E_I^W$9,T1][SP\@>>/[EBY+VH4"H744,"DF][(KVSQD'QZR+'4*F
M/T_PK%QQ?01J;SKMVY::\%]C,3%W%=W+XNG A"P,DG%"11U>GR2#I]2A;"L!
MB@H!W%9:8?TA%=Z!7*VT%_%UB'OQ^,TQ3UZD8+,_[[H%=%OW*\R9N;M%4G2P
MFO57K::WN:A._/UL.]S?<G':N9 &TVB&IKW3T:##M+\Y^H95"W=;FRJ+=S_W
MF>-E&S0-P/\SA051W: )FNO[Y=]02P,$%     @ 6&B=5,&11-6+!P  ZQ(
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M6"R,7##MRJ@R52N1DRCX(\,XB;H1S52><\*\0&SYY%G+?.L1><2G77J_6Y.
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M'>Y+?KG$!54:/H#O<XWJU&Q80'OEO?H74$L#!!0    ( %AHG52^C\]0WP,
M $()   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;+56;6_;1@S^*X16
M##:@1=))BN74,> X[A(@;TB<[L.P#V>)LH1*.O?N%*?[]>.=9"=]2=H-W0?[
M7OGP(7DD-=D*^4$5B!H>ZZI1QTZA]>;(\U1:8,W5@=A@0R>YD#77M)1K3VTD
M\LP*U97'?/_0JWG9.-.)W;N1TXEH=54V>"-!M77-Y:<3K,3VV F<W<9MN2ZT
MV?"FDPU?XQWJ^\V-I)6W1\G*&AM5B@8DYL?.+#@ZB<Q]>^%]B5OU; [&DI40
M'\SB/#MV?$,(*TRU0> T/. <J\H $8V//::S5VD$G\]WZ.^L[63+BBN<B^J/
M,M/%L9,XD&'.VTK?BNT9]O;$!B\5E;+_L.WN1H<.I*W2HNZ%B4%=-MW('WL_
M/!-(_!<$6"_ +.].D65YRC6?3J38@C2W"<U,K*E6FLB5C0G*G99T6I*<GL[F
M\_O+^XO9<G$*U\NSQ2W,KR]O;A=GBZN[\_<+.+^B]0(&%]=W=\.)ITFE$?32
M'OZD@V<OP(=P*1I=*%@T&6:?RWM$=<^7[?B>L%<!+[D\@#!P@?F,O8(7[NT/
M+5[X M[B8UOJ3_#G;*6TI"?RURN8T1XSLIC1_^73GP@/RP(A%Q4E7]FL0?-5
MA:I/P?)OA+3@S9IVR@8TW>1IVM9MQ35F]-@KWJ1T1JD/R-,"4E%O1(.-!I'#
M['I^[I)<6K69@4Y;*>GHMPW*4F0@"$Y:"8F%2>('-)=%C3"HA%)#X$U&:9U6
M7*DR+U-NLE0!%8XG=*/9T.HP%1"6(AV8'9!=$O&SUP7T-HCD[G' ?4-5JB(C
M,_B=JI/Z>F,I-*^LJIVQP#6<8HKUBLCW2 &\@2!V$S^FR2!PPU$X-%N1&X4,
MKK]KYPK)#%J%+F/QD!!\EXTB,PG=:#P>P@4J=01KHK03>7(+<<VEJ#N2D1N,
M0_CUEX0%[&V_6O)'P#RG(K<_8&Z8A/W_%=7U?QV9P<B-@L2.R3@P3&,W](GI
MEZ[ZPN-O("&E(^.FL<L.(^.F03(:#;\;K>"G1<LW.IGO^BPQZD,W2<8V;H=N
M$)()/QRO8$S&AR;@XXC"%HQH3'X\5@/FCF(VW =EM_Y&O*(HM+__%"O&W,,H
M-C1CG^!9X 8$]6J@S(,FJ6!DQRY@L>O[$5"C YYEI4E%\G56*FI!MO]22GZ=
MJT_6*HKNE= (<6=5\)8"(\L';GHNG#=47%MJY5K9K#_#;&U*!E4UJC3KDFK,
MP;?JKO>LK]4HU[9[*W)'V^BNQ>UW]Q\(LZXO/EWOOB[( 6OSB"K,2=0_&,4.
MR*YC=PLM-K9+KH2FGFNG!7WDH#07Z#P79%Z_, KVGTW3?P!02P,$%     @
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MVVGL5)WN+=9$!Q?=:U<(+44;VO;-Z)6A=/H><FBD+SC.V_MJPP6TM'.@B:C
M6K0DC7&V:737(K#>3R9/X]C%9#]FF-0II&UP0O^C22M ;F!5FF;A*<,&S4KQ
MW:PT5#"AXT,8K.D8STO@.W;NYG<9:@AG70PDG5.H-TK@PPZQ]V#_NPJ(9R_5
M71.2B@)YV;%KX%$@2JSQ5N%8"T-%]WVP03?> YP64'JJOJI"CM)NC(RBJ@.B
M\?)?B-E^TX&OH;LCCR!E>8WW&L#FT=Z)/;C1F>A)5<;#: L^':NCYVZKC@<7
MB,B55;@F==&\>)?8K_8WL>?Q G*W/5[CHIT!*S'ABB5(1T>S_ "*A*O1^.)-
M':XC%\8C,</C&F@L+&W ]Z4!?K8O)*"_GS[[-U!+ P04    " !8:)U4],YG
MN,$#   ""   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RM56UO(C<0
M_BNC;52UTH:%70A<"DC Y=2HR@6%7/NAZ@=G=V"M>.T]VT#HK^^,%_8XJ>1#
M50GAL7=>GGEF/![OC7UU):*'MTII-XE*[^O;)'%YB95P'5.CIB]K8ROA:6LW
MB:LMBB(852I)N]V;I!)21]-Q.%O:Z=ALO9(:EQ;<MJJ$/<Q1F?TDZD6G@R>Y
M*3T?)--Q+3:X0O^E7EK:):V70E:HG30:+*XGT:QW.^^S?E#X7>+>G<G F;P8
M\\J;^V(2=1D0*LP]>Q"T['"!2K$C@O'UZ#-J0[+AN7SR_BGD3KF\"(<+H_Z0
MA2\GT2B" M=BJ_R3V?^*QWP&["\WRH5_V#>Z_2R"?.N\J8[&A*"2NEG%VY&'
M,X-1]X)!>C1( ^XF4$#Y47@Q'5NS!\O:Y(V%D&JP)G!2<U%6WM)7279^NGI^
M7/QV/9^M[C["XO%A>?=Y-7N^?_P\3CQY9YTD/WJ:-Y[2"YXR>##:EP[N=('%
M]_8)H6JAI2=H\_1=AP_"=B#KQ9!VT_0=?UF;:A;\99=2+87%:RYA 4MQH,[R
M,+-6Z T&^<_9B_.6VN2O=X+UVV#]$*S_/_#ZWSS!<XFP,%4M] %*X8!Z)7\M
MC2K07HNZMF9'B>+7K?0'D#JG%*G_H59"._"E\, JLD"@JTT'"!OBPDN] ;,&
MAW8G\Q-=%HD9F7L20Q38:ND=_/2T^N)^CJD?[2OZHRZ?Q5"C#1-#MSZ:\\;<
MU'PE'0A=@*'0%/]0H^/ 8B]L00 -< 2L:F4.B&1IUFL"9!LC;?3UZ1L4TM(=
M-]9U A\T,42X\?C&,G+R:DL]24+(\TC:CS^,TM[P%T=[ZEC-&$ER1LE"<*8K
M3PMW1L#%1A9+'D?$XKW.3=4P)Y1JLCKFF9]#$-_ZR\&>BD2_M5$T"MTM%= 2
M^O-;$UJ=_WH4S_E0"*&(F"OHQUEZ0^M-W!_UX D="IN7@8P"=S1<Z]#$O6'<
M^]#E9= ;PHJF'14TA@UJM$(%=5'0')'<ZJ$ATILX(]5T$ ^Z W@V7KR3SXE2
MPC.,1UG&P@<RS(BM"R:4P]6@D]+P(BQ,"4&XZG?Z[0'3DHM:4F#Y=Z@2%U_O
M*!UC#VUW^L!6U;"%@:V'0,%I1 3/S%W,_5ICF/?J0$UQYOQB9M*156XV.J@Q
MI.\*L*?*!Q@65>@.NCS%-O=L1RU3=/YM9B1G<[E"NPFO#WO>:M^,Z/:T?>!F
MS5S_IMZ\CI3J1M*-4;@FTVYG.(C -B].L_&F#E/^Q7AZ,X)8TB.-EA7H^]H8
M?]IP@/;9G_X#4$L#!!0    ( %AHG53"+0+5GP0  +P+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;*U667/B1A#^*UU**N6MTAH=@( %5_D@M7XP
M)CZR#ZD\#%*#5)9FM#,C8_Y]>D:'(;').I47I!EU?WU]W?1T*^232A$UO!0Y
M5S,GU;J<]'HJ3K%@ZE24R.G+6LB":3K*34^5$EEBE8J\%WC>L%>PC#MG4WNW
ME&=34>D\X[B4H*JB8')W@;G8SAS?:2_NLDVJS47O;%JR#=ZC?BR7DDZ]#B7)
M"N0J$QPDKF?.N3^YZ!MY*_![AENU]PXFDI403^9PG<P<SSB$.<;:(#!Z/.,E
MYKD!(C>^-YA.9](H[K^WZ+_:V"F6%5-X*?)O6:+3F3-R(,$UJW)])[9?L8EG
M8/!BD2O["]M:-O0<B"NE1=$HDP=%QNLG>VGRL*<P>D\A:!0"ZW=MR'IYQ30[
MFTJQ!6FD"<V\V%"M-CF7<5.4>RWI:T9Z^FPQ?X#KQ>7MS1R6\SN@EYO;!=Q_
M/;^;3WN:#!BQ7MR 7=1@P3M@(=P(KE,%<YY@<JC?(\<Z[X+6NXO@*. -DZ<0
M^BX$7A <P0N[:$.+%[Z#-V>29WRC8(D2[E,F$?XX7RDMB1Q_'L'O=_A]B]__
M?[)Y%,RTXT25+,:90_VF4#ZC<\P"+(5&KC.6YSO(E*K8*D=0)DH%8@VQ* KJ
M Z)4_ 09C_,JZ3YWXE5)(CI%P!>4<:;0:%(S*\UX0JD#+,I<[! ;'%'6S;5E
M,E'NWVQTH$0':5$O15$ROOOEIU'@1U^(*"U:78QE)>.4>@R6.>-P,K]?+C^Y
MI/Z,2F,"=_>/9.,MG .[*>8)K'96</';U260ZR1!J>$;2E#M%X_?R(K$G!E#
M6KQCA3R1.C,Q);C2I_! 4FN1TV@SN=%UQE$KNI0ZM2!DH*PTLVDB>S1"LMAZ
ME&1Y98QA2\J2DM2Z8]-QLG^B(IG*B$J1LOHT(=N2$K??<;9-S(\/BZI R;20
M$UC0:+_F!(5N8_UG\ //C<8C\Q:Y8>3#>9),2$HC&=)4?!KZBN0YZ9+3FKVX
M0([L)X 3VQ0$;C0,P68H^')@J@W/& O=P=!_-7:%7- LJ]W[9@<G)I\90=/_
M !P&O<>]UGU_%+KCL4=/WXVB .;K-<UXXZ>U25.>:A!7,M,9J@G<6HHJ4]2R
MY==!U0?#/OBNYWNFX$?I2ZF-8&$#[[OA<- %_@.*_4:1?(^\3O%QG]ODQ<"/
MC"^A?PA9OM7:Q#$P+=*%1>!>!.%@;'GYL1[QHQ#\<?BA<K0E]L=]=S0:4D'J
MK!@:9)8&_^#T*P6]T^'0/BCO1Q5>B40JH7UX8Z(9L"3);%LU[8K?JTQ3?C@-
M=*(_UZH=<TG=.]AT*%N)9W3W+E9F.0$[98U6E^WWIJ=.F88M]0IU2F-@+47Q
M8_W^3J# E-'?U;B,['_NZ'SRD=;_5[X/W< ;FE_BV@<8WU*VKO$'&-\JULP_
M9'S?[5--Z4O@_3?&!X,1L=Z'!Z&I7KPJ5N0 Y?U-_::<OD?VJ,]&-#Y">.M_
MO[>W4=$@W=B]T;10Q76]7'6WW6IZ7F]DK^+U7DL[S(8H"3FN2=4[C08.R'I7
MK ]:E'8_6PE-VYY]36F]1FD$Z/M:4"C-P1CH%O:SOP!02P,$%     @ 6&B=
M5#V4?:S_!   / L  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULM59+
M4R,W$/XK70ZU)Z\? P2R"U3QVH0#++60Y)#*09[1>)352+-ZV/C?YVMIQA@J
M["7)Q1Y)W5_WUR_I9&W=5]](&>BIU<:?CIH0N@_3J2\;V0H_L9TT.*FM:T7
MTBVGOG-25$FIU=-B-OMQV@IE1F<G:>_>G9W8&+0R\MZ1CVTKW.9":KL^'<U'
MP\87M6P";TS/3CJQE \R_-K=.ZRF6Y1*M=)X90TY69^.SN<?+@Y8/@G\IN3:
M[WP3,UE8^Y47-]7I:,8.22W+P @"?RMY*;5F(+CQK<<<;4VRXN[W@/XI<0>7
MA?#RTNK?516:T]'QB"I9BZC#%[O^1?9\#AFOM-JG7UIGV<-B1&7TP;:],CQH
ME<G_XJF/PX["\>P-A:)7*)+?V5#R\DH$<7;B[)H<2P.-/Q+5I WGE.&D/ 2'
M4P6]<';Y^?;VYO'V^N[Q@<[OKNCR\]WCS=W/UW>7-]</)], $RPX+7NXBPQ7
MO &W3[?6A,;3M:ED]5)_"M>V_A6#?Q?%=P%OA9O0_GQ,Q:PHOH.WO^6[G_#V
MW^)KVU8%5%7P)$Q%EW!7F:4TI9*>KI0OM?712?KC?.&#0]'\^1VK!UNK!\GJ
MP7\5Y7\!]XK2)V=;"N@C"K;_;R1DVDZ8#2E/RJRL7LD*'Z3E4NC4*=8@/DYY
M /$!ZQCN DVEC<Y+LC4IQ' 1(2*]G] C1#IG2RSXT$D/6%9'ZP3I/#"<C<N&
MM IJ*5)/6D<6T(Y:*6 P>8,ELJ,W%$TI7<!<28E2@8\[Z[U::"8A O8A5(N5
M=8+WDLF8@6MV&6X.QN&UKDA4*RPDP$5=8R[LQF*<^  #_9P88/"YY*8?4ZV,
M0#P3?5.IP?E2^(9J#+:>?P_U[H?C8G[TT1.2  R-N'!,2\D4D ;YA)D*YW*X
M:XDT"4]>NA5D..[,!0WD<E9@TO1#;*U"TZOUS,8I.@ 59>FB),QI1%@L%(<9
M8.M&(J\(6P^,%"U2M%@-8]Q;@^6&I$=Q\,'DN8 "W8M-[I7S%!)T8]ELVW'\
MHI363"$N_DIAM>ST -(-(-CS*M/:L;S-*0SL'1T?3PXQZ+0&7:3$E#I67$5[
M^\<_36;#"?2U"#(3-R2% Y /N$8PDE>X:KHV679VZ42+@)0<\(IJ[@8!OY6K
MX)<+FZ&Z:Y0U8OLM8A,%"5] <9ZBM%<4A_^G:2^YJ%Z9GDWH<VJ-W8FU4V,4
M.:-<2:X?95HLT C!.DX[NB,:Q=6>RX %<JLI@TR'F%L<' # =SL-S?;EG6B[
MCU?YODS*J;91KJ*U,<U-E%%.#&@AZX/&4-:O:QFA6"'MU81NWI@DPQ1Y65&@
MS*VK#+Q<81C9Z-&(<+6+*$-<Q4!XCDWG4+].(1E,"H.(IWB^]*EK!"R6$JQ+
M&$8]H085JXVWO#$'L6'=YOV08!5DFR,WR*3DO<_)&U@/5,=LM(JY3Y_Y0[L6
M)7?C)M5_<*]$)F_TEH]8[A)<HW'Z-F7O>/YU,/F4UJ"]-Y\?[?:.T)IQUXT"
M4%+VC77A/8+:OAA7A%A"VMOG8@VR;(S5=HFQR!,E@^09[.2WJ%QN +0V.;L1
M.A59[,"KCH$C[X7FF.Q.A.TT-Y'GES*JC:V?_-/].MUYT;32+=.[+4UQ$_+C
M9KN[?1J>YQ?1LWA^5R*N2]0\IF8-U=GDZ'!$+K_5\B+8+KV/%C;@M94^&SQO
MI6,!G-?6AF'!!K8/YK._ 5!+ P04    " !8:)U45\]=J!0'   J$@  &0
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M&TWY.J8 /.HX1!#.UNX@IB&R&0L-8G"!D]%&530!3HU9BMNL T^+FUPA)]%
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M^!:;DDM?)M)%L'7\&K"R(=@J_BS!FN3X )X7%F&T%VR@_SQT_B=02P,$%
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M<XY_#I3Q 3@_U=KM.GZ!]N_&]3]02P,$%     @ 6&B=5$(HFA.L!   B L
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MKJ7\;<POC%RZ&]!,&KQ/N=<<+[!4607\/I<XCE4+ZZ"^$E_\"U!+ P04
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M1G!<V*1,C<*O'/>9L\OQW>1^-)O<CV%R,YW=??HPOIE-871S">_'EU>3FRO
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MW9/AP +9%.)FH,6N+GX;H:F4UMV4OEU0F@VTG@BA#P/CH/L:FOX-4$L#!!0
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M)>JM;Y<&<E5+V[P;G;7IR OJR+YS'=GO1K?+48_]?MQV\/!'^*;]TVN\Y=*
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MARP&Q++^%G&8YO^CAR+6F:#%)E7QNFBL%:R#:/=7?"\FHM+ I2T-<-$ =VU
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M?"K%ED@CC=K,PN;&HC$:7A@:'[7$IQQQ>GX+DF^8226Y*Y26%5*D%6%%0CY
MDO(B)2C.-*0<%+DDCS7=1*S(75XB"6;U$Y9+C?DHE$*YE10YV:E6N%8\+5!-
M0IAJ-7<MGMV"9CP[1QM?'F_)V9MS\H;P@ORR%I5"U6KJ:HS7>.TNF]ANZMC\
M([$%Y),H]%J1=T4"R6N\BWEJD^6_).O&'U3XB<DK$M +XGN^W^//XM_#Z8 [
M0<M=8/4%/\3=A:6#G!DJSLGO'Q%$[C3DZH\!DV%K,K0FPR,F'V #105]7-3
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M_HS D2DUX6:P0I7>58PU)NO)O-YH4=KA]DEH')7M<HU?,R"- #Y?":%?-L9
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MZ9V-J=BV[CGU!$T9GNW"(#6!,%Q3FP;K VA_:0SN)[X3M(T_^PM02P,$%
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M] $7PX0>3*C=!EI?*65W$Z>@?H*-_P)02P,$%     @ 6&B=5+RK*>1D!
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MA%[2P1&DYU&$$P.(D2?'D1_BQJ@OCZ(^P-P0AVWF)Z-<R6T!8N(,-C(M6?!
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M4]9W8Y9__;NXO:>U+IM#/NO^R4\^ 5!+ 0(4 Q0    ( %AHG50'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 6&B=5 G.F)KO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 6&B=5)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !8
M:)U4*J"V1#0%  !C%0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 6&B=5.[S:0E6!P  #AP  !@
M         ("!> T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( %AHG50BZ_6KD@(  -P&   8              " @005  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !8:)U4T%C2;Y8%  ":%
M&               @(',%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 6&B=5#@2\,>+!@  E1L  !@              ("!F!T  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %AHG53 'FD+* @
M )D@   8              " @5DD  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !8:)U4**8ZCD4(  !T%0  &               @(&W
M+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 6&B=5+K"
M9JHQ!@  UPX  !@              ("!,C4  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( %AHG51Q+=6<+ @  (,2   8
M  " @9D[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !8
M:)U4/WW-;[8%  #*#P  &0              @('[0P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %AHG53!D435BP<  .L2   9
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M970Q-2YX;6Q02P$"% ,4    " !8:)U4PBT"U9\$  "\"P  &0
M    @(&N:0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M %AHG50]E'VL_P0  #P+   9              " @81N  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 6&B=5%?/7:@4!P  *A(  !D
M             ("!NG,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !8:)U4;")G+2H%  !Z#   &0              @($%>P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %AHG51"*)H3K 0
M (@+   9              " @6:   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 6&B=5+#+W5U6!0  '@\  !D              ("!
M284  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !8:)U4
MB3U5!: %  !B#@  &0              @('6B@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( %AHG53[03'N=@0  ) *   9
M      " @:V0  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 6&B=5+%FFX;> P  &0D  !D              ("!6I4  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !8:)U4GS87+M$$  #="P
M&0              @(%OF0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( %AHG503)*-#ZP(   <&   9              " @7>>  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 6&B=5+% )_Q\
M!   (0L  !D              ("!F:$  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !8:)U48)8)PR0*  !>/   &0
M@(%,I@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %AH
MG51YE6@+3@(  !\%   9              " @:>P  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 6&B=5 >NK6)J P  XP@  !D
M         ("!++,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !8:)U4IMT-7,X#   +"P  &0              @('-M@  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %AHG52\;=4.4@,  &0(
M   9              " @=*Z  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ 6&B=5$:U97-1 P  /@@  !D              ("!6[X
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !8:)U4LS=B
MO'<$  #I#0  &0              @('CP0  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( %AHG53[%2O]L@8   \R   9
M  " @9'&  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M6&B=5+=]X2OG @  &@<  !D              ("!>LT  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !8:)U4O7+Z\,@"  "9!P  &0
M            @(&8T   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( %AHG51EW&4M[@(  ,$)   9              " @9?3  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 6&B=5$"<JC/B P
MD!$  !D              ("!O-8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !8:)U4';#]U; #   K#0  &0              @('5
MV@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %AHG50*
M/XZG8 (   0&   9              " @;S>  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ 6&B=5$#QHI3#!   :!(  !D
M     ("!4^$  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M" !8:)U4()K7HO$"  #8"   &0              @(%-Y@  >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %AHG51F=7Y\+@8  $<:   9
M              " @77I  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!
M A0#%     @ 6&B=5&IMPQ0"!   C@T  !D              ("!VN\  'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !8:)U4O*LIY&0$
M  "K$P  &0              @($3]   >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;%!+ 0(4 Q0    ( %AHG52T\>GU/ 0  -D1   9              "
M@:[X  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 6&B=
M5-/ZC-X- P  -0P  !D              ("!(?T  'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !8:)U4F!&D6PD#  !)"@  &0
M        @(%E  $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( %AHG500NV$?50(  $@%   9              " @:4# 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 6&B=5%I>VV?)!   NQ,
M !D              ("!,08! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !8:)U4U:T=])D#  "P#@  &0              @($Q"P$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %AHG51<M**7
M"P,  (,(   9              " @0$/ 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ 6&B=5&4H;C48 P  BA$   T
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;72YX;6Q02P4&     #T /0"B$   ?1\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>218</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2138109 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2142110 - Disclosure - NET INCOME PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE</Role>
      <ShortName>NET INCOME PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables</Role>
      <ShortName>SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables</Role>
      <ShortName>DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/DEBT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - NET INCOME PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables</Role>
      <ShortName>NET INCOME PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail</Role>
      <ShortName>Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Supplemental Financial Statements Information - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail</Role>
      <ShortName>Supplemental Financial Statements Information - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Supplemental Financial Statements Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails</Role>
      <ShortName>Supplemental Financial Statements Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Supplemental Financial Statements Information - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Supplemental Financial Statements Information - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail</Role>
      <ShortName>Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail</Role>
      <ShortName>Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail</Role>
      <ShortName>Derivative Instruments and Hedging Strategies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail</Role>
      <ShortName>Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail</Role>
      <ShortName>Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail</Role>
      <ShortName>Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DebtAdditionalInformationDetail</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Debt - Summary of Convertible Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail</Role>
      <ShortName>Debt - Summary of Convertible Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail</Role>
      <ShortName>Debt - Summary of Interest Expense on Convertible Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail</Role>
      <ShortName>Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail</Role>
      <ShortName>Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail</Role>
      <ShortName>Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail</Role>
      <ShortName>Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Stock-Based Compensation - Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/StockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Net Income Per Common Share - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails</Role>
      <ShortName>Net Income Per Common Share - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bmrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bmrn-20220331.htm">bmrn-20220331.htm</File>
    <File>bmrn-20220331.xsd</File>
    <File>bmrn-20220331_cal.xml</File>
    <File>bmrn-20220331_def.xml</File>
    <File>bmrn-20220331_lab.xml</File>
    <File>bmrn-20220331_pre.xml</File>
    <File>brmn-31mar22xexx101.htm</File>
    <File>exhibit311-31mar22x10q.htm</File>
    <File>exhibit312-31mar22x10q.htm</File>
    <File>exhibit321-31mar22x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="636">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bmrn-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 210,
   "dts": {
    "calculationLink": {
     "local": [
      "bmrn-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmrn-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bmrn-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmrn-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 419,
   "entityCount": 1,
   "hidden": {
    "http://www.bmrn.com/20220331": 2,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 7
   },
   "keyCustom": 19,
   "keyStandard": 199,
   "memberCustom": 32,
   "memberStandard": 47,
   "nsprefix": "bmrn",
   "nsuri": "http://www.bmrn.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.bmrn.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - DEBT",
     "role": "http://www.bmrn.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138109 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142110 - Disclosure - NET INCOME PER COMMON SHARE",
     "role": "http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE",
     "shortName": "NET INCOME PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables",
     "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)",
     "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables",
     "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - DEBT (Tables)",
     "role": "http://www.bmrn.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)",
     "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)",
     "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables",
     "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - NET INCOME PER COMMON SHARE (Tables)",
     "role": "http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables",
     "shortName": "NET INCOME PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)",
     "role": "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail",
     "shortName": "Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i6ca8e30ed951424daed017118d432eef_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i6ca8e30ed951424daed017118d432eef_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Supplemental Financial Statements Information - Schedule of Inventory (Detail)",
     "role": "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail",
     "shortName": "Supplemental Financial Statements Information - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Supplemental Financial Statements Information - Narrative (Details)",
     "role": "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails",
     "shortName": "Supplemental Financial Statements Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Supplemental Financial Statements Information - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Supplemental Financial Statements Information - Schedule of Intangible Assets (Details)",
     "role": "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails",
     "shortName": "Supplemental Financial Statements Information - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)",
     "role": "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail",
     "shortName": "Supplemental Financial Statements Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
       "span",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i67c5cd0a2b524859bbb3035e15216170_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)",
     "role": "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
       "span",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i67c5cd0a2b524859bbb3035e15216170_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i2e3e175895dd4eddaf85bea4d5710175_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)",
     "role": "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail",
     "shortName": "Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i2e3e175895dd4eddaf85bea4d5710175_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail)",
     "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
     "shortName": "Derivative Instruments and Hedging Strategies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i6fb2fa6470f64208b9cca9caed841242_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail)",
     "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail",
     "shortName": "Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i6fb2fa6470f64208b9cca9caed841242_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)",
     "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
     "shortName": "Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)",
     "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
     "shortName": "Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i2f2446e5da1e4149a96a95c2f3e99378_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Debt - Additional Information (Detail)",
     "role": "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
     "shortName": "Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i9a61fb3318b44b2ba23a29e3998e0700_I20181031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Debt - Summary of Convertible Debt (Detail)",
     "role": "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail",
     "shortName": "Debt - Summary of Convertible Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i5017a08d58224e19b728357a77f28248_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail)",
     "role": "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail",
     "shortName": "Debt - Summary of Interest Expense on Convertible Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i1e4b03eea6b3449db1a69b0fdcd00882_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i63654500f0694941a974905d3087a5ea_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)",
     "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
     "shortName": "Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)",
     "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
     "shortName": "Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)",
     "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
     "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "ic74a170ac59147cca285f25489fe3660_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)",
     "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail",
     "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i8b9f090883124d2198ad6215aa997c28_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)",
     "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail",
     "shortName": "Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i8f27ff45db3449aa89a5e2effbff78e0_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Stock-Based Compensation - Expense (Detail)",
     "role": "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "if1c36f51afd949d2922a9403458ff14e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "if1c36f51afd949d2922a9403458ff14e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Net Income Per Common Share - Schedule of Earnings Per Share (Details)",
     "role": "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails",
     "shortName": "Net Income Per Common Share - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)",
     "role": "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
     "shortName": "Net Income Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - FINANCIAL INSTRUMENTS",
     "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION",
     "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION",
     "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmrn-20220331.htm",
      "contextRef": "i64c521ed6b634139a5e7823fc05f4479_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.25% Senior Subordinated Convertible Notes Due in May 2027",
        "label": "1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]",
        "terseLabel": "1.25% Senior Subordinated Convertible Notes Due in May 2027"
       }
      }
     },
     "localname": "A125SeniorSubordinatedConvertibleNotesDueInMay2027Member",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued rebates payable"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan",
        "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan",
        "negatedTerseLabel": "Common stock held by the NQDC"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuable for employee Stock Purchase Plan [Member]",
        "label": "Common Stock Issuable To Employee Stock Purchase Plan [Member]",
        "terseLabel": "Common stock potentially issuable for ESPP purchases"
       }
      }
     },
     "localname": "CommonStockIssuableToEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ConcentrationRiskAndGeographicInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and geographic information.",
        "label": "Concentration Risk And Geographic Information [Abstract]",
        "terseLabel": "Concentration Risk And Geographic Information [Abstract]"
       }
      }
     },
     "localname": "ConcentrationRiskAndGeographicInformationAbstract",
     "nsuri": "http://www.bmrn.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bmrn_ConcentrationRiskAndGeographicInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and geographic information.",
        "label": "Concentration Risk And Geographic Information [Line Items]",
        "terseLabel": "Concentration Risk And Geographic Information [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskAndGeographicInformationLineItems",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ConcentrationRiskAndGeographicInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and geographic information.",
        "label": "Concentration Risk And Geographic Information [Table]",
        "terseLabel": "Concentration Risk And Geographic Information [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskAndGeographicInformationTable",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk and segment reporting disclosure.",
        "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ContingentPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Payment",
        "label": "Contingent Payment [Member]",
        "terseLabel": "Contingent Payment"
       }
      }
     },
     "localname": "ContingentPaymentMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.",
        "label": "Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones",
        "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones"
       }
      }
     },
     "localname": "ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes Due Two Thousand Twenty Four [Member]",
        "verboseLabel": "Common stock issuable under the 2024 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDueTwoThousandTwentyFourMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due Two Thousand Twenty Seven",
        "label": "Convertible Senior Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "Common stock issuable under the 2027 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDueTwoThousandTwentySevenMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Four",
        "label": "Customer Four [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerFourMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1",
        "label": "Customer One [Member]",
        "terseLabel": "Customer A",
        "verboseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerOneTwoThreeAndFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One, Two, Three, And Four",
        "label": "Customer One, Two, Three, And Four [Member]",
        "terseLabel": "Customer A, B, C, &amp; D"
       }
      }
     },
     "localname": "CustomerOneTwoThreeAndFourMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 3",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 2",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer B",
        "verboseLabel": "Customer Two"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_CustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers.",
        "label": "Customers [Member]",
        "terseLabel": "Customers"
       }
      }
     },
     "localname": "CustomersMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_EarlyStageDevelopmentProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Stage Development Program",
        "label": "Early Stage Development Program [Member]",
        "terseLabel": "Early Stage Development Program"
       }
      }
     },
     "localname": "EarlyStageDevelopmentProgramMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement",
        "verboseLabel": "Foreign exchange remeasurement of Euro denominated contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign government and other debt securities.",
        "label": "Foreign Government And Other Debt Securities [Member]",
        "terseLabel": "Foreign and other"
       }
      }
     },
     "localname": "ForeignGovernmentAndOtherDebtSecuritiesMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_IntangibleAssetAmortizationAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.",
        "label": "Intangible Asset Amortization And Contingent Consideration",
        "terseLabel": "Intangible asset amortization and contingent consideration"
       }
      }
     },
     "localname": "IntangibleAssetAmortizationAndContingentConsideration",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_LongTermMarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities maturity period.",
        "label": "Long Term Marketable Securities Maturity Period",
        "terseLabel": "Long term marketable securities maturity period"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMaturityPeriod",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified deferred compensation plan assets.",
        "label": "Nonqualified Deferred Compensation Plan Assets [Member]",
        "terseLabel": "NQDC Plan assets"
       }
      }
     },
     "localname": "NonqualifiedDeferredCompensationPlanAssetsMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified deferred compensation plan liability.",
        "label": "Nonqualified Deferred Compensation Plan Liability [Member]",
        "terseLabel": "NQDC Plan liability"
       }
      }
     },
     "localname": "NonqualifiedDeferredCompensationPlanLiabilityMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_OperatingAndFinanceLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease Liability, Current",
        "label": "Operating And Finance Lease Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherAssetsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets current fair value disclosure.",
        "label": "Other Assets Current Fair Value Disclosure",
        "verboseLabel": "Fair value of other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherAssetsNoncurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets noncurrent fair value disclosure.",
        "label": "Other Assets Noncurrent Fair Value Disclosure",
        "verboseLabel": "Fair value of other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities current fair value disclosure.",
        "label": "Other Liabilities Current Fair Value Disclosure",
        "verboseLabel": "Fair value of other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities noncurrent fair value disclosure.",
        "label": "Other Liabilities Noncurrent Fair Value Disclosure",
        "verboseLabel": "Fair value of other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentFairValueDisclosure",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ProceedsFromSaleOfNonfinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Nonfinancial Assets",
        "label": "Proceeds From Sale Of Nonfinancial Assets",
        "terseLabel": "Proceeds from sale of nonfinancial assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNonfinancialAssets",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ProductEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Eight",
        "label": "Product Eight [Member]",
        "terseLabel": "Voxzogo"
       }
      }
     },
     "localname": "ProductEightMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 4 [Member]",
        "label": "Product Four [Member]",
        "terseLabel": "Vimizim"
       }
      }
     },
     "localname": "ProductFourMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 1 [Member]",
        "label": "Product One [Member]",
        "terseLabel": "Aldurazyme"
       }
      }
     },
     "localname": "ProductOneMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 7 [Member]",
        "label": "Product Seven [Member]",
        "terseLabel": "Palynziq"
       }
      }
     },
     "localname": "ProductSevenMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product six.",
        "label": "Product Six [Member]",
        "terseLabel": "Brineura"
       }
      }
     },
     "localname": "ProductSixMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 3 [Member]",
        "label": "Product Three [Member]",
        "terseLabel": "Kuvan"
       }
      }
     },
     "localname": "ProductThreeMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product 2 [Member]",
        "label": "Product Two [Member]",
        "terseLabel": "Naglazyme"
       }
      }
     },
     "localname": "ProductTwoMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ProductsExcludingProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products excluding product one.",
        "label": "Products Excluding Product One [Member]",
        "terseLabel": "Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim"
       }
      }
     },
     "localname": "ProductsExcludingProductOneMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of world.",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RestrictedInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted investments.",
        "label": "Restricted Investments [Member]",
        "terseLabel": "Restricted Investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_RoyaltyAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and other.",
        "label": "Royalty And Other [Member]",
        "terseLabel": "Royalty and other revenues"
       }
      }
     },
     "localname": "RoyaltyAndOtherMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmrn_ScheduleOfInterestExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of interest expenses.",
        "label": "Schedule Of Interest Expenses [Line Items]",
        "terseLabel": "Schedule Of Interest Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInterestExpensesLineItems",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_ScheduleOfInterestExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of interest expenses table.",
        "label": "Schedule Of Interest Expenses [Table]",
        "terseLabel": "Schedule Of Interest Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfInterestExpensesTable",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior unsecured revolving two thousand eighteen credit facility.",
        "label": "Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]",
        "terseLabel": "The 2018 Credit Facility"
       }
      }
     },
     "localname": "SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities maturity period.",
        "label": "Short Term Marketable Securities Maturity Period",
        "terseLabel": "Short term marketable securities maturity period"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMaturityPeriod",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency.",
        "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency",
        "verboseLabel": "Issuances under equity incentive plans, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares.",
        "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares",
        "terseLabel": "Issuances under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "bmrn_StrategicInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment.",
        "label": "Strategic Investment [Member]",
        "terseLabel": "Strategic Investment"
       }
      }
     },
     "localname": "StrategicInvestmentMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.",
        "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets",
        "terseLabel": "Decrease in accounts payable and accrued liabilities related to fixed assets"
       }
      }
     },
     "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets",
        "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets",
        "terseLabel": "Increase (decrease) in accounts payable and accrued liabilities related to intangible assets"
       }
      }
     },
     "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmrn_ThirdPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party.",
        "label": "Third Party [Member]",
        "terseLabel": "Third Party"
       }
      }
     },
     "localname": "ThirdPartyMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ValoctocogeneRoxaparvovecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valoctocogene Roxaparvovec",
        "label": "Valoctocogene Roxaparvovec [Member]",
        "terseLabel": "Valoctocogene Roxaparvovec"
       }
      }
     },
     "localname": "ValoctocogeneRoxaparvovecMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.",
        "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]",
        "terseLabel": "0.599% Senior Subordinated Convertible Notes Due in August 2024"
       }
      }
     },
     "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember",
     "nsuri": "http://www.bmrn.com/20220331",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bmrn.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r179",
      "r262",
      "r266",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r252",
      "r282",
      "r284",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r442",
      "r446",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r252",
      "r282",
      "r284",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r442",
      "r446",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r179",
      "r262",
      "r266",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r176",
      "r262",
      "r264",
      "r405",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r176",
      "r262",
      "r264",
      "r405",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r252",
      "r272",
      "r282",
      "r284",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r442",
      "r446",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r252",
      "r272",
      "r282",
      "r284",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r442",
      "r446",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r262",
      "r265",
      "r444",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r262",
      "r265",
      "r444",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts\u00a0payable\u00a0and accrued\u00a0liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued operating expenses"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r19",
      "r180",
      "r181"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r14",
      "r16",
      "r306",
      "r411",
      "r428"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r205"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r60",
      "r68",
      "r69",
      "r70",
      "r71",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent",
        "verboseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r60",
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Available for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r58",
      "r59",
      "r60",
      "r431",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r68",
      "r69",
      "r70",
      "r111",
      "r112",
      "r113",
      "r325",
      "r447",
      "r448",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "verboseLabel": "AOCI attributable to parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r294",
      "r295",
      "r296",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r285",
      "r286",
      "r299",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r286",
      "r290",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r83",
      "r98",
      "r243",
      "r383"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of discount on convertible notes"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r78",
      "r98",
      "r243",
      "r385"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r98",
      "r243",
      "r249",
      "r250",
      "r385"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total number of potentially issuable shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r190",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r105",
      "r165",
      "r168",
      "r174",
      "r192",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r322",
      "r326",
      "r371",
      "r390",
      "r392",
      "r409",
      "r427"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r48",
      "r105",
      "r192",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r322",
      "r326",
      "r371",
      "r390",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Fair value of financial assets, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r186",
      "r194"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r183",
      "r187",
      "r194",
      "r415"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r185",
      "r194"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term Marketable Securities",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r185",
      "r194"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term Marketable Securities",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r334",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r281",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r281",
      "r283",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r97",
      "r319"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Non-cash changes in the fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Long-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r32",
      "r392",
      "r455",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r100"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r100",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r374"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "terseLabel": "Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockIssuedEmployeeStockTrust": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.",
        "label": "Common Stock Issued, Employee Stock Trust",
        "negatedLabel": "Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)"
       }
      }
     },
     "localname": "CommonStockIssuedEmployeeStockTrust",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; 184,901,764 and 183,912,514 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r76",
      "r419",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r75",
      "r85",
      "r418",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r179",
      "r368",
      "r369",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r179",
      "r368",
      "r369",
      "r454",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r179",
      "r368",
      "r369",
      "r454",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r152",
      "r153",
      "r179",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r150",
      "r152",
      "r153",
      "r154",
      "r368",
      "r370",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r179",
      "r368",
      "r369",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r259",
      "r260",
      "r263"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r262",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r262",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r15",
      "r412",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Total convertible debt, net"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Total fair value of fixed-rate convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r230",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Long-term convertible debt, net",
        "totalLabel": "Convertible notes, net of unamortized discount and deferred offering costs"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r273",
      "r280",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r80",
      "r105",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r371"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r151",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r104",
      "r109",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r386",
      "r410",
      "r412",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r245",
      "r412",
      "r426"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Convertible notes",
        "verboseLabel": "Carrying value of equity component"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes stated rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r104",
      "r109",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r104",
      "r109",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r254",
      "r255",
      "r256",
      "r257",
      "r383",
      "r384",
      "r386",
      "r387",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail",
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r234",
      "r246",
      "r247",
      "r248",
      "r385"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized discount net of deferred offering costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.",
        "label": "Deferred Compensation, Share-based Payments [Member]",
        "terseLabel": "Company Stock Held By NQDC"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedPaymentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r106",
      "r307",
      "r311",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r98",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense, net of amounts capitalized into inventory"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r163"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r337",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r337",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gains (Losses) Recognized in Earnings"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r51",
      "r335",
      "r338",
      "r342",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r332",
      "r335",
      "r342",
      "r345",
      "r346",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Foreign currency exchange forward contracts"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Maturity of derivatives"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r340",
      "r342",
      "r347",
      "r348",
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated As Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Total Net Product Revenues Based on Patient Location"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r77",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r127",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r354",
      "r355",
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per common share, basic (in dollars per share)",
        "verboseLabel": "NET INCOME PER SHARE, BASIC (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r77",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r127",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r354",
      "r355",
      "r420",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per common share, diluted (in dollars per share)",
        "verboseLabel": "NET INCOME PER SHARE, DILUTED (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation expense capitalized to inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r145",
      "r193",
      "r253",
      "r258",
      "r294",
      "r295",
      "r296",
      "r308",
      "r309",
      "r353",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r447",
      "r448",
      "r449",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Strategic investments fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r357",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r357",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r247",
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r358",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r360",
      "r361",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r236",
      "r273",
      "r274",
      "r279",
      "r280",
      "r358",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:",
        "verboseLabel": "Quoted\u00a0Price\u00a0in Active Markets For Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r247",
      "r248",
      "r273",
      "r274",
      "r279",
      "r280",
      "r358",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:",
        "verboseLabel": "Significant\u00a0Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r236",
      "r247",
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r358",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r362",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r362",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "terseLabel": "Financial assets remeasured"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "Changes in the fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Contingent consideration as of September 30, 2021",
        "periodStartLabel": "Contingent consideration as of December 31, 2020",
        "terseLabel": "Liabilities remeasured"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r247",
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail",
      "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal repayments of financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r202",
      "r406"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r99",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange (gain) loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r51",
      "r273",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Forward Foreign Exchange Contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain on sale of nonfinancial assets, net",
        "negatedTerseLabel": "Gain on sale of nonfinancial assets, net",
        "terseLabel": "Gain on sale of nonfinancial assets, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r196",
      "r197",
      "r392",
      "r408"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r332",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r407",
      "r416",
      "r422",
      "r439"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r122",
      "r123",
      "r164",
      "r305",
      "r310",
      "r314",
      "r440"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r95",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r132",
      "r133",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r198",
      "r200"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r162",
      "r382",
      "r385",
      "r421"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total interest expense on convertible debt"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r84",
      "r242",
      "r249",
      "r250"
     ],
     "calculation": {
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Coupon interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense on Debt"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r126",
      "r129",
      "r138"
     ],
     "calculation": {
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Add: Interest expense, net of tax, on convertible notes"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r92",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r195"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r46",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r195"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r195"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r82",
      "r161"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r105",
      "r169",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r323",
      "r326",
      "r327",
      "r371",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r105",
      "r192",
      "r371",
      "r392",
      "r414",
      "r433"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r105",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r323",
      "r326",
      "r327",
      "r371",
      "r390",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of financial liabilities, Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r15",
      "r412",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Outstanding amount"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates an ownership position in, or purchase of, a security.",
        "label": "Long [Member]",
        "terseLabel": "Purchase"
       }
      }
     },
     "localname": "LongMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MiddleEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Middle East.",
        "label": "Middle East [Member]",
        "terseLabel": "Middle East"
       }
      }
     },
     "localname": "MiddleEastMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r62",
      "r65",
      "r70",
      "r74",
      "r99",
      "r105",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r122",
      "r123",
      "r134",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r355",
      "r371",
      "r417",
      "r435"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "NET INCOME",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r124",
      "r125",
      "r135",
      "r138",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net Income, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r135",
      "r138"
     ],
     "calculation": {
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of operating business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before \u00a0\u00a0\u00a0\u00a0 reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expenses as reported"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "INCOME FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r47",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Cash Flow Hedging Gains (Losses) Reclassified into Earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r69",
      "r71",
      "r75",
      "r253",
      "r375",
      "r380",
      "r381",
      "r418",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r66",
      "r320",
      "r321",
      "r324"
     ],
     "calculation": {
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net current-period other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r320",
      "r321",
      "r324"
     ],
     "calculation": {
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Tax effect"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r334",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other\u00a0current\u00a0assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r88",
      "r184"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of available-for-sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PositionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by position taken for a security.",
        "label": "Position [Axis]",
        "terseLabel": "Position"
       }
      }
     },
     "localname": "PositionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PositionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates position taken for a security.",
        "label": "Position [Domain]",
        "terseLabel": "Position"
       }
      }
     },
     "localname": "PositionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r90",
      "r293"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercises of awards under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r204"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r206",
      "r392",
      "r424",
      "r434"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property Plant and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r17",
      "r413",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments and other minimum contractual obligations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "terseLabel": "Less: gain (loss) reclassified from AOCI"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r302",
      "r404",
      "r486"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested RSUs",
        "verboseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r258",
      "r297",
      "r392",
      "r432",
      "r450",
      "r452"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r193",
      "r294",
      "r295",
      "r296",
      "r308",
      "r309",
      "r353",
      "r447",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r159",
      "r160",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r179",
      "r261",
      "r262",
      "r405"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "REVENUES:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r8",
      "r36"
     ],
     "calculation": {
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Value added taxes payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SupplementalFinancialStatementsInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred directly to consumer.",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "terseLabel": "Marketed by Company"
       }
      }
     },
     "localname": "SalesChannelDirectlyToConsumerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred through intermediary.",
        "label": "Sales Channel, Through Intermediary [Member]",
        "terseLabel": "Marketed by Sanofi"
       }
      }
     },
     "localname": "SalesChannelThroughIntermediaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail",
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r152",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net Product Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r60",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r335",
      "r342",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Carrying Amount of Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NETINCOMEPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r286",
      "r289",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Net Product Revenues by Product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "terseLabel": "Summary of Derivatives Designated as Hedging Instruments Outstanding"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r150",
      "r152",
      "r153",
      "r154",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Net Product Revenue Concentrations Attributed to Largest Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates the sale of a borrowed security or written option.",
        "label": "Short [Member]",
        "terseLabel": "Sell"
       }
      }
     },
     "localname": "ShortMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasandNotDesignatedasHedgingInstrumentsOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r68",
      "r69",
      "r70",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r145",
      "r193",
      "r253",
      "r258",
      "r294",
      "r295",
      "r296",
      "r308",
      "r309",
      "r353",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r447",
      "r448",
      "r449",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r145",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "The Company\u2019s common stock held by the NQDC"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r105",
      "r182",
      "r192",
      "r371",
      "r392"
     ],
     "calculation": {
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r108",
      "r273",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r126",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r124",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bmrn.com/role/NetIncomePerCommonShareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=123585891&loc=d3e19833-108362"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r490": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r491": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r492": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001048477-22-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001048477-22-000018-xbrl.zip
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M3&0H:"T#-A#%>A:!R>J?)(/D9W?U]<8PDRH(X;GT3##NC-%6(F1X]#C$60V
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M7]W0=P_OORRF#XO @T-:8TU8E$Z+X")U\-=:@F5L3%\#O@>S?-0@SY'R/LK
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M2N%4]SU#V.F,L6@RK2/)*+@Q09#R*#11P!T<X*:W0E(C1ZW/0D1@5XDSF75
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M>NNGQHTJ_:>\K?)"[RTS; V/@DM[;?@6O&(^&K;<?C50^.N#=-/K#;Y/-WT
M.?U$4\B//KA&)/^AP36Z*I"<_^C:JA)L[G=5JUK-OZV<KF)&?GPD4-\G?)Y
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M#G[!T[F=?3-LQ;P7?,OT>G!&JA.7!G;_&>=I6'=4M&R8G@ WGH[L3B[%-"V
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M-;B%Z,^TV6AL[I9@V@&K=8E7E##K42[E)J?P>S( <A_#8=P_XWPR=0AVXZ
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MJC9K8=8Y.^_[DW'^9*-;9!%-R\BD@O<P+I>OG<6[G@S&E;QO$Z\D4EF *B9
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MN18F,J1X M6%DHNBTD^085D,Z;[*[_.4Z++819;HQY/H69[A8!1G8SP0'!I
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MD*-L5%@*/RBF>KN8X:R+E T[\S$<7E&G9+)G(J0!U=0!)00!V/C@-+$2I@*
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M;:<#JR"IK=WWL+6[]S>T'IO(,H"C& -*7  J* ^0<I9ZSB%%9F.+<ER7>.&
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MW7:@W:U9?=X>ZDX.+U].;>VK"7\;Y[O1W1G-]A3BY)B1TI#HQWQ!2"V03G\
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M%DXJRP5"*RBVR$8!94@'IZAR6&&L%86$,AD"HB.QA5EL'U=LR8S81FAET/(
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MHD@K015DCD I-//ZWE[.J6V_5VSZ?/B6=?CNWV*$U,)8Y WPBE! !79 4TT
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M-'*)"I2T</"'3)J3.<0M%(8M#/O4&78)"+;$?BR$0V<Z&U@;J<1(V]S9@.&
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MYI>][Y\VWG]I'OP-S_S^ZZ</KPZ:IYTTR2UL[F#<VGV#FV\^!V,<QU8@ZD1
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MDXP+KA9*X\_H(*C\;5&]J+)Q2\7?-W)N<=3,)-+OV<2TW_NF%QO6'VK(G?<
M*[=G#>6/".5EQZ_V1+-$)Z(/A" .VAAQ1PDR.%?N5-*+1$@0*@&6JV7U\$CW
M^TK&$_N?:UA[P;#V4"/UGK!6&Z:_C6C-M8D>AD[GWMX&.8LUXB%(I*EU2"I'
M@P]<:A-F?6I60UH-:96'M(<:X#53FR^N33 U:A6WWA,49 2K6X'!;1QEB#,"
MJDI[+^/",;7G6:KL0M?B*M4KFVBM>W$-*U0+['F-\GEFY(Z3TB]6V'_RQ-SZ
M&G>XQDO*H#W;G"=UT;*Z4L<5=#C%&(F.409NN%?*8)\X21%CIKUFY.[G41?T
M?5VN8Q[DN#'MQE2)>1(H4HI@,/J!)AL%?[APCBAN@E.Q>O4Z:C"JP6@<KT\E
M59)XDH-]*7<&1RT=&'R1<(F->E0PJIV/OXU#4\Y'H97CFB*?>^WR(#!R3'J4
M=!!<)(Z-M,\XH[E&HH5'HFAT3!Y'0H/E3'"+,R!ID?MWVB3ND95=TZ+YP]$$
M+4HX&>:21J!1#.*1"V2E8(BZ2'7N1"<(JQXMFF4X3C6MU-PV#4::?2@@?(-V
MB*.&;(_J1'F9:52>6.)C\";&P%VRCM$8M>*,*^(5>5PSKV96OPEE'Z<L/*6U
M9$H))))/B!/BD;%6(FV"#)9%DF9_K%NAD]L7+L4V-WUV'%;< HF.QJA(K) ^
M\)0B-M<T *Y9225$>3I"0V%J@)7 ,GK$O0O(8*X0=M1X[43@P2V]E7P9/SQ^
MN);DBDDR5SI*&80*7'+AK36P&[ 5*9"8='2U)%=9DB>4,G I)YC02'@,2AD'
MB2PA&$G#/$L&%C;P"DKRBTAM]M.'M)7-<+Y3>-GB8=WLDIQKK)LSUGV:,D"H
MCI3(@)'1U@+648-T+ENI;;)22R6U,+/UI50FJK2&@ HD.]<0,'<(F#1<N$B
M CG?60 .<$[!<.%2(2%#(DQ9AW6:%=VI,>#98,#L,I]K#)@_!DR:/-%310A'
M7).(> 3Q=S(X!(N9(C"#I)( #)"+Q .>9Y3JJ&],I]?]AH:Q?U"I:-5GVJ%E
M(099!\'6]>LK&T!:5S69DV;W4P8^URH 1Z-@X,<<0^HL<L$E) 2QLM3K/%:P
MBGTMS)4-P*PKD\U#CB>M=$<UH9X3A*D@^5!"(!LQ_*'.$D.B\'9VD0*U(%=,
MD!\E?K'6RO.3Y@FM;'G40*8H2B%HQ 4.R B+49($)Z\,(T%44"O?8F2$]N"P
M8T_R8./-\O\R/EE/URRGZWD4K'OHP?5L:J&,Q/JJA.^77"QE%K.RX#QC1G7O
M+K",FEL\)K?8GRY^9ZW"3#.%6$H2Y6@TY%C22 9.+.-)ZY1+JHAERN5L2ZK,
M0'X6HY14#9\U?#YF?;T:/N<'GU..%B$)J$&+-"46<6LHLM$EL,]H\M[A: 29
M<?1G#9\U?-;P.;M:?C5\SA$^)]DGLQ1SI9$'[8<XBPII1Q/"G 3AI#-2^*6W
MVCPK]EEZ+OX86OC1M^/FO1<Z(U^XEH^PW?OPM?*SYW<V&A_<5<<>#N*;LP=_
MGGE)VMU2KLHO_7E@^]_:W;/;O:*E</E[H[?_/&Z'X5Z6Q!4\DL:Q?V7\R^.W
M5\JW)N9[])X@*X:H:]_&*^2_?\LG=--5)MX31-_U]^]\6X2M:$Y_Z[+U8&\?
MK+C396]Q^-TCD.;NCL=;+TK$U&>OH!HC09ZG=KVZ*F?6;T6IX(I&M%F]C=J>
MVT'12\5Z]/' Q7[!R'*1*R-<@M9*3O\%]GD/U*[BTNS S[83#*$['.FU\OSM
M7Z[_Q]LM!Y?\D=&\?+K9/3P:#LJ'KS[$'[%3T-=W<0[/*I+M^4QT.8>?NKU;
MYG>T'JR>Y+M/<GEZ<1_X6- RQZ,ZX'<)I;T[Z,VK?N^,XUGK0<X\Z':!0LS/
M,FWM7 1BAK'3]37N<(V7%"Y^YQYQCXCH#XY96S3?YO.K(1AX[K/CK,'6\?R'
M<B=H$)9AHZR6I7>2$'K75I\O.M=M/^S!;Y"MUC\'N^\_T>;Z=KMY^H5OK?_U
M?7?_X^GN^G?2.-UM[^YO[TUZ*)MT ^[GDVA^WOV^"[\!]\>:^]]XX_WV07.]
M^7VK]>FT>?"?@^;[=ZFYAD\G.WL+++B*$AD;(^(V661,R!T_D\&:<JUS,5.Z
MC#FK4.1=#4,U#(W/F+D25)D8;! \$FREBL19;K'TE!G_6##TW&+YYX= 9 *!
M6+(4)Q90TEXACCE'6A&"M C>&>ZE"O09A_+7&+3P&&2P,,F0@*.5G'AMF;<B
MR:Q! 8)<K*E0)8&(30 1<<H!Y4E(.,U0S@I#VF*##'/:>84)=[)Z5.@Y.UT6
MSMGR3+/I%V*0M0_GB;SR+S,'<=;^CY>>?C@GO;\U[0+Q- 2@; R!M<$1EQHC
M0ZU$(F&C@<=1,"I![[-E0ZO40:$6XRKZ#UYP.8#Y2?"D"X'XX"RQ%%&9.\-%
MP9#QS*-H<]"L O9._#-V(;QP$9ZU^5UKXGG)\:0%[CQ7CE*.F H.Y#@I9%*@
M(,R""B\$K'2HH":>JPE^(9)Z_'V4/_R&\M)DF:>,;L?!L-_VPQB*=O<'/!D%
M6YXMP0S&(5:TN,-0_CSL#=IY$[SIQXX=MG_$/[/AB-@*N2(@W-E!S%=8>ON*
M_(IY*\/4G]C#\#*[10@@7"X&'Y0*//!H"*.2"\TTP"I)IL;O:N+WSI0E)4V*
MBE&,6-(2\#O76;.)H5R=!WO'3(PX>U -KU*GB%J*9R'%6CIJA>3>& J&E# ,
MK"F=,(\X8I$>DX75AM3O"O"D(:6\"\H$B:+( JQ)0I9P@P01N:5/THZQN@';
M<Q5A$ZC"1,9H..%6,.N9R0K9*PGBS%BMB*LJQY.&%.4N<B\X(H0HQ 6)R++(
M$/ LR23'Q%%6/45<%PBK2BFQ1>R%U;MP9+PX)V,OK4]&,E$;&K'S8.PEL!.,
MU5PZKQ-Q'NR^6L=44L<TLGXYF6@\KJ*5,6C$?(B(<RN1S?YWS3!V4E@JF0<E
M(Y>U7)@N&34"/'YS4$N=\$+QR!T77+LH"' 5'"6F2=:&8C6%O[ES6?B)B990
MP9!B4B,.NQOD7E(D,* Z9]YC6+\9'[G5TK_XTL\2E999G 3G7$7A7+*8@:[P
MP@8:5*W_JPL!$_K?A92LP@&!B$L$1J5%AFJ.K!".1"W!R!2+IO]?1-'EN=A(
MLZF-]R)+WSW[RG8/-0+/*MN-5$ -_(\*_)M3AA^5.M)H'!+$@^&GK$,FJP B
M97+6@#FH-0"_7H979UO4[NFI7PUK-:P]EF5[3UBKK=G?1K1):U9SZBP7$2EE
M!5#9F) U,D>?2:T24T'9V5FS-:35D+8HD/90<[UF:O/%M4D7O9.!<NWSP2\!
MIN89LD13%!533./@8_"+QM2>9Z&]#_=K7%V]:GM7%)JN8"6[YS7*YYG[/2Y_
M<-]>[A5) :^O<8=KO*1<[?NT9Z]+[M5U9FY(.1=1"9+ 4O6!>YH<ML:RD)*D
M.CA"[GYV=H%MU,5FYD'-/TTY44FP1&C%D HR%]ZS##E%%)):$N9P(-Z'ZE6;
MJ<&H!J,1&&&BD^&6<2,HYTP8R:PWGE,973#!/BH8U:[/W\:A2==G/JUW-FCD
MI,2(^\2038SG\WRJB.2.!?Z,<^=K)%IX)(I61TJIYU('#HI3$ZX5-<HJC[T+
MO*9%58:C25KD$^&)!J2H!3C"R2#MC :")+56F$3O>/5HT2S#AJIISZ[!)V"D
MV2\#PC=HA]BW>=(KXIAYH0E[22K-H@Y,"4 _YY@B7HH<G*$%B$W-P:H(>E^F
M;$$?@M(\'SI;FQ 7*2&C'$-,:[#S74I&A3KM]KE*,9 6)W+10*XP3X$:,*>"
M)MJD1+%/]RA!5O.7N8ORI#D%)K$P1E,DA;&(<V^1]5JCJ)/'(4:7O%AZR_4R
M9;,Z<:TEN2J2+"+SVDM.<@*]5\PHAF5(5$@5C"6XEN0J2_*$4N8<<RF<0T2
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M4!>"%(I7GW;67R_#V$$Y]V%RRP]DHWVE6!N'P,& X<7!53.18QI"S'9F^:O
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MWE*^+!Y>-NZ^,E)Q)U,-<,\8X( VNESY4E*6B_-$&Y./%.P)+IRFPM7,LJ(
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MQ,1>^)O'6 *6#]09[K @BG)#K4D)()9(YKU-WI.O0B^=?6GO_.#DT'Z+R '
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M[;5/($$]&$,.ZSL[B"FZL3QO"3'%?A_>Z"5XD!V@/I>*N-8'0^\W-U<B=47
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M^41;+5/**A3V7V?M5#@:I1;C1Q?C"7ZA<UD)(R.*DBK@%U(C0UD ?A$IMIX
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MHYS1!3[?MTPT^DN36W^;,%=0$Q-3"DL(<[UT3'K%O.(B)4*P+5/KR22UGMR
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M+C%1OJ#NTEY)#=*][.!NQ_:_QV$,^03O\(S/:0D]JSF&JU<>@7V*J.P(("V
MLI%8<$>EPUPK93@A2G&#>>US+1,T;^VM#9N[5>6:YOI'W%S?^"J]!$\K142"
ML8A'0I"AE*,8E=!$<Q():!O7<RE$=BL56J(EK&>%"3@F#08=6T="=M*=,-)Z
MRT*F.)3,U(M;2X<)Q].8H*1FGJ.D%6 "30)9@17RWF,7L&;&.L $HAI*XJ7
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MWED4:-"*Z@0_W'0)A4O*!2Q,^90$XMT[ K=A7.2AU6Z#K]FOBCO ]R#N61K
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M[.$"?&;_,_9_M'Q$%8"#IP;@65K;\BWE,L"@>+&S^W'P1V-<)W)\;?ZL,8G
M,I!?^+RZO7=X!JHE:7$Q/#Z,)<#;(]L/IU@(2-ON'<>,IKWL[I9KW' 3S#&:
M? >>,+@  -J [0]$4;R=-L8OWZW&Z0P#SJ/$6CO[#6,.8P#[_2[,;GA?!J4E
M=#Q?H/A^]!5;87"0%A'.\VDZ+I"C@2&BM#4A"4)3F@:*E"P-$6-GB.0T".UP
MM,:%O$L6 PW30'%^-DI?(L<LITN:8T]YVEUZT\L*G67VS?F]VUUP0V(5@)2L
M[AV(GP[@NJQ5F]V\ %)J$CA1E92/Y=Z?;X+M@X[MCY]RE!V$P9C^>/!RD@OP
M*PB[,=>P*;'H4L2[=@QKBN*:HG@1&EM3%"\?1?'2,!'?AA7WJH2J2W*J%G%^
M;THM?)-N/H_A>G2Z8!B\!SVU"LYHZ?7;]E)6*KTF"_FW>0QOE%Z\&&=9;EXZ
M[]:=7L ,T5ML2Q/#I7!$*!T]#X%J;PBV21/E?+3NNC.[L_7QQE%=#)<'?1M5
ME+$D)?%^+_ ;YUO_^V#KVT%[Z]/'GUN=+=(\V?GVN;/3^KP7#IJ?(.C[])%O
M[VU"\'=)2;S.QO'VNX\_O^QM''\^^<B:[YJM+^_^?="D&^3S7K/]96]?;'UK
M?L\E\2ZA3<8B"H:E0X[E8WO&,J1%2,A&F5,EN9::K+SB#4;OG>IT#GG5-=35
M4#<7J,/,AR254$0&SI0WDC-F/ ' <\&-"RO?IA1H#74/#G731TO 2&&2M$"$
MB(2XL!(YF%=D@U#2<J9I2"NO9(/K.1]TNS^H>P0BF ?VIW?B();1<Y5Q<IJ!
ML(2N=<T)\\M2]@FG(!E-(@5.(M6YMCTAWD;C7?2V=BX7'7%G69DC@*R7SJ$H
M:,@)W K<3)\0A ZYO+;G"JM<DZ-!#%X,7HA:H>?G0F$=-#7:)4(XH<Z",*AH
M66;D)M1?Q]Y2*_0"*/2T"\6=PB8HA;!S$"TRJI&1X%$E2;@,C$?A6:G0XNZ%
M=N:HT$]_V7$WMN'#_4:Q'[ME4G>931HZK6ZKK/_:^A&7T&.JF4U_!;#, <0J
MIZ+,V&J8-J"5H(#8.J8U4;7'M.  >PDO,AA('K%VB$:,$>=6(:TE1=0)EN K
MX@Q=>45E@\VMDMD"+;D]<X7F>3F=1IJM+!?:F&2DY[G&1+!6)5Y[3(NOT-,>
MDX0@E@E"D%$J$QW0B%P^2!A8$ *^$WD27U'1$/C._)ES5.@Y+2PMF)=4LM1=
MG5(VSFI;0D?IFDCTNOM^R8+S2R*<)[G7,?]166Z[]%OIOK5=6B"[-$OY1Y2)
M,F^&2*T#XMAS9"UWB!@6J;5"^:177G'5T(S-*9*?GSX]\L)>#:<UG-XEC483
MYI2,6$C*F9/:*:*PCU[$%%F]M[P,<#JS,!JXXHI$I"!&1YQYC4Q@'"F3"QLH
M30C)M(4&W/RG Z<7Z01G#E7>\IS%HY\"V[TJ+NBE6[&WW-5=FJ%QF<\)J3?V
ML 7A3_YTK9//\"X) \P#'ZB"]T-[-FGS!!3[V^?C7)+(T92(R#&\D)5RVZ08
M2CP$ICD-D8"O)%9G2TC^-@/076U$+4.+)$/;'[Y*#<A/=4(N2PZ/6B%G\LYX
MLLI(9E7P$/7S7[%(Y4-N_FP",F5+#W[\ *SL]<\H"V[-"W.1!^W<%%^]4M(J
MJ8O&\I%/WOGS:>]G+$43EH,IMJ+?.(__&T;CJC/ZXP>/L3_?\.=A;U"2$[PL
M&PPC<7:>[A\7CRV/VX'/;K$.NC0:7GW+S,&,AS1J>9O@PEB?^WESP@*%3PD+
M#OIGYW[V(W+]:+\#'$*W7MKVD3T>K/SSXOS!3(U;I/)D38_2E6.1TGS'HA(3
M@*8Q(<G+BN6B5:ZVV<=M0 $Z"[#_/]?/!(&9V"O/E)8G9[N9&FCP?_^T5\OY
M XG?Y<02KS>WM]9V-IO%^W^M[6RMO=GXN+?Y9NVO8K/YYFJFH$=M<7-[;V.W
MV-LNWFPWUS>:%2]"<W?[K\WUM3WXX^UF<ZWY9A/ZL+L''VQM-/=V"U2\.#U=
M_<=B]NO%9DF%,X)'A/+8]<?5W=5B/9] SH1O\:>/$ 8<1E#O@Y)XIE/QON1S
MV(.*6N"H-<@4 26/QTP_%XK.A.![YS/9L/TN!% #\(Y*9VI!" C8UBECXA?P
M2?+W:R>?][YS\$6.X+Y6Z:-\^GRTM?Z!??[F^=;>%IYA3.S =]"6K?7FP?;>
M/FNNKT$;-X^^?'O=_O)M[:A9^DG[/[=.=L#7V3INKGUE)#EG5414&O!O C7(
M,H,1 8_5:N&Q-7::@L!:JB*$S=[HQ*DWEFJ+8^)&<X-U4-,4!,V-O0P<VUL;
MQ?N-G4Q7LK7=+'8!639^@Z[DVK<O+%W)^PDA7&;S&PQ&%<5 %L(QL5,'O+\Q
M/\B8H6'R]>GEH\->Y:+%G['OLV+#G;W1,#-&Y86!4[Z0"SPC8TZ1QM0[3A^:
M#=JE1!"3\*,H=:5X/P*'%-S*XGT;QNS%QN[[]W\TX/8?<3 \)3BY[#D7WGL0
MVZ=4B<T/ZV\J+K%RHO=+NL+<KI+_:GI4+K)O7?*6;KGPD?L4HANNSHC3PS"C
M3$$,Q&LMO]8-ZZWL;X;2#7C.L+.U]E4:8H,W B6<,XQIP!!@"8:"M2$J99*7
M,S"RJ&J]5[)R9@:3DN*STNI8\6D.*PZ_'(2-AJ>K4KD&AA]36)8B4<2QR)2&
M?"+RI<J]./_7A!BO\@;^>'DG:I2:XJ2F.'G\QM84)S7%R4)3G"P)8<>=^$WF
M0FZR) -U+\PFB[?/7[JY=@@O6,*\N)OF&]_@&7/C]%FL1C["">)'D.$X'/,*
M-BJ?>0E%^8XY24\UJ^@)Y07-/<T2Q+Z2^K]Z@\':#]MJERL&O3=E)+A[1G([
M*%<6EB)!Z'<7&B8)0O#V@\Z7]<^\N>[S/?3+M[=PS]_?OW0^LNWUM]^V]S[\
M;.[MM&<3A+;H]CMXY[=]W#S)BQ/0ND^;\*Z=SI<]>,^G+=%<S_5._[[L*#3W
MP8*$,!12LHA[8I$./.7E4IZ$85*1?!2:XH8R=RYNNGAGH6MX6GIXFGO:8@U/
MCP=/T_F+6"OO3*#(RYR>XKW)!:\BDB%J)5S0.I==)JK!U)W)<1;T8#<5JVHA
MO=>U$%Z"^PIQ;QP,)X>4&D4W5C51[,]&+@MR?L^BVQL^1?+)9WX\=.[^X42F
MMKMOSH1G/;HA(/-VVK,_:\B=%^1><M0[D<0\MPQA;"CB@2ED-'7(4\5(L(8&
MS%=>T8:2=\X8KT]Z+Y@JS]V7NJ4JI];/&-!)[/=J+;Z=%D\[3IXSG[!RB!+#
M$6="(^=,0I%ZK:B"P ZSE5=E9@']<X'T^-FM^XUWR)?0*YK/:<1G>=CPR9\E
M?,0UPW$64NTCSLVZS)[2UCZH))Q&*DJ%.*8R6Q>*J'00D+.D;<X')Y0UA)Q7
M7/[$3F'7N/<4<>\1%R-KW)L_[DU[U91&@J7U*(K@$)>,((>90\K3:%BR(E ^
MY^7(Q>/J7I8,D?682^]VZQR1\S)TR7G\!4P2N6DKGT6T^*G\(P9DH2EV/Q87
M,Z;/'8YXLEDD-UJ6>RJ4U=6\WG= -9&JM4JHFJ..B_WM5![H&&R?R52]QSE?
MIV(V!<-(+8/'"KE$.>)*4 BFF$+,*Z6"$^!S$' J-&N8FH[^*>KVW(.&6K<?
M2[>G X80O'4Z1L18"H@'EY VF81) H@G:VGD(NLV:2@U2]/R-!(8%M:QVD@I
M^C)9H5R$SU6^!]&/^JUA*PZ>><BPT,^8I]N_L.DUV^7)YD$^"WPX.99\_K#P
M$LIG[0E<XPGXD***FIE($B=6.A$2YIGD*REO^>V+36UV?3_FNF2V/5XQ+%^[
M-ASV6VXTG*PEYJWY04FOE??F=T]!L#;_MS#_V[/[)$$HEW!P*%&G$;=8(*L,
M1E*'3+K%>(IRY960L^Q:M5N_],H<&5-,.:RI,9P1K4U@*A!J25"8*/T;R31W
M5.;:T9^;ID\[^DSSZ&B(2$N7B5:E089S@I1G,/>!:*K 7)(&3/<"Z?JSR%-^
M<PTG#"B?*IIU:O+31&$M&*$AV*0EY0(3@Q, K02/BA!NW>VK4=4HO" H#&T:
M-G?QSXS$S?6/&#[_ZG7 -AB!B,YICUABI .QR"<LA?'!.,++LO%RD:K:U,H^
MKY74F*@@0F-)!>?:&!.H<-8RYZR(,CZNRU5G-_^^GA]/Z;GS$$&QA+!@><^$
M:>0@0$:V9"U63G/!GWIZ\S([7'QI':XZ[+T&@[%UP1 ;K8V2IRB<3M(:)W&*
M*I'H:X=K>8%X8\;API%3FEQ$W'J)N",4.24<"B1)"E;8>!M67K&&48L4]];*
M/B=E%PPS3!T&7PMS(:2F"?0?7'#/ Y&T=KB65L^G'*Z N=12>Q2"S'79#$5:
M@>O%'#,:/#'*$YF;PU6O<-U.9S^>)RA>0I^JCFNO@5D:G$B<$99]*AFE85X'
M'BB-W!B/2>U3+2_6;LWX5%RX)*.%D-;8?+I*2&2%=$AJ K:66!5I)CUIB+K6
M^E-4=I92S'M&$#(9KB*V@B6E4Z+<,*=QJ/<-EUK9IQPKP'4L33*(ZES$S5.'
MK,8.$<N#(H8!S*MRXY#=^411O8YUAW6LP\N*6^3:9KE(Q&F&UC)Z7W60>PT@
M.TE"X"9Z21FWPKH429 QT*A(TH+765D+C;D?9APLIY(Q@@;D0LA%@40 !XM1
M9+A)H<S/B>!@,7QG]ZI>LEH\;19$I."%CXY(SC7647A/4W(V\> (>7CWJM;F
MVVGSE =E*2!SX@1) 3$3=UP@<),A>@J>))QH8IB"-@NS0-K\+):E]FY;*&L)
MG:<ZFKW.>5*4>.M 02WEE$N(;>#/$.!7(GA(M?.TT'#[<<9Y4D$;YDA"SL:$
MN" &:4\<8CR&*!+56OC,@5&S0SY!;0[&N&@3AFY3;J.R.FHA3&2$218BKIVG
M1=?FZ40JQHP7%B-%A4?<< B*3 !?2L5D>1+>4G">B%DD;:Y9/Z98/YXLA^1M
MHM6[\:HM)1H_%"G(F%ILAC^@WAF8'S1_GG&TDF)61H=1HBQO T:*M*$"28JY
MX%AHD5>IB.$-K>6RL(W5P/"4&$5J8'@08)C>,O1*L4@$2HIPQ!,3R.8D@< D
M"=Y$BVUF(=1S.>;R4,#P9&D(,]EWJZ3PG"E^O;Q\;=<$RK>@^GL&'+BW[O0R
MV9_1(+R/_=("S-<[I=,V:&-<0W[RNC%[U=B8X-J8W,"8^!DOTSI)"$\88:HP
MXL%J9'U0"!,P(\QAFC1XF7A5WMG%O*T://)B7XUA-8;=U9&N,>Q^,&S*(3:!
MD!"-S\>\P2'6AB$#\X,83I@:IQUW/&/8W;DW'@K#YK3$N7B(\TMO^,FN8]XP
MNJJFXS+VZYMQ8S\9:W,/P_(T[-%]^]2G121JBW0+B[0_XU4+S"UC,2(294+Y
M=^289\B+9**UV"A-2J_ZSOMJ\U>5Y:B?4V-EC96/Z[O76/F;6#GEO<=H?3)*
M(*VT0#PHCPR#'S2H1)@URD2:L1+/*X%S ;"R].__6::WP+^A]>/5I&_-40<4
MQ$\$?OSG'+R B\*\ZP]B&+7C=EKK#EL3_NNSQ)J-G[X]"C&\[?<Z.8=S-+3#
M,O]F6@OVH%6OVSW_?3FEOQW_M7/\Y5,X=)3++QWX#MJRM=X\V-[+DKP&;01)
M_O:Z_>7;VE%S/;1 PG]NG>SDLUS'6_M?M0E<"^R1%2[S7R2*K/(6,<:-BR$1
MI<1*$0$B#F'TA_U1#BU@OB="VK']_59W(HN$ AB./RJ#2SJQ3:UNB-WA2R9+
M6_D0L$LS[&YVBRSM)>0.>V6B;OSOJ#4\AB!N +W)F5N#'-"5P@*_E)>4<EU8
MU_L!0=W9!RZV>T?%83\.RKM.3U2=YK2DB^G!PP,[+(YB']XYEL8B@3B63_1G
M,IGO*_=1"ML-DQCRJB"SL(-\_W'U7 OO1Z?D[R_*YO=&,%YA\,<9 7RIGE?/
MF9Z=,YBBJLL3**H !::J;0\'\>7DES\G,6>K6XY]>=.?%Y^?LY.FL*24B.KK
M/X]:87B0C>0JK@SE>-5@_.;QUZOE5U, 67VG\*K6],JO\2KYQ\-'V%=<^:N6
M37TGB+YIGVX\5#E93-YXJ&[Q'5/\?AI[L\=>L]IT"Q[_F\_PM0\U,Y=>XJS[
MF N,/Z1[JJXXZM"/L=B"ZPX&Q09@=?@_U__GJRW;]P<%(XT++LIC#/=]7'F;
M^@ZW6#!=Q/G-;M0-EB5OU,WG,5SD-B*_O-D=3[!*QQP/03S#U+NYE_"X8WRV
MUH%Y&3Z#A#QHUQ;=/-JB'T^V]CZ*YK<//YOO_MWZLOZ1;KW[2+;V_OWM\Z<M
M_KGS]MOT"L;G;]]//G];._FRM_6SN?>=-M<W\.?.O[\W]^!]>Q]_;G6:!Y]/
M#EJ?/S735FNFR@>-(LHD#(K,)\0E-L@9DY!E1$6;F'?)K+R2#8J?6PY%C14/
M6R&DQHI%PXKI.B'"9%XG3E$,.:E?>8ZL8AZ5QR9)BD&F6&+%W+B]'CM7X7'=
MFV6^\LDF@3SIBBPU <M#5V2Y!ZOWU)B#'\C@-=^<<XY/X-JUK\9$'05V")<$
MX5Y*I"V72 7#A18)!XX7D3BX5O=%K<E2.[F+IO-L2N>5=S(9B9'!ED- 3!1R
MQ%CDI"9!XQB<UG.JPK1XG$Q+Z6XM;SV6FK+EH>NQU.[6 D'O]%JDCEP392V2
MSH*[175 6BB-G**,"D,H2W(1"V/5ZKZH%5EJ=VO1='YZ35%+3V1,$F5&8@BQ
MDD96"H*L#=$%Q0/#9$XUF!:/Q6GQW*UEK\921[0/78VEAMC%@MC9+5[C&0T,
M?-2@"4;<L8B,\Q11J4)@G">L8XYH^=P.]-1K6 ND\7,OR5)K_*)I_+13Y;A)
MC&"+M,EK6-$[I'4T"#O-668^Y=B43A5=I,*6SV,-Z^G68JG#VX>NQ3(G)*[!
M]N9@>SSC7GEKK" )(R(RV.)$D2:>(\\32R#/"F._\HH*O4#Q:ZW2BUJ0I5;I
M1U#I:?\)PU0&K!GBLJRQA"ERU%$D)&/."IK3/7*-I26J:K=X&6++<N637>O;
MZPUMN^B6=+CY'.JEGFF%>DOHC<Z?A/GR,_=7YZ@^49,W=^+V>CUAH>SA]N[L
MQBQ+C.;S(52&B#A1$3DL.;(L@(\;G1&6K;PBN&'HO,H.SD/GEFCIL8:8>Z6
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MV[+9H)FJ3PMMX5[$I "PMP0CJ[C-Q4FT3$%B[NC**T+4+SUGVVYGH3HZ:($
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M+&SHN[P16C,.QR;AR1F#VE-^](WQ>ANMEJ[[6@K]W=32N9F#ZTY4+^#ALO(
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MUV\#"6&2%F9(X=(,5&6V:P*C'ENMX.V#/J5!,L):,"S/]V[6 <"%)'VP%N2
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MS6V@Q_R '"O1<(W"Z$_I@@A:<>(?R$K^5 <%[%G!\^H9.<I>^@ANI%99 D(
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MI 0K)MZ%DSTD%H8Q9A/6%$^,F-O5X5CF%;?C-2O1(8O&>&0=;V%H*ZBEJEV
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M^TL.$L!L:9QO7KD12<FC1!N*Q4P" Q@_+28+&Z(CW(^0+)CO4KDBEAX([H;
M(*OWU^T-5]'G$].R^QIH+F(9>1 6XDBY/DXC@RS;!H0&V;%FQZ\NK-H-'ZP
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M^J_T6M_,+&D6I)'DQ(G'3S1E)\Y$L9;EQ,_H[FH2$1KHX$**_O5?G7TN=0I
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M<FKX#G;SB*'*8.3A UE](V92$VUB<WB#>RP?1\7=]%35(;W1\6#2E128&N1
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M+UV*$RP<I"8!/8SF(SY]6PU67>-)1$*>ZHH $J9AR5A*5CWD_WH6/X_$V-+
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M?)D2A &L['XZC/$0]:?BWB^WEMJ*:SU$6 TNWRX'L*V!#4]K_6#76A&G3(%
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M7,@_F+NX<7 ,?C^;./K:%'DY-:F4MM,63^MSCC'8 FZ6^OZ4#ES#/4=UZ=*
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M,D!7"V 9[O3D54UX#>0SE6UZQ^ 8Y'L('UIV]*IFFXT$+)M^0TWA**\=^AJ
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M*6L[J1Z[V5YTN5;<>F6>?OOX[%*:,\X5OKE,TBSN0+GK4(H YM<M7N&/XWC
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MZQY)295SBO[:KJE*UR2@2!!RQ]//S^,^'4E0ZJTL#3!?Y^=OX:AP :EMWSO
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ML0E]FVS(V45H-BQ-H*;"VP8\H0G7IAK"-\P4F[ZCY&$6M-$3TYL+F7H899]
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M3MHR2A")*?2A"WX8S5IW_:JL#Y+WA QRE+ ()14'!>5L$A=PL?1$,$BS]=.
M*C4.SKYF+A/A%X_4J:0DIAXX2'S$%U.F[4[+6'!4V.;&L@M7G/YUB=/XYPQP
M24A#%M:1F.G=2"XWN&.N7K7[/+6(=:W8R#2CA.6IE%L4/'KOIKB7+? 9)ZGN
M:FM0(@%G'G?0PH?KD 3S^'PM(Q+5M!"2S/ F $MN0"G_NK* S!8>*@5>M_K?
M6.]&\I(1_-+-MCIZ,T;S$^P(348$U'T/K I5#Y2:9:BG-$>?J"=M6[COJRQ#
MX;*4DE1=N#PRIPGR1ZEJY:+1;F7_(6GWA1UC[][P)=/,=9^4A&30!!U'='&[
MI7%_7FRI;!2;>R =.(TL'TR2_R0'C&3O-..A +Q3 !AV,2=LH7,8#B>+NHT'
M(L!E"E*Z'$O*T76VI:@S'=>0D$4QW.R?B#9!R_2-K&D4L5A2.-JY[4Y9*#F8
MH*!34F2T*30IRB;5^A]=,>[[]\ON/T]3N%JX4JO<*RQ)YV98M!>@5KI?>+?2
M$F_%"^1>H>S*=6N B1*K%R+Y#E[0VOO9C!$!I6+<6XN:RTT(/ G/S O0GZ#R
M&K5S% :Q<6D84(:SH2J-,'N!/U06IJB&(&7<.:/]KM)D.A$7PW72H'47F#_,
M50C>B24J"=5BJ>D!8,N,!AIE$W".KZ)UV_-NE(C/90(JGRA'(H4-1>]0ER)Y
MT/5P1F1YQO7Q]=K8(JMX=?59$:R)RFGRA!T+U]K,9E_,_U,I,[:8PKFK)<!9
M0I5<6&L4YN)F=#:B#A9Z5*8>6BF1,Q*.02+53K[W7,"[YR%#Z^LUH<="RBNQ
MSA@92! 9*9SII-\EC,7V<HF50-VS25JU=W#<LS7!W$NFY*I>R9M49[HM57XA
M%3'*9))S:3)-LVE I1.5.,4S-=%E+?.RG=Q//9_0"\KHH&"40O6C6++]2-:W
M'-F SVQ&3F:=I!%J&=P5N371?R9B*$(3,PNGU7@ZLXRT@D)'Q\*)TV;;\^L.
MQ2#Q/3:S!953[*^PMM3K1>U<CMYS$[E-I"H! NO<T^&A2Y_<]"B  BX" @-A
M1*)/U8R81:TK0!S&8I"HB2TYLNJE@O]!01/^)>M6 J*B)QO!N-*H0HWYD4"-
MN3>!UHY7?CP#4XE)@G3W?J+81X8PGA'7LA ?E/*OT.3<@*U=K,"GPE#VHZAV
M2JM!WA11D:'VJ4\H9ZY&&!$ZHPGANYB#!WP!)8#<V%*7;C+R_VGQ+7L%"C]9
M)D*ZCL!1:(Z]-Q&J[AGED,R8BM3!0#5S//AC"K@MSO,R2L?8"&"']*VL\29$
MN2D7%=+H<*!,+&(O58<\M*@H*..K8;3!H3"]PN4: -J^XM1#E;A$5%Y!EJE^
M6B%4/D>)!@6I?S4/CFN?4D1VXB'7-;+&B;$"0'%K@"<@+;.U32CU8Z]O!:O,
M9?Y@!+UA:/;XGW= ]7,27 WYK[\GMW\F5PF^X&DPO!O_&?]!1F!F2SYODO(;
MBU^\;SZ,S,WQ=[\;7?%G/**A07<PUL 'D\J7BQDR\($!XSOECQMW[KB3C1T%
MC37]!%\I36X#LX37Q@;I.]O-2_2ZNEJIW84*$:R+7.%S;#=751ZK*H]W4N7!
MH0IU,E=O=H_U7E!\E#I#-$X?T^C<#.4S5)(9@SBI[1NKH&=$NC8V)QRC/ZFS
M[C( 9^_/9"P8&6DQ.%MB&3'&J=P$*U?K+@A7>MB@7X[X(VAG<^@9_>%IY:F'
M/);!C3WO[#$HS8<CKN5&=Q+\,5"+A5]@5P4BO'OCTF/AL+; VLI1[\60+F,T
M](UG,$3Z4C"OATD2LF\DQ?%H55*M(+L_9#5XH2]+@/N V?IHX]23C<?:D(7T
M?95M4.>,&J6VM-&@?A'6540B0CH@J-=-4B_=3"GI/$(^&C1DD$M@;)N<"W5+
M.K# UFI6\AQ[KR7)3[E(4+F3HAAO)LD-A &F.36.T-A+G8N7<RV4X>F"0YY,
MVD 1 D%HN2FI_'4^J_ H>VM=S+?+.C>,N4? )[\&],TA9-=2I/P5WB0(0,BG
M2%_NLJD5:O$&&QZU'BG7KG5Z10R#0W QFT +%T4W 0Y.-_M>,A--N]G:<[7(
MC'"$R=N;>!BB0JD9(4M_0."9?@[N!H)I@@>!:P^A1ZC!@$8@7/RAM+]9#T.2
MZC/IEV+\_C[E419XYPOUBLQP.J,+Z0FE&4"",5.9F[JB@!IB^;41",3(" GY
MG8H+1)R56-C\%-W1;(N;( TE9RH%TY+LZ0=I>B? =)(-=SV'G#@7]8)AG9&+
MQD#9@9<;LK4DV%:) <II*L3W!11\>V0X[]&^NU<!\]Y<Y/(HRU<]]W'FH+,N
M0%GTTR021'H;6'IW(RO7M;\S-YT_BDO.W,[1#6;=*QU$FRT3*JV]5)5UCF0]
M'E\*.*;EBTUMM@!. J-JV8GLWSG2-G<-]@L8E5.R*/B](Z:.?48<.A *HHS9
M".YA42V'ZIZL41D/Q8V4>IP8%L-12,>7;HPJ0<13+H;1/8D"._6,;AOG>IM>
M0N:(C;I)@.@=<=]UKF8UI\A<T5_H>G$%:<6(-AUU?M,@8-\QJ9KBTYJ)IS&7
M@\]1I%>3\R^Q4=JA K?CY %/G16N:^QDU2AX4A$N5[*H(D</22G^#E$[6"0=
MND5FM9X'80[OXJBFW<6:9P08U&?*?O[CJ/^8_(3J3"%<#NR/$;VW$PV0AG3J
M7L5GS=9I.>\ME%DP"2:._"Z7;M!+F4#4T=3 *O<DEA&["]S2"#Q!>,7XZNB,
M.*-=^J( 5BSEZHXI#M%':<,J2S<ND>0P(J^*X!+BM$"WD<\&\53]H5W 7(#<
M%')[J6)ZOP3.E24,&<"O>-L'U]J!4 1@TP#-A6@TM1^HXROX 1K!;\5#FV>@
M&@2ENBL2H@5P_AC^S.D"5&<)9<T$+2@SWP8(=2./0DN%\O? U@"^AD,"H=0J
M.)_\QJR966O'7(-$0>/[GLR\ 2Z(#VQH165C1FV[OM%UNBQ!4?#NBJ*I;FKW
MKN_78:J0W:H;<:N*0F?<JJ60LZ/9PU1'R1V[1T$%:\5:W&_Z!A)VD-7<U-5R
M>I;K=A$Q+Z!*4^TOHL+ZGE,T@5M<L^A^<Z7ZW:I*_!(7;*G..2A^%_./0X9/
M50.2Y^RE D?% S&&@$.(=XIUI&X<L&7/?!?^B.X)2-BI>JXH_NN_+]+-?\W>
M)0[_^<L<$<C6[B\//+M9C/WN-8NQ7_ADH3G4/!K][;]:V\V/[0;].?O?[V-"
M.T+DQ7-$-C*K=V@L!K,8YY3&%RWWG:(*IV!(16$VSY)LO[%R.#$*<R[9N>=%
MGRDZ[=92BTZG4G0^D?V3U;Y/S.EX'HW-2:E$9B4>\XE'=ZG%HULI'E\ Z_ \
MN 0?X9,MVED2L<B1P,)8EX #\<8"LK/4 K)5*2!?T<96=(C+(1JOIS'^6JGZ
M5G6J_A&[H].TN^.U$OQF@/T-,U5@87_(IB. 4?^X_%E_;UC1+3(_?_Q92P'*
MUO!M].%VI3X\I#6P)V3.L'Z\O2%0MX$=7I,L^B!_^6A\R\DPN/L0C_&I^".1
M3M8)(([0"0[!$M[ON!;T-<O]WFZCO;,%HI^GYM]0'LR[HH&[8C,/2[YK-[I[
MVY5?-QNMZI_><]O=K4:GV9WKMIOXRO3:9F)@^O[Y2^<7IPYP<WYH3VYK+=F:
M- ^P7XMS0].R(%V(VH97OG8R!4!A*\H\[&4<T2=$KIQXI[I:J<)1MX?:\?ZA
M-F&@O\PU*]ZE+RL;1M\O<AK;C=;+2P.- 37DP@8R_['STL^>.7;&B3MQ!GD^
M^;"Y>7-STS"OU;A*KC=[:7\ 342;47@5I)O0D+#9:G9WNSL[F^;E6JV]3JN]
MU=KNMCO=G>W-L-7:V>NVPNBVW6H,<K/)>LSZ#1&3LP@;@L+:-RZBE@C_-T=*
MT1.83>2BA!]B",:Q4W2 G:*U5;<8S/MQ\B5(XW$1IN]HW"=\_!Y4')A'8*KE
MO-%K0&M$=,U5,Y=(0&QA&<X/#S03+W)AM+:1 )#5DI%"2:)Q"8:E>3G@!.(9
M8<^;^WPVUGQM=^-_:FN?H43A)&G4S+1MM+=WVCN6QCE&E&$!(H4<31I![!%2
M) A7W(\ :"*U.*/Y $F(Z7W6H&&':N$@X C!*X!I7*?$  +Y):,XA^]U'TZ
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M@(N@**LS#9<3!WPU42[632U+(\C@^*9]9;@;>G_QF63T<=*+ZP]KK]2X.V.
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MLG[/K_#QOA[$N%]2FVPYMKSK*B=RV<YFWUBX-&Q6*%)GAI*M_?6G,=3]2HD
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M[U$MTI<K=+:\-M_T^,?9L%A#%-4V+BX^"XF\\^TXOZ7X@%^GL]DD&D]5PL"
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MNVIO,^_/=?7!_QQ,/XW.I^\QY,%I;2>$XS/23L6PO*0X.AN=#Z?'48>HN<K
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M&R&*5,#2*\54,<K(-KW96ZSF 5G3S\-I.C^=MP4:G9[^.AK_&<;Y&#V+S&(
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M]G=H+G;W&UONL4>+M,=*B*6$.I8I@N=20#$D)A8-^=AMDM>V!/J=;G0MU=G
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MMPB^Q^VCU;E:9UL$1/#4BU*(I0ZI(5$$TP!'D(F )2F2*(WDP&6NIIKKTK_
MTO'<#N?S:+;R'FEV!OZ^##DQ8]2]&C0EYQ1]IE[UZE@ZCXLA!TSV6;^L$6.>
M'R8)%''J0Y30!*:,$I@()CB)<"RD5>LK*^E3HUGSC)2>M&HW-Z9;F ,A/OA>
MICNPATG^&90<[3287NK/,0+L-TC/SG^/3_/EJU!.;?Z2,;&__LKYO'PLRI!Q
M'9_RL,C^*7CE]5XLBU5Q09ZR%9GKWYX_ZM.B61 QB1,OAEBM$2!B'H68)RE,
M4!J(D*" <Z-P[X'UG!J-EK5MZAI-K&49$-_USP*PC05@M2R#?\M0 <L>@@/-
MNAGM3F N!R;HHZ6V*HU!RP:'?0B'A==ME\*!=!VWA^&P@.]T.!Q87)^TGW4"
M4MG,3!2KRXJOBL_K\&3, C^*&(?4#_29&O4@25,"HS!E,8FH#*GYF9J!P,E1
M>Y,.>"-!HS1HM.X12VX,O,$&M6,XAV;7]T+2)I?(+:)C916U4E:S!MG:]7!V
M"&@!37>BD<$X(Z8<F5NUG7QD<9^KT,^;U3>1U\&E5:^&6408];TX@0FF$40>
M#F$:1 D,L91^)&A 97!JZ.>N6*-78-30SU)'T-3W(:66IX9][H';S%%V!N&[
MAGU6D#9QY.?=D#J(^SR,T<!QGWL$OW/<YV$HCL=]=MS[[NF05:Y%$D<B$8Q!
M/Q4"(B*)YBP)(RZB*/3]2&*K*B.N%9R:!SI4;ER?[!GG#X,9H[[G% _,ON\T
MN^^9]#A<RI!S)?]5DQT[$Y4&D]/S Y,M=''QS_K[=:L$L^R)S.OMMV(6HI1'
MC'IJME$*$0TY3&//@P$+)&>I1"A>)S?=6WPTNH3V\&_O1_@0K/4$N7BJ5=5+
M/EG:HNEAKLVQ='R[X3?DYY/1'(EL*SU!J>@9V #:Z.J0+TT@<4M^G1+'93(3
MXW=HR>BF'MN<[58&.OW@1EXO%_5+0^;UTHY'!(6!#*!'_! B[9_B$%/HHR!%
MD:XY'!LU$S66.#4W<[N[3$&J[:1%2V^K=;4Y\@8;G:[Q')AFUE!J?<M4);WG
MV5;YV'JZ[T-LOM/I&M*1MCI/A]9NU],&ILYM3Z.!QMOWM+%K:^/3ZL83<KIN
M%N+^]^6]PE0WF/FD'J Z5<<C,D*"1)#[@0<59WN0>BR&- U)RD*$?&I4_<)(
MVM1(NM$7G)^!#V?@X@S\.WE\^BOXV"/WZ2#"!H3L$K>!R7@-F=+U#"AMU1]:
MWS.@- 9:Y5,2R Z"V".CS 68(Z>8'0;5<>K9,6R,<M$.#C)^<MHQ>_9FJQV]
MJ=\"_/I9#W(C;YZ$[BBY>+@3#]7JSTM"%E/AP80BG:# $T@"F>B#)IZ0 $F<
M)K,7D=.EZ;K[H"R;A[PM<;AGO%)5.\'+1EE GXML(8H"%)7:=DOMPT";+;.=
M@#<PW6Y06VL)&C7=K:Z/(N%T97U8VJBKZJ-&OUU1'[^A'V&LQZO/O.M/GN\G
M89)0M7 F?@Q1@F/=@2N!*56/BO CCT=6=<GVBYF:2[9YS)N("[5.UCMTRWS5
M$1]H ZP9.YP.U\#4L$&JUG" 5GS=(#AEA0.B1J6$;G/?\L&1JWN&HK\I1JZ/
M#=@,1[%/>1##,"3*7XB]!-($22@8XG'L8QJPR,YSV"MG@E[#Y3VXNKZX^7()
M;B^_@KN?S[]>JK7:^=W5!?@A6P"^G,])7NB,8%!H._YD&0.^%^XPQ,SC"$'F
M:[B9X)#02*V,8Q:G49A0']G%[9\*]BC]T,1*-[E6GG&)IOKA<;FH0#T#5&L\
M(.)FG'PRC@-3\FZOBK/RC)DYC&OO@L!M5/I>2>/&E'<9NQ,1WGEQ/S;^4"]0
M+I:/-%N4NP#K3*25^JG(>/D-T#5JJ\/?IESES O2V&.Q+D<2^[I$N7;?J(!>
MF(B4"A8EB57[Y/ZJ3(UH[KXI7ZZJ\\#6%N@?-R;84<H)LV3&.^-@/S Y-4:
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MAUCD(11#AH7N LH1I"))8"2)ES!&28"B7GE7N[*FYE>4N@'_+ST3*?: &?,
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M4PP3RHA'*)8!#GO62?T7[DT_;P>_]6A0?P1T4S?!%90#L\FG-6XZ@% MW39
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M9U"F(9<4>3Z3HE=JWQ'!4R.]5G<"]89M>AI4-8+*3>E679">>7[')L.,[H:
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M[(+SK.1/C3,:]<$/C0%_TK6SVS;\WZ#)V]5V@-H0RT1FVVDRXYP!P1^8C ;
MO4>L8"_T'(<0VNDP<F1A+X!V P[[#=,_1_)35C R_U^"Y)_4;XJ9E"3D,I4P
M98Q %&$.<1H*&&!*:.P1B;%1@<(.&5,CMG428*4GT(J"4E/[),FW<':3DR.0
MAEX#VN/3*TOR  (G9TF^'7?T+,D#ANW+DCQT:8_STI(YKHKB6?"/:J6U>+@5
M>;;D9;KUM?B]_!==BO#RN^Y+IA98'\1"R&RE?OJH_LLRL6"O924>Q0HA1\Q/
M*"0X#'3I!@FI%P>*&D1, NIY:6J40>E:L:E1B=:=J.>B ,\+-4U 5)_EK P
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M;8\FY$D^3WEYH5DE2ZY:?2C=J*S_!-FQVR"P!R:\NFAPJPK"7Y45H#8#M.T
M.W<.I2W^&/!B.+V28G]M!N7)BT';I\[+!^QYLD]G<E4G3-S+=1V+GV$F8BHQ
ME*DRM<\-2<8H@5BS9)9F.:7*K?;Y,2EC8T&M&&CV,;6NCH?T1[&T/)6_%*'
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MUKVF/> PT&HNM;N@!D8;$_<:&#VQ&;@&1AJH!L81ZVUJ8+0?&[P&QA&=C]7
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M?I6,KN5J(F4>$<$X)#'1%)$0!2DO,A@GC.)8"872R-IQ/"=M;&311!0M*_5
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M_CE=360J1,PY@8A1; K "*B_61BF:8HP)9R@S"E]YIB0L;&,T1$:)<L:P%?
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M]RIRX )01XT#IV$N3HJ8KZ=E+-;TAWPTAV!E!/#M3SY[%5*8A%[SHGQ=UQ5
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M29(F^CZ_(F_-ZXW.V)>V[AFC)"J+-DI1(S&K9NX++!8/";= 0 6 2K%__7@
MX Y06$[@!-535L8$(1#'ER\\W#T\W/_MOW^_'/WR#::SX63\[W]A_T+_\@N,
MXR0-QY___2]_7+PE]B___;_]E__R;_\/(?_KU<=WO[R9Q*M+&,]_>3T%/X?T
MRY_#^9=?_IY@]H]?\G1R^<O?)]-_#+]Y0O[;XH]>3[Y>3X>?O\Q_X93SQ_\Z
M_5<>C+8@/ $E))%9"1*,ST0E*I/*GCG-_M_/_RH8S88Y2@Q5C$AG&7$!_X!Y
M"\Q%D[5PBR\=#<?_^-?R(_@9_(+,C6>+7__]+U_F\Z__^NNO?_[YY[]\#]/1
MOTRFGW_EE(I?;S[]E]7'OS_Y_)]B\6GFG/MU\:^W'YT-UWT0OY;]^K]^?_<I
M?H%+3X;CV=R/8WG ;/BOL\6;[R;1SQ<R_R%=OVS\1/F-W'R,E+<(XT2P?_D^
M2W_Y;__EEU^6XIA.1O 1\B_EOW]\/'OPR' Y'?]+G%S^6O[QU]<3A,('_[F0
MNOC3^?57^/>_S(:77T>W[WV90O[WOY0_)$6G5"P?^%_O_OC7NV=_G<(,X;+@
M]1V^L?J.\K3=Z8#O<Q@G6/)V\X31)#[XT*A(=C*]^<N1#S!:O#M(,!PLOODD
MS.93'^<#$((BJE!FWBHB)3?$6YT(E9X':KQ7QCUDNY \0YH7BIA!_)?/DV^_
MXA>C0CC[IRPOR?+E0B9/'KF4S7ZTWZR]"_SL0'.6>7"*:*T#KHA,25!&$F-,
M5*B4G*T]F/3[3WQ(^7V]GDSC+Y-I@BD:D)M'^FE\HN.'X%U]XM>O?HI?1.*7
MX2C=_'6Q)%WH;#[I0'I+U2"Y?_D%N<XPG4)ZM]3,1N86G,W1K,+BDUUH_7]>
M^2E^X^CZ(WR=3.<#QW.4(3.B!1I-&;PB(2E%P($U%GB23G4&@$</WPH+O'TL
M'"+31F#Q :;#23H=IS>X'0\X#Y'FE(D'#[B=HBRL3YPD,#%++QF([D#QX-%;
M04*T#XG]Y=D(("ZF?CP;%L&O0.U!I>"E)")'!#48A1*1ACB#1M!II\#H[G:*
M1T_?"A:R?5@<)-6>D7$ZG@_GUV^'(WA_=1E@.@!I6>1!$RF (JJ=(4$G1YR.
MD7%P6@E_,"(>/W4K)*AVD7"0%)M P$?X/"Q"&,_?^TL8L(BHY3D39C0*PFA-
M@F4)Z?=6A!AXI+PC%#Q\\E9(T*TCX0!I-H&&,PSSIVC*%H+_A/*'UY.K\7QZ
M_7J28$"EY1FC.Y)=2$1&#+BMI89(#R$:RZ4PIB-P/$O(5E@QK6.E.UDW 9T+
M__TLH?B&>;C,8JPLH@2%;C*3!,T@1_=9>A*<$\0H[W-T2MI(.P+-!A*V@HMM
M'2Y=R+<)H)RDA"J8K?[S;C@&-O *(VR/L39-9>\$CZ(Q5!!((0+*AG,K.@+)
MFL=O!1#7.D .E6M+X'B-+\^G%Y,_QP-'J94B*6(@12(U!N)>>TX\A:!X--'[
MT"TT[AZ^77J+OA!D["G4EG"QV";/IQ^FDV_#<82!3<IS%3TQO(3B3N(NZ3'T
M"EH&ECADE[O:7-93L!U"&LZ =B;>EF#R83*;^]'_-_RZ<*4\!E]46$^L!N3"
M1DT<!PS-N=819+9*=VQ!'CQ_.X@TG!CM2+0] Z18OY,I^ 7=06N7D#J2F,$P
M/6A+G+*4F!1]IC:K9 Y/B=Y_XG8@:#@5NK?X>E9[.5,=??@R&=]D:)R0T:>L
M"%CG2SI?$$M5)C9RM&H!C/-PL.H?/W4[]3><\CQ(C#U#X!/$JRG"E_%P,9R/
M8*"S]]2CU4J4H=62,9+ %[N<,.C]:"O@\"37XZ=N!X&&<YT'B;%G"%Q,?:E>
M^71]&2:C =<JI2 M23(G(IG-) 3K"(0<$W?>1'KX,?F#1VZG_(;3F_L+L)'%
M?_H]?O'CS[#(R\:L<_8A$.1"H%^;-/$Q(!,:O5O064F=.C, ]Y^\'0X:3ET>
M+,XFPH375],BKN6I78$UZN!J-I!4 =HT3WARF4C0)=(I![N!*Z&I3 *Z"A36
M4[ =/)I/578@WB9@<C;&;T-Q#+_!&S_W*[8&*0H?(E6$.BF)U$YA^&,%P4!9
M)(QZ0*G#@X?G*-@.)LTG+#L0;Q,P*<>_T]=^#I\GT^L!Y9H;A7;09AJ)3$FA
M5R31/PJ987@44C"'.Q=K'KQ=^57SN<K]A=D$%CY=^M'HU=5L.(;9;&!3]EPZ
M01+&Q$124&5/5(11QY,.3!B9.\+"@P=OAX7FLY+["[,)+)Q>PO0S;G^_32=_
MSK^\GEQ^]>/K0:+:))9\J2WER(;FQ'-KD W-0685DI4=86(M =MAH_ETY.'"
M;0(CG[[ :'1#/0<6+(LH!Q54L7:16 ^9*-#>6Z:53%U!X_YSMT-$P[G) T79
M!!"0\,M2!C*)__CT!>4V.[^:EQLB)>H>:! 0/?I F?- 9$FX>Q6!.)LH)$.#
M=UWM(\_1L1U0&LYB=BSJGH%S<@GC5.I0WX[\YT%2B1E.#4G9,B(YE\0F(4D.
MC$5'G0DZ'HR1!X_<#@X-9S3W%V C9=UOA[/H1_\;_/0MOC,;.*VLD4D3:CV"
M%\"0\CO11F<J==21'6XG-CQ\.S0TG.+L0JA-X6)Y:V')A$C.!IDHT4XB$]E'
MXH1Q&%Y+IV,P'DGI&!GW'K\=-AI.>W8CV#8<#61CZD=GXP3?_P=@B!V9]LQQ
MHDNF14I6&&!H (5$?&O/3>@LZ?GPT=NAHOULYP$"[;LF8IERN[-X-U><O&=H
MXQ#0+C-$==0&7R5)(N4YZP3*=5 RL^GIV^&BX?1F)V+M#!K_]NL3.;[#-_:Z
M"G[^_LWI^T^G;_#%I_-W9V].+D[?O#IY=_+^]>FGOYZ>7GQZ2/V6=\1__*V'
M7Q[?D?(#;Y5?S<AG[[\.%@5U9>,XSV^'8S^.0]P])LL[8[<P4U(X4 :(3MJB
M@Y$2\4Y)4GQ.Y1!_RCUWK2+[65A 8/70Q8K[%4;SV<T[BX5'*%MU ?BONU"W
MKWFY><;); ;SV2VO.F4/(2D2HT!>HP)BN?2%=6,9@/#I.<.R/Z\/Z>CGWGHU
M5-P8GPZ$WN..])#ZE1&]98*QY%R*EBB?T;WBY2Z5I$ $;K8Q!1F9>>Y^XJ'(
M>41.OP Z1+]KH7*(L!M S&L_^W(R3N4_I_^\&G[S(V1F=C)_[:?3Z^'X\]_\
MZ IWWP 0I)<$/7/<?4.,Y4I5(B6&8QJX4/RYLJ_]$;05>2T@ZB 83&KKI &@
MG7SS0WQ[!&\GTT_(T:H<9@BS-Q#F=[_=G&7+F*1BX(@0(6($8 +Q,2% (HTA
M>QWSLW7&!QBMW0CMIW='/?#5U-/>,,30(DRZ F*,Y;+H["-$P+6%G+Z'^6T%
MA92"2>4)"@KC3NIQ4<GL2;:")BU]N3%8!W7/4-5/+Y"*$.M* PV8M;/Q-Z1Z
M,KU&%C#JC1J]2U-NJ;OB31@2,CJ>R!&W3E&?8AU'ZSX5_;0(J8>6O27< #K.
MYU]@^D D T$A4\D80;M8SMFM0%%83<!FZ;@' ,JJ8.0I+?VT$*F'E .EW0!>
M'A*O1#9.2T-H,)E(!9IX;RTQ(AB=C-2&/5=KW5'<UD][D8J[S]XRWA\@D[D?
M=0B0]Y-Q?"01"3F'2 .J,B$?(96$*_-$0BQ7#D*6[+E3JD.Q\I2B%OSB#L/\
M T7>@FW9TK&_XW2@$N?<.4_ 0VF0P3T)N"X(2]()X5A2OE+B:&=:6\@!'(J1
M/2.Q/1761##V83KY"M/Y]8>11ZF-4\EW?"WYW>+L<8PKLU,W>0WN2F@I48S%
M+(,V!MAS=3G[P^\YJEJP:QT#K3,E-&#ESE 9X\]#7#4K4<'\]'L<794*M=\F
MD_3G<#3"3=^*+"WJG9?4F<R2^&0#8=IK+CR-&%=4BM-^3%T+T7[' .M<*0T
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MM,],:&WKW*LXA.I^>PJV!.K*&F\R!+L7;ZX1\+WZW;LAJ;<^U/YERET\]O!
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MHYFF6O<67VKMY4XHV*/V<A>5-("R=86 S(-CR5+"H\$=6O)8QA, B4Y%JDP
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M4$0G/"W>D&9 GQ*M\>4$V;C":>'G/5BE3]%P02':B/"/0J WH/"C#,1&0O'
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M7B2K,5#U%?XVJ :31 NP>KSSWJ5I^/K-S?^YVGZN].\WA@ Q ;>?"NA>$1*
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MY$:9QA24$U[IW5("'C][W#Z+ \N[)\L:D?AY,:DW7>YYEEIPA:>9<^C.$32
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M+J*:1-\ 2M=;F3(A38X14DP45V4HH#6F0>)'&I/2G-69%+H;?:,7TPV,BX[
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MHVC+)*Q6DD7PK(RF*J,V30DS6N.RRYE+:>ID.AQ$6]ZYE<^\:=VJ@Q(9*>-
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M[7U*[YZW[Y7F>0B& \7]KL%HGSA#"F7C[=/! P0J/EU9YG0>X#[*1*#S@6Y
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MQX)&BU'$R'S?@,-*Y><ZE<"=I@G*BDRAB]ZLMF^)2*7J$'JG=]H"!#+#L<!
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M%M:WDZ41B^9;"859)NGA*O\@Z[DJJ@%C+>9TA\*+\>5%S1M%Y%1GLFP!F19
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M:G5D 1D-9-Q<@S\'&(ME&A*=!T^#)?"SB#Y>NKZ7F$IV>:VTZ5H# [P57"N
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MH=JFK?ADQN9?2 -\$3#4O(0OW34W('J$]]$8+ -_KQ)@/T2\^@OVH\GMKNH
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MEU\6*99^W(KVGG9V47MI^1,->7,!HFY[2!,^8SF?"6;$3(HY2,/ETK+?*FZ
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MT3KVOT90.P=+CUW03DG_T83,L!66>M?D&V=1ZVMU,F;/Z([^!E!+ 0(4 Q0
M   ( %AHG5017%@K%)$" ' G&@ 1              "  0    !B;7)N+3(P
M,C(P,S,Q+FAT;5!+ 0(4 Q0    ( %AHG51I*\.]-A(  +*M   1
M      "  4.1 @!B;7)N+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( %AHG530
M49:E)QT  )\5 0 5              "  :BC @!B;7)N+3(P,C(P,S,Q7V-A
M;"YX;6Q02P$"% ,4    " !8:)U4<'"^9$A0  "N> , %0
M@ $"P0( 8FUR;BTR,#(R,#,S,5]D968N>&UL4$L! A0#%     @ 6&B=5)P
MQK'_Q@  P@$( !4              ( !?1$# &)M<FXM,C R,C S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( %AHG51-$.2$\GD  #AK!0 5              "
M :_8 P!B;7)N+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4    " !8:)U4B0[9
MR6=B  "U"P, %P              @ '44@0 8G)M;BTS,6UA<C(R>&5X>#$P
M,2YH=&U02P$"% ,4    " !8:)U4M-V_(,@'  !#(@  &@
M@ %PM00 97AH:6)I=#,Q,2TS,6UA<C(R>#$P<2YH=&U02P$"% ,4    " !8
M:)U48-REAMX'   V(P  &@              @ %PO00 97AH:6)I=#,Q,BTS
M,6UA<C(R>#$P<2YH=&U02P$"% ,4    " !8:)U4V<ZNEEL%  #^$P  &@
M            @ &&Q00 97AH:6)I=#,R,2TS,6UA<C(R>#$P<2YH=&U02P4&
2      H "@"G @  &<L$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
